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reamble (UPDATED)
is important that the medical profession play a significant
le in critically evaluating the use of diagnostic procedures
d therapies as they are introduced and tested in the
tection, management, or prevention of disease states. Rig-
ous and expert analysis of the available data documenting
solute and relative benefits and risks of those procedures
d therapies can produce helpful guidelines that improve the
fectiveness of care, optimize patient outcomes, and favor-
ly affect the overall cost of care by focusing resources on
e most effective strategies.
The American College of Cardiology Foundation (ACCF)
d the American Heart Association (AHA) have jointly
gaged in the production of such guidelines in the area of
rdiovascular disease since 1980. The ACCF/AHA Task
orce on Practice Guidelines (Task Force), whose charge is to
velop, update, or revise practice guidelines for important
rdiovascular diseases and procedures, directs this effort.
riting committees are charged with the task of performing
assessment of the evidence and acting as an independent sooup of authors to develop, update, or revise written recom-
endations for clinical practice.
Experts in the subject under consideration have been
lected from both organizations to examine subject-specific
ta and write guidelines. The process includes additional
presentatives from other medical practitioner and specialty
oups when appropriate. Writing committees are specifically
arged to perform a literature review, weigh the strength of
idence for or against a particular treatment or procedure,
d include estimates of expected health outcomes where
ta exist. Patient-specific modifiers and comorbidities and
sues of patient preference that may influence the choice of
rticular tests or therapies are considered, as well as fre-
ency of follow-up and cost-effectiveness. When available,
formation from studies on cost will be considered; however,
view of data on efficacy and clinical outcomes will consti-
te the primary basis for preparing recommendations in these
idelines.
The guidelines will be reviewed annually by the Task
orce and will be considered current unless they are updated,
vised, or sunsetted and withdrawn from distribution. Keep-
g pace with the stream of new data and evolving evidence
which guideline recommendations are based is an ongoing
allenge to timely development of clinical practice guide-
nes. In an effort to respond promptly to new evidence, the
ask Force has created a “focused update” process to revise
e existing guideline recommendations that are affected by
olving data or opinion. New evidence is reviewed in an
going fashion to more efficiently respond to important
ience and treatment trends that could have a major impact
patient outcomes and quality of care.
For the 2012 focused update, the standing guideline writing
mmittee along with the parent Task Force identified trials
d other key data through October 2011 that may impact
ideline recommendations, specifically in response to the
proval of new oral antiplatelets, and to provide guidance on
w to incorporate these agents into daily practice (Section 1.1,
ethodology and Evidence”). Now that multiple agents are
ailable, a comparison of their use in various settings within
inical practice is provided. This iteration replaces the
ctions in the 2007 ACC/AHA Guidelines for the Manage-
ent of Patients With Unstable Angina/Non–ST-Elevation
yocardial Infarction that were updated by the 2011 ACCF/
HA Focused Update of the Guidelines for the Management
Patients With Unstable Angina/Non–ST-Elevation Myo-
rdial Infarction (1,2). The focused update is not intended to
based on a complete literature review from the date of the
evious guideline publication but rather to include pivotal
w evidence that may affect changes to current recommen-
tions. See the 2012 focused update for the complete
eamble and evidence review period (3).
In analyzing the data and developing recommendations and
pporting text, the writing group uses evidence-based meth-
ologies developed by the Task Force (4). The Class of
ecommendation (COR) is an estimate of the size of the
eatment effect, with consideration given to risks versus
nefits, as well as evidence and/or agreement that a given
eatment or procedure is or is not useful/effective and in
me situations may cause harm. The Level of Evidence
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June 11, 2013:e179–347 UA/NSTEMI Guideline: 2012 Update IncorporatedOE) is an estimate of the certainty or precision of the
eatment effect. The writing group reviews and ranks evi-
nce supporting each recommendation, with the weight of
idence ranked as LOE A, B, or C, according to specific
finitions that are included in Table 1. Studies are identified
observational, retrospective, prospective, or randomized,
appropriate. For certain conditions for which inadequate
ta are available, recommendations are based on expert
nsensus and clinical experience and are ranked as LOE C.
hen recommendations at LOE C are supported by historical
inical data, appropriate references (including clinical re-
ews) are cited if available. For issues for which sparse data
e available, a survey of current practice among the clini-
ans on the writing group is the basis for LOE C recommen-
tions, and no references are cited. The schema for COR and
ble 1. Applying Classification of Recommendations and Level
A recommendation with Level of Evidence B or C does not imply that the recomme
emselves to clinical trials. Although randomized trials are unavailable, there may be a
*Data available from clinical trials or registries about the usefulness/efficacy
yocardial infarction, history of heart failure, and prior aspirin use.
†For comparative effectiveness recommendations (Class I and IIa; Level of Evirect comparisons of the treatments or strategies being evaluated.OE is summarized in Table 1, which also provides sug-
sted phrases for writing recommendations within each
OR. A new addition to this methodology for the 2012
cused update is separation of the Class III recommenda-
ons to delineate whether the recommendation is determined
be of “no benefit” or is associated with “harm” to the
tient. In addition, in view of the increasing number of
mparative effectiveness studies, comparator verbs and sug-
sted phrases for writing recommendations for the compar-
ive effectiveness of one treatment or strategy versus another
ve been added for COR I and IIa, LOE A or B only.
In view of the advances in medical therapy across the
ectrum of cardiovascular diseases, the Task Force has desig-
ted the term guideline-directed medical therapy (GDMT) to
present optimal medical therapy as defined by ACCF/AHA
ence
s weak. Many important clinical questions addressed in the guidelines do not lend
r clinical consensus that a particular test or therapy is useful or effective.
rent subpopulations, such as sex, age, history of diabetes, history of prior
and B only), studies that support the use of comparator verbs should involveof Evid
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rm, GDMT, is incorporated into the 2012 focused update and
ill be used throughout all future guidelines.
Because the ACCF/AHA practice guidelines address pa-
ent populations (and healthcare providers) residing in North
merica, drugs that are not currently available in North America
e discussed in the text without a specific COR. For studies
rformed in large numbers of subjects outside North America,
ch writing group reviews the potential impact of different
actice patterns and patient populations on the treatment effect
d relevance to the ACCF/AHA target population to determine
hether the findings should inform a specific recommendation.
The ACCF/AHA practice guidelines are intended to assist
althcare providers in clinical decision making by describ-
g a range of generally acceptable approaches to the diag-
sis, management, and prevention of specific diseases or
nditions. The guidelines attempt to define practices that
eet the needs of most patients in most circumstances. The
timate judgment about care of a particular patient must be
ade by the healthcare provider and patient in light of all the
rcumstances presented by that patient. As a result, situations
ay arise in which deviations from these guidelines may be
propriate. Clinical decision making should consider the
ality and availability of expertise in the area where care is
ovided. When these guidelines are used as the basis for
gulatory or payer decisions, the goal should be improve-
ent in quality of care. The Task Force recognizes that
tuations arise in which additional data are needed to inform
tient care more effectively; these areas will be identified
ithin each respective guideline when appropriate.
Prescribed courses of treatment in accordance with these
commendations are effective only if they are followed. Be-
use lack of patient understanding and adherence may ad-
rsely affect outcomes, physicians and other healthcare provid-
s should make every effort to engage the patient’s active
rticipation in prescribed medical regimens and lifestyles. In
dition, patients should be informed of the risks, benefits, and
ternatives to a particular treatment and should be involved in
ared decision making whenever feasible, particularly for COR
a and IIb, for which the benefit-to-risk ratio may be lower.
The Task Force makes every effort to avoid actual, poten-
al, or perceived conflicts of interest that may arise as a result
industry relationships or personal interests among the
embers of the writing group. All writing group members
d peer reviewers of the guideline are required to disclose all
rrent healthcare–related relationships, including those ex-
ting 12 months before initiation of the writing effort.
For the 2007 guidelines, all members of the writing
mmittee, as well as peer reviewers of the document, were
ked to provide disclosure statements of all such relation-
ips that may be perceived as real or potential conflicts of
terest. Writing committee members are also strongly en-
uraged to declare a previous relationship with industry that
ay be perceived as relevant to guideline development.
In December 2009, the ACCF and AHA implemented a
w policy for relationships with industry and other entities
WI) that requires the writing group chair plus a minimum
50% of the writing group to have no relevant RWIppendix 4 includes the ACCF/AHA definition of rele- (Unce). These statements are reviewed by the Task Force and
l members during each conference call and/or meeting of
e writing group and are updated as changes occur. All
ideline recommendations require a confidential vote by
e writing group and must be approved by a consensus of the
ting members. Members are not permitted to draft or vote
any text or recommendations pertaining to their RWI.
he 2012 members who recused themselves from voting are
dicated in the list of writing group members, and specific
ction recusals are noted in Appendix 4. 2007 and 2012
thors’ and peer reviewers’ RWI pertinent to this guideline
e disclosed in Appendixes 1, 2, 4, and 5, respectively.
dditionally, to ensure complete transparency, writing group
embers’ comprehensive disclosure informationincluding
WI not pertinent to this documentis available as an online
pplement. Comprehensive disclosure information for the
ask Force is also available online at www.cardiosource.org/
CC/About-ACC/Leadership/Guidelines-and-Documents-Task-
rces.aspx. The work of the 2012 writing group is supported
clusively by the ACCF, and AHA, without commercial support.
riting group members volunteered their time for this activity.
In April 2011, the Institute of Medicine released 2 reports:
inding What Works in Health Care: Standards for System-
ic Reviews and Clinical Practice Guidelines We Can Trust
,6). It is noteworthy that the ACCF/AHA practice guide-
nes were cited as being compliant with many of the
andards that were proposed. A thorough review of these
ports and our current methodology is under way, with
rther enhancements anticipated.
The 2007 executive summary and recommendations are
blished in the August 7, 2007, issue of the Journal of the
merican College of Cardiology and August 7, 2007, issue of
irculation. The full-text guidelines are e-published in the same
sue of the journals noted above, as well as posted on the ACC
ttp://www.cardiosource.org) and AHA (my.americanheart.org)
eb sites. Guidelines are official policy of both the ACCF
d AHA.
The current document is a re-publication of the “ACCF/AHA
07 Guidelines for the Management of Patients With Unstable
ngina/Non–ST-Elevation Myocardial Infarction” (7), revised
incorporate updated recommendations and text from the 2012
ocused Update (3). For easy reference, this online-only version
notes sections that have been updated. The sections that have
t been updated could contain text or references that are not
rrent, as these sections have not been modified.
Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
. Introduction (UPDATED)
.1. Organization of Committee and
vidence Review (UPDATED)
he ACC/AHA Task Force on Practice Guidelines was
rmed to make recommendations regarding the diagnosis
d treatment of patients with known or suspected cardiovas-
lar disease (CVD). Coronary artery disease (CAD) is the
ading cause of death in the United States. Unstable angina
A) and the closely related condition of non–ST-segment
el
m
co
li
20
th
pr
de
ou
m
w
T
pr
w
ex
ge
of
A
fr
(A
S
fo
an
w
in
te
an
A
G
E
20
ti
fo
cu
G
C
bl
N
ag
w
re
gr
ic
E
S
an
pr
m
C
20
co
tr
m
ab
fo
in
pl
in
1
(U
T
no
re
re
as
E
ra
an
th
on
is
er
A
C
of
1
T
pa
N
of
S
re
di
U
av
ye
pa
vi
di
C
ca
N
es
in
ci
w
ti
m
ag
an
eg
av
th
re
de
U
e185JACC Vol. 61, No. 23, 2013 Anderson et al.
June 11, 2013:e179–347 UA/NSTEMI Guideline: 2012 Update Incorporatedevation myocardial infarction (NSTEMI) are very common
anifestations of this disease.
The 2007 guideline committee members reviewed and
mpiled published reports through a series of computerized
terature searches of the English-language literature since
02 and a final manual search of selected articles. Details of
e specific searches conducted for particular sections are
ovided when appropriate. Detailed evidence tables were
veloped whenever necessary with the specific criteria
tlined in the individual sections. The recommendations
ade were based primarily on these published data. The
eight of the evidence was ranked highest (A) to lowest (C).
he final recommendations for indications for a diagnostic
ocedure, a particular therapy, or an intervention in patients
ith UA/NSTEMI summarize both clinical evidence and
pert opinion.
The 2007 committee consisted of acknowledged experts in
neral internal medicine representing the American College
Physicians (ACP), family medicine from the American
cademy of Family Physicians (AAFP), emergency medicine
om the American College of Emergency Physicians
CEP), thoracic surgery from the Society of Thoracic
urgeons (STS), interventional cardiology from the Society
r Cardiovascular Angiography and Interventions (SCAI),
d general and critical care cardiology, as well as individuals
ith recognized expertise in more specialized areas, includ-
g noninvasive testing, preventive cardiology, coronary in-
rvention, and cardiovascular surgery. Both the academic
d private practice sectors were represented.
The 2007 guidelines overlap several previously published
CC/AHA practice guidelines, including the ACC/AHA
uidelines for the Management of Patients With ST-
levation Myocardial Infarction (8), the ACC/AHA/SCAI
05 Guideline Update for Percutaneous Coronary Interven-
on (9), the AHA/ ACC Guidelines for Secondary Prevention
r Patients With Coronary and Other Atherosclerotic Vas-
lar Disease: 2006 Update (10), and the ACC/AHA 2002
uideline Update for the Management of Patients With
hronic Stable Angina (11).
For the 2012 focused update, members of the 2011 Unsta-
e Angina/Non–ST-Elevation Myocardial Infarction (UA/
STEMI) focused update writing group were invited and all
reed to participate (referred to as the 2012 focused update
riting group). Members were required to disclose all RWI
levant to the data under consideration. The 2012 writing
oup included representatives from the ACCF, AHA, Amer-
an Academy of Family Physicians, American College of
mergency Physicians, American College of Physicians,
ociety for Cardiovascular Angiography and Interventions,
d Society of Thoracic Surgeons.
For the 2012 focused update, late-breaking clinical trials
esented at the 2008, 2009, and 2010 annual scientific
eetings of the ACC, AHA, and European Society of
ardiology, as well as selected other data through October
11, were reviewed by the standing guideline writing
mmittee along with the parent Task Force to identify those
ials and other key data that may impact guideline recom-
endations. On the basis of the criteria/considerations noted
ove, and the approval of new oral antiplatelets, the 2012 thcused update was initiated to provide guidance on how to
corporate these agents into daily practice. Now that multi-
e agents are available, a comparison is provided on their use
various settings within clinical practice.
.2. Document Review and Approval
PDATED)
he 2007 document was reviewed by 2 outside reviewers
minated by each of the ACC and AHA and by 49 peer
viewers.
The 2012 focused update was reviewed by 2 official
viewers each nominated by the ACCF and the AHA, as well
1 or 2 reviewers each from the American College of
mergency Physicians, Society for Cardiovascular Angiog-
phy and Interventions, and Society of Thoracic Surgeons,
d 29 individual content reviewers, including members of
e ACCF Interventional Scientific Council. The information
reviewers’ RWI was distributed to the writing group and
published in this document (Appendix 5).
This document was approved for publication by the gov-
ning bodies of the ACCF and the AHA and endorsed by the
merican College of Emergency Physicians, Society for
ardiovascular Angiography and Interventions, and Society
Thoracic Surgeons.
.3. Purpose of These Guidelines
hese guidelines address the diagnosis and management of
tients with UA and the closely related condition of
STEMI. These life-threatening disorders are a major cause
emergency medical care and hospitalization in the United
tates. In 2004, the National Center for Health Statistics
ported 1,565,000 hospitalizations for primary or secondary
agnosis of an acute coronary syndrome (ACS), 669,000 for
A and 896,000 for myocardial infarction (MI) (12). The
erage age of a person having a first heart attack is 65.8
ars for men and 70.4 years for women, and 43% of ACS
tients of all ages are women. In 2003, there were 4,497,000
sits to US emergency departments (EDs) for primary
agnosis of CVD (12). The prevalence of this presentation of
VD ensures that many health care providers who are not
rdiovascular specialists will encounter patients with UA/
STEMI in the course of the treatment of other diseases,
pecially in outpatient and ED settings. These guidelines are
tended to assist both cardiovascular specialists and nonspe-
alists in the proper evaluation and management of patients
ith an acute onset of symptoms suggestive of these condi-
ons. These clinical practice guidelines also provide recom-
endations and supporting evidence for the continued man-
ement of patients with these conditions in both inpatient
d outpatient settings. The diagnostic and therapeutic strat-
ies that are recommended are supported by the best
ailable evidence and expert opinion. The application of
ese principles with carefully reasoned clinical judgment
duces but does not eliminate the risk of cardiac damage and
ath in patients who present with symptoms suggestive of
A/NSTEMI. Appendix 3 lists the abbreviations found in
is document.
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cute Coronary Syndromes
.4.1. Definition of Terms
nstable angina/NSTEMI constitutes a clinical syndrome
bset of the ACS that is usually, but not always, caused by
herosclerotic CAD and is associated with an increased risk
cardiac death and subsequent MI. In the spectrum of ACS,
A/NSTEMI is defined by electrocardiographic (ECG) ST-
gment depression or prominent T-wave inversion and/or
sitive biomarkers of necrosis (e.g., troponin) in the absence
ST-segment elevation and in an appropriate clinical setting
hest discomfort or anginal equivalent) (Table 2, Figure 1).
he results of angiographic and angioscopic studies suggest
at UA/NSTEMI often results from the disruption or erosion
an atherosclerotic plaque and a subsequent cascade of
thological processes that decrease coronary blood flow.
ost patients who die during UA/NSTEMI do so because of
dden death or the development (or recurrence) of acute MI.
he efficient diagnosis and optimal management of these
tients must derive from information readily available at the
me of the initial clinical presentation. The clinical presen-
tion of patients with a life-threatening ACS often overlaps
at of patients subsequently found not to have CAD. More-
er, some forms of MI cannot always be differentiated from
A at the time of initial presentation.
“Acute coronary syndrome” has evolved as a useful
erational term to refer to any constellation of clinical
mptoms that are compatible with acute myocardial isch-
ia (Figure 1). It encompasses MI (ST-segment elevation
d depression, Q wave and non-Q wave) and UA. These
idelines focus on 2 components of this syndrome: UA and
STEMI. In practice, the term “possible ACS” is often
signed first by ancillary personnel, such as emergency
edical technicians and triage nurses, early in the evaluation
ocess. A guideline of the National Heart Attack Alert
rogram (16) summarizes the clinical information needed to
ake the diagnosis of possible ACS at the earliest phase of
inical evaluation (Table 2). The implication of this early
agnosis for clinical management is that a patient who is
nsidered to have an ACS should be placed in an environ-
ent with continuous ECG monitoring and defibrillation
pability, where a 12-lead ECG can be obtained expedi-
ously and definitively interpreted, ideally within 10 min of
rival in the ED. The most urgent priority of early evaluation
to identify patients with ST-elevation MI (STEMI) who
ould be considered for immediate reperfusion therapy and
recognize other potentially catastrophic causes of patient
mptoms, such as aortic dissection.
Patients diagnosed as having STEMI are excluded from
anagement according to these guidelines and should be
anaged as indicated according to the ACC/AHA Guidelines
r the Management of Patients With ST-Elevation Myocar-
alInfarction (8,17). Similarly, management of electrocar-
ographic true posterior MI, which can masquerade as
STEMI, is covered in the STEMI guidelines (8). The
anagement of patients who experience periprocedural myo-
rdial damage, as reflected in the release of biomarkers of rocrosis, such as the MB isoenzyme of creatine kinase
K-MB) or troponin, also is not considered here.
Patients with MI and with definite ischemic ECG changes
r whom acute reperfusion therapy is not suitable should be
agnosed and managed as patients with UA. The residual
oup of patients with an initial diagnosis of ACS will include
any patients who will ultimately be proven to have a
n-cardiac cause for the initial clinical presentation that was
ggestive of ACS. Therefore, at the conclusion of the initial
aluation, which is frequently performed in the ED but
metimes occurs during the initial hours of inpatient hospi-
lization, each patient should have a provisional diagnosis of
ACS (Figure 1), which in turn is classified as a) STEMI, a
ndition for which immediate reperfusion therapy (fibrino-
sis or percutaneous coronary intervention [PCI]) should be
nsidered, b) NSTEMI, or c) UA (definite, probable, or
ssible); 2) a non-ACS cardiovascular condition (e.g., acute
ricarditis); 3) a noncardiac condition with another specific
sease (e.g., chest pain secondary to esophageal spasm); or
a noncardiac condition that is undefined. In addition, the
itial evaluation should be used to determine risk and to treat
fe-threatening events.
In these guidelines, UA and NSTEMI are considered to be
osely related conditions whose pathogenesis and clinical
esentations are similar but of differing severity; that is, they
ffer primarily in whether the ischemia is severe enough to
use sufficient myocardial damage to release detectable
antities of a marker of myocardial injury, most commonly
oponin I (TnI), troponin T (TnT), or CK-MB. Once it has
en established that no biomarker of myocardial necrosis
s been released (based on 2 or more samples collected at
ast 6 h apart, with a reference limit of the 99th percentile of
e normal population) (18), the patient with ACS may be
nsidered to have experienced UA, whereas the diagnosis of
STEMI is established if a biomarker has been released.
arkers of myocardial injury can be detected in the blood-
ream with a delay of up to several hours after the onset of
chemic chest pain, which then allows the differentiation
tween UA (i.e., no biomarkers in circulation; usually
ansient, if any, ECG changes of ischemia) and NSTEMI
.e., elevated biomarkers). Thus, at the time of presentation,
tients with UA and NSTEMI can be indistinguishable and
erefore are considered together in these guidelines.
.4.2. Pathogenesis of UA/NSTEMI
hese conditions are characterized by an imbalance between
yocardial oxygen supply and demand. They are not a
ecific disease, such as pneumococcal pneumonia, but rather
syndrome, analogous to hypertension. A relatively few
nexclusive causes are recognized (19) (Table 3).
The most common mechanisms involve an imbalance that
caused primarily by a reduction in oxygen supply to the
yocardium, whereas with the fifth mechanism noted below,
e imbalance is principally due to increased myocardial
ygen requirements, usually in the presence of a fixed,
stricted oxygen supply:
The most common cause of UA/NSTEMI is reduced
yocardial perfusion that results from coronary artery nar-
wing caused by a thrombus that developed on a disrupted
at
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lization of platelet aggregates and components of the
srupted plaque are believed to be responsible for the release
myocardial markers in many of these patients. An occlu-
ve thrombus/plaque also can cause this syndrome in the
esence of an extensive collateral blood supply.
The most common underlying molecular and cellular
thophysiology of disrupted atherosclerotic plaque is arterial
flammation, caused by noninfectious (e.g., oxidized lipids)
d, possibly, infectious stimuli, which can lead to plaque
pansion and destabilization, rupture or erosion, and throm-
genesis. Activated macrophages and T lymphocytes lo-
ted at the shoulder of a plaque increase the expression of
zymes such as metalloproteinases that cause thinning and
sruption of the plaque, which in turn can lead to UA/
STEMI.
A less common cause is dynamic obstruction, which may be
iggered by intense focal spasm of a segment of an epicardial
ronary artery (Prinzmetal’s angina) (see Section 6.7). This
cal spasm is caused by hypercontractility of vascular
ooth muscle and/or by endothelial dysfunction. Large-
ssel spasm can occur on top of obstructive or destabilized
ble 2. Guidelines for the Identification of ACS Patients by ED
gistration/clerical staff
Patients with the following chief complaints require immediate assessment b
● Chest pain, pressure, tightness, or heaviness; pain that radiates to neck, ja
● Indigestion or “heartburn”; nausea and/or vomiting associated with chest d
● Persistent shortness of breath
● Weakness, dizziness, lightheadedness, loss of consciousness
iage nurse
Patients with the following symptoms and signs require immediate assessm
● Chest pain or severe epigastric pain, nontraumatic in origin, with compone
X Central/substernal compression or crushing chest pain
X Pressure, tightness, heaviness, cramping, burning, aching sensation
X Unexplained indigestion, belching, epigastric pain
X Radiating pain in neck, jaw, shoulders, back, or 1 or both arms
● Associated dyspnea
● Associated nausea and/or vomiting
● Associated diaphoresis
If these symptoms are present, obtain stat ECG.
edical history
The triage nurse should take a brief, targeted, initial history with an assessm
● CABG, PCI, CAD, angina on effort, or MI
● NTG use to relieve chest discomfort
● Risk factors, including smoking, hyperlipidemia, hypertension, diabetes me
● Regular and recent medication use
e brief history must not delay entry into the ACS protocol.
ecial considerations
Women may present more frequently than men with atypical chest pain and
Diabetic patients may have atypical presentations due to autonomic dysfunc
Elderly patients may have atypical symptoms such as generalized weakness
Adapted from National Heart Attack Alert Program. Emergency Department: rap
D: US Department of Health and Human Services. US Public Health Service. Na
H Publication No. 93-3278 (6).
ACS  acute coronary syndrome; CABG  coronary artery bypass graft sur
partment; MI  myocardial infarction; NTG  nitroglycerin; PCI  percutaneaque, resulting in angina of “mixed” origin or UA/ NSTEMI. Dynamic coronary obstruction can also be caused
diffuse microvascular dysfunction; for example, due to
dothelial dysfunction or the abnormal constriction of small
tramural resistance vessels. Coronary spasm also is the
esumed mechanism underlying cocaine-induced UA/
STEMI.
A third cause of UA/NSTEMI is severe narrowing without
asm or thrombus. This occurs in some patients with
ogressive atherosclerosis or with restenosis after a PCI.
A fourth cause of UA/NSTEMI is coronary artery dissec-
on (e.g., as a cause of ACS in peripartal women).
The fifth mechanism is secondary UA, in which the
ecipitating condition is extrinsic to the coronary arterial
d. Patients with secondary UA usually, but not always,
ve underlying coronary atherosclerotic narrowing that lim-
s myocardial perfusion, and they often have chronic stable
gina. Secondary UA is precipitated by conditions that
increase myocardial oxygen requirements, such as fever,
chycardia, or thyrotoxicosis; 2) reduce coronary blood flow,
ch as hypotension; or 3) reduce myocardial oxygen deliv-
y, such as anemia or hypoxemia. These causes of UA/
ation Clerks or Triage Nurses
iage nurse and should be referred for further evaluation:
lders, back, or 1 or both arms
rt
he triage nurse for the initiation of the ACS protocol:
cal of myocardial ischemia or MI:
current or past history of:
mily history, and cocaine or methamphetamine use
ms.
syncope, or a change in mental status.
ification and treatment of patients with acute myocardial infarction. Bethesda,
stitutes of Health. National Heart, Lung and Blood Institute, September 1993.
D  coronary artery disease; ECG  electrocardiogram; ED  emergency
onary intervention.Registr
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UA/NSTEMI Guideline: 2012 Update Incorporated June 11, 2013:e179–347gure 1. Acute Coronary Syndromes. The top half of the figure illustrates the chronology of the interface between the patient and the
inician through the progression of plaque formation, onset, and complications of UA/NSTEMI, along with relevant management con-
derations at each stage. The longitudinal section of an artery depicts the “timeline” of atherogenesis from 1) a normal artery to 2) le-
on initiation and accumulation of extracellular lipid in the intima, to 3) the evolution to the fibrofatty stage, to 4) lesion progression
ith procoagulant expression and weakening of the fibrous cap. An acute coronary syndrome (ACS) develops when the vulnerable or
gh-risk plaque undergoes disruption of the fibrous cap (5); disruption of the plaque is the stimulus for thrombogenesis. Thrombus re-
rption may be followed by collagen accumulation and smooth muscle cell growth (6). After disruption of a vulnerable or high-risk
aque, patients experience ischemic discomfort that results from a reduction of flow through the affected epicardial coronary artery.
e flow reduction may be caused by a completely occlusive thrombus (bottom half, right side) or subtotally occlusive thrombus (bot-
m half, left side). Patients with ischemic discomfort may present with or without ST-segment elevation on the ECG. Among patients
ith ST-segment elevation, most (thick white arrow in bottom panel) ultimately develop a Q-wave MI (QwMI), although a few (thin white
row) develop a non–Q-wave MI (NQMI). Patients who present without ST-segment elevation are suffering from either unstable angina
A) or a non–ST-segment elevation MI (NSTEMI) (thick red arrows), a distinction that is ultimately made on the basis of the presence
absence of a serum cardiac marker such as CK-MB or a cardiac troponin detected in the blood. Most patients presenting with
STEMI ultimately develop a NQMI on the ECG; a few may develop a QwMI. The spectrum of clinical presentations ranging from UA
rough NSTEMI and STEMI is referred to as the acute coronary syndromes. This UA/NSTEMI guideline, as diagrammed in the upper
nel, includes sections on initial management before UA/NSTEMI, at the onset of UA/NSTEMI, and during the hospital phase. Sec-
dary prevention and plans for long-term management begin early during the hospital phase of treatment. *Positive serum cardiac
arker. Modified with permission from Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation
01;104:365 (7); © 2001 Lippincott, Williams & Wilkins; The Lancet, 358, Hamm CW, Bertrand M, Braunwald E. Acute coronary syn-
ome without ST elevation: implementation of new guidelines, 1553–8. Copyright 2001, with permission from Elsevier (8); and Davies
J. The pathophysiology of acute coronary syndromes. Heart 2000;83:361–6 (9). © 2000 Lippincott, Williams & Wilkins. CK-MB  MB
action of creatine kinase; Dx  diagnosis; ECG  electrocardiogram.
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here are 3 principal presentations of UA: 1) rest angina
ngina commencing when the patient is at rest), 2) new-onset
ess than 2 months) severe angina, and 3) increasing angina
ncreasing in intensity, duration, and/or frequency) (Table 4)
1). Criteria for the diagnosis of UA are based on the
ration and intensity of angina as graded according to the
anadian Cardiovascular Society classification (Table 5)
2). Non–ST-elevation MI generally presents as prolonged,
ore intense rest angina or angina equivalent.
.5. Management Before UA/NSTEMI and
nset of UA/NSTEMI
he ACS spectrum (UA/MI) has a variable but potentially
rious prognosis. The major risk factors for development of
ronary heart disease (CHD) and UA/NSTEMI are well
ble 3. Causes of UA/NSTEMI*
rombus or thromboembolism, usually arising on disrupted or eroded
plaque
● Occlusive thrombus, usually with collateral vessels†
● Subtotally occlusive thrombus on pre-existing plaque
● Distal microvascular thromboembolism from plaque-associated
thrombus
romboembolism from plaque erosion
● Non–plaque-associated coronary thromboembolism
ynamic obstruction (coronary spasm‡ or vasoconstriction) of epicardial
and/or microvascular vessels
ogressive mechanical obstruction to coronary flow
ronary arterial inflammation
condary UA
ronary artery dissection§
*These causes are not mutually exclusive; some patients have 2 or more
uses.
†DeWood MA, Stifter WF, Simpson CS, et al. Coronary arteriographic
dings soon after non–Q-wave myocardial infarction. N Engl J Med 1986;
5:417–23 (13).
‡May occur on top of an atherosclerotic plaque, producing missed-etiology
gina or UA/NSTEMI.
§Rare. Modified with permission from Braunwald E. Unstable angina: an
iologic approach to management. Circulation 1998;98:2219–22 (12).
UA  unstable angina; UA/NSTEMI  unstable angina/non–ST-elevation
yocardial infarction.
ble 4. Three Principal Presentations of UA
Class Presentation
st angina* Angina occurring at rest and prolonged, usually greater
than 20 min
w-onset
angina
New-onset angina of at least CCS class III severity
creasing angina Previously diagnosed angina that has become distinctly
more frequent, longer in duration, or lower in
threshold (i.e., increased by 1 or more CCS class to
at least CCS class III severity)
*Patients with non–ST-elevated myocardial infarction usually present with
gina at rest. Adapted with permission from Braunwald E. Unstable angina: a
assification. Circulation 1989;80:410–4 (14).
CCS  Canadian Cardiovascular Society classification; UA  unstable
cagina.tablished. Clinical trials have demonstrated that modifica-
on of those risk factors can prevent the development of
HD (primary prevention) or reduce the risk of experiencing
A/NSTEMI in patients who have CHD (secondary preven-
on). All practitioners should emphasize prevention and refer
tients to primary care providers for appropriate long-term
eventive care. In addition to internists and family physi-
ans, cardiologists have an important leadership role in
imary (and secondary) prevention efforts.
.5.1. Identification of Patients at
isk of UA/NSTEMI
ASS I
Primary care providers should evaluate the presence and
status of control of major risk factors for CHD for all patients at
regular intervals (approximately every 3 to 5 years). (Level of
Evidence: C)
Ten-year risk (National Cholesterol Education Program [NCEP]
global risk) of developing symptomatic CHD should be calcu-
lated for all patients who have 2 or more major risk factors to
assess the need for primary prevention strategies. (Level of
Evidence: B) (23,24)
Patients with established CHD should be identified for second-
ary prevention efforts, and patients with a CHD risk equivalent
(e.g., atherosclerosis in other vascular beds, diabetes mellitus,
chronic kidney disease, or 10-year risk greater than 20% as
calculated by Framingham equations) should receive equally
intensive risk factor intervention as those with clinically appar-
ent CHD. (Level of Evidence: A)
Major risk factors for developing CHD (i.e., smoking,
mily history, adverse lipid profiles, diabetes mellitus, and
evated blood pressure) have been established from large,
ng-term epidemiological studies (25,26). These risk factors
e predictive for most populations in the United States.
rimary and secondary prevention interventions aimed at
ese risk factors are effective when used properly. They
ble 5. Grading of Angina Pectoris According to
S Classification
lass Description of Stage
“Ordinary physical activity does not cause . . . angina,” such as
walking or climbing stairs. Angina occurs with strenuous, rapid,
or prolonged exertion at work or recreation.
“Slight limitation of ordinary activity.” Angina occurs on walking or
climbing stairs rapidly; walking uphill; walking or stair climbing
after meals; in cold, in wind, or under emotional stress; or only
during the few hours after awakening. Angina occurs on
walking more than 2 blocks on the level and climbing more
than 1 flight of ordinary stairs at a normal pace and under
normal conditions.
“Marked limitations of ordinary physical activity.” Angina occurs
on walking 1 to 2 blocks on the level and climbing 1 flight of
stairs under normal conditions and at a normal pace.
“Inability to carry on any physical activity without discomfort—
anginal symptoms may be present at rest.”
Adapted with permission from Campeau L. Grading of angina pectoris
tter). Circulation 1976;54:522–3 (15).
CCS  Canadian Cardiovascular Society.n also be costly in terms of primary care provider time,
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alth care needs, and expense, and they may not be
fective unless targeted at higher-risk patients (27). It is
erefore important for primary care providers to make the
entification of patients at risk, who are most likely to
nefit from primary prevention, a routine part of every-
e’s health care. The Third Report of the NCEP provides
idance on identifying such patients (25). Furthermore,
e Writing Committee supports public health efforts to
ach all adults at risk, not just those under the care of a
imary care physician.
Patients with 2 or more risk factors who are at increased
-year and lifetime risk will have the greatest benefit from
imary prevention, but any individual with a single elevated
sk factor is a candidate for primary prevention (26). Waiting
til the patient develops multiple risk factors and increased
-year risk contributes to the high prevalence of CHD in the
nited States (25,28). Such patients should have their risk
ecifically calculated by any of the several valid prognostic
ols available in print (25,29), on the Internet (30), or for use
a personal computer or personal digital assistant (PDA)
5). Patients’ specific risk levels determine the absolute risk
ductions they can obtain from preventive interventions and
ide selection and prioritization of those interventions. For
ample, target levels for lipid lowering and for antihyper-
nsive therapy vary by patients’ baseline risk. A specific risk
mber can also serve as a powerful educational intervention
motivate lifestyle changes (31).
The detection of subclinical atherosclerosis by noninva-
ve imaging represents a new, evolving approach for
fining individual risk in asymptomatic individuals be-
nd traditional risk factor assessment alone. A recent
HA scientific statement indicates that it may be reason-
le to measure atherosclerosis burden using electron-
am or multidetector computed tomography (CT) in
inically selected intermediate-CAD-risk individuals
.g., those with a 10% to 20% Framingham 10-year risk
timate) to refine clinical risk prediction and to select
tients for aggressive target values for lipid-lowering
erapies (Class IIb, Level of Evidence: B) (32).
.5.2. Interventions to Reduce Risk of UA/NSTEMI
he benefits of prevention of UA/NSTEMI in patients with
HD are well documented and of large magnitude (10,28,33–35).
atients with established CHD should be identified for
condary prevention efforts, and patients with a CHD risk
uivalent should receive equally intensive risk factor inter-
ntion for high-risk primary prevention regardless of sex
6). Patients with diabetes mellitus and peripheral vascular
sease have baseline risks of UA/NSTEMI similar to pa-
ents with known CHD, as do patients with multiple risk
ctors that predict a calculated risk of greater than 20% over
years as estimated by the Framingham equations (25).
uch patients should be considered to have the risk equiva-
nts of CHD, and they can be expected to have an absolute
nefit similar to those with established CHD.
All patients who use tobacco should be encouraged to quit
d should be provided with help in quitting at every
portunity (37). Recommendations by a clinician to avoid cabacco can have a meaningful impact on the rate of cessation
tobacco use. The most effective strategies for encouraging
itting are those that identify the patient’s level or stage of
adiness and provide information, support, and, if necessary,
armacotherapy targeted at the individual’s readiness and
ecific needs (33,38). Pharmacotherapy may include nico-
ne replacement or withdrawal-relieving medication such as
propion. Varenicline, a nicotine acetylcholine receptor
rtial antagonist, is a newly approved nonnicotine replace-
ent therapy for tobacco avoidance (39–42). Many patients
quire several attempts before they succeed in quitting
rmanently (43,44). Additional discussion in this area can be
und in other contemporary documents (e.g., the ACC/AHA
02 Guideline Update for the Management of Patients With
hronic Stable Angina (11).
All patients should be instructed in and encouraged to
aintain appropriate low-saturated-fat, low-trans-fat, and
w-cholesterol diets high in soluble (viscous) fiber and rich
vegetables, fruits, and whole grains. All patients also
ould be encouraged to be involved with a regular aerobic
ercise program, including 30 to 60 min of moderate-
tensity physical activity (such as brisk walking) on most
d preferably all days of the week (10,45). For those who
ed to weigh less, an appropriate balance of increased
ysical activity (i.e., 60 to 90 min daily), caloric restriction,
d formal behavioral programs is encouraged to achieve and
aintain a body mass index between 18.5 and 24.9 kg/m2 and
waist circumference of less than or equal to 35 inches in
omen and less than or equal to 40 inches in men. For those
ho need lipid lowering beyond lifestyle measures, the statin
ugs have the best outcome evidence supporting their use
d should be the mainstay of pharmacological intervention
8). The appropriate levels for lipid management are depen-
nt on baseline risk; the reader is referred to the NCEP
port (http://www.nhlbi.nih.gov/guidelines/cholesterol/
dex.htm) for details (24,25,46–48).
Primary prevention patients with high blood pressure
ould be treated according to the recommendations of
e Seventh Joint National Committee on High Blood
ressure (JNC 7) (49,50). Specific treatment recommenda-
ons are based on the level of hypertension and the patient’s
her risk factors. A diet low in salt and rich in vegetables,
uits, and low-fat dairy products should be encouraged for all
pertensive patients, as should a regular aerobic exercise
ogram (51–54). Most patients will require more than 1
edication to achieve blood pressure control, and pharmaco-
erapy should begin with known outcome-improving medi-
tions (primarily thiazide diuretics as first choice, with the
dition of beta blockers, angiotensin-converting enzyme
CE] inhibitors, angiotensin receptor blockers, and/or long-
ting calcium channel blockers) (49,55). Systolic hyperten-
on is a powerful predictor of adverse outcome, particularly
ong the elderly, and it should be treated even if diastolic
essures are normal (56).
Detection of hyperglycemic risk (e.g., metabolic syn-
ome) and diabetes mellitus should be pursued as part of risk
sessment. Lifestyle changes and pharmacotherapy are indi-
ted in individuals with diabetes mellitus to achieve a
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oid hypoglycemia (10,57,58).
Aspirin prophylaxis can uncommonly result in hemor-
agic complications and should only be used in primary
evention when the level of risk justifies it. Patients whose
-year risk of CHD is 10% or more are most likely to
nefit, and 75 to 162 mg of aspirin (ASA) per day as primary
rophylaxis should be discussed with such patients
6,45,59–62).
.6. Onset of UA/NSTEMI
.6.1. Recognition of Symptoms by Patient
arly recognition of symptoms of UA/NSTEMI by the
tient or someone with the patient is the first step that must
cur before evaluation and life-saving treatment can be
tained. Although many laypersons are generally aware that
est pain is a presenting symptom of UA/NSTEMI, they are
aware of the other common symptoms, such as arm pain,
wer jaw pain, shortness of breath (63), and diaphoresis (64)
anginal equivalents, such as dyspnea or extreme fatigue
3,65). The average patient with NSTEMI or prolonged rest
A (e.g., longer than 20 min) does not seek medical care for
proximately 2 h after symptom onset, and this pattern
pears unchanged over the last decade (65–67). A baseline
alysis from the Rapid Early Action for Coronary Treatment
EACT) research program demonstrated longer delay times
ong non-Hispanic blacks, older patients, and Medicaid-
ly recipients and shorter delay times among Medicare
cipients (compared with privately insured patients) and
tients who came to the hospital by ambulance (65). In
e majority of studies examined to date, women in both
ivariate- and multivariate-adjusted analyses (in which
e and other potentially confounding variables have been
ntrolled) exhibit more prolonged delay patterns than
en (68).
A number of studies have provided insight into why
tients delay in seeking early care for heart symptoms (69).
ocus groups conducted for the REACT research program
0,71) revealed that patients commonly hold a preexisting
pectation that a heart attack would present dramatically
ith severe, crushing chest pain, such that there would be no
ubt that one was occurring. This was in contrast to their
tual reported symptom experience of a gradual onset of
scomfort involving midsternal chest pressure or tightness,
ith other associated symptoms often increasing in intensity.
he ambiguity of these symptoms, due to this disconnect
tween prior expectations and actual experience, resulted in
certainty about the origin of symptoms and thus a “wait-
d-see” posture by patients and those around them (69).
ther reported reasons for delay were that patients thought
e symptoms were self-limited and would go away or were
t serious (72–74); that they attributed symptoms to other
eexisting chronic conditions, especially among older adults
ith multiple chronic conditions (e.g., arthritis), or some-
mes to a common illness such as influenza; that they were
raid of being embarrassed if symptoms turned out to be a
alse alarm”; that they were reluctant to trouble others (e.g.,
alth care providers, Emergency Medical Services [EMS])less they were “really sick” (72–74); that they held stereo-
pes of who is at risk for a heart attack; and that they lacked
areness of the importance of rapid action, knowledge of
perfusion treatment, or knowledge of the benefits of calling
MS/9-1-1 to ensure earlier treatment (69). Notably, women
d not perceive themselves to be at risk (75).
.6.2. Silent and Unrecognized Events
atients experiencing UA/NSTEMI do not always present
ith chest discomfort (76). The Framingham Study was the
rst to show that as many as half of all MIs may be clinically
lent and unrecognized by the patient (77). Canto et al. (78)
und that one third of the 434,877 patients with confirmed
I in the National Registry of Myocardial Infarction pre-
nted to the hospital with symptoms other than chest
scomfort. Compared with MI patients with chest discom-
rt, MI patients without chest discomfort were more likely to
older, to be women, to have diabetes, and/or to have prior
art failure [HF]. Myocardial infarction patients without
est discomfort delayed longer before they went to the
spital (mean 7.9 vs 5.3 h) and were less likely to be
agnosed as having an MI when admitted (22.2% vs 50.3%).
hey also were less likely to receive fibrinolysis or primary
CI, ASA, beta blockers, or heparin. Silent MI patients were
2 times more likely to die during the hospitalization
n-hospital mortality rate 23.3% vs 9.3%). Unexplained
spnea, even without angina, is a particularly worrisome
mptom, with more than twice the risk of death than for
pical angina in patients undergoing cardiovascular evalua-
on (63). Recently, the prognostic significance of dyspnea
s been emphasized in patients undergoing cardiac evalua-
on. Self-reported dyspnea alone among 17,991 patients
dergoing stress perfusion testing was an independent pre-
ctor of cardiac and total mortality and increased the risk of
dden cardiac death 4-fold even in those with no prior
story of CAD (63).
Health care providers should maintain a high index of
spicion for UA/NSTEMI when evaluating women, patients
ith diabetes mellitus, older patients, those with unexplained
spnea (63), and those with a history of HF or stroke, as well
those patients who complain of chest discomfort but who
ve a permanent pacemaker that may confound recognition
UA/NSTEMI on their 12-lead ECG (79).
. Initial Evaluation and Management
.1. Clinical Assessment
ecause symptoms are similar and the differentiation of
A/NSTEMI and STEMI requires medical evaluation, we
ill refer to prediagnostic clinical presentation as ACS,
fined as UA or MI (NSTEMI or STEMI) (Figure 2).
ecommendations
ASS I
Patients with symptoms that may represent ACS (Table 2)
should not be evaluated solely over the telephone but should be
referred to a facility that allows evaluation by a physician and
2.
3.
4.
5.
6.
CL
1.
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(e.g., an ED or other acute care facility). (Level of Evidence: C)
Patients with symptoms of ACS (chest discomfort with or
without radiation to the arm[s], back, neck, jaw or epigas-
trium; shortness of breath; weakness; diaphoresis; nausea;
lightheadedness) should be instructed to call 9-1-1 and should
be transported to the hospital by ambulance rather than by
friends or relatives. (Level of Evidence: B)
Health care providers should actively address the following
issues regarding ACS with patients with or at risk for CHD
and their families or other responsible caregivers:
a. The patient’s heart attack risk; (Level of Evidence: C)
b. How to recognize symptoms of ACS; (Level of Evidence: C)
c. The advisability of calling 9-1-1 if symptoms are unim-
proved or worsening after 5 min, despite feelings of uncer-
tainty about the symptoms and fear of potential embarrass-
ment; (Level of Evidence: C)
d. A plan for appropriate recognition and response to a
potential acute cardiac event, including the phone number
to access EMS, generally 9-1-1. (Level of Evidence: C) (80)
Prehospital EMS providers should administer 162 to 325 mg of
ASA (chewed) to chest pain patients suspected of having ACS
unless contraindicated or already taken by the patient. Al-
though some trials have used enteric-coated ASA for initial
dosing, more rapid buccal absorption occurs with non–enteric-
coated formulations. (Level of Evidence: C)
gure 2. Algorithm for Evaluation and Management of Patients Su
d a more detailed discussion in the text, each box is assigned a
allocated from left to right across the diagram on a given level. A
ion; ACS  acute coronary syndrome; ECG  electrocardiogram; LV Health care providers should instruct patients with suspected
ACS for whom nitroglycerin [NTG] has been prescribed previ-
ously to take not more than 1 dose of NTG sublingually in
response to chest discomfort/pain. If chest discomfort/pain is
unimproved or is worsening 5 min after 1 NTG dose has been
taken, it is recommended that the patient or family member/
friend/caregiver call 9-1-1 immediately to access EMS before
taking additional NTG. In patients with chronic stable angina, if
symptoms are significantly improved by 1 dose of NTG, it is
appropriate to instruct the patient or family member/friend/
caregiver to repeat NTG every 5 min for a maximum of 3 doses
and call 9-1-1 if symptoms have not resolved completely. (Level
of Evidence: C)
Patients with a suspected ACS with chest discomfort or other
ischemic symptoms at rest for greater than 20 min, hemody-
namic instability, or recent syncope or presyncope should be
referred immediately to an ED. Other patients with suspected
ACS who are experiencing less severe symptoms and who have
none of the above high-risk features, including those who
respond to an NTG dose, may be seen initially in an ED or an
outpatient facility able to provide an acute evaluation. (Level of
Evidence: C)
ASS IIa
It is reasonable for health care providers and 9-1-1 dispatchers
to advise patients without a history of ASA allergy who have
ed of Having ACS. To facilitate interpretation of this algorithm
code that reflects its level in the algorithm and a number that
HA  American College of Cardiology/American Heart Associ-spect
letter
CC/Aleft ventricular.
2.
3.
4.
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June 11, 2013:e179–347 UA/NSTEMI Guideline: 2012 Update Incorporatedsymptoms of ACS to chew ASA (162 to 325 mg) while awaiting
arrival of prehospital EMS providers. Although some trials have
used enteric-coated ASA for initial dosing,more rapid buccal absorp-
tion occurs with non–enteric-coated formulations. (Level of Evi-
dence: B)
It is reasonable for health care providers and 9-1-1 dispatchers
to advise patients who tolerate NTG to repeat NTG every 5 min
for a maximum of 3 doses while awaiting ambulance arrival.
(Level of Evidence: C)
It is reasonable that all prehospital EMS providers perform
and evaluate 12-lead ECGs in the field (if available) on chest
pain patients suspected of ACS to assist in triage decisions.
Electrocardiographs with validated computer-generated in-
terpretation algorithms are recommended for this purpose.
(Level of Evidence: B)
If the 12-lead ECG shows evidence of acute injury or ischemia,
it is reasonable that prehospital ACLS providers relay the ECG
to a predetermined medical control facility and/or receiving
hospital. (Level of Evidence: B)
Patients with suspected ACS must be evaluated rapidly.
ecisions made on the basis of the initial evaluation have
bstantial clinical and economic consequences (81). The first
iage decision is made by the patient, who must decide
hether to access the health care system. Media campaigns such
“Act in Time,” sponsored by the National Heart, Lung, and
lood Institute (NHLBI), provide patient education regarding
is triage decision (www.nhlbi.nih.gov/actintime). The cam-
ign urges both men and women who feel heart attack
mptoms or observe the signs in others to wait no more than
few minutes, 5 min at most, before calling 9-1-1 (82,83).
ampaign materials point out that patients can increase their
ance of surviving a heart attack by learning the symptoms
d filling out a survival plan. They also are advised to talk
ith their doctor about heart attacks and how to reduce their
sk of having one. The patient materials include a free
ochure about symptoms and recommended actions for
rvival, in English (84) and Spanish (85), as well as a free
allet card that can be filled in with emergency medical
formation (86). Materials geared directly to providers
clude a Patient Action Plan Tablet (87), which contains the
art attack warning symptoms and steps for developing a
rvival plan, individualized with the patient’s name; a quick
ference card for addressing common patient questions
out seeking early treatment to survive a heart attack (88),
cluding a PDA version (89); and a warning signs wall chart
0). These materials and others are available on the “Act in
ime” Web page (www.nhlbi.nih.gov/health/public/heart/mi/
re_bk.pdf) (83).
When the patient first makes contact with the medical care
stem, a critical decision must be made about where the
aluation will take place. The health care provider then must
ace the evaluation in the context of 2 critical questions: Are
e symptoms a manifestation of an ACS? If so, what is the
ognosis? The answers to these 2 questions lead logically to
series of decisions about where the patient will be best
anaged, what medications will be prescribed, and whether
angiographic evaluation will be required.
Given the large number of patients with symptoms com-
tible with ACS, the heterogeneity of the population, and a knustering of events shortly after the onset of symptoms, a
rategy for the initial evaluation and management is essen-
al. Health care providers may be informed about signs and
mptoms of ACS over the telephone or in person by the
tient or family members. The objectives of the initial
aluation are first to identify signs of immediate life-
reatening instability and then to ensure that the patient is
oved rapidly to the most appropriate environment for the
vel of care needed based on diagnostic criteria and an
timation of the underlying risk of specific negative out-
mes.
Health practitioners frequently receive telephone calls
om patients or family members/friends/caregivers who are
ncerned that their symptoms could reflect heart disease.
ost such calls regarding chest discomfort of possible
rdiac origin in patients without known CAD do not repre-
nt an emergency; rather, these patients usually seek reas-
rance that they do not have heart disease or that there is
ttle risk due to their symptoms. Despite the frequent incli-
tion to dismiss such symptoms over the telephone, health
re providers, EMS dispatchers, and staff positioned to
ceive these calls should advise patients with possible
celerating angina or angina at rest that an evaluation cannot
performed solely via the telephone. This advice is essential
cause of the need for timely evaluation, including a
ysical examination, ECG, and appropriate blood tests to
easure cardiac biomarkers.
Patients with known CAD—including those with chronic
able angina, recent MI, or prior intervention (i.e., coro-
ry artery bypass graft surgery [CABG] or PCI)—who
ntact a physician or other appropriate member of the
alth care team because of worsening or recurrent symp-
ms should be instructed to proceed rapidly to an ED,
eferably one equipped to perform prompt reperfusion
erapy. When the discomfort is moderate to severe or
stained, they should be instructed to access the EMS
stem directly by calling 9-1-1. Patients who have been
aluated recently and who are calling for advice regarding
odification of medications as part of an ongoing treat-
ent plan represent exceptions.
Even in the most urgent subgroup of patients who present
ith acute-onset chest pain, there usually is adequate time for
ansport to an environment in which they can be evaluated
d treated (91). In a large study of consecutive patients with
est pain suspected to be of cardiac origin who were
ansported to the ED via ambulance, one third had a final
agnosis of MI, one third had a final diagnosis of UA, and
e third had a final diagnosis of a noncardiac cause; 1.5% of
ese patients developed cardiopulmonary arrest before ar-
val at the hospital or in the ED (92).
Every community should have a written protocol that
ides EMS system personnel in determining where to take
tients with suspected or confirmed ACS. Active involve-
ent of local health care providers, particularly cardiolo-
sts and emergency physicians, is needed to formulate
cal EMS destination protocols for these patients. In
neral, patients with suspected ACS should be taken to
e nearest appropriate hospital; however, patients with
own STEMI and/or cardiogenic shock should be sent as
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rgical capability (8).
The advent of highly effective, time-dependent treatment
r ACS, coupled with the need to reduce health care costs,
ds further incentive for clinicians to get the right answer
ickly and to reduce unnecessary admissions and length of
spital stay. Investigators have tried various diagnostic
ols, such as clinical decision algorithms, cardiac biomark-
s, serial ECGs, echocardiography, myocardial perfusion
aging, and multidetector (e.g., 64-slice) coronary CT an-
ography (CCTA), in an attempt to avoid missing patients
ith MI or UA. The most successful strategies to emerge thus
r are designed to identify MI patients and, when clinically
propriate, screen for UA and underlying CAD. Most
rategies use a combination of cardiac biomarkers, short-
rm observation, diagnostic imaging, and provocative stress
sting. An increasing number of high-quality centers now
e structured protocols, checklists, or critical pathways to
reen patients with suspected MI or UA (93–105). It does
t appear to matter whether the institution designates itself a
est pain center; rather, it is the multifaceted, multidisci-
inary, standardized, and structured approach to the problem
at appears to provide clinical, cost-effective benefit
06,107). One randomized trial has confirmed the safety,
ficacy, and cost-effectiveness of the structured decision-
aking approach compared with standard, unstructured care
08).
Regardless of the approach used, all patients presenting to
e ED with chest discomfort or other symptoms suggestive
MI or UA should be considered high-priority triage cases
d should be evaluated and treated on the basis of a
edetermined, institution-specific chest pain protocol. The pro-
col should include several diagnostic possibilities (Figure 2)
09). The patient should be placed on a cardiac monitor
mediately, with emergency resuscitation equipment, in-
uding a defibrillator, nearby. An ECG also should be
rformed immediately and evaluated by an experienced
ergency medicine physician, with a goal of within 10 min
ED arrival. If STEMI is present, the decision as to whether
e patient will be treated with fibrinolytic therapy or primary
CI should be made within the next 10 min (8). For cases in
hich the initial diagnosis and treatment plan are unclear to
e emergency medicine physician or are not covered directly
an institutionally agreed-upon protocol, immediate cardi-
ogy consultation is advisable.
Morbidity and mortality from ACS can be reduced signif-
antly if patients and bystanders recognize symptoms early,
tivate the EMS system, and thereby shorten the time to
finitive treatment. Patients with possible symptoms of MI
ould be transported to the hospital by ambulance rather
an by friends or relatives, because there is a significant
sociation between arrival at the ED by ambulance and early
perfusion therapy in STEMI patients (110–113). In addi-
on, emergency medical technicians and paramedics can
ovide life-saving interventions (e.g., early cardiopulmonary
suscitation [CPR] and defibrillation) if the patient develops
rdiac arrest. Approximately 1 in every 300 patients with
est pain transported to the ED by private vehicle goes into
rdiac arrest en route (114). paSeveral studies have confirmed that patients with ACS
equently do not call 9-1-1 and are not transported to the
spital by ambulance. A follow-up survey of chest pain
tients presenting to participating EDs in 20 U.S. com-
unities who were either released or admitted to the
spital with a confirmed coronary event revealed that the
erage proportion of patients who used EMS was 23%,
ith significant geographic difference (range 10% to 48%).
ost patients were driven by someone else (60%) or drove
emselves to the hospital (16%) (115). In the National
egistry of Myocardial Infarction 2, just over half (53%)
all patients with MI were transported to the hospital by
bulance (111).
Even in areas of the country that have undertaken substan-
al public education campaigns about the warning signs of
CS and the need to activate the EMS system rapidly, either
ere were no increases in EMS use (65,116–119) or EMS
e increased (as a secondary outcome measure) but was still
boptimal, with a 20% increase from a baseline of 33% in all
communities in the REACT study (70) and an increase
om 27% to 41% in southern Minnesota after a community
mpaign (120). Given the importance of patients using EMS
r possible acute cardiac symptoms, communities, including
edical providers, EMS systems, health care insurers, hos-
tals, and policy makers at the state and local level, need to
ve agreed-upon emergency protocols to ensure patients
ith possible heart attack symptoms will be able to access
1-1 without barriers, to secure their timely evaluation and
eatment (121).
As part of making a plan with the patient for timely
cognition and response to an acute event, providers should
view instructions for taking NTG in response to chest
scomfort/pain (Figure 3). If a patient has previously been
escribed NTG, it is recommended that the patient be
vised to take 1 NTG dose sublingually promptly for chest
scomfort/pain. If symptoms are unimproved or worsening 5
in after 1 NTG dose has been taken, it also is recommended
at the patient be instructed to call 9-1-1 immediately to
cess EMS. Although the traditional recommendation is for
tients to take 1 NTG dose sublingually, 5 min apart, for up
3 doses before calling for emergency evaluation, this
commendation has been modified by the UA/NSTEMI
riting Committee to encourage earlier contacting of EMS
patients with symptoms suggestive of ACS. While await-
g ambulance arrival, patients tolerating NTG can be in-
ructed by health care providers or 9-1-1 dispatchers to take
ditional NTG every 5 min up to 3 doses. Self-treatment
ith prescription medication, including nitrates, and with
nprescription medication (e.g., antacids) has been docu-
ented as a frequent cause of delay among patients with
CS, including those with a history of MI or angina (72,123).
oth the rate of use of these medications and the number of
ses taken were positively correlated with delay time to
spital arrival (72).
Family members, close friends, caregivers, or advocates
ould be included in these discussions and enlisted as
inforcement for rapid action when the patient experiences
mptoms of a possible ACS (80,124,125) (Figure 3). For
tients known to their providers to have frequent angina,
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June 11, 2013:e179–347 UA/NSTEMI Guideline: 2012 Update Incorporatedysicians may consider a selected, more tailored message
at takes into account the frequency and character of the
tient’s angina and their typical time course of response to
TG. In many of these patients with chronic stable angina, if
est pain is significantly improved by 1 NTG, it is still
propriate to instruct the patient or family member/friend/
regiver to repeat NTG every 5 min for a maximum of 3
ses and to call 9-1-1 if symptoms have not resolved
mpletely. Avoidance of patient delay associated with self-
edication and prolonged reevaluation of symptoms are
ramount. An additional consideration in high-risk CHD
tients is to train family members in CPR and/or to have
me access to an automatic external defibrillator, now
ailable commercially to the public.
The taking of aspirin by patients in response to acute symp-
ms has been reported to be associated with a delay in calling
MS (115). Patients should focus on calling 9-1-1, which
tivates the EMS system, where they may receive instructions
om emergency medical dispatchers to chew aspirin (162 to 325
g) while emergency personnel are en route, or emergency
rsonnel can give an aspirin while transporting the patient to the
spital (126). Alternatively, patients may receive an aspirin as part
their early treatment once they arrive at the hospital if it has not
en given in the prehospital setting (124).
Providers should target those patients at increased risk for
CS, focusing on patients with known CHD, peripheral
gure 3. Patient (Advance) Instructions for NTG Use and EMS Co
patients experience chest discomfort/pain and have been previo
recommended that they be instructed (in advance) to take 1 dos
in is unimproved or worsening 5 min after taking 1 NTG subling
cess EMS. In patients with chronic stable angina, if the symptom
struct the patient or family member/friend/caregiver to repeat NT
ve not totally resolved. If patients are not previously prescribed
est discomfort/pain is unimproved or worsening 5 min after it st
nts should notify their physician of the episode. (For those patie
TG, it is appropriate to discourage them from seeking someone e
ials have used enteric-coated aspirin for initial dosing, more rapid
S  emergency medical services; NTG  nitroglycerin.scular disease, or cerebral vascular disease, those with
abetes, and patients with a 10-year Framingham risk of
HD of more than 20% (127). They should stress that the
est discomfort will usually not be dramatic, such as is
mmonly misrepresented on television or in the movies as a
ollywood heart attack.” Providers also should describe angi-
l equivalents and the commonly associated symptoms of ACS
.g., shortness of breath, a cold sweat, nausea, or lightheaded-
ss) in both men and women (63,112), as well as the increased
equency of atypical symptoms in elderly patients (78).
.1.1. Emergency Department or
utpatient Facility Presentation
is recommended that patients with a suspected ACS with
est discomfort or other ischemic symptoms at rest for more
an 20 min, hemodynamic instability, or recent syncope or
esyncope to be referred immediately to an ED or a
ecialized chest pain unit. For other patients with a sus-
cted ACS who are experiencing less severe symptoms and
e having none of the above high-risk features, the recom-
endation is to be seen initially in an ED, a chest pain unit,
an appropriate outpatient facility. Outcomes data that
rmly support these recommendations are not available;
wever, these recommendations are of practical importance
cause differing ACS presentations require differing levels
emergent medical interventions, such as fibrinolytics or
n the Setting of Non–Trauma-Related Chest Discomfort/Pain.
escribed NTG and have it available (right side of algorithm), it
TG immediately in response to symptoms. If chest discomfort/
is recommended that the patient call 9-1-1 immediately to
significantly improved after taking 1 NTG, it is appropriate to
y 5 min for a maximum of 3 doses and call 9-1-1 if symptoms
ft side of algorithm), it is recommended that they call 9-1-1 if
the symptoms subside within 5 min of when they began, pa-
h newonset chest discomfort who have not been prescribed
TG [e.g., from a neighbor, friend, or relative].) *Although some
l absorption occurs with non–enteric-coated formulations.ntact i
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sophisticated diagnostic evaluation such as nuclear stress
sting or CCTA. When symptoms have been unremitting for
ore than 20 min, the possibility of MI must be considered.
iven the strong evidence for a relationship between delay in
eatment and death (128–130), an immediate assessment that
cludes a 12-lead ECG is essential. Patients who present
ith hemodynamic instability require an environment in
hich therapeutic interventions can be provided, and for
ose with presyncope or syncope, the major concern is the
sk of sudden death. Such patients should be encouraged to
ek emergency transportation when it is available. Transport
a passenger in a private vehicle is an acceptable alternative
ly if the wait for an emergency vehicle would impose a
lay of greater than 20 to 30 min.
.1.2. Questions to Be Addressed
the Initial Evaluation
he initial evaluation should be used to provide information
out the diagnosis and prognosis. The attempt should be
ade to simultaneously answer 2 questions:
What is the likelihood that the signs and symptoms
present ACS secondary to obstructive CAD (Table 6)?
What is the likelihood of an adverse clinical outcome
able 7)? Outcomes of concern include death, MI (or
current MI), stroke, HF, recurrent symptomatic ischemia,
d serious arrhythmia.
For the most part, the answers to these questions form a
quence of contingent probabilities. Thus, the likelihood that
e signs and symptoms represent ACS is contingent on the
kelihood that the patient has underlying CAD. Similarly, the
ognosis is contingent on the likelihood that the symptoms
present acute ischemia. However, in patients with symp-
ms of possible ACS, traditional risk factors for CAD are
ss important than are symptoms, ECG findings, and cardiac
omarkers. Therefore, the presence or absence of these
aditional risk factors ordinarily should not be heavily
ble 6. Likelihood That Signs and Symptoms Represent an ACS
Feature
High Likelihood
Any of the following:
Absenc
pre
story Chest or left arm pain or discomfort as chief
symptom reproducing prior documented
angina Known history of CAD, including MI
Chest or le
sympto
Age greate
Male sex
Diabetes m
amination Transient MR murmur, hypotension,
diaphoresis, pulmonary edema, or rales
Extracardia
G New, or presumably new, transient ST-
segment deviation (1 mm or greater) or
T-wave inversion in multiple precordial
leads
Fixed wave
ST depress
greater
rdiac markers Elevated cardiac TnI, TnT, or CK-MB Normal
Modified with permission from Braunwald E, Mark DB, Jones RH, et al. Unstab
d Research and the National Heart, Lung, and Blood Institute, U.S. Public Hea
. 94-0602 (124).
ACS acute coronary syndrome; CAD coronary artery disease; CK-MB MR  mitral regurgitation; TnI  troponin I; TnT  troponin T.eighed in determining whether an individual patient should
admitted or treated for ACS.
.2. Early Risk Stratification
ecommendations for Early Risk Stratification
ASS I
A rapid clinical determination of the likelihood risk of obstruc-
tive CAD (i.e., high, intermediate, or low) should be made in all
patients with chest discomfort or other symptoms suggestive
of an ACS and considered in patient management. (Level of
Evidence: C)
Patients who present with chest discomfort or other ischemic
symptoms should undergo early risk stratification for the risk of
cardiovascular events (e.g., death or [re] MI) that focuses on
history, including anginal symptoms, physical findings, ECG
findings, and biomarkers of cardiac injury, and results should
be considered in patient management. (Level of Evidence: C)
A 12-lead ECG should be performed and shown to an experi-
enced emergency physician as soon as possible after ED
arrival, with a goal of within 10 min of ED arrival for all patients
with chest discomfort (or anginal equivalent) or other symp-
toms suggestive of ACS. (Level of Evidence: B)
If the initial ECG is not diagnostic but the patient remains
symptomatic and there is high clinical suspicion for ACS, serial
ECGs, initially at 15- to 30-min intervals, should be performed
to detect the potential for development of ST-segment eleva-
tion or depression. (Level of Evidence: B)
Cardiac biomarkers should be measured in all patients who
present with chest discomfort consistent with ACS. (Level of
Evidence: B)
A cardiac-specific troponin is the preferred marker, and if
available, it should be measured in all patients who present
with chest discomfort consistent with ACS. (Level of
Evidence: B)
Patients with negative cardiac biomarkers within 6 h of the
onset of symptoms consistent with ACS should have biomark-
ers remeasured in the time frame of 8 to 12 h after symptom
dary to CAD
ediate Likelihood
h-likelihood features and
f any of the following:
Low Likelihood
Absence of high- or intermediatelikelihood
features but may have:
ain or discomfort as chief
0 years
Probable ischemic symptoms in absence
of any of the intermediate likelihood
characteristics
Recent cocaine use
lar disease Chest discomfort reproduced by palpation
to 1 mm or T-wave inversion
m
T-wave flattening or inversion less than
1 mm in leads with dominant waves
Normal ECG
Normal
a: diagnosis and management. Rockville, MD: Agency for Health Care Policy
ce, U.S. Department of Health and Human Service, 1994. AHCPR publication
on of creatine kinase; ECG electrocardiogram; MI myocardial infarction;Secon
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take into account the uncertainties often present with the
exact timing of onset of pain and the sensitivity, precision, and
institutional norms of the assay being utilized as well as the
release kinetics of the marker being measured.) (Level of
Evidence: B)
The initial evaluation of the patient with suspected with
ACS should include the consideration of noncoronary causes
for the development of unexplained symptoms. (Level of
Evidence: C)
ASS IIa
Use of risk-stratification models, such as the Thrombolysis
In Myocardial Infarction (TIMI) or Global Registry of Acute
Coronary Events (GRACE) risk score or the Platelet Glyco-
protein IIb/IIIa in Unstable Angina: Receptor Suppression
Using Integrilin Therapy (PURSUIT) risk model, can be useful
to assist in decision making with regard to treatment options in
patients with suspected ACS. (Level of Evidence: B)
It is reasonable to remeasure positive biomarkers at 6-to
8-h intervals 2 to 3 times or until levels have peaked, as
an index of infarct size and dynamics of necrosis. (Level of
ble 7. Short-Term Risk of Death or Nonfatal MI in Patients Wi
Feature
High Risk
At least 1 of the following features
must be present:
No high
story Accelerating tempo of ischemic symptoms in
preceding 48 h
Prior MI, p
or CABG
aracter of
pain
Prolonged ongoing (greater than 20 min)
rest pain
Prolonged
resolved
CAD
Rest angin
with res
Nocturnal
New-onset
angina
(greater
interme
Table 6
inical findings Pulmonary edema, most likely due to
ischemia
New or worsening MR murmur S3 or new/
worsening rales
Hypotension, bradycardia, tachycardia Age
greater than 75 years
Age greate
G Angina at rest with transient ST-segment
changes greater than 0.5 mm
Bundle-branch block, new or presumed new
Sustained ventricular tachycardia
T-wave ch
Pathologic
than 1 m
inferior,
rdiac markers Elevated cardiac TnT, TnI, or CK-MB (e.g.,
TnT or TnI greater than 0.1 ng per ml)
Slightly ele
(e.g., Tn
0.1 ng
*Estimation of the short-term risks of death and nonfatal cardiac ischemic eve
table such as this; therefore, this table is meant to offer general guidance
idelines No. 10, Unstable Angina: Diagnosis and Management, May 1994 (12
CABG  coronary artery bypass graft surgery; CAD  coronary artery diseas
G  electrocardiogram; MI  myocardial infarction; MR  mitral regurgitatio
gina/ non–ST-elevation myocardial infarction.Evidence: B)It is reasonable to obtain supplemental ECG leads V7
through V9 in patients whose initial ECG is nondiagnostic to
rule out MI due to left circumflex occlusion. (Level of
Evidence: B)
Continuous 12-lead ECG monitoring is a reasonable alternative
to serial 12-lead recordings in patients whose initial ECG is
nondiagnostic. (Level of Evidence: B)
ASS IIb
For patients who present within 6 h of the onset of symptoms
consistent with ACS, assessment of an early marker of cardiac
injury (e.g., myoglobin) in conjunction with a late marker (e.g.,
troponin) may be considered. (Level of Evidence: B)
For patients who present within 6 h of symptoms suggestive of
ACS, a 2-h delta CK-MB mass in conjunction with 2-h delta
troponin may be considered. (Level of Evidence: B)
For patients who present within 6 h of symptoms suggestive of
ACS, myoglobin in conjunction with CK-MB mass or troponin
when measured at baseline and 90 min may be considered.
(Level of Evidence: B)
Measurement of B-type natriuretic peptide (BNP) or NT-pro-
BNP may be considered to supplement assessment of global
NSTEMI*
termediate Risk
ture, but must have 1 of the
following:
Low Risk
No high- or intermediate-risk feature
but may have any of the following
features:
l or cerebrovascular disease,
spirin use
than 20 min) rest angina, now
oderate or high likelihood of
er than 20 min) or relieved
lingual NTG
ressive CCS class III or IV
st 2 weeks without prolonged
min) rest pain but with
high likelihood of CAD (see
Increased angina frequency, severity, or
duration
Angina provoked at a lower threshold
New onset angina with onset 2 weeks
to 2 months prior to presentation
0 years
or resting ST-depression less
ultiple lead groups (anterior,
Normal or unchanged ECG
ardiac TnT, TnI, or CK-MB
er than 0.01 but less than
Normal
A (or NSTEMI) is complex multivariable problem that cannot be fully specified
tration rather than rigid algorithms. Adapted from AHCPR Clinical Practice
Canadian Cardiovascular Society; CK-MB  creatine kinase, MB fraction;
 nitroglycerin; TnI  troponin I; TnT  troponin T; UA/NSTEMI  unstableth UA/
In
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n; NTGrisk in patients with suspected ACS. (Level of Evidence: B)
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Total CK (without MB), aspartate aminotransferase (AST, SGOT),
alanine transaminase, beta-hydroxybutyric dehydrogenase, and/or
lactate dehydrogenase should not be utilized as primary tests
for the detection of myocardial injury in patients with chest
discomfort suggestive of ACS. (Level of Evidence: C)
.2.1. Estimation of the Level of Risk
he medical history, physical examination, ECG, assessment
renal function, and cardiac biomarker measurements in
tients with symptoms suggestive of ACS at the time of the
itial presentation can be integrated into an estimation of the
sk of death and nonfatal cardiac ischemic events. The latter
clude new or recurrent MI, recurrent UA, disabling angina
at requires hospitalization, and urgent coronary revascular-
ation. Estimation of the level of risk is a multivariable
oblem that cannot be accurately quantified with a simple
ble; therefore, Tables 6 and 7 are meant to be illustrative of
e general relationships between history, clinical and ECG
ndings, and the categorization of patients into those at low,
termediate, or high risk of the presence of obstructive CAD
d the short-term risk of cardiovascular events, respectively.
ptimal risk stratification requires accounting for multiple
ognostic factors simultaneously by a multivariable ap-
oach (e.g., the TIMI and GRACE risk score algorithms [see
low]).
.2.2. Rationale for Risk Stratification
ecause patients with ischemic discomfort at rest as a group
e heterogeneous in terms of risk of cardiac death and
n-fatal ischemic events, an assessment of the prognosis
ides the initial evaluation and treatment. An estimation of
sk is useful in 1) selection of the site of care (coronary care
it, monitored step-down unit, or outpatient setting) and
selection of therapy, including platelet glycoprotein (GP)
b/IIIa inhibitors (see Section 3.2) and invasive management
rategy (see Section 3.3). For all modes of presentation of an
CS, a strong relationship exists between indicators of the
kelihood of ischemia due to CAD and prognosis (Tables 6
d 7). Patients with a high likelihood of ischemia due to
AD are at a greater risk of an untoward cardiac event than
e patients with a lower likelihood of CAD. Therefore, an
sessment of the likelihood of CAD is the starting point for
e determination of prognosis in patients who present with
mptoms suggestive of ACS. Other important elements for
ognostic assessment are the tempo of the patient’s clinical
urse, which relates to the short-term risk of future cardiac
ents, principally MI, and the patient’s likelihood of survival
ould an MI occur.
Patients can present with ischemic discomfort but without
T-segment deviation on the 12-lead ECG in a variety of
inical scenarios, including no known prior history of CAD,
prior history of stable CAD, soon after MI, and after
yocardial revascularization with CABG or PCI (19,132,133).
s a clinical syndrome, ischemic discomfort without ST-
gment elevation (UA and NSTEMI) shares ill-defined
rders with severe chronic stable angina, a condition asso-
ated with lower immediate risk, and STEMI, a presentation
ith a higher risk of early death and cardiac ischemic events. sihe risk is highest at the time of presentation and subse-
ently declines. Yet, the risk remains high past the acute
ase. By 6 months, UA/NSTEMI mortality rates higher than
at after STEMI can be seen (134); and by 12 months, the
tes of death, MI, and recurrent instability in contemporary
ndomized controlled trials and registry studies exceed 10%
d are often related to specific risk factors such as age,
abetes mellitus, renal failure, and impairment of left ven-
icular (LV) function. Whereas the early events are related to
e activity of 1 culprit coronary plaque that has ruptured and
the site of thrombus formation, events that occur later are
ore related to the underlying pathophysiological mecha-
sms that trigger plaque activity and that mark active
herosclerosis (135–141).
A few risk scores have been developed that regroup
arkers of the acute thrombotic process and other markers of
gh risk to identify high-risk patients with UA/NSTEMI.
he TIMI, GRACE, and PURSUIT risk scores are discussed
detail in Section 2.2.6.
.2.3. History
atients with suspected UA/NSTEMI may be divided into
ose with and those without a history of documented CAD.
articularly when the patient does not have a known history
CAD, the physician must determine whether the patient’s
esentation, with its constellation of specific symptoms and
gns, is most consistent with chronic ischemia, acute isch-
ia, or an alternative disease process. The 5 most important
ctors derived from the initial history that relate to the
kelihood of ischemia due to CAD, ranked in the order of
portance, are 1) the nature of the anginal symptoms,
prior history of CAD, 3) sex, 4) age, and 5) the number of
aditional risk factors present (142–146). In patients with
spected ACS but without preexisting clinical CHD, older
e appears to be the most important factor. One study found
at for males, age younger than 40 years, 40 to 55 years, and
der than 55 years and for females, age younger than 50
ars, 50 to 65 years, and older than 65 years was correlated
ith low, intermediate, and high risk for CAD, respectively
45). Another study found that the risk of CAD increased in
incremental fashion for each decade above age 40 years,
ith male sex being assigned an additional risk point
46,147). In these studies, being a male older than 55 years
a female older than 65 years outweighed the importance of
l historical factors, including the nature of the chest pain
45,146).
.2.4. Anginal Symptoms and Anginal Equivalents
he characteristics of angina, which are thoroughly described
the ACC/AHA 2002 Guideline Update for the Manage-
ent of Patients With Chronic Stable Angina (11), include
ep, poorly localized chest or arm discomfort that is repro-
cibly associated with physical exertion or emotional stress
d is relieved promptly (i.e., in less than 5 min) with rest
d/or the use of sublingual NTG. Patients with UA/NSTEMI
ay have discomfort that has all of the qualities of typical
gina except that the episodes are more severe and pro-
nged, may occur at rest, or may be precipitated by less
ertion than in the past. Although it is traditional to use themple term “chest pain” to refer to the discomfort of ACS,
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pecially when they are mild or atypical. Terms such as
schemic-type chest discomfort” or “symptoms suggestive
ACS” have been proposed to more precisely capture the
aracter of ischemic symptoms. Although “chest discom-
rt” or “chest press” is frequently used in these guidelines for
iformity and brevity, the following caveats should be kept
early in mind. Some patients may have no chest discomfort
t present solely with jaw, neck, ear, arm, shoulder, back, or
igastric discomfort or with unexplained dyspnea without
scomfort (63,148,149). If these symptoms have a clear
lationship to exertion or stress or are relieved promptly with
TG, they should be considered equivalent to angina. Occa-
onally, such “anginal equivalents” that occur at rest are the
ode of presentation of a patient with UA/NSTEMI, but
ithout the exertional history or known prior history of CAD,
may be difficult to recognize their cardiac origin. Other
fficult presentations of the patient with UA/NSTEMI in-
ude those without any chest (or equivalent) discomfort.
olated unexplained new-onset or worsened exertional dys-
ea is the most common anginal equivalent symptom,
pecially in older patients; less common isolated presenta-
ons, primarily in older adults, include nausea and vomiting,
aphoresis, and unexplained fatigue. Indeed, older adults and
omen with ACS not infrequently present with atypical
gina or nonanginal symptoms. Rarely do patients with ACS
esent with syncope as the primary symptom or with other
nanginal symptoms.
Features that are not characteristic of myocardial ischemia
clude the following:
Pleuritic pain (i.e., sharp or knifelike pain brought on by
respiratory movements or cough)
Primary or sole location of discomfort in the middle or
lower abdominal region
Pain that may be localized at the tip of 1 finger, particularly
over the left ventricular apex or a costochondral junction
Pain reproduced with movement or palpation of the chest
wall or arms
Very brief episodes of pain that last a few seconds or less
Pain that radiates into the lower extremities
Documentation of the evaluation of a patient with sus-
cted UA/NSTEMI should include the physician’s opinion
whether the discomfort is in 1 of 3 categories: high,
termediate, or low likelihood of acute ischemia caused by
AD (Table 6).
Although typical characteristics substantially increase the
obability of CAD, features not characteristic of typical
gina, such as sharp stabbing pain or reproduction of pain on
lpation, do not entirely exclude the possibility of ACS. In
e Multicenter Chest Pain Study, acute ischemia was diag-
sed in 22% of patients who presented to the ED with sharp
stabbing pain and in 13% of patients with pain with
euritic qualities. Furthermore, 7% of patients whose pain
as fully reproduced with palpation were ultimately recog-
zed to have ACS (150). The Acute Cardiac Ischemia
ime-Insensitive Predictive Instrument (ACI-TIPI) project
51,152) found that older age, male sex, the presence of
est or left arm pain, and the identification of chest pain or inessure as the most important presenting symptom all
creased the likelihood that the patient was experiencing
ute ischemia.
The relief of chest pain by administration of sublingual
TG in the ED setting is not always predictive of ACS. One
udy reported that sublingual NTG relieved symptoms in
% of patients with active CAD (defined as elevated cardiac
omarkers, coronary vessel with at least 70% stenosis on
ronary angiography, or positive stress test) compared with
% of patients without active CAD (153). Furthermore, the
lief of chest pain by the administration of a “GI cocktail”
.g., a mixture of liquid antacid, viscous lidocaine, and
ticholinergic agent) does not predict the absence of ACS
54).
.2.5. Demographics and History in
iagnosis and Risk Stratification
most studies of ACS, a prior history of MI has been
sociated not only with a high risk of obstructive CAD (155)
t also with an increased risk of multivessel CAD. There are
fferences in the presentations of men and women with ACS
ee Section 6.1). A smaller percentage of women than men
esent with STEMI, and of the patients who present without
T-segment elevation, fewer women than men have MIs
56). Women with suspected ACS are less likely to have
structive CAD than are men with a similar clinical presen-
tion, and when CAD is present in women, it tends to be less
vere. On the other hand, when STEMI is present, the
tcome in women tends to be worse even when adjustment
made for the older age and greater comorbidity of women.
owever, the outcome for women with UA is significantly
tter than the outcome for men, and the outcomes are similar
r men and women with NSTEMI (157,158).
Older adults (see Section 6.4) have increased risks of both
derlying CAD (159,160) and multivessel CAD; further-
ore, they are at higher risk for an adverse outcome than are
unger patients. The slope of the increased risk is steepest
yond age 70 years. This increased risk is related in part to
e greater extent and severity of underlying CAD and the
ore severe LV dysfunction in older patients; however, age
self exerts a strong, independent prognostic risk as well,
rhaps at least in part because of comorbidities. Older
ults also are more likely to have atypical symptoms on
esentation.
In patients with symptoms of possible ACS, some of the
aditional risk factors for CAD (e.g., hypertension, hyper-
olesterolemia, and cigarette smoking) are only weakly
edictive of the likelihood of acute ischemia (152,161) and
e far less important than are symptoms, ECG findings, and
rdiac biomarkers. Therefore, the presence or absence of
ese traditional risk factors ordinarily should not be used to
termine whether an individual patient should be admitted
treated for ACS. However, the presence of these risk
ctors does appear to relate to poor outcomes in patients with
tablished ACS. Although not as well investigated as the
aditional risk factors, a family history of premature CAD
s been demonstrated to be associated with increased coro-
ry artery calcium scores greater than the 75th age percentile
asymptomatic individuals (162) and increased risk of 30-d
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f special interest is that sibling history of premature CAD
s a stronger relationship than parental history (164). How-
er, several of these risk factors have important prognostic
d therapeutic implications. Diabetes and the presence of
tracardiac (carotid, aortic, or peripheral) vascular disease
e major risk factors for poor outcome in patients with ACS
ee Section 6.2). For both STEMI (165) and UA/NSTEMI
35), patients with these conditions have a significantly
gher mortality rate and risk of acute HF. For the most part,
is increase in risk is due to a greater extent of underlying
AD and LV dysfunction, but in many studies, diabetes
rries prognostic significance over and above these findings.
imilarly, a history of hypertension is associated with an
creased risk of a poor outcome.
The current or prior use of ASA at the time and presenta-
on of ACS has been associated in 1 database with increased
rdiovascular event risk (166). Although the rationale is not
lly elucidated, it appears those taking prior ASA therapy
ve more multivessel CAD, are more likely to present with
rombus present, may present later in the evolution of ACS,
may be ASA resistant. Surprisingly, current smoking is
sociated with a lower risk of death in the setting of ACS
66–168), primarily because of the younger age of smokers
ith ACS and less severe underlying CAD. This “smokers’
radox” seems to represent a tendency for smokers to
velop thrombi on less severe plaques and at an earlier age
an nonsmokers.
Being overweight and/or obese at the time of ACS presen-
tion is associated with lower short-term risk of death;
wever, this “obesity paradox” is primarily a function of
unger age at time of presentation, referral for angiography
an earlier stage of disease, and more aggressive ACS
anagement (167). Although short-term risk may be lower
r overweight/obese individuals, these patients have a higher
ng-term total mortality risk (168–172). Increased long-term
rdiovascular risk appears to be primarily limited to severe
esity (173).
Cocaine use has been implicated as a cause of ACS,
esumably owing to the ability of this drug to cause coronary
sospasm and thrombosis in addition to its direct effects on
art rate and arterial pressure and its myocardial toxic
operties (see Section 6.6) (174). Recently, the use of
ethamphetamine has grown, and its association with ACS
so should be considered. It is important to inquire about the
e of cocaine and methamphetamine in patients with sus-
cted ACS, especially in younger patients (age less than 40
ars) and others with few risk factors for CAD. Urine
xicology should be considered when substance abuse is
spected as a cause of or contributor to ACS.
.2.6. Estimation of Early Risk at Presentation
number of risk assessment tools have been developed to assist
assessing risk of death and ischemic events in patients with
A/NSTEMI, thereby providing a basis for therapeutic decision
aking (Table 8, Figure 4) (122,165,175). It should be recog-
zed that the predictive ability of these commonly used risk
sessment scores for nonfatal CHD risk is only moderate. ofAntman et al. developed the TIMI risk score (166), a
mple tool composed of 7 (1-point) risk indicators rated on
esentation (Table 8). The composite end points (all-cause
ortality, new or recurrent MI, or severe recurrent ischemia
ompting urgent revascularization within 14 d) increase as
e TIMI risk score increases. The TIMI risk score has been
lidated internally within the TIMI 11B trial and 2 separate
horts of patients from the Efficacy and Safety of Subcuta-
ous Enoxaparin in Unstable Angina and Non-Q-Wave
yocardial Infarction (ESSENCE) trial (175). The model
mained a significant predictor of events and appeared
latively insensitive to missing information, such as knowl-
ge of previously documented coronary stenosis of 50% or
ore. The model’s predictive ability remained intact with a
toff of 65 years of age. The TIMI risk score was recently
udied in an unselected ED population with chest pain
ndrome; its performance was similar to that in the ACS
pulation in which it was derived and validated (176). The
IMI risk calculator is available at www.timi.org. The TIMI
sk index, a modification of the TIMI risk score that uses the
riables age, systolic blood pressure, and heart rate, has not
ly been shown to predict short-term mortality in STEMI
t has also been useful in the prediction of 30-d and 1-year
ortality across the spectrum of patients with ACS, including
A/NSTEMI (177).
The PURSUIT risk model, developed by Boersma et al.
78), based on patients enrolled in the PURSUIT trial, is
other useful tool to guide the clinical decision-making
ocess when the patient is admitted to the hospital. In the
URSUIT risk model, critical clinical features associated
ith an increased 30-d incidence of death and the com-
site of death or myocardial (re)infarction were (in order
ble 8. TIMI Risk Score for Unstable Angina/
on–ST-Elevation MI
TIMI
Risk
core
All-Cause Mortality, New or Recurrent MI, or
Severe Recurrent Ischemia Requiring Urgent
Revascularization Through 14 d After
Randomization, %
0–1 4.7
2 8.3
3 13.2
4 19.9
5 26.2
6–7 40.9
The TIMI risk score is determined by the sum of the presence of 7 variables
admission; 1 point is given for each of the following variables: age 65 y or
der; at least 3 risk factors for CAD; prior coronary stenosis of 50% or more;
-segment deviation on ECG presentation; at least 2 anginal events in prior
h; use of aspirin in prior 7 d; elevated serum cardiac biomarkers. Prior
ronary stenosis of 50% or more remained relatively insensitive to missing
formation and remained significant predictor of events. Reprinted with
rmission from Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score
r unstable angina/non–ST-elevation MI: method for prognostication and
erapeutic decision making. JAMA 2000;284:835–42 (159). Copyright ©
00 American Medical Association.
CAD coronary artery disease; ECG electrocardiogram; MI myocardial
farction; Y  year.strength) age, heart rate, systolic blood pressure, ST-
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78).
The GRACE risk model, which predicts in-hospital mor-
lity (and death or MI), can be useful to clinicians to guide
gure 4. GRACE Prediction Score Card and Nomogram for All-C
on from Eagle KA, Lim MJ, Dabbous OH, et al. A validated predi
k of 6-month postdischarge death in an international registry. JA
ssociation.eatment type and intensity (122,179). The GRACE risk tool Gas developed on the basis of 11,389 patients in GRACE,
lidated in subsequent GRACE and GUSTO IIb cohorts, and
edicts in-hospital death in patients with STEMI, NSTEMI,
UA (C statistic  0.83). The 8 variables used in the
ortality From Discharge to 6 Months. Reprinted with permis-
odel for all forms of acute coronary syndrome: estimating the
04;291:2727–33 (168). Copyright © 2004 American Medicalause M
ction m
MA 20RACE risk model are older age (odds ratio [OR] 1.7 per 10
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R 1.4 per 20 mm Hg decrease), ST-segment deviation (OR
4), cardiac arrest during presentation (OR 4.3), serum
eatinine level (OR 1.2 per 1-mg per dL increase), positive
itial cardiac biomarkers (OR 1.6), and heart rate (OR 1.3
r 30-beat per min increase). The sum of scores is applied
a reference monogram to determine the corresponding
l-cause mortality from hospital discharge to 6 mo. The
RACE clinical application tool can be downloaded to a
ndheld PDA to be used at the bedside and is available at
ww.outcomes-umassmed.org/grace (Figure 4) (179). An
alysis comparing the 3 risk scores (TIMI, GRACE, and
URSUIT) concluded that all 3 demonstrated good predic-
ve accuracy for death and MI at 1 year, thus identifying
tients who might be likely to benefit from aggressive
erapy, including early myocardial revascularization
80).
The ECG provides unique and important diagnostic and
ognostic information (see also Section 2.2.6.1 below).
ccordingly, ECG changes have been incorporated into
antitative decision aids for the triage of patients presenting
ith chest discomfort (181). Although ST elevation carries
e highest early risk of death, ST depression on the present-
g ECG portends the highest risk of death at 6 months, with
e degree of ST depression showing a strong relationship to
tcome (182).
Dynamic risk modeling is a new frontier in modeling that
counts for the common observation that levels and predic-
rs of risk constantly evolve as patients pass through their
sease process. Excellent models have been developed based
presenting features, but information the next day about
inical (e.g., complications), laboratory (e.g., biomarker
olution), and ECG (e.g., ST resolution for STEMI) changes
ovides additional data relevant to decisions at key
ecision-node” points in care (183). Dynamic modeling
ncepts promise more sophisticated, adaptive, and individ-
lly predictive modeling of risk in the future.
Renal impairment has been recognized as an additional
gh-risk feature in patients with ACS (184). Mild to mod-
ate renal dysfunction is associated with moderately in-
eased short- and long-term risks, and severe renal dysfunc-
on is associated with severely increased short- and long-
rm mortality risks. Patients with renal dysfunction
perience increased bleeding risks, have higher rates of HF
d arrhythmias, have been underrepresented in cardiovascu-
r trials, and may not enjoy the same magnitude of benefit
ith some therapies observed in patients with normal renal
nction (185) (see also Section 6.5).
Among patients with UA/NSTEMI, there is a progres-
vely greater benefit from newer, more aggressive therapies
ch as low-molecular-weight heparin (LMWH) (175,186),
atelet GP IIb/IIIa inhibition (187), and an invasive strategy
88) with increasing risk score.
.2.6.1. ELECTROCARDIOGRAM
he ECG is critical not only to add support to the clinical
spicion of CAD but also to provide prognostic information
sed on the pattern and magnitude of the abnormalities
34,181,189,190). A recording made during an episode of (ee presenting symptoms is particularly valuable. Impor-
ntly, transient ST-segment changes (greater than or equal to
05 mV [i.e., 0.5 mm]) that develop during a symptomatic
isode at rest and that resolve when the patient becomes
ymptomatic strongly suggest acute ischemia and a very
gh likelihood of underlying severe CAD. Patients whose
rrent ECG suggests ischemia can be assessed with greater
agnostic accuracy if a prior ECG is available for compari-
n (Table 6) (191).
Although it is imperfect, the 12-lead ECG lies at the center
the decision pathway for the evaluation and management
patients with acute ischemic discomfort (Figure 1, Table
. The diagnosis of MI is confirmed with serial cardiac
omarkers in more than 90% of patients who present with
T-segment elevation of greater than or equal to 1 mm (0.1
V) in at least 2 contiguous leads, and such patients should
considered candidates for acute reperfusion therapy. Pa-
ents who present with ST-segment depression are initially
nsidered to have either UA or NSTEMI; the distinction
tween the 2 diagnoses is ultimately based on the detection
markers of myocardial necrosis in the blood (18,133,192).
Up to 25% of patients with NSTEMI and elevated CK-MB
on to develop Q-wave MI during their hospital stay,
hereas the remaining 75% have non–Q-wave MI. Acute
brinolytic therapy is contraindicated for ACS patients with-
t ST-segment elevation, except for those with electrocar-
ographic true posterior MI manifested as ST-segment de-
ession in 2 contiguous anterior precordial leads and/or
olated ST-segment elevation in posterior chest leads (193–
5). Inverted T waves may also indicate UA/NSTEMI. In
tients suspected of having ACS on clinical grounds,
arked (greater than or equal to 2 mm [0.2 mV]) symmetrical
ecordial T-wave inversion strongly suggests acute isch-
ia, particularly that due to a critical stenosis of the left
terior descending coronary artery (LAD) (196). Patients
ith this ECG finding often exhibit hypokinesis of the
terior wall and are at high risk if given medical treatment
one (197). Revascularization will often reverse both the
-wave inversion and wall-motion disorder (198). Nonspe-
fic ST-segment and T-wave changes, usually defined as
T-segment deviation of less than 0.5 mm (0.05 mV) or
-wave inversion of less than or equal to 2 mm (0.2 mV), are
ss diagnostically helpful than the foregoing findings. Estab-
shed Q waves greater than or equal to 0.04 s are also less
lpful in the diagnosis of UA, although by suggesting prior
I, they do indicate a high likelihood of significant CAD.
olated Q waves in lead III may be a normal finding,
pecially in the absence of repolarization abnormalities in
y of the inferior leads. A completely normal ECG in a
tient with chest pain does not exclude the possibility of
CS, because 1% to 6% of such patients eventually are
oved to have had an MI (by definition, an NSTEMI), and at
ast 4% will be found to have UA (190,199,200).
The common alternative causes of ST-segment and
-wave changes must be considered. In patients with ST-
gment elevation, the diagnoses of LV aneurysm, pericardi-
s, myocarditis, Prinzmetal’s angina, early repolarization
.g., in young black males), apical LV ballooning syndrome
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arkinson-White syndrome represent several examples to be
nsidered. Central nervous system events and drug therapy
ith tricyclic antidepressants or phenothiazines can cause
ep T-wave inversion.
Acute MI due to occlusion of the left circumflex coronary
tery can present with a nondiagnostic 12-lead ECG. Ap-
oximately 4% of acute MI patients show the presence ST
evation isolated to the posterior chest leads V7 through V9
d “hidden” from the standard 12 leads (193,201,202). The
esence of posterior ST elevation is diagnostically impor-
nt because it qualifies the patient for acute reperfusion
erapy as an acute STEMI (8,203). The presence or
sence of ST-segment elevation in the right ventricular
4R through V6R) or posterior chest leads (V7 through
9) also adds prognostic information in the presence of
ferior ST-segment elevation, predicting high and low
tes of in-hospital life-threatening complications, respec-
vely (202).
With reference to electrocardiographic true posterior MI,
w terminology recently has been proposed based on the
andard of cardiac magnetic resonance (CMR) imaging
calization. CMR studies indicate that abnormally increased
waves, the Q-wave equivalent in leads V1 and V2, indicate
MI localized to the lateral LV wall and that abnormal Q
aves in I and VL (but not V6) indicate a mid-anterior wall
I. Thus, the electrocardiographic terms “posterior” and
igh lateral MI” refer to anatomic “lateral wall MI” and
id-anterior wall MI” (204). The impact of these findings
d recommendations for standard electrocardiographic ter-
inology are unresolved as of this writing.
Several investigators have shown that a gradient of risk of
ath and cardiac ischemic events can be established based
the nature of the ECG abnormality (189,205,206). Patients
ith ACS and confounding ECG patterns such as bundle-
anch block, paced rhythm, or LV hypertrophy are at the
ghest risk for death, followed by patients with ST-segment
viation (ST-segment elevation or depression); at the lowest
sk are patients with isolated T-wave inversion or normal
CG patterns. Importantly, the prognostic information con-
ined within the ECG pattern remains an independent pre-
ctor of death even after adjustment for clinical findings and
rdiac biomarker measurements (205–208).
In addition to the presence or absence of ST-segment
viation or T-wave inversion patterns as noted earlier, there
evidence that the magnitude of the ECG abnormality
ovides important prognostic information. Thus, Lloyd-
nes et al. (209) reported that the diagnosis of acute
n–Q-wave MI was 3 to 4 times more likely in patients with
chemic discomfort who had at least 3 ECG leads that
owed ST-segment depression and maximal ST depression
greater than or equal to 0.2 mV. Investigators from the
IMI III Registry (205) reported that the 1-year incidence of
ath or new MI in patients with at least 0.5 mm (0.05 mV)
ST-segment deviation was 16.3% compared with 6.8% for
tients with isolated T-wave changes and 8.2% for patients
ith no ECG changes. NPhysicians frequently seek out a previous ECG for com-
rison in patients with suspected ACS. Studies have dem-
strated that patients with an unchanged ECG have a
duced risk of MI and a very low risk of in-hospital
fe-threatening complications even in the presence of con-
unding ECG patterns such as LV hypertrophy (210–212).
Because a single 12-lead ECG recording provides only a
apshot view of a dynamic process (213), the usefulness of
taining serial ECG tracings or performing continuous
T-segment monitoring has been studied (181,214). Al-
ough serial ECGs increase the ability to diagnose UA and
I (214–218), the yield is higher with serial cardiac bio-
arker measurements (218–220). However, identification of
w injury on serial 12-lead ECG (and not elevated cardiac
omarkers) is the principal eligibility criterion for emer-
ncy reperfusion therapy, so that monitoring of both is
commended. Continuous 12-lead ECG monitoring to detect
T-segment shifts, both symptomatic and asymptomatic, also
n be performed with microprocessor-controlled program-
able devices. An injury current was detected in an addi-
onal 16% of chest pain patients in 1 study (219). The
entification of ischemic ECG changes on serial or contin-
us ECG recordings frequently alters therapy and provides
dependent prognostic information (218,221,222).
.2.6.2. PHYSICAL EXAMINATION
he major objectives of the physical examination are to
entify potential precipitating causes of myocardial isch-
ia, such as uncontrolled hypertension, thyrotoxicosis, or
strointestinal bleeding, and comorbid conditions that could
pact therapeutic risk and decision making, such as pulmo-
ry disease and malignancies, as well as to assess the
modynamic impact of the ischemic event. Every patient
ith suspected ACS should have his or her vital signs
easured (blood pressure in both arms if dissection is
spected, as well as heart rate and temperature) and should
dergo a thorough cardiovascular and chest examination.
atients with evidence of LV dysfunction on examination
ales, S3 gallop) or with acute mitral regurgitation have a
gher likelihood of severe underlying CAD and are at a high
sk of a poor outcome. Just as the history of extracardiac
scular disease is important, the physical examination of the
ripheral vessels can also provide important prognostic
formation. The presence of bruits or pulse deficits that
ggest extracardiac vascular disease identifies patients with
higher likelihood of significant CAD.
Elements of the physical examination can be critical in
aking an important alternative diagnosis in patients with
est pain. In particular, several disorders carry a significant
reat to life and function if not diagnosed acutely. Aortic
ssection is suggested by pain in the back, unequal pulses, or
murmur of aortic regurgitation. Acute pericarditis is sug-
sted by a pericardial friction rub, and cardiac tamponade
n be evidenced by pulsus paradoxus. Pneumothorax is
spected when acute dyspnea, pleuritic chest pain, and
fferential breath sounds are present.
The importance of cardiogenic shock in patients withSTEMI should be emphasized. Although most literature on
ca
em
ge
20
w
cl
(1
of
th
pe
N
2
S
In
an
ex
em
(e
ag
is
sh
ca
sh
ca
m
na
th
st
cr
er
pr
pr
an
th
ch
pe
su
C
su
su
su
is
po
ca
ev
pa
of
ep
pa
A
ha
2
an
C
ad
A
fo
th
m
an
se
in
de
ti
ex
m
an
af
ca
m
ti
pe
pe
ab
a
ex
du
(1
an
in
st
a
S
of
fo
(W
ar
sp
of
ta
ab
w
ad
cr
br
po
M
m
of
bu
sy
ar
ca
pe
bl
fu
st
di
lo
or
fo
so
e204 Anderson et al. JACC Vol. 61, No. 23, 2013
UA/NSTEMI Guideline: 2012 Update Incorporated June 11, 2013:e179–347rdiogenic shock has focused on STEMI, the SHould we
ergently revascularize Occluded Coronaries for cardio-
nic shocK (SHOCK) study (223) found that approximately
% of all cardiogenic shock complicating MI was associated
ith NSTEMI. The Global Use of Strategies to Open Oc-
uded Coronary Arteries (GUSTO)-II (224) and PURSUIT
35) trials found that cardiogenic shock occurs in up to 5%
patients with NSTEMI and that mortality rates are greater
an 60%. Thus, hypotension and evidence of organ hypo-
rfusion can occur and constitute a medical emergency in
STEMI.
.2.7. Noncardiac Causes of Symptoms and
econdary Causes of Myocardial Ischemia
formation from the initial history, physical examination,
d ECG (Table 6) can enable the physician to classify and
clude from further assessment patients “not having isch-
ic discomfort.” This includes patients with noncardiac pain
.g., pulmonary embolism, musculoskeletal pain, or esoph-
eal discomfort) or cardiac pain not caused by myocardial
chemia (e.g., acute pericarditis). The remaining patients
ould undergo a more complete evaluation of the secondary
uses of UA that might alter management. This evaluation
ould include a physical examination for evidence of other
rdiac disease, an ECG to screen for arrhythmias, measure-
ent of body temperature and blood pressure, and determi-
tion of hemoglobin or hematocrit. Cardiac disorders other
an CAD that can cause myocardial ischemia include aortic
enosis and hypertrophic cardiomyopathy. Factors that in-
ease myocardial oxygen demand or decrease oxygen deliv-
y to the heart can provoke or exacerbate ischemia in the
esence of significant underlying CAD or secondary angina;
eviously unrecognized gastrointestinal bleeding that causes
emia is a common secondary cause of worsening angina or
e development of symptoms of ACS. Acute worsening of
ronic obstructive pulmonary disease (with or without su-
rimposed infection) can lower oxygen saturation levels
fficiently to intensify ischemic symptoms in patients with
AD. Evidence of increased cardiac oxygen demand can be
spected in the presence of fever, signs of hyperthyroidism,
stained tachyarrhythmias, or markedly elevated blood pres-
re. Another cause of increased myocardial oxygen demand
arteriovenous fistula in patients receiving dialysis.
The majority of patients seen in the ED with symptoms of
ssible ACS will be judged after their workup not to have a
rdiac problem. One clinical trial of a predictive instrument
aluated 10,689 patients with suspected ACS (81). To
rticipate, patients were required to be greater than 30 years
age with a chief symptom of chest, left arm, jaw, or
igastric pain or discomfort; shortness of breath; dizziness;
lpitations; or other symptoms suggestive of acute ischemia.
fter evaluation, 7,996 patients (75%) were deemed not to
ve acute ischemia.
.2.8. Cardiac Biomarkers of Necrosis
d the Redefinition of AMI
ardiac biomarkers have proliferated over recent years to
dress various facets of the complex pathophysiology of
CS. Some, like the cardiac troponins, have become essential
r risk stratification of patients with UA/NSTEMI and for Ee diagnosis of MI. Others, such as the inflammatory
arkers, are opening new perspectives on pathophysiology
d risk stratification, and the use in clinical practice of
lected new markers may be recommended for clinical use
the near future. Still other promising markers are being
veloped as part of translational research and await prospec-
ve validation in various populations. New developments are
pected in the fields of proteomic and genomics, cell
arkers and circulating microparticles, and microtechnology
d nanotechnology imaging.
Current markers of necrosis leak from cardiomyocytes
ter the loss of membrane integrity and diffuse into the
rdiac interstitium, then into the lymphatics and cardiac
icrovasculature. Eventually, these macromolecules, collec-
vely referred to as cardiac biomarkers, are detectable in the
ripheral circulation. Features that favor their diagnostic
rformance are high concentrations in the myocardium and
sence in nonmyocardial tissue, release into the blood within
convenient diagnostic time window and in proportion to the
tent of myocardial injury, and quantification with repro-
cible, inexpensive, and rapid and easily applied assays
8). The cardiac troponins possess many of these features
d have gained wide acceptance as the biomarkers of choice
the evaluation of patients with ACS for diagnosis, risk
ratification, and treatment selection.
The traditional definitions of MI were revisited in 2000 in
consensus document of a joint committee of the European
ociety of Cardiology (ESC) and ACC (225) and at the time
publication is being updated by an expanded joint task
rce of the ESC, ACC, AHA, World Heart Federation
HF), and World Health Organization. The new definitions
e inspired by the emergence of new highly sensitive and
ecific diagnostic methods that allow the detection of areas
cell necrosis as small as 1 g. Myocardial necrosis in the
sk force document is defined by an elevation of troponin
ove the 99th percentile of normal. Myocardial infarction,
hich is necrosis related to ischemia, is further defined by the
dition to the troponin elevation of at least 1 of the following
iteria: ischemic ST and T-wave changes, new left bundle-
anch block, new Q waves, PCI-related marker elevation, or
sitive imaging for a new loss of viable myocardium.
yocardial infarction can still be diagnosed in the absence of
easurement of troponin when there is evidence of a new loss
viable myocardium, ST-segment elevation, or new left
ndle-branch block with sudden cardiac death within 1 h of
mptoms, or a postmortem pathological diagnosis. Coronary
tery bypass graft-related MI is diagnosed by an increase of
rdiac biomarkers to more than 5- to 10-fold the 99th
rcentile of normal, new Q waves or new left bundle-branch
ock on the ECG, or a positive imaging test. The task force
rther recommended further defining MI by the circum-
ances that cause it (spontaneous or in the setting of a
agnostic or therapeutic procedure), by the amount of cell
ss (infarct size), and by the timing of MI (evolving, healing,
healed) (225,226). Providing fold-elevations above normal
r diagnostic biomarkers, to allow for meaningful compari-
ns among clinical trials, is also endorsed.
At the present time, the implications of using the newSC/ACC redefinition of MI have not been fully explored;
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June 11, 2013:e179–347 UA/NSTEMI Guideline: 2012 Update Incorporateduch of the present database for UA/NSTEMI derives from
K/CK-MB–based definitions of MI. Moreover, troponin
says have rapidly evolved through several generations over
e past decade, becoming increasingly more sensitive and
ecific. Thus, it is important to recognize that the recom-
endations in this section are formulated from studies that
equently utilize modified World Health Organization crite-
a or definitions of MI based on earlier-generation troponin
says.
.2.8.1. CREATINE KINASE-MB
reatine kinase-MB, a cytosolic carrier protein for high-
ergy phosphates, has long been the standard marker for the
agnosis of MI. Creatine kinase-MB, however, is less
nsitive and less specific for MI than the cardiac troponins.
ow levels of CK-MB can be found in the blood of healthy
rsons, and elevated levels occur with damage to skeletal
uscle (227).
When a cardiac troponin is available, the determination of
K-MB remains useful in a few specific clinical situations.
ne is the diagnosis of early infarct extension (reinfarction),
cause the short half-life of CK-MB compared with troponin
rmits the detection of a diagnostic new increase after initial
ak. Although routine determination of CK-MB has been
ggested for the diagnosis of an eventual infarct extension, a
ngle CK-MB determination obtained when symptoms recur
ay serve as the baseline value for comparison with samples
tained 6 to 12 h later. Another situation is the diagnosis of
periprocedural MI, because the diagnostic and prognostic
lue of CK-MB in these situations has been extensively
lidated. When assessed, CK-MB should be measured by
ass immunoassays and not by other methods previously
ed (228). The use of other, older biochemistry assays of
nspecific markers such as alanine transaminase, aspartate
ansaminase, and lactate dehydrogenase should generally be
oided in contemporary practice.
.2.8.2. CARDIAC TROPONINS
he troponin complex consists of 3 subunits: T (TnT), I
nI), and C (TnC) (229). The latter is expressed by both
rdiac and skeletal muscle, whereas TnT and TnI are derived
om heart-specific genes. Therefore, the term “cardiac tro-
nins” (cTn) in these guidelines refers specifically to either
nT or cTnI. Cardiac troponin as a biomarker provides
bust results that are highly sensitive and specific in detect-
g cell necrosis; an early release is attributable to a cytosolic
ol and a late release to the structural pool (225,230).
Because cTnT and cTnI generally are not detected in the
ood of healthy persons, the cutoff value for elevated cTnT
d cTnI levels may be set to slightly above the upper limit
the performance characteristics of the assay for a normal
althy population. High-quality analytic methods are needed
achieve these high standards (231). One issue with the use
cTnI is the multiplicity of existing assays that have
fferent analytical sensitivities, some being unable to detect
e lower values with a reasonable precision (232). Physi-
ans therefore need to know the sensitivity of the tests used
r TnI in their hospitals at the cutoff concentrations used for
inical decisions. Such heterogeneity does not exist for abnT, which exists as a single test; this test is now a
ird-generation immunoassay that uses recombinant mono-
onal human antibodies (230). Rare patients may have
ocking antibodies to part of the troponin molecule, which
ould result in false-negative results (233).
.2.8.2.1. Clinical Use. Although troponins can be de-
cted in blood as early as 2 to 4 h after the onset of
mptoms, elevation can be delayed for up to 8 to 12 h. This
ming of elevation is similar to that of CK-MB but persists
nger, for up to 5 to 14 d (Figure 5). An increasing pattern
serial levels best helps determine whether the event is
ute, distinct from a previous event, subacute, or chronic.
The proportion of patients showing a positive cTn value
pends on the population of patients under evaluation.
pproximately 30% of patients with typical rest chest dis-
mfort without ST-segment elevation who would be diag-
sed as having UA because of a lack of CK-MB elevation
tually have NSTEMI when assessed with cardiac-specific
oponin assays. The diagnosis of MI in the community at
rge when cTn is used results in a large increase in the
cidence of MIs, by as much as 41% compared with use of
ly CK-MB alone, and a change in the case mix, with a
rvival rate that is better than that of MI identified by the
evious criteria (234). Troponin elevation conveys prognos-
c information beyond that supplied by the clinical charac-
ristics of the patient, the ECG at presentation, and the
edischarge exercise test (206,207,235–237). Furthermore, a
antitative relationship exists between the amount of eleva-
on of cTn and the risk of death (206,207) (Figure 6). The
cremental risk of death or MI in troponin-positive versus
oponin-negative patients is summarized in (Table 9). It
ould be cautioned, however, that cTn should not be used as the
le marker of risk, because patients without troponin elevations can
ill have a substantial risk of an adverse outcome.
Although cTn accurately identifies myocardial necrosis, it
es not inform as to the cause or causes of necrosis; these can
multiple (230) and include noncoronary causes such as
chyarrhythmia, cardiac trauma by interventions, chest trauma
om motor vehicle accidents, HF, LV hypertrophy, myocarditis,
d pericarditis, as well as severe noncardiac conditions such as
psis, burns, respiratory failure, acute neurological diseases,
lmonary embolism, pulmonary hypertension, drug toxicity,
ncer chemotherapy, and renal insufficiency (236). Therefore, in
aking the diagnosis of NSTEMI, cTns should be used in conjunc-
n with other criteria of MI, including characteristics of the
chemic symptoms and the ECG.
In all of these situations, equivalent information is gener-
ly obtained with cTnI and cTnT, except in patients with
nal dysfunction, in whom cTnI assessment appears to have
specific role (233). Among patients with end-stage renal
sease and no clinical evidence of acute myocardial
crosis, 15% to 53% show increased cTnT, but fewer than
% have increased cTnI; dialysis generally increases
nT but decreases cTnI. The exact reasons for the high
tes of elevation in the cTn, especially cTnT, in renal
ilure are not clear; they can relate to cardiac damage,
fferential clearance, or to other biochemical or metabolic
normalities (233). Whatever the reasons and the sources,
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UA/NSTEMI Guideline: 2012 Update Incorporated June 11, 2013:e179–347elevation of cTn, including cTnT, in patients with renal
sufficiency is associated with a higher risk of morbidity
gardless of the presence of cardiac symptoms or docu-
ented CAD. Among 7,033 patients enrolled in the
USTO IV trial with suspected ACS, TnT level was
dependently predictive of risk across the entire spectrum
renal function enrolled (239).
Aggressive preventive measures for patients with renal
sufficiency have been suggested, because most deaths in
nal failure are of cardiac origin (233). Unfortunately, some
andard therapies, such as lipid lowering with statins or PCI,
ve been less effective in improving survival in certain
tient populations with advanced renal insufficiency
40,241). Furthermore, patients with suspected UA/
STEMI have particularly unfavorable outcomes when in
nal failure, with an event rate that correlates with the
crease in creatinine clearance (242–245). A sequential
ange in cTn levels in the first 24 h of observation for a
spected ACS supports new myocardial injury, whereas
changing levels are more consistent with a chronic disease
ate without ACS.
Troponin elevation has important therapeutic implications.
permits the identification of high-risk patients and of
gure 5. Timing of Release of Various Biomarkers After Acute
yocardial Infarction. The biomarkers are plotted showing the
ultiples of the cutoff for acute myocardial infarction (AMI) over
e. The dashed horizontal line shows the upper limit of normal
LN; defined as the 99th percentile from a normal reference
pulation without myocardial necrosis; the coefficient of varia-
n of the assay should be 10% or less). The earliest rising bio-
arkers are myoglobin and CK isoforms (leftmost curve). CKMB
ashed curve) rises to a peak of 2 to 5 times the ULN and typi-
lly returns to the normal range within 2 to 3 d after AMI. The
rdiac-specific troponins show small elevations above the ULN
small infarctions (e.g., as is often the case with NSTEMI) but
e to 20 to 50 times the ULN in the setting of large infarctions
.g., as is typically the case in STEMI). The troponin levels may
ay elevated above the ULN for 7 d or more after AMI. Modi-
d from Shapiro BP, Jaffe AS. Cardiac biomarkers. In: Murphy
, Lloyd MA, editors. Mayo Clinic Cardiology: Concise Text-
ok. 3rd ed. Rochester, MN: Mayo Clinic Scientific Press and
ew York: Informa Healthcare USA, 2007:773–80 (70). Used
ith permission of Mayo Foundation for Medical Education and
esearch. CK  creatine kinase; CKMB  MB fraction of crea-
e kinase; CV  coefficient of variation; MI  myocardial in-
rction; NSTEMI  non–ST-elevation myocardial infarction; UA/
STEMI  unstable angina/non–ST-elevation myocardial
farction.bsets of patients who will benefit from specific therapies. 19hus, among patients with UA/NSTEMI, those with elevated
n benefit from treatment with platelet GP IIb/IIIa inhibi-
rs, whereas those without such elevation may not benefit or
ay even experience a deleterious effect. For example, in the
E3 Fab Antiplatelet Therapy in Unstable Refractory An-
na (CAPTURE) trial, the rates of death or nonfatal MI with
nT elevation were 23.9% with placebo versus 9.5% with
ciximab (p0.002) (246). Similar results have been re-
rted for cTnI and cTnT with use of tirofiban (247). The
nefit of LMWH was also greater in UA/NSTEMI patients
ith positive cTn. In the Fragmin during Instability in
oronary Artery Disease (FRISC) trial, the rates of death or
nfatal MI through 40 d increased progressively in the
acebo group from 5.7% in the lowest tertile to 12.6% and
.7% in the second and third tertiles, respectively, compared
ith rates of 4.7%, 5.7%, and 8.9%, respectively, in the
lteparin group, which represents risk reductions in events
increasing tertiles of 17.5%, 43%, and 55% 248. Similar
fferential benefits were observed with enoxaparin versus
fractionated heparin (UFH) in the ESSENCE trial (175).
y contrast and of interest, patients with UA/NSTEMI but
ithout elevated cTnT in the Clopidogrel in Unstable
gina to prevent Recurrent ischemic Events (CURE) trial
nefited as much from clopidogrel, a platelet P2Y12
enosine diphosphate (ADP) receptor inhibitor, as pa-
ents with elevated levels (249). The placebo-controlled
tracoronary Stenting and Antithrombotic Regimen–
apid Early Action for Coronary Treatment (ISAR-
EACT)-2 trial compared triple-antiplatelet therapy with
SA, clopidogrel, and abciximab to double therapy with
SA and clopidogrel in patients with UA/NSTEMI under-
ing PCI; 52% of patients were troponin positive, and
% were troponin negative. The 30-d event rates were
gure 6. Troponin I Levels to Predict the Risk of Mortality in
cute Coronary Syndromes. Mortality rates are at 42 d (without
justment for baseline characteristics) in patients with acute
ronary syndrome. The numbers at the bottom of each bar are
e numbers of patients with cardiac troponin I levels in each
nge, and the numbers above the bars are percentages.
0.001 for the increase in the mortality rate (and the risk ratio
r mortality) with increasing levels of cardiac troponin I at en-
llment. Reprinted with permission from Antman EM, Tanasi-
vic MJ, Thompson B, et al. Cardiac-specific troponin I levels
predict the risk of mortality in patients with acute coronary
ndromes. N Engl J Med 1996;335:1342–9 (201). Copyright ©
96 Massachusetts Medical Society. All rights reserved.
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June 11, 2013:e179–347 UA/NSTEMI Guideline: 2012 Update Incorporatedmilar at 4.6% in patients with normal cTnT levels but
ere reduced by close to 30% with the triple therapy
3.1% vs 18.3%) in patients with elevated levels (250).
he reasons for the differential benefit could pertain to a
nefit that does not emerge in the low-risk patient, or that
overshadowed by complications related to treatment.
Such also appears to be the case with the GP IIb/IIIa
tagonists and with an invasive management strategy that
cludes application of interventional procedures. Indeed, in 2
ials that compared an early routine invasive strategy to a
utine noninvasive strategy, the FRISC-II and Treat Angina
ith Aggrastat and determine Cost of Therapy with Invasive
Conservative Strategy (TACTICS) TIMI-18 trials, patients
ho profited from the early invasive treatment strategy were
ose at high risk as determined by cTnT levels and the
mission ECG. In the FRISC study, the invasive strategy
duced the 12-month risk of death or MI by 40% (13.2% vs
.1%, p0.001) in the cohort with both ST depression and
cTnT level of 0.03 mcg per liter or greater, but the absolute
in of the invasive strategy was insignificant in the cohorts
ith either ST depression, cTnT level elevation, or neither of
ese findings (251). In the TACTICS TIMI-28 study, sub-
oups of patients with no ECG changes, a low TIMI score,
d no cTn elevation showed no benefit from the invasive
rategy, whereas those with positive cTn, independent of the
esence of elevated CK-MB levels, showed markedly re-
ced odds of adverse clinical events of 0.13 at 30 d (95%
nfidence interval [CI]  0.04 to 0.39) and 0.29 at 180 d
5% CI  0.16 to 0.52) (252).
.2.8.2.1.1. Clinical Use of Marker Change Scores. A newer
ethod to both identify and exclude MI within 6 h of
mptoms is to rely on changes in serum marker levels
elta values) over an abbreviated time interval (e.g., 2 h)
ble 9. Risk of Death Associated With a Positive Troponin Test
Events/Total
Subgroup Negative Troponin Positive Tr
T
Total death 32/1,187 46/473
Cardiac death 31/1,689 52/744
UA patients* 21/397 26/198
Chest pain patients* 43/2,479 73/1,0
I
Total death 34/1,451 49/815
Cardiac death 3/905 26/384
UA patients* 2/70 2/22
Chest pain patients* 35/2,286 73/1,1
T and TnI combined†
Total death 42/2,088 69/1,0
Cardiac death 28/1,641 55/792
*Outcomes of cardiac death and total death are pooled.
†Some studies provided both troponin T (TnT) and I (TnI) data. For the combi
m Heidenreich PA, Go A, Melsop KA, et al. Prediction of risk for patients with
SF-Stanford Evidence-Based Practice Center under contract no. 290-97-0013
ality, December 2000. Available at: http://www.ncbi.nlm.nih.gov/books/bv.fcg
ACS  4 acute coronary syndrome; CI  confidence interval; RR  relativeopposed to the traditional approach of performing serial measurements over 6 to 8 h (218,220,253–256). Because
says are becoming more sensitive and precise, this
ethod permits the identification of increasing values
hile they are still in the normal or indeterminate range of
e assay. By relying on delta values for the identification
exclusion of MI, higher-risk patients with positive delta
lues can be selected earlier for more aggressive anti-
chemic therapy (e.g., GP IIb/IIIa inhibitors), and lower-
sk patients with negative delta values can be considered
r early stress testing (218,220,255–257). One study of
042 patients found the addition of a 3-h delta CK-MB to
sult in a sensitivity of 93% and a specificity of 94% for
I (254). In another study of 2074 consecutive ED chest
ain patients, a 2-h delta CK-MB in conjunction with a
-h delta troponin I measurement had a sensitivity for
ute MI of 93% and specificity of 94% in patients whose
itial ECG was nondiagnostic for injury. When com-
ined with physician judgment and selective nuclear stress
sting, the sensitivity for MI was 100% with specificity of
2%, and the sensitivity for 30-d ACS was 99.1% with
ecificity of 87% (220). Because there are no
anufacturer-recommended delta cutoff values, the ap-
ropriate delta values for identification and exclusion of
I should take into account the sensitivity and precision
the specific assay utilized and should be confirmed by
-house studies. It also is important for delta values to be
easured on the same instrument owing to subtle varia-
ons in calibration among individual instruments, even of
e same model.
Another method to exclude MI within 6 h of symptom
set is the multimarker approach, which utilizes the serial
ients With Suspected ACS
Summary RR 95% CI No. of Studies
3.1 2.0 to 4.9 5
3.8 2.4 to 6.0 7
2.5 1.4 to 4.5 5
4.0 2.7 to 5.9 7
3.1 2.0 to 4.9 3
25.0 11 to 55 2
3.2 0.3 to 40 1
5.1 3.4 to 7.6 4
3.3 2.2 to 4.8 7
5.0 3.2 to 7.9 7
lysis, data from 1 marker were chosen randomly. Reprinted with permission
le angina. Evidence Report/Technology Assessment No. 31 (prepared by the
publication no. 01-E001. Rockville, MD: Agency for Healthcare Research and
tat1.chapter.45627. Accessed August 10, 2006 (232).
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UA/NSTEMI Guideline: 2012 Update Incorporated June 11, 2013:e179–347mbination with the serial measurements of cTn and/or
K-MB (i.e., a later marker) (258–262). Studies have
ported that multimarker measurements at baseline and
0 min have a sensitivity for MI of approximately 95%
ith a high negative predictive value, thus allowing for the
rly exclusion of MI when combined with clinical judg-
ent (260,261). However, because of the low specificity of
e multimarker strategy (mainly due to the lower speci-
city of myoglobin), a positive multimarker test is inade-
uate to diagnose MI and requires confirmation with a
ter-appearing definitive marker (260,263).
.2.8.2.1.2. Bedside Testing for Cardiac Markers. Cardiac
arkers can be measured in the central chemistry labora-
ry or with point-of-care instruments in the ED with
esktop devices or handheld bedside rapid qualitative
says (235). When a central laboratory is used, results
ould be available as soon as possible, with a goal of
ithin 60 min. Point-of-care systems, if implemented at
e bedside, have the advantage of reducing delays due to
ansportation and processing in a central laboratory and
n eliminate delays due to the lack of availability of
ntral laboratory assays at all hours. Certain portable
evices can simultaneously measure myoglobin, CK-MB,
d troponin I (255). These advantages of point-of-care
stems must be weighed against the need for stringent
uality control and appropriate training of ED personnel
assay performance and the higher costs of point-of-care
sting devices relative to determinations in the central
boratory. In addition, these point-of-care assays at pres-
t are qualitative or, at best, semiquantitative. To date,
edside testing has not succeeded in becoming widely
cepted or applied.
.2.8.3. MYOGLOBIN AND CK-MB SUBFORMS
OMPARED WITH TROPONINS
yoglobin, a low-molecular-weight heme protein found in
th cardiac and skeletal muscle, is not cardiac specific, but
is released more rapidly from infarcted myocardium than
e CK-MB and cTn and can be detected as early as 2 h after
e onset of myocardial necrosis. However, the clinical value
serial determinations of myoglobin for the diagnosis of MI
limited by its brief duration of elevation of less than 24 h.
hus, an isolated early elevation in patients with a nondiag-
stic ECG should not be relied on to make the diagnosis of
I but should be supplemented by a more cardiac-specific
arker (264). Creatine kinase-MB subforms are also efficient
r the early diagnosis of MI and have a similar specificity to
at of CK-MB but require special expertise, with no real
vantage over better standardized and more easily applied
n testing.
.2.8.4. SUMMARY COMPARISON OF BIOMARKERS OF
ECROSIS: SINGLY AND IN COMBINATION
able 10 compares the advantages and disadvantages of
rdiac biomarkers of necrosis that are currently used for the
aluation and management of patients with suspected ACS but
ithout ST-segment elevation on the 12-lead ECG. Given the
erlapping time frame of the release pattern of cardiac bio- duarkers, it is important that clinicians incorporate the time from
e onset of the patient’s symptoms into their assessment of the
sults of biomarker measurements (18,258,265,266) (Figure 5).
Many patients with suspected ACS have combined assess-
ents of troponin and CK-MB. When baseline troponin and
K-MB were used together for diagnostic and risk assess-
ent across the spectrum of chest pain syndromes in a large
tabase that consisted of several clinical trials, those with
sitive results for both markers were at highest short-term
4 h and 30 d) risk of death or MI (267). However, those
ith baseline troponin elevation without CK-MB elevation
so were at increased 30-d risk, whereas risk with isolated
K-MB elevation was lower and not significantly different
an if both markers were negative (267).
In summary, the cTns are currently the markers of choice
r the diagnosis of MI. They have a sensitivity and speci-
city as yet unsurpassed, which allows for the recognition of
ry small amounts of myocardial necrosis. These small areas
infarction are the consequence of severe ischemia and/or
stal microembolization of debris from an unstable throm-
genic plaque. The unstable plaques are likely responsible for
e high-risk situation. Thus, cTns as biomarkers are not only
arkers of cell necrosis but also of an active thrombogenic
aque, and hence, they indicate prognosis and are useful in
iding therapies. Although not quite as sensitive or specific as
e cTns, CK-MB by mass assay is a second-choice marker that
mains useful for the diagnosis of MI extension and of peripro-
dural MI. Routine use of myoglobin and other markers is not
nerally recommended.
Because many methods exist, many with multiple test
nerations, for cardiac biomarker testing in practice and in
blished reports, physicians should work with their clinical
boratories to ensure use of and familiarity with contempo-
ry test technology, with appropriate, accurate ranges of
rmal and diagnostic cutoffs, specific to the assay used.
.2.9. Other Markers and Multimarker Approaches
esides markers of myocardial necrosis, markers of patho-
ysiological mechanisms implicated in ACS are under
vestigation and could become useful to determine patho-
ysiology, individualize treatment, and evaluate therapeutic
fects. In considering the clinical application of new bio-
arkers, it is important to determine that they provide
cremental value over existing biomarkers. A multimarker
proach to risk stratification of UA/NSTEMI (e.g., simulta-
ous assessment of cTnI, C-reactive protein [CRP], and
NP) has been advocated as a potential advance over single
o-marker assessment (268,269). Further evaluation of a
ultimarker approach will be of interest.
.2.9.1. ISCHEMIA
ther new biochemical markers for the detection of myocar-
al necrosis are either less useful or have been less well
udied than those mentioned above. An example is ischemia-
odified albumin found soon after transient coronary occlu-
on and preceding any significant elevations in myoglobin,
K-MB, or cTnI. This modified albumin depends on a
duced capacity of human albumin to bind exogenous cobalt
ring ischemia (270,271). Choline is released upon the cleav-
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chemia. Growth-differentiation factor-15 (GDF-15), a member
the transforming growth factor- cytokine superfamily that is
duced after ischemia-and-reperfusion injury, is a new bio-
arker that has been reported to be of incremental prognostic
lue for death in patients with UA/NSTEMI (272).
.2.9.2. COAGULATION
arkers of activity of the coagulation cascade, including
evated plasma levels of fibrinogen, the prothrombin frag-
ents, fibrinopeptide, and d-dimers, are elevated in ACS but
ve little discriminative ability for a specific pathophysiol-
y, diagnosis, or treatment assessments (273,274). In exper-
ental studies, markers of thrombin generation are blocked
anticoagulants but reactivate after their discontinuation
75) and are not affected by clopidogrel (276).
.2.9.3. PLATELETS
latelet activation currently is difficult to assess directly in vivo.
ew methods, however, are emerging that should allow a better
d more efficient appraisal of their state of activation and of
ble 10. Biochemical Cardiac Markers for the Evaluation and M
-Segment Elevation on 12-Lead ECG
Marker Advantages Disadvantages
rdiac
troponins
1. Powerful tool for risk
stratification
2. Greater sensitivity and
specificity than CK-MB
3. Detection of recent MI
up to 2 weeks after
onset
4. Useful for selection of
therapy
5. Detection of
reperfusion
1. Low sensitivity in very early
phase of MI (less than 6 h
after symptom onset) and
requires repeat
measurement at 8 to 12 h,
if negative
2. Limited ability to detect
late minor reinfarction
-MB 1. Rapid, cost-efficient,
accurate assays
2. Ability to detect early
reinfarction
1. Loss of specificity in
setting of skeletal muscle
disease or injury, including
surgery
2. Low sensitivity during very
early MI (less than 6 h
after symptom onset) or
later after symptom onset
(more than 36 h) and for
minor myocardial damage
(detectable with troponins)
yoglobin 1. High sensitivity
2. Useful in early
detection of MI
3. Detection of
reperfusion
4. Most useful in ruling
out MI
1. Very low specificity in
setting of skeletal muscle
injury or disease
2. Rapid return to normal
range limits sensitivity for
later presentations
ACS  acute coronary syndrome; CK-MB  MB fraction of creatine kinas
n–ST-elevation MI.ug effects (277–279). Alternative markers of platelet activity cee also being studied, including CD40L, platelet-neutro-phil coag-
egates, P-selectin, and platelet microparticles.
.2.9.4. INFLAMMATION
ystemic markers of inflammation are being widely studied
d show promise for providing additional insights into
tho-physiological mechanisms proximal to and triggering
rombosis, as well as suggesting novel therapeutic ap-
oaches. White blood cell counts are elevated in patients
ith MI, and this elevation has prognostic implications.
atients without biochemical evidence of myocardial ne-
osis but who have elevated CRP levels on admission or
st the acute-phase reaction after 1 month and who have
lues in the highest quartile are at an increased risk of
adverse outcome (280 –282). Elevated levels of
terleukin-6, which promotes the synthesis of CRP, and
other proinflammatory cytokines also have been studied
r their prognostic value (283). Other potentially useful
arkers are levels of circulating soluble adhesion mole-
les, such as intercellular adhesion molecule-1, vascular
ment of Patients With Suspected ACS But Without
t of Care
Available? Comment Clinical Recommendation
Yes Data on diagnostic
performance and potential
therapeutic implications
increasingly available from
clinical trials
Useful as a single test to
efficiently diagnose
NSTEMI (including
minor myocardial
damage), with serial
measurements.
Clinicians should
familiarize themselves
with diagnostic
“cutoffs” used in their
local hospital
laboratory
Yes Familiar to majority of
clinicians
Prior standard and still
acceptable diagnostic
test in most clinical
circumstances
Yes More convenient early marker
than CK-MB
isoformsbecause of
greateravailability of assays
for myoglobin; rapid-
release kinetics make
myoglobin useful for
noninvasive monitoring of
reperfusion in patients with
established MI
 electrocardiogram; h  hours; MI  myocardial infarction; NSTEMI anage
Poin
Test
e; ECGll adhesion molecule-1, and E-selectin (284); the preg-
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nding matrix metalloproteinase released with neorevas-
larization and believed to be a marker of incipient
laque rupture (285); myeloperoxidase, a leukocyte-
rived protein that generates reactive oxidant species that
ntribute to tissue damage, inflammation, and immune
ocesses within atherosclerotic lesions (286); and others.
t this writing, none of these have been adequately studied
validated to be recommended for routine clinical appli-
tion in UA/NSTEMI.
.2.9.5. B-TYPE NATRIURETIC PEPTIDES
ne newer biomarker of considerable interest that now may
considered in the guidelines recommendations is BNP.
-type natriuretic peptide is a cardiac neurohormone released
on ventricular myocyte stretch as proBNP, which is enzymat-
ally cleaved to the N-terminal proBNP (NT-proBNP) and,
bsequently, to BNP. The usefulness of assessing this neuro-
rmone was first shown for the diagnosis and evaluation of HF.
ince then, numerous prospective studies and data from large
ta sets have documented its powerful prognostic value inde-
ndent of conventional risk factors for mortality in patients with
able and unstable CAD (269,287–291). A review of available
udies in ACS showed that when measured at first patient
ntact or during the hospital stay, the natriuretic peptides are
rong predictors of both short- and long-term mortality in
tients with STEMI and UA/NSTEMI (287). Increasing levels
NT-proBNP are associated with proportionally higher short-
d long-term mortality rates; at 1 year, mortality rates with
creasing quartiles were 1.8%, 3.9%, 7.7%, and 19.2%, respec-
ely (p0.001) in the GUSTO-IV trial of 6,809 patients (291).
his prognostic value was independent of a previous history of
F and of clinical or laboratory signs of LV dysfunction on
mission or during hospital stay (287) B-type natriuretic pep-
e and NT-proBNP levels can now be measured easily and
pidly in most hospital laboratories.
.3. Immediate Management
ecommendations
ASS I
The history, physical examination, 12-lead ECG, and initial car-
diac biomarker tests should be integrated to assign patients with
chest pain into 1 of 4 categories: a noncardiac diagnosis, chronic
stable angina, possible ACS, and definite ACS. (Level of Evidence: C)
Patients with probable or possible ACS but whose initial
12-lead ECG and cardiac biomarker levels are normal should be
observed in a facility with cardiac monitoring (e.g., chest pain
unit or hospital telemetry ward), and repeat ECG (or continuous
12-lead ECG monitoring) and repeat cardiac biomarker mea-
surement(s) should be obtained at predetermined, specified
time intervals (see Section 2.2.8). (Level of Evidence: B)
In patients with suspected ACS in whom ischemic heart
disease is present or suspected, if the follow-up 12-lead ECG
and cardiac biomarkers measurements are normal, a stress
test (exercise or pharmacological) to provoke ischemia should
be performed in the ED, in a chest pain unit, or on an outpatient
basis in a timely fashion (within 72 h) as an alternative to toinpatient admission. Low-risk patients with a negative diagnos-
tic test can be managed as outpatients. (Level of Evidence: C)
In low-risk patients who are referred for outpatient stress
testing (see above), precautionary appropriate pharmacother-
apy (e.g., ASA, sublingual NTG, and/or beta blockers) should
be given while awaiting results of the stress test. (Level of
Evidence: C)
Patients with definite ACS and ongoing ischemic symptoms,
positive cardiac biomarkers, new ST-segment deviations, new
deep T-wave inversions, hemodynamic abnormalities, or a
positive stress test should be admitted to the hospital for
further management. Admission to the critical care unit is
recommended for those with active, ongoing ischemia/injury
or hemodynamic or electrical instability. Otherwise, a teleme-
try step-down unit is reasonable. (Level of Evidence: C)
Patients with possible ACS and negative cardiac bio-markers
who are unable to exercise or who have an abnormal resting
ECG should undergo a pharmacological stress test. (Level of
Evidence: B)
Patients with definite ACS and ST-segment elevation in leads
V7 to V9 due to left circumflex occlusion should be evaluated
for immediate reperfusion therapy. (Level of Evidence: A)
Patients discharged from the ED or chest pain unit should be
given specific instructions for activity, medications, additional
testing, and follow-up with a personal physician. (Level of
Evidence: C)
ASS IIa
In patients with suspected ACS with a low or intermediate
probability of CAD, in whom the follow-up 12-lead ECG and
cardiac biomarkers measurements are normal, performance of
a noninvasive coronary imaging test (i.e., CCTA) is reasonable
as an alternative to stress testing. (Level of Evidence: B)
By integrating information from the history, physical
amination, 12-lead ECG, and initial cardiac biomarker
sts, clinicians can assign patients to 1 of 4 categories:
ncardiac diagnosis, chronic stable angina, possible ACS,
d definite ACS (Figure 2).
Patients who arrive at a medical facility in a pain-free state,
ve unchanged or normal ECGs, are hemodynamically stable,
d do not have elevated cardiac biomarkers represent more of
diagnostic than an urgent therapeutic challenge. Evaluation
gins in these patients by obtaining information from the
story, physical examination, and ECG (Tables 6 and 7) to be
ed to confirm or reject the diagnosis of UA/NSTEMI.
Patients with a low likelihood of CAD should be evaluated for
her causes of the noncardiac presentation, including musculo-
eletal pain; gastrointestinal disorders, such as esophageal
asm, gastritis, peptic ulcer disease, or cholecystitis; intratho-
cic disease, such as musculoskeletal discomfort, pneumonia,
eurisy, pneumothorax, pulmonary embolus, dissecting aortic
eurysm, myocarditis, or pericarditis; and neuropsychiatric
sease, such as hyperventilation or panic disorder (Figure 2,
1). Patients who are found to have evidence of 1 of these
ternative diagnoses should be excluded from management with
ese guidelines and referred for appropriate follow-up care
igure 2, C1). Reassurance should be balanced with instructions
return for further evaluation if symptoms worsen or if the
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gina may also be diagnosed in this setting (Figure 2, B2), and
tients with this diagnosis should be managed according to the
CC/AHA 2002 Guideline Update for the Management of
atients With Chronic Stable Angina (11).
Patients with possible ACS (Figure 2, B3 and D1) are
ndidates for additional observation in a specialized facility
.g., chest pain unit) (Figure 2, E1). Patients with definite
CS (Figure 2, B4) are triaged on the basis of the pattern of
e 12-lead ECG. Patients with ST-segment elevation (Figure 2,
3) are evaluated for immediate reperfusion therapy
igure 2, D3) and managed according to the ACC/AHA
uidelines for the Management of Patients With ST-Elevation
yocardial Infarction (8), whereas those without ST-segment
evation (Figure 2, C2) are either managed by additional
servation (Figure 2, E1) or admitted to the hospital (Figure 2,
3). Patients with low-risk ACS (Table 6) without transient
T-segment depressions greater than or equal to 0.05 mV (0.5
m) or T-wave inversions greater than or equal to 0.2 mV (2
m), without positive cardiac biomarkers, and with a negative
ress test or CCTA (Figure 2, H1) may be discharged and
eated as outpatients (Figure 2, I1). Low-risk patients may have
stress test within 3 d of discharge.
.3.1. Chest Pain Units
o facilitate a more definitive evaluation while avoiding the
necessary hospital admission of patients with possible ACS
igure 2, B3) and low-risk ACS (Figure 2, F1), as well as the
appropriate discharge of patients with active myocardial
chemia without ST-segment elevation (Figure 2, C2), spe-
al units have been established that are variously referred to
“chest pain units” and “short-stay ED coronary care units.”
ersonnel in these units use critical pathways or protocols
signed to arrive at a decision about the presence or absence
myocardial ischemia and, if present, to characterize it
rther as UA or NSTEMI and to define the optimal next step
the care of the patient (e.g., admission, acute intervention)
3,220,292,293). The goal is to arrive at such a decision after
finite amount of time, which usually is between 6 and 12 h
t may extend up to 24 h depending on the policies in
dividual hospitals. Typically, the patient undergoes a pre-
termined observation period with serial cardiac biomarkers
d ECGs. At the end of the observation period, the patient is
evaluated and then generally undergoes functional cardiac
sting (e.g., resting nuclear scan or echocardiography) and/or
ress testing (e.g., treadmill, stress echocardiography, or
ress nuclear testing) or noninvasive coronary imaging study
.e., CCTA) (see Section 2.3.2). Those patients who have a
currence of chest pain strongly suggestive of ACS, a
sitive biomarker value, a significant ECG change, or a
sitive functional/stress test or CCTA are generally
mitted for inpatient evaluation and treatment. Although
est pain units are useful, other appropriate observation
eas in which patients with chest pain can be evaluated
ay be used as well, such as a section of the hospital’s
rdiac telemetry ward.
The physical location of the chest pain unit or the site
here patients with chest pain are observed is variable,
nging from a specifically designated area of the ED to aparate hospital unit with the appropriate equipment to
servational status (24-h admission) on a regular hospital
lemetry ward (294). Similarly, the chest pain unit may be
ministratively a part of the ED and staffed by emergency
ysicians or may be administered and staffed separately or
part of the hospital cardiovascular service. Capability of
est pain units generally includes continuous monitoring of
e patient’s ECG, ready availability of cardiac resuscitation
uipment and medications, and appropriate staffing with
rses and physicians. The ACEP has published guidelines
at recommend a program for the continuous monitoring of
tcomes of patients evaluated in such units and the impact
hospital resources (295). A consensus panel statement
om ACEP emphasized that chest pain units should be
nsidered as part of a multifaceted program that includes
forts to minimize patient delays in seeking medical care and
lays in the ED itself (295).
It has been reported, both from studies with historical
ntrols and from randomized trials, that the use of chest pain
its is cost-saving compared with an in-hospital evaluation
“rule out MI” (296,297). The potential cost savings of a
est pain unit varies depending on the practice pattern for the
sposition of chest pain patients at individual hospitals (296).
ospitals with a high admission rate of low-risk patients to
le out MI (70% to 80%) will experience the largest cost
vings by implementing a chest pain unit approach but will
ve the smallest impact on the number of missed MI
tients. In contrast, hospitals with relatively low admission
tes of such patients (30% to 40%) will experience greater
provements in the quality of care because fewer MI
tients will be missed but will experience a smaller impact
costs because of the low baseline admission rate.
Farkouh et al. (108) extended the use of a chest pain unit
a separate portion of the ED to include patients at an
termediate risk of adverse clinical outcome on the basis of
e previously published Agency for Healthcare Research and
uality guidelines for the management of UA (131) (Table
. They reported a 46% reduction in the ultimate need for
spital admission in intermediate-risk patients after a me-
an stay of 9.2 h in the chest pain unit. Extension of the use
chest pain units to intermediate-risk patients in an effort to
duce inpatient costs is facilitated by making available
agnostic testing modalities such as treadmill testing and
ress imaging (echocardiographic, nuclear, or magnetic res-
ance) or CCTA 7 d a week (298).
Patients with chest discomfort for whom a specific diag-
sis cannot be made after a review of the history, physical
amination, initial 12-lead ECG, and cardiac biomarker data
ould undergo a more definitive evaluation. Several catego-
es of patients should be considered according to the algo-
thm shown in (Figure 2):
Patients with possible ACS (Figure 2, B3) are those who
had a recent episode of chest discomfort at rest not entirely
typical of ischemia but who are pain free when initially
evaluated, have a normal or unchanged ECG, and have no
elevations of cardiac biomarkers.
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fort that either is of new onset or is severe or that exhibits
an accelerating pattern of previous stable angina (espe-
cially if it has occurred at rest or is within 2 weeks of a
previously documented MI) should initially be considered
to have a “definite ACS” (Figure 2, B4). However, such
patients may be at a low risk if their ECG obtained at
presentation has no diagnostic abnormalities and the initial
serum cardiac biomarkers (especially cardiac-specific tro-
ponins) are normal (Figure 2, C2 and D1). As indicated in
the algorithm, patients with either “possible ACS” (Figure
2, B3) or “definite ACS” (Figure 2, B4) but with nondi-
agnostic ECGs and normal initial cardiac markers (Figure
2, D1) are candidates for additional observation in the ED
or in a specialized area such as a chest pain unit (Figure 2,
E1). In contrast, patients who present without ST-segment
elevation but who have features indicative of active
ischemia (ongoing pain, ST-segment and/or T-wave
changes, positive cardiac biomarkers, or hemodynamic
instability; (Figure 2, D2) should be admitted to the
hospital (Figure 2, H3).
.3.2. Discharge From ED or Chest Pain Unit
he initial assessment of whether a patient has UA/NSTEMI
d which triage option is most suitable generally should be
ade immediately on the patient’s arrival at a medical
cility. Rapid assessment of a patient’s candidacy for addi-
onal observation can be accomplished based on the status of
e symptoms, ECG findings, and initial serum cardiac
omarker measurement.
Patients who experience recurrent ischemic discomfort,
olve abnormalities on a follow-up 12-lead ECG or on
rdiac biomarker measurements, or develop hemodynamic
normalities such as new or worsening HF (Figure 2, D2)
ould be admitted to the hospital (Figure 2, H3) and
anaged as described in Section 3.
Patients who are pain free, have either a normal or
ndiagnostic ECG or one that is unchanged from previous
acings, and have a normal set of initial cardiac biomarker
easurements are candidates for further evaluation to screen
r nonischemic discomfort (Figure 2, B1) versus a low-risk
CS (Figure 2, D1). If the patient is low risk (Table 7) and
es not experience any further ischemic discomfort and a
llow-up 12-lead ECG and cardiac biomarker measurements
ter 6 to 8 h of observation are normal (Figure 2, F1), the
tient may be considered for an early stress test to provoke
chemia or CCTA to assess for obstructive CAD (Figure 2,
1). This test can be performed before the discharge and
ould be supervised by an experienced physician. Alterna-
vely, the patient may be discharged and return for stress
sting as an outpatient within 72 h. The exact nature of the
st may vary depending on the patient’s ability to exercise on
ther a treadmill or bicycle and the local expertise in a given
spital setting (e.g., availability of different testing modali-
es at different times of the day or different days of the week)
99). Patients who are capable of exercise and who are free
confounding features on the baseline ECG, such as
ndle-branch block, LV hypertrophy, or paced rhythms, canevaluated with routine symptom-limited conventional paercise stress testing. Patients who are incapable of exercise
who have an uninterpretable baseline ECG should be
nsidered for pharmacological stress testing with either
uclear perfusion imaging or 2-dimensional echo-
rdiography, or magnetic resonance (181,300,301). Alterna-
vely, it is reasonable to perform a non-invasive coronary
aging test (i.e., CCTA). An imaging-enhanced test also
ay be more predictive in women than conventional ECG
ercise stress testing (see Section 6.1).
Two imaging modalities, CMR and multidetector com-
ted tomography for coronary calcification and CCTA, are
creasingly becoming clinically validated and applied and
ld promise as alternative or supplementary imaging modal-
ies for assessing patients who present with chest pain
ndromes (32,301,302). Cardiac magnetic resonance has the
pability of assessing cardiac function, perfusion, and via-
lity in the same setting. Its advantages are excellent reso-
tion (approximately 1 mm) of cardiac structures and avoid-
ce of exposure to radiation and iodinated contrast.
isadvantages include long study time, confined space
laustrophobia), and (current) contraindication to the pres-
ce of pacemakers/defibrillators. To evaluate for ischemic
art disease, an adenosine first-pass gadolinium perfusion
udy is combined with assessment of regional and global
nction and viability (gadolinium delayed study). Direct
ronary artery imaging is better assessed by CCTA (see
low). One study indicated a sensitivity of 89% and
ecificity of 87% for combined adenosine stress and
dolinium delayed enhancement (viability) CMR testing
r CAD (303). Dobutamine CMR stress testing can be
ed as an alternative to adenosine perfusion CMR (e.g., in
thmatic patients).
Coronary CT angiography with current multidetector tech-
logy (i.e., 64 slices beginning in 2005) has been reported to
ve 90% to 95% or greater sensitivity and specificity for
clusive CAD in early clinical trial experience (304–306).
or evaluation of potential UA/NSTEMI, coronary artery
lcium scoring followed by CCTA is typically done in the
me sitting. The advantages of CCTA are good to excellent
solution (approximately 0.6 mm) of coronary artery anat-
y and short study time (single breath hold). Disadvantages
e radiation dose (8 to 24 mSv), contrast dye exposure, and
cessity to achieve a slow, regular heart rate (beta blockers
e usually required). A lack of large controlled comparative
ials and reimbursement issues are current limitations to
ese technologies. In summary, the high negative predictive
lue of CCTA is its greatest advantage: if no evidence of
ther calcified or noncalcified (soft/fibrous) plaque is found,
en it is highly unlikely that the patient’s symptoms are due
UA/NSTEMI of an atherosclerotic origin. (Note that
imary [micro]vascular dysfunction causes of chest pain are
t excluded.) In contrast, the positive predictive value of
CTA in determining whether a given plaque or stenosis is
using the signs and symptoms of possible UA/NSTEMI is
ss clear because although it gives valuable anatomic infor-
ation, it does not provide functional or physiological
sessment. Coronary CT angiography has been judged to be
eful for evaluation of obstructive CAD in symptomatic
tients (Class IIa, Level of Evidence: B) (32) and appropriate
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d possibly low pre-test probability of CAD when serial
CG and biomarkers are negative (301). It may be particu-
rly appropriate for those with acute chest pain syndromes
ith intermediate pretest probability of CAD in the setting of
ndiagnostic ECG and negative cardiac biomarkers (301).
Because LV function is so integrally related to prognosis
d greatly affects therapeutic options, strong consideration
ould be given to the assessment of LV function with
hocardiography or another modality (i.e., CMR, radionu-
ide, CCTA, or contrast angiography) in patients with
cumented ischemia. In sites at which stress tests are not
ailable, low-risk patients may be discharged and referred for
tpatient stress testing in a timely fashion. Prescription of
ecautionary anti-ischemic treatment (e.g., ASA, sublingual
TG, and beta blockers) should be considered in these patients
hile awaiting results of stress testing. Specific instructions also
ould be given on whether or not to take these medications
.g., beta blockers) before testing, which may vary depending
the test ordered and patient-specific factors. These patients
so should be given specific instructions on what to do and how
seek emergency care for recurrence or worsening of symp-
ms while awaiting the stress test.
Patients who develop recurrent symptoms during observa-
on suggestive of ACS or in whom the follow-up studies
2-lead ECG, cardiac biomarkers) show new abnormalities
igure 2, F2) should be admitted to the hospital (Figure 2,
3). Patients in whom ACS has been excluded should be
assessed for need for further evaluation of other potentially
rious medical conditions that may mimic ACS symptom-
ology (e.g., pulmonary embolism and aortic dissection).
Because continuity of care is important in the overall
anagement of patients with a chest pain syndrome, the
tient’s primary physician (if not involved in the care of the
tient during the initial episode) should be notified of
e results of the evaluation and should receive a copy of the
levant test results. Patients with a noncardiac diagnosis and
ose with low risk or possible ACS with a negative stress test
ould be counseled to make an appointment with their primary
re physician as outpatients for further investigation into the
use of their symptoms (Figure 2, I1). They should be seen by
physician as soon after discharge from the ED or chest pain unit
practical and appropriate, that is, usually within 72 h.
Patients with possible ACS (Figure 5, B3) and those with
definite ACS but a nondiagnostic ECG and normal cardiac
omarkers when they are initially seen (Figure 2, D1) at
stitutions without a chest pain unit (or equivalent facility)
ould be admitted to an inpatient unit. The inpatient unit to
hich such patients are to be admitted should have the same
ovisions for continuous ECG monitoring, availability of
suscitation equipment, and staffing arrangements as de-
ribed above for the design of chest pain units.
. Early Hospital Care
atients with UA/NSTEMI, recurrent symptoms suggestive
ACS and/or ECG ST-segment deviations, or positive
rdiac biomarkers who are stable hemodynamically should
admitted to an inpatient unit for bed rest with continuous anythm monitoring and careful observation for recurrent
chemia (a step-down unit) and managed with either an
vasive or conservative strategy (Appendix 6 has replaced
able 11). Patients with continuing discomfort and/or hemo-
namic instability should be hospitalized for at least 24 h in
coronary care unit characterized by a nursing-to-patient
tio sufficient to provide 1) continuous rhythm monitoring,
frequent assessment of vital signs and mental status,
documented ability to perform defibrillation quickly after the
set of ventricular fibrillation, and 4) adequate staff to perform
ese functions. Patients should be maintained at that level of
re until they have been observed for an adequate period of
e, generally at least 24 h, without any of the following major
mplications: sustained ventricular tachycardia or fibrillation,
nus tachycardia, high-degree atrioventricular (AV) block, sus-
ined hypotension, recurrent ischemia documented by symptoms
ST-segment change, new mechanical defect (ventricular septal
fect or mitral regurgitation), or HF. Shorter periods of monitoring
ight be appropriate for selected patients who are successfully
perfused and who have normal LV function and minimal or no
crosis.
Once a patient with documented high-risk ACS is admit-
d, standard medical therapy is indicated as discussed later.
nless a contraindication exists, these patients generally
ould be treated with ASA, a beta blocker, anticoagulant
erapy, a GP IIb/IIIa inhibitor, and a thienopyridine (i.e.,
opidogrel; initiation may be deferred until a revasculariza-
on decision is made). Critical decisions are required regard-
g the angiographic (invasive) strategy. One option is a
utine angiographic approach in which coronary angiogra-
y and revascularization are performed unless a contra-
dication exists. Within this approach, a common past
rategy has called for a period of medical stabilization.
creasingly, physicians are taking a more aggressive ap-
oach, with coronary angiography and revascularization
rformed within 24 h of admission; the rationale for the
ore aggressive approach is the protective effect of carefully
ministered anticoagulant and antiplatelet therapy on proce-
ral outcome. The alternative approach, commonly referred
as the “initial conservative strategy” (see Section 3.3), is
ided by ischemia, with angiography reserved for patients
ith recurrent ischemia or a high-risk stress test despite
edical therapy. Regardless of the angiographic strategy, an
sessment of LV function is recommended in patients with
cumented ischemia because of the imperative to treat
tients who have impaired LV function with ACE inhibitors,
ta blockers, and, when HF or diabetes mellitus is present,
dosterone antagonists; when the coronary anatomy is appro-
iate (e.g., 3-vessel coronary disease), CABG is appropriate
ee Section 4). When the coronary angiogram is obtained, a left
ntriculogram may be obtained at the same time. When
ronary angiography is not scheduled, echocardiography, nu-
ear ventriculography, or magnetic resonance imaging or CT
ble 11. Selection of Initial Treatment Strategy:
vasive Versus Conservative Strategy
leted. Replaced by Appendix 6.giography can be used to evaluate LV function.
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ecommendations for Anti-Ischemic Therapy
ASS I
Bed/chair rest with continuous ECG monitoring is recom-
mended for all UA/NSTEMI patients during the early hospital
phase. (Level of Evidence: C)
Supplemental oxygen should be administered to patients with
UA/NSTEMI with an arterial saturation less than 90%, respira-
tory distress, or other high-risk features for hypoxemia. (Pulse
oximetry is useful for continuous measurement of SaO2.) (Level
of Evidence: B)
Patients with UA/NSTEMI with ongoing ischemic discomfort should
receive sublingual NTG (0.4 mg) every 5 min for a total of 3 doses,
after which assessment should be made about the need for intrave-
nous NTG, if not contraindicated. (Level of Evidence: C)
Intravenous NTG is indicated in the first 48 h after UA/NSTEMI
for treatment of persistent ischemia, HF, or hypertension. The
decision to administer intravenous NTG and the dose used
should not preclude therapy with other proven mortality-
reducing interventions such as beta blockers or ACE inhibitors.
(Level of Evidence: B)
Oral beta-blocker therapy should be initiated within the first 24 h for
patients who do not have 1 or more of the following: 1) signs of HF,
2) evidence of a low-output state, 3) increased risk* for cardiogenic
shock, or 4) other relative contraindications to beta blockade (PR
interval greater than 0.24 s, second or third degree heart block,
active asthma, or reactive airway disease). (Level of Evidence: B)
In UA/NSTEMI patients with continuing or frequently recurring
ischemia and in whom beta blockers are contraindicated, a
nondihydropyridine calcium channel blocker (e.g., verapamil or
diltiazem) should be given as initial therapy in the absence of
clinically significant LV dysfunction or other contraindications.
(Level of Evidence: B)
AnACE inhibitor should be administered orally within the first 24 h to
UA/NSTEMI patients with pulmonary congestion or LV ejection
fraction (LVEF) less than or equal to 0.40, in the absence of
hypotension (systolic blood pressure less than 100 mm Hg or less
than 30 mm Hg below baseline) or known contraindications to that
class of medications. (Level of Evidence: A)
An angiotensin receptor blocker should be administered to UA/
NSTEMI patients who are intolerant of ACE inhibitors and have
either clinical or radiological signs of HF or LVEF less than or equal to
0.40. (Level of Evidence: A)
Because of the increased risks of mortality, reinfarction, hy-
pertension, HF, and myocardial rupture associated with their
use, nonsteroidal anti-inflammatory drugs (NSAIDs), except for
ASA, whether nonselective or cyclooxygenase (COX)-2–selec-
tive agents, should be discontinued at the time a patient
presents with UA/NSTEMI. (Level of Evidence: C)
ASS IIa
It is reasonable to administer supplemental oxygen to all
patients with UA/NSTEMI during the first 6 h after presenta-
tion. (Level of Evidence: C)
In the absence of contradictions to its use, it is reasonable to
administer morphine sulfate intravenously to UA/NSTEMI pa-
tients if there is uncontrolled ischemic chest discomfort de- hespite NTG, provided that additional therapy is used to manage
the underlying ischemia. (Level of Evidence: B)
It is reasonable to administer intravenous (IV) beta blockers at
the time of presentation for hypertension to UA/NSTEMI pa-
tients who do not have 1 or more of the following: 1) signs of
HF, 2) evidence of low-output state, 3) increased risk* for
cardiogenic shock, or 4) other relative contraindications to
beta blockade (PR interval greater than 0.24 s, second or third
degree heart block, active asthma, or reactive airway disease).
(Level of Evidence: B)
Oral long-acting nondihydropyridine calcium channel blockers
are reasonable for use in UA/NSTEMI patients for recurrent
ischemia in the absence of contraindications after beta block-
ers and nitrates have been fully used. (Level of Evidence: C)
An ACE inhibitor administered orally within the first 24 h of
UA/NSTEMI can be useful in patients without pulmonary
congestion or LVEF less than or equal to 0.40 in the absence of
hypotension (systolic blood pressure less than 100 mm Hg or
less than 30 mm Hg below baseline) or known contraindica-
tions to that class of medications. (Level of Evidence: B)
Intra-aortic balloon pump (IABP) counterpulsation is reason-
able in UA/NSTEMI patients for severe ischemia that is con-
tinuing or recurs frequently despite intensive medical therapy,
for hemodynamic instability in patients before or after coronary
angiography, and for mechanical complications of MI. (Level of
Evidence: C)
ASS IIb
The use of extended-release forms of nondihydropyridine cal-
cium channel blockers instead of a beta blocker may be
considered in patients with UA/NSTEMI. (Level of Evidence: B)
Immediate-release dihydropyridine calcium channel blockers in
the presence of adequate beta blockade may be considered in
patients with UA/NSTEMI with ongoing ischemic symptoms or
hypertension. (Level of Evidence: B)
ASS III
Nitrates should not be administered to UA/NSTEMI patients
with systolic blood pressure less than 90 mm Hg or greater
than or equal to 30 mm Hg below baseline, severe bradycardia
(less than 50 beats per minute), tachycardia (more than 100
beats per minute) in the absence of symptomatic HF, or right
ventricular infarction. (Level of Evidence: C)
Nitroglycerin or other nitrates should not be administered to
patients with UA/NSTEMI who had received a phosphodiester-
ase inhibitor for erectile dysfunction within 24 h of sildenafil or
48 h of tadalafil use. The suitable time for the administration of
nitrates after vardenafil has not been determined. (Level of
Evidence: C)
Immediate-release dihydropyridine calcium channel blockers
should not be administered to patients with UA/NSTEMI in the
absence of a beta blocker. (Level of Evidence: A)
An intravenous ACE inhibitor should not be given to patients
within the first 24 h of UA/NSTEMI because of the increased
risk of hypotension. (A possible exception may be patients with
refractory hypertension.) (Level of Evidence: B)
isk factors for cardiogenic shock (the greater the number of risk factors present,
e higher the risk of developing cardiogenic shock): age greater than 70 years,
stolic blood pressure less than 120 mm Hg, sinus tachycardia greater than 110 or
art rate less than 60, increased time since onset of symptoms of UA/NSTEMI.
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UA/NSTEMI patients who have contraindications to beta
blockade, signs of HF or low-output state, or other risk factors*
for cardiogenic shock. (Level of Evidence: A)
Nonsteroidal anti-inflammatory drugs (except for ASA), whether
nonselective or COX-2–selective agents, should not be ad-
ministered during hospitalization for UA/NSTEMI because of
the increased risks of mortality, rein-farction, hypertension,
HF, and myocardial rupture associated with their use. (Level
of Evidence: C)
The optimal management of UA/NSTEMI has the twin
als of the immediate relief of ischemia and the preven-
on of serious adverse outcomes (i.e., death or myocardial
e] infarction). This is best accomplished with an ap-
oach that includes anti-ischemic therapy (Table 12),
tithrombotic therapy, ongoing risk stratification, and the
e of invasive procedures. Patients who are at intermedi-
e or high risk for adverse outcomes, including those with
going ischemia refractory to initial medical therapy and
ose with evidence of hemodynamic instability, should be
mitted whenever possible to a critical care environment
ble 12. Class I Recommendations for Anti-Ischemic
erapy: Continuing Ischemia/Other Clinical High-Risk Features
esent*
d/chair rest with continuous ECG monitoring
pplemental oxygen with an arterial saturation less than 90% respiratory
distress, or other high-risk features for hypoxemia. Pulse oximetry can be
useful for continuous measurement of SaO2.
G 0.4 mg sublingually every min for total of doses; afterward, assess
need for IV NTG
G IV for first 48 h after UA/NSTEMI for treatment of persistent ischemia,
HF, or hypertension
cision to administer NTG IV and dose should not preclude therapy with
other mortality-reducing interventions such as beta blockers or ACE
inhibitors
ta blockers (via oral route) within 24 h without a contraindication
(e.g., HF) irrespective of concomitant performance of PCI
hen beta blockers are contraindicated, nondihydropyridine calcium channel
blocker (e.g., verapamil or diltiazem) should be given as initial therapy in
the absence of severe LV dysfunction or other contraindications
E inhibitor (via oral route) within first 24 h with pulmonary congestion,
or LVEF less than or equal to 0.40, in the absence of hypotension
(systolic blood pressure less than 100 mm Hg or less than 30 mm Hg
below baseline) or known contraindications to that class of
medications
B should be administered to UA/NSTEMI patients who are intolerant of
ACE inhibitors and have either clinical or radiological signs of heart failure
or LVEF less than or equal to 0.40.
*Recurrent angina and/or ischemia-related ECG changes (0.05 mV or greater
-segment depression or bundle-branch block) at rest or with low-level
tivity; or ischemia associated with HF symptoms, S3 gallop, or new or
orsening mitral regurgitation; or hemodynamic instability or depressed LV
nction (LVEF less than 0.40 on noninvasive study); or serious ventricular
rhythmia.
ACE angiotensin-converting enzyme; ARB angiotensin receptor blocker; HF
art failure; IV  intravenous; LV  left ventricular; LVEF  left ventricular
ection fraction; NTG  nitroglycerin; MI  myocardial infarction; PCI 
rcutaneous coronary intervention; UA/NSTEMI  unstable angina/non–ST-
evation myocardial infarction.ith ready access to invasive cardiovascular diagnosis and inerapeutic procedures. Ready access is defined as ensured,
mely access to a cardiac catheterization laboratory with
rsonnel who have appropriate credentials and experience
invasive coronary procedures, as well as to emergency
urgent cardiovascular surgery and cardiac anesthesia
,307).
The approach to the achievement of the twin goals described
re includes the initiation of pharmacological management and
anning of a definitive treatment strategy for the underlying
sease process. Most patients are stable at presentation or
abilize after a brief period of intensive pharmacological man-
ement and, after appropriate counseling, will be able to
rticipate in the choice of an approach for definitive therapy
ee Section 3.3 for a full discussion of conservative vs invasive
rategy selection). A few patients will require prompt triage to
ergency or urgent cardiac catheterization and/or the place-
ent of an IABP.
.1.1. General Care
he severity of symptoms dictates some of the general care
at should be given during the initial treatment. Patients
ould be placed on bed rest while ischemia is ongoing but
n be mobilized to a chair and use a bedside commode when
mptom free. Subsequent activity should not be inappropri-
ely restrictive; instead, it should be focused on the preven-
on of recurrent symptoms and liberalized as judged appro-
iate when response to treatment occurs. Patients with
anosis, respiratory distress, or other high-risk features
ould receive supplemental oxygen. Adequate arterial oxy-
n saturation should be confirmed with direct measurement
specially with respiratory distress or cyanosis) or pulse
imetry. No evidence is available to support the administra-
on of oxygen to all patients with ACS in the absence of signs
respiratory distress or arterial hypoxemia. Its use based on
e evidence base can be limited to those with questionable
spiratory status and documented hypoxemia. Nevertheless,
is the opinion of the Writing Committee that a short
riod of initial routine oxygen supplementation is reason-
le during initial stabilization of the patient, given its
fety and the potential for underrecognition of hypox-
ia. Inhaled oxygen should be administered if the arterial
ygen saturation (SaO2) declines to less than 90%. Finger
lse oximetry is useful for the continuous monitoring of
aO2 but is not mandatory in patients who do not appear to
at risk of hypoxemia. Patients should undergo contin-
us ECG monitoring during their ED evaluation and early
spital phase, because sudden, unexpected ventricular
brillation is the major preventable cause of death in this
rly period. Furthermore, monitoring for the recurrence of
T-segment shifts provides useful diagnostic and prognos-
c information, although the system of monitoring for
T-segment shifts must include specific methods intended
provide stable and accurate recordings.
.1.2. Use of Anti-Ischemic Therapies
.1.2.1. NITRATES
itroglycerin reduces myocardial oxygen demand while enhanc-
g myocardial oxygen delivery. Nitroglycerin, an endothelium-
dependent vasodilator, has both peripheral and coronary vas-
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d), it increases venous pooling to decrease myocardial pre-
ad, thereby reducing ventricular wall tension, a determinant of
yocardial oxygen demand (MVO2). More modest effects on
e arterial circulation decrease systolic wall stress (afterload),
hich contributes to further reductions in MVO2. This decrease
myocardial oxygen demand is in part offset by reflex increases
heart rate and contractility, which counteract the reductions in
VO2 unless a beta blocker is concurrently administered.
itroglycerin dilates normal and atherosclerotic epicardial cor-
ary arteries and smaller arteries that constrict with certain
ressors (e.g., cold, mental or physical exercise). With severe
herosclerotic coronary obstruction and with less severely
structed vessels with endothelial dysfunction, physiological
sponses to changes in myocardial blood flow are often im-
ired (i.e., loss of flow-mediated dilation), so maximal dilation
es not occur unless a direct-acting vasodilator like NTG is
ministered. Thus, NTG promotes the dilation of large coro-
ry arteries, as well as collateral flow and redistribution of
ronary blood flow to ischemic regions. Inhibition of platelet
gregation also occurs with NTG (307), but the clinical
gnificance of this action is not well defined.
Intravenous NTG can benefit patients whose symptoms are
t relieved in the hospital with three 0.4-mg sublingual NTG
blets taken 5 min apart (Tables 12 and 14; Table 13 is
leted in this document because it is no longer current; refer
stead to Appendixes 7 and 8) and with the initiation of an
al or intravenous beta blocker (when there are no contra-
dications), as well as those with HF or hypertension. Note
at NTG is contraindicated after the use of sildenafil within
e previous 24 h or tadalafil within 48 h or with hypotension
08–310). The suitable delay before nitrate administration
ter the use of vardenafil has not been determined, although
ood pressure had generally returned to baseline by 24 h
11). These drugs inhibit the phosphodiesterase that de-
ble 13. Dosing Table for Antiplatelet and Anticoagulant
erapy in Patients With UA/NSTEMI
leted. See Appendixes 7 and 8.
ble 14. NTG and Nitrates in Angina
Compound Route
G Sublingual tablets 0
Spray 0
Transdermal 0
Intravenous 5
sorbide dinitrate Oral 5
Oral, slow release 4
sorbide mononitrate Oral 20 mg twice daily 1
Oral, slow release 6
ntaerythritol tetranitrate Sublingual 1
ythritol tetranitrate Sublingual 5
Oral 1
Adapted from Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 gui
: http://www.acc.org/qualityandscience (4).
NTG  nitroglycerin.ades cyclic guanosine monophosphate, and cyclic guanos-
e monophosphate mediates vascular smooth muscle relax-
ion by nitric oxide. Thus, NTG-mediated vasodilatation is
arkedly exaggerated and prolonged in the presence of
osphodiesterase inhibitors. Nitrate use within 24 h after
ldenafil or the administration of sildenafil in a patient who
s received a nitrate within 24 h has been associated with
ofound hypotension, MI, and even death (310). Similar
ncerns apply to tadalafil and vardenafil (308,311).
Intravenous NTG may be initiated at a rate of 10 mcg per min
rough continuous infusion via nonabsorbing tubing and in-
eased by 10 mcg per min every 3 to 5 min until some relief of
mptoms or blood pressure response is noted. If no response is
en at 20 mcg per min, increments of 10 and, later, 20 mcg per
in can be used. If symptoms and signs of ischemia are relieved,
ere is no need to continue to increase the dose to effect a blood
essure response. If symptoms and signs of ischemia are not
lieved, the dose should be increased until a blood pressure
sponse is observed. Once a partial blood pressure response is
served, the dosage increase should be reduced and the interval
tween increments lengthened. Side effects of NTG include
adache and hypotension. Systolic blood pressure generally
ould not be titrated to less than 110 mm Hg in previously
rmotensive patients or to greater than 25% below the starting
ean arterial blood pressure if hypertension was present. Nitro-
ycerin should be avoided in patients with initial systolic blood
essure less than 90 mm Hg or 30 mm Hg or more below
seline or with marked bradycardia or tachycardia. Although
commendations for a maximal dose are not available, a ceiling
200 mcg per min is commonly used. Even prolonged (2 to 4
eeks) infusion at 300 to 400 mcg per min does not increase
ethemoglobin levels (312).
Topical or oral nitrates are acceptable alternatives for patients
ho require antianginal therapy but who do not have ongoing
fractory ischemic symptoms. Tolerance to the hemodynamic
fects of nitrates is dose and duration dependent and typically
comes important after 24 h of continuous therapy with any
rmulation. Patients who require continued intravenous NTG
yond 24 h may require periodic increases in infusion rate to
aintain efficacy. An effort must be made to use non–tolerance-
Dose/Dosage Duration of Effect
6 mg up to 1.5 mg 1 to 7 min
s needed Similar to sublingual tablets
8 mg per h every 12 h 8 to 12 h during intermittent therapy
mcg per min Tolerance in 7 to 8 h
g, 2 or 3 times daily Up to 8 h
or 2 times daily Up to 8 h
h
0 mg once daily
s needed Not known
g as needed Not known
mg 3 times daily Not known
pdate for the management of patients with chronic stable angina. Available.3 to 0.
.4 mg a
.2 to 0.
to 200
to 80 m
0 mg 1
2 to 24
0 to 24
0 mg a
to 10 m
0 to 30
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June 11, 2013:e179–347 UA/NSTEMI Guideline: 2012 Update Incorporatedoducing nitrate regimens (lower doses and intermittent dos-
g). When patients have been free of ischemic discomfort and
her manifestations of ischemia for 12 to 24 h, an attempt
ould be made to reduce the dose of intravenous NTG and to
itch to oral or topical nitrates. It is not appropriate to continue
travenous NTG in patients who remain free of signs and
mptoms of ischemia. When ischemia recurs during continuous
travenous NTG therapy, responsiveness to nitrates can often
restored by increasing the dose and, after symptoms have
en controlled for several hours, attempting to add a nitrate-free
terval. This strategy should be pursued as long as symptoms
e not adequately controlled. In stabilized patients, intravenous
TG should generally be converted within 24 h to a nonparen-
ral alternative (Table 14) administered in a non–tolerance-
oducing regimen to avoid the potential reactivation of symp-
ms. A practical method for converting intravenous to topical
TG has been published (313).
Most studies of nitrate treatment in UA/NSTEMI have been
all and uncontrolled, and there are no randomized, placebo-
ntrolled trials that address either symptom relief or reduction
cardiac events. One small randomized trial compared intra-
nous NTG with buccal NTG and found no significant differ-
ce in the control of ischemia (314). An overview of small
udies of NTG in MI from the prefibrinolytic era suggested a
% reduction in mortality rates (315); in contrast, both the
ourth International Study of Infarct Survival (ISIS-4) (316) and
ruppo Italiano per lo Studio della Sopravvivenza nell’infarto
iocardico (GISSI-3) (317) trials formally tested this hypothesis
patients with suspected MI in the reperfusion era and failed to
nfirm this magnitude of benefit. However, these large trials are
nfounded by frequent prehospital and hospital use of NTG in
e “control” groups. Nevertheless, a strategy of routine as
posed to selective use of nitrates did not reduce mortality. The
rupt cessation of intravenous NTG has been associated with
acerbation of ischemic changes on the ECG (318), and a
aded reduction in the dose of intravenous NTG is advisable.
hus, the rationale for NTG use in UA/NSTEMI is extrapolated
om pathophysiological principles and extensive, although un-
ntrolled, clinical observations (307).
.1.2.2. MORPHINE SULFATE
orphine sulfate (1 to 5 mg IV) is reasonable for patients
hose symptoms are not relieved despite NTG (e.g., after 3
rial sublingual NTG tablets) or whose symptoms recur
spite adequate anti-ischemic therapy. Unless contraindicated by
potension or intolerance, morphine may be administered with
travenous NTG, with careful blood pressure monitoring, and may
repeated every 5 to 30 min as needed to relieve symptoms and
aintain patient comfort.
Morphine sulfate has potent analgesic and anxiolytic effects,
well as hemodynamic effects, that are potentially beneficial in
A/NSTEMI. No randomized trials have defined the unique
ntribution of morphine to the initial therapeutic regimen or its
timal administration schedule. Morphine causes venodilation
d can produce modest reductions in heart rate (through
creased vagal tone) and systolic blood pressure to further reduce
yocardial oxygen demand. The major adverse reaction to mor-
ine is an exaggeration of its therapeutic effect, causing hypoten-on, especially in the presence of volume depletion and/or vasodi- wtor therapy. This reaction usually responds to supine or
rendelenburg positioning or intravenous saline boluses and atro-
ne when accompanied by bradycardia; it rarely requires pressors
naloxone to restore blood pressure. Nausea and vomiting occur in
proximately 20% of patients. Respiratory depression is the most
rious complication of morphine; severe hypoventilation that
quires intubation occurs very rarely in patients with UA/NSTEMI
eated with morphine. Naloxone (0.4 to 2.0 mg IV) may be
ministered for morphine overdose with respiratory or circulatory
pression. Other narcotics may be considered in patients allergic to
orphine. A cautionary note on morphine use has been raised by
ta from a large observational registry (n  443 hospitals) that
rolled patients with UA/NSTEMI (n  57,039) (319). Those
ceiving morphine (30%) had a higher adjusted likelihood of death
ropensity-adjusted OR  1.41, 95% CI 1.26 to 1.57), which
rsisted across all subgroups (319). Although subject to uncon-
olled selection biases, these results raise a safety concern and
ggest the need for a randomized trial. Meanwhile, the Writing
ommittee has downgraded the recommendation for morphine use
r uncontrolled ischemic chest discomfort from a Class I to a Class
a recommendation.
.1.2.3. BETA-ADRENERGIC BLOCKERS
eta blockers competitively block the effects of catecholamines on
ll membrane beta receptors. Beta-1 adrenergic receptors are
cated primarily in the myocardium; inhibition of catecholamine
tion at these sites reduces myocardial contractility, sinus node
te, and AV node conduction velocity. Through these actions, they
unt the heart rate and contractility responses to chest pain,
ertion, and other stimuli. They also decrease systolic blood
essure. All of these effects reduce MVO2. Beta-2 adrenergic
ceptors are located primarily in vascular and bronchial smooth
uscle; the inhibition of catecholamine action at these sites pro-
ces vasoconstriction and bronchoconstriction (307). In UA/
STEMI, the primary benefits of beta blockers are due to inhibition
beta-1 adrenergic receptors, which results in a decrease in cardiac
ork and myocardial oxygen demand. Slowing of the heart rate
so has a favorable effect, acting not only to reduce MVO2 but also
increase the duration of diastole and diastolic pressure-time, a
terminant of forward coronary flow and collateral flow.
Beta blockers, administered orally, should be started early
the absence of contraindications. Intravenous administra-
on may be warranted in patients with ongoing rest pain,
pecially with tachycardia or hypertension, in the absence of
ntraindications (see below) (Table 12).
The benefits of routine early intravenous use of beta
ockers in the fibrinolytic era have been challenged by 2
ter randomized trials of intravenous beta blockade
20,321) and by a post hoc analysis of the use of atenolol in
e GUSTO-I trial (322). A subsequent systematic review of
rly beta-blocker therapy in STEMI found no significant
duction in mortality (34). Most recently, the utility of early
travenous followed by oral beta blockade (metoprolol) was
sted in 45,852 patients with MI (93% had STEMI, 7% had
STEMI) in the COMMIT study (323). Neither the compos-
e of death, reinfarction, or cardiac arrest nor death alone was
duced for up to 28 d in the hospital. Overall, a modest
duction in reinfarction and ventricular fibrillation (which
as seen after day 1) was counterbalanced by an increase in
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UA/NSTEMI Guideline: 2012 Update Incorporated June 11, 2013:e179–347rdiogenic shock, which occurred early (first day) and primarily
those who were hemodynamically compromised or in HF or
ho were stable but at high risk of development of shock. Thus,
rly aggressive beta blockade poses a substantial net hazard in
modynamically unstable patients and should be avoided. Risk
ctors for shock were older age, female sex, time delay, higher
illip class, lower blood pressure, higher heart rate, ECG
normality, and previous hypertension. There was a
oderate net benefit for those who were relatively stable
d at low risk of shock. Whether to start beta blockade
travenously or orally in these latter stable patients is
clear, and patterns of use vary. In an attempt to balance
e evidence base overall for UA/NSTEMI patients, beta
ockers are recommended in these guidelines to be
itiated orally, in the absence of contraindications (e.g.,
F), within the first 24 h. Greater caution is now suggested
the early use of intravenous beta blockers, which should
targeted to specific indications and should be avoided
ith HF, hypotension, and hemodynamic instability.
The choice of beta blocker for an individual patient is
sed primarily on pharmacokinetic and side effect criteria, as
ell as on physician familiarity (Table 15). There are no
mparative studies between members of this class in the
ute setting. Beta blockers without intrinsic sympathomi-
etic activity are preferred, however. Agents studied in the
ute setting include metoprolol, propranolol, and atenolol.
arvedilol may be added to the list of agents studied for
st-MI use. Comparative studies among different beta block-
s in the chronic setting after UA/NSTEMI also are not
ailable to establish a preference among agents. In patients
ith HF, 1 study suggested greater benefit with carvedilol,
ith mixed beta-blocking and alpha-adrenergic-blocking ef-
cts, than metoprolol, a relatively selective beta-1 blocker
24). In patients with hypertension, the relative cardiovas-
lar benefit of atenolol has been questioned on the basis of
cent clinical trial analyses (325,326).
Patients with marked first-degree AV block (i.e., ECG PR
terval greater than 0.24 s), any form of second- or third-
gree AV block in the absence of a functioning implanted
cemaker, a history of asthma, severe LV dysfunction or HF
.g., rales or S3 gallop) or at high risk for shock (see above)
ould not receive beta blockers on an acute basis (11).
atients with evidence of a low-output state (e.g., oliguria) or
nus tachycardia, which often reflects low stroke volume,
gnificant sinus bradycardia (heart rate less than 50 beats per
inute), or hypotension (systolic blood pressure less than 90
m Hg) should not receive acute beta-blocker therapy until
ese conditions have resolved. Patients at highest risk for
rdiogenic shock due to intravenous beta blockade in the
OMMIT trial were those with tachycardia or in Killip Class II
III (323). However, beta blockers are strongly recommended
fore discharge in those with compensated HF or LV systolic
sfunction for secondary prevention (327). Patients with sig-
ficant chronic obstructive pulmonary disease who may have a
mponent of reactive airway disease should be given beta
ockers very cautiously; initially, low doses of a beta-1–
lective agent should be used. If there are concerns about
ssible intolerance to beta blockers, initial selection should thvor a short-acting beta-1–specific drug such as metoprolol or
molol. Mild wheezing or a history of chronic obstructive
lmonary disease mandates a short-acting cardioselective agent
a reduced dose (e.g., 12.5 mg of metoprolol orally) rather than
e complete avoidance of a beta blocker.
In the absence of these concerns, previously studied
gimens may be used. Intravenous metoprolol may be given
5-mg increments by slow intravenous administration (5 mg
er 1 to 2 min), repeated every 5 min for a total initial dose
15 mg. In patients who tolerate the total 15-mg IV dose,
al therapy can be initiated 15 min after the last intravenous
se at 25 to 50 mg every 6 h for 48 h. Thereafter, patients
ould receive a maintenance dose of up to 100 mg twice
ily. Alternatively, intravenous propranolol may be admin-
tered as an initial dose of 0.5 to 1.0 mg, followed in 1 to 2 h
40 to 80 mg by mouth every 6 to 8 h. Monitoring during
travenous beta-blocker therapy should include frequent
ecks of heart rate and blood pressure and continuous ECG
onitoring, as well as auscultation for rales and bronchos-
sm. Beta blockade also may be started orally, in smaller
itial doses if appropriate, within the first 24 h, in cases in
hich a specific clinical indication for intravenous initiation
absent or the safety of aggressive early beta blockade is a
ncern. Carvedilol, 6.25 mg by mouth twice daily, uptitrated
dividually at 3- to 10-d intervals to a maximum of 25 mg
ice daily, can reduce mortality and reinfarction when given
patients with recent (3 to 21 d) MI and LV dysfunction
27). After the initial intravenous load, if given, patients
ithout limiting side effects may be converted to an oral
gimen. The target resting heart rate is 50 to 60 beats per
inute unless a limiting side effect is reached. Selection of
e oral agent should include the clinician’s familiarity with
ble 15. Properties of Beta Blockers in Clinical Use
Drugs Selectivity
Partial
Agonist
Activity Usual Dose for Angina
opranolol None No 20 to 80 mg twice daily
etoprolol Beta1 No 50 to 200 mg twice daily
enolol Beta1 No 50 to 200 mg per d
dolol None No 40 to 80 mg per d
molol None No 10 mg twice daily
ebutolol Beta1 Yes 200 to 600 mg twice daily
taxolol Beta1 No 10 to 20 mg per d
soprolol Beta1 No 10 mg per d
molol
(intravenous)
Beta1 No 50 to 300 mcg per kg per min
betalol* None Yes 200 to 600 mg twice daily
ndolol None Yes 2.5 to 7.5 mg times daily
rvedilol None Yes 6.25 mg twice daily, uptitrated
to a maximum of 25 mg
twice daily
*Labetalol and carvedilol are combined alpha and beta blockers. Adapted
m Table 25 of Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002
ideline update for the management of patients with chronic stable angina.
ailable at: http://www.acc.org/qualityandscience (4).e agent. Maintenance doses are given in Table 15.
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d uncontrolled. An overview of double-blind, randomized
ials in patients with threatening or evolving MI suggests an
proximately 13% reduction in the risk of progression to MI
28). These trials were conducted prior to the routine use of
SA, heparin, clopidogrel, GP IIb/IIIa inhibitors, and revascu-
rization. These trials lack sufficient power to assess the effects
these drugs on mortality rates for UA. Pooled results from the
valuation of c7E3 for the Prevention of Ischemic Complica-
ns (EPIC), Evaluation of PTCA and Improve Long-term
utcome by c7E3 GP IIb/IIIa receptor blockade (EPILOG),
valuation of Platelet IIb/IIIa Inhibitor for STENTing (EPIS-
ENT), CAPTURE, and ReoPro in Acute myocardial infarction
d Primary PTCA Organization and Randomization Trial
APPORT) studies were used to evaluate the efficacy of
ta-blocker therapy in patients with ACS who were undergoing
CI (329). At 30 d, death occurred in 0.6% of patients receiving
ta-blocker therapy versus 2.0% of patients not receiving such
erapy (p0.001). At 6 months, death occurred in 1.7% of
tients receiving beta-blocker therapy versus 3.7% not receiv-
g this therapy (p0.001). Thus, patients receiving beta-blocker
erapy who undergo PCI for UA or MI have a lower short-term
ortality (329).
Overall, the rationale for beta-blocker use in all forms of
AD, including UA, is generally favorable, with the excep-
on of initial HF. In the absence of contraindications, the new
idence appears sufficient to make beta blockers a routine
rt of care. A related group shown to benefit are high- or
termediate-risk patients who are scheduled to undergo
rdiac or noncardiac surgery (330). A recent exception to
ta-blocker benefit was COMMIT, a large trial of mostly
TEMI patients, which showed no overall mortality effect.
ubgroup analysis suggested this to be due to an increased
sk in those with initial HF or risk factors for cardiogenic
ock (323). In contrast to this adverse experience with early,
gressive beta blockade, carvedilol, begun in low doses 3 to
d after MI in patients with LV dysfunction (ejection
action of 0.40 or less) and gradually uptitrated, decreased
bsequent death or nonfatal recurrent MI when given in
njunction with modern ACS therapies in the most contem-
rary oral beta blocker post-MI trial, CAPRICORN (Carve-
lol Post-Infarct Survival Control in LV Dysfunction) (327).
In conclusion, evidence for the beneficial effects of the use
beta blockers in patients with UA is based on limited
ndomized trial data along with pathophysiological consid-
ations and extrapolation from experience with CAD pa-
ents who have other types of ischemic syndromes (stable
gina or compensated chronic HF). The duration of benefit
ith long-term oral therapy is uncertain and likely varies with
e extent of revascularization.
.1.2.4. CALCIUM CHANNEL BLOCKERS
alcium channel blockers (CCBs) reduce cell transmembrane
ward calcium flux, which inhibits both myocardial and
scular smooth muscle contraction; some also slow AV
nduction and depress sinus node impulse formation. Agents
this class vary in the degree to which they produce
sodilation, decreased myocardial contractility, AV block,
d sinus node slowing. Nifedipine and amlodipine have the anost peripheral arterial dilatory effects but few or no AV or
nus node effects, whereas verapamil and diltiazem have
ominent AV and sinus node effects and some peripheral
terial dilatory effects as well. All 4 of these agents, as well
other approved agents, have coronary dilatory properties
at appear to be similar. Although different CCBs are
ructurally and, potentially, therapeutically diverse, superi-
ity of 1 agent over another in UA/NSTEMI has not been
monstrated, except for the increased risks posed by rapid-
lease, short-acting dihydropyridines such as nifedipine
able 16). Beneficial effects in UA/NSTEMI are believed to
due to variable combinations of decreased myocardial
ygen demand (related to decreased afterload, contractility,
d heart rate) and improved myocardial flow (related to
ronary arterial and arteriolar dilation) (307,331). These
ents also have theoretically beneficial effects on LV relax-
ion and arterial compliance. Major side effects include
potension, worsening HF, bradycardia, and AV block.
Calcium channel blockers may be used to control ongoing
recurring ischemia-related symptoms in patients who
ready are receiving adequate doses of nitrates and beta
ockers, in patients who are unable to tolerate adequate
ses of 1 or both of these agents, and in patients with variant
gina (see Section 6.7). In addition, these drugs have been
ed for the management of hypertension in patients with
current UA (331). Rapid-release, short-acting dihydropyri-
nes (eg, nifedipine) must be avoided in the absence of
ncomitant beta blockade because of increased adverse potential
32–334). Verapamil and diltiazem should be avoided in patients
ith pulmonary edema or evidence of severe LV dysfunction
35–337). Amlodipine and felodipine are reasonably well tolerated
patients with mild LV dysfunction (335–340), although their use
UA/NSTEMI has not been studied. The CCB evidence base in
A/NSTEMI is greatest for verapamil and diltiazem (334,337).
Several randomized trials during the 1980s tested CCBs in
A/NSTEMI and found that they relieve or prevent signs and
mptoms of ischemia to a degree similar to the beta
ockers. The Danish Study Group on Verapamil in Myocar-
al Infarction (DAVIT) (338,339) studied 3,447 patients
ith suspected UA/NSTEMI. A benefit was not proved, but
ath or nonfatal MI tended to be reduced. The Diltiazem
einfarction Study (DRS) studied 576 patients with UA/
STEMI (335). Diltiazem reduced reinfarction and refractory
gina at 14 d without an increase in mortality rates.
etrospective analysis of the non–Q-wave MI subset of
tients in the Multicenter Diltiazem Postinfarction Trial
DPIT) suggested similar findings (340). The Holland
teruniversity Nifedipine/metoprolol Trial (HINT), tested
fedipine and metoprolol in a 2  2 factorial design in 515
tients (333). The study was stopped early because of
ncern for harm with the use of nifedipine alone. In contrast,
tients already taking a beta blocker appeared to benefit
om the addition of nifedipine (risk ratio [RR] 0.68) (341).
Meta-analyses combining UA/NSTEMI studies of all
CBs have suggested no overall benefit (328,342), whereas
ose excluding nifedipine (e.g., for verapamil alone) have
ported favorable effects on outcomes (338). Retrospective
alyses of DAVIT and MDPIT suggested that verapamil
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tes in patients with LV dysfunction (335,336). In con-
ast, verapamil reduced diuretic use in DAVIT-2 (339).
urthermore, subsequent prospective trials with verapamil
ministered to MI patients with HF who were receiving
ACE inhibitor suggested a benefit (336,343). The
iltiazem as Adjunctive Therapy to Activase (DATA) trial
so suggested that intravenous diltiazem in MI patients
n be safe; death, MI, and recurrent ischemia were
creased at 35 d and 6 months (344).
In summary, definitive evidence for a benefit of CCBs in
A/NSTEMI is predominantly limited to symptom control.
or immediate-release nifedipine, an increase in serious
ents is suggested when administered early without a beta
ocker. The heart rate–slowing CCB drugs (verapamil and
ltiazem) can be administered early to patients with UA/
STEMI without HF without overall harm and with trends
ward a benefit. Therefore, when beta blockers cannot be
ed, and in the absence of clinically significant LV dysfunc-
on, heart rate–slowing CCBs are preferred. Greater caution
indicated when combining a beta blocker and CCB for
fractory ischemic symptoms, because they may act in
nergy to depress LV function and sinus and AV node
nduction. The risks and benefits in UA/NSTEMI of newer
CBs, such as the dihydropyridines amlodipine and felodip-
e, relative to the older agents in this class that have been
viewed here, remain undefined, which suggests a cautious
proach, especially in the absence of beta blockade.
.1.2.5. INHIBITORS OF THE
ENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
ngiotensin-converting enzyme inhibitors have been shown
reduce mortality rates in patients with MI or who recently
d an MI and have LV systolic dysfunction (345–347), in
tients with diabetes mellitus with LV dysfunction (348),
d in a broad spectrum of patients with high-risk chronic
AD, including patients with normal LV function (349).
ollow-up of patients with LV dysfunction after MI in the
ble 16. Properties of Calcium Channel Blockers in Clinical Use
Drug Usual Dose
hydropyridines
Nifedipine* Immediate release: 30 to 90 mg daily orally
Slow release: 30 to 180 mg orally
Amlodipine 5 to 10 mg once daily
Felodipine 5 to 10 mg once daily
Isradipine 2.5 to 10 mg twice daily
Nicardipine 20 to 40 mg 3 times daily
Nisoldipine 20 to 40 mg once daily
Nitrendipine 20 mg once or twice daily
iscellaneous
Diltiazem Immediate release: 30 to 90 mg 4 times daily
Slow release: 120 to 360 mg once daily
Verapamil Immediate release: 80 to 160 mg 3 times daily
Slow release: 120 to 480 mg once daily
*Immediate-release nifedipine not recommended for UA/NSTEMI except wit
atterjee K, et al. ACC/AHA 2002 guideline update for the management of patieRACE (TRAndolapril Cardiac Evaluation) trial showed that Se beneficial effect of trandolapril on mortality and hospitaliza-
n rate was maintained for at least 10 to 12 years (350). A
stematic review assessing potential ASA–ACE inhibitor inter-
tions showed clinically important benefits with ACE
hibitor therapy, irrespective of whether concomitant
SA was used, and only weak evidence of a reduction in
e benefit of ACE inhibitor therapy added to ASA (351);
ese data did not solely involve patients with MI. Accord-
gly, ACE inhibitors should be used in patients receiving
SA and in those with hypertension that is not controlled
ith beta blockers. Recent data on ACE inhibitor patients
ith stable CAD are summarized in the section on long-
rm medical therapy (see Section 5.2.3).
In patients with MI complicated by LV systolic dysfunc-
on, HF, or both, the angiotensin receptor blocker valsartan
as as effective as captopril in patients at high risk for
rdiovascular events after MI. The combination of valsartan
d captopril increased adverse events and did not improve
rvival (352). Although not in the acute care setting,
eatment of patients with chronic HF with candesartan (at
ast half of whom had an MI) in the CHARM (Candesartan
Heart failure Assessment in Reduction of Mortality)-
verall program showed a reduction in cardiovascular deaths
d hospital admissions for HF, independent of ejection
action or baseline treatment (353).
The selective aldosterone receptor blocker eplerenone,
ed in patients with MI complicated by LV dysfunction
d either HF or diabetes mellitus, reduced morbidity and
ortality in the Eplerenone Post-acute myocardial infarc-
on Heart failure Efficacy and SUrvival Study (EPHESUS)
54). This complements data from the earlier Randomized
Ldactone Evaluation Study (RALES), in which aldoste-
ne receptor blockade with spironolactone decreased
orbidity and death in patients with severe HF, half of
hom had an ischemic origin (355). Indications for long-
rm use of aldosterone receptor blockers are given in
ion of Action Side Effects
Short Hypotension, dizziness, flushing, nausea,
constipation, edema
Long Headache, edema
Long Headache, edema
Medium Headache, fatigue
Short Headache, dizziness, flushing, edema
Short Similar to nifedipine
Medium Similar to nifedipine
Short
Long
Hypotension, dizziness, flushing, bradycardia, edema
Short
Long
Hypotension, myocardial depression, heart failure,
edema, bradycardia
mitant beta blockade. Modified from Table 27 in Gibbons RJ, Abrams J,
chronic stable angina. Available at: http://www.acc.org/qualityandscience (4).Durat
h concoection 5.2.3.
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ther less extensively studied therapies for the relief of ischemia,
ch as spinal cord stimulation (356) and prolonged external
unterpulsation (357,358), are under evaluation. Most experience
s been gathered with spinal cord stimulation in “intractable
gina” (359). in which anginal relief has been described. They
ve not been applied in the acute setting for UA/NSTEMI.
The KATP channel openers have hemodynamic and cardio-
otective effects that could be useful in UA/NSTEMI. Nic-
andil is such an agent that has been approved in a number of
untries but not in the United States. In a pilot double-blind,
acebo-controlled study of 245 patients with UA, the addition of
is drug to conventional treatment significantly reduced the number
episodes of transient myocardial ischemia (mostly silent) and of
ntricular and supraventricular tachycardia (360). Further evalua-
n of this class of agents is underway.
Ranolazine is a newly approved (January 2006) agent that
erts antianginal effects without reducing heart rate or blood
essure (361). Currently, ranolazine is indicated alone or in
mbination with amlodipine, beta-blockers, or nitrates for the
eatment of chronic angina that has failed to respond to standard
tianginal therapy. The recommended initial dose is 500 mg
ally twice daily, which can be escalated as needed to a
aximum of 1,000 mg twice daily. The mechanism of action of
nolazine has not been fully characterized but appears to
pend on membrane ion-channel effects (similar to those after
ronic amiodarone) (362). It is contraindicated in patients with
T-prolonging conditions. Preliminary results of a large
6,560) patient trial of ranolazine, begun within 48 h of
A/NSTEMI, suggested safety and symptom relief (reduction in
gina) but did not achieve the primary efficacy end point of a
duction in the composite of cardiovascular death, MI, or recurrent
chemia (hazard ratio [HR] 0.92, 95% CI 0.83 to 1.02) (363,364).
hus, ranolazine may be safely administered for symptom relief
ter UA/NSTEMI, but it does not appear to significantly improve
e underlying disease substrate.
.1.2.7. INTRA-AORTIC BALLOON PUMP COUNTERPULSATION
xperience with IABP for refractory ischemia dates back
ore than 30 years. In a prospective registry of 22,663 IABP
tients, 5,495 of whom had acute MI, placement of an IABP
MI patients primarily was performed for cardiogenic shock,
r hemodynamic support during catheterization and/or angio-
asty, before high-risk surgery, for mechanical complications of
I, or for refractory post-MI UA. Balloon insertions were
ccessful in 97.7% of patients, and major complications oc-
rred in 2.7% of patients during a median use of 3 d (365). The
acement of an IABP could be useful in patients with recurrent
chemia despite maximal medical management and in those
ith hemodynamic instability until coronary angiography and
vascularization can be completed.
.1.2.8. ANALGESIC THERAPY
ecause of the known increased risk of cardiovascular events
ong patients taking COX-2 inhibitors and NSAIDs (366–368),
tients who are taking them at the time of UA/NSTEMI should
scontinue them immediately (see Section 5.2.16 for additional
scussion). A secondary analysis of the Enoxaparin and Throm-
lysis Reperfusion for Acute Myocardial Infarction Treatment heXTRACT)-TIMI-25 data (369) demonstrated an increased
sk of death, reinfarction, HF, or shock among patients who
ere taking NSAIDs within 7 d of enrollment. Longer term
anagement is considered in Section 5.2.16.
.2. Recommendations for Antiplatelet/
nticoagulant Therapy in Patients for Whom
iagnosis of UA/NSTEMI Is Likely or Definite
PDATED)
.2.1. Antiplatelet Therapy: Recommendations
PDATED)
ee Appendixes 7, 8, 9 and the Online Data
upplement)
ASS I
Aspirin should be administered to UA/NSTEMI patients as soon as
possible after hospital presentation and continued indefinitely in
patients who tolerate it. (Level of Evidence: A) (370–377)
A loading dose followed by daily maintenance dose of either
clopidogrel (Level of Evidence: B), (249,378,379) prasugrel†
(in PCI-treated patients) (Level of Evidence: C), (380) or
ticagrelor‡ (Level of Evidence: C) (381) should be administered
to UA/NSTEMI patients who are unable to take aspirin be-
cause of hypersensitivity or major GI intolerance.
Patients with definite UA/NSTEMI at medium or high risk and
in whom an initial invasive strategy is selected (Appendix 6)
should receive dual antiplatelet therapy on presentation. (Level
of Evidence: A) (249,382–384) Aspirin should be initiated on
presentation. (Level of Evidence: A) (370,372–377) The
choice of a second antiplatelet therapy to be added to aspirin
on presentation includes 1 of the following (note that there are no
data for therapywith 2 concurrent P2Y12 receptor inhibitors, and this
is not recommended in the case of aspirin allergy):
Before PCI:
a. Clopidogrel (Level of Evidence: B) (249,382); or
b. Ticagrelor‡ (Level of Evidence: B) (381); or
c. An IV GP IIb/IIIa inhibitor. (Level of Evidence: A)
(135,137,383,385,386) IV eptifibatide and tirofiban
atients weighing 60 kg have an increased exposure to the active metabolite of
asugrel and an increased risk of bleeding on a 10-mg once-daily maintenance dose.
onsideration should be given to lowering the maintenance dose to 5 mg in patients
o weigh 60 kg, although the effectiveness and safety of the 5-mg dose have not
en studied prospectively. For post-PCI patients, a daily maintenance dose should be
en for at least 12months for patients receivingDES and up to 12months for patients
ceiving BMS unless the risk of bleeding outweighs the anticipated net benefit afforded
a P2Y12 receptor inhibitor. Do not use prasugrel in patients with active pathological
eeding or a history of TIA or stroke. In patients age75 years, prasugrel is generally
t recommended because of the increased risk of fatal and intracranial bleeding and
certain benefit except in high-risk situations (patients with diabetes or a history of prior
yocardial infarction), in which its effect appears to be greater and its usemay be considered.
o not start prasugrel in patients likely to undergo urgent CABG. When possible,
continue prasugrel at least 7 days before any surgery (395). Additional risk factors for
eding include body weight 60 kg, propensity to bleed, and concomitant use of
edications that increase the risk of bleeding (e.g., warfarin, heparin, fibrinolytic therapy, or
ronic use of nonsteroidal anti-inflammatory drugs) (395).
‡The recommended maintenance dose of aspirin to be used with ticagrelor is 81
g daily (398). Ticagrelor’s benefits were observed irrespective of prior therapy with
pidogrel (381). When possible, discontinue ticagrelor at least 5 days before any
rgery (399). Issues of patient compliance may be especially important. Consid-
ation should be given to the potential and as yet undetermined risk of intracranial
morrhage in patients with prior stroke or TIA.
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dence: B) (135,137)
At the time of PCI:
• Clopidogrel if not started before PCI (Level of Evidence:
A) (249,382); or
• Prasugrel† (Level of Evidence: B) (380); or
• Ticagrelor‡ (Level of Evidence: B) (381); or
• An IV GP IIb/IIIa inhibitor. (Level of Evidence: A)
(135,137,387)
For UA/NSTEMI patients in whom an initial conservative (i.e.,
noninvasive) strategy is selected, clopidogrel or ticagrelor‡
(loading dose followed by daily maintenance dose) should be
added to aspirin and anticoagulant therapy as soon as possible
after admission and administered for up to 12 months. (Level of
Evidence: B) (249,381,388)
For UA/NSTEMI patients in whom an initial conservative
strategy is selected, if recurrent symptoms/ischemia, heart
failure, or serious arrhythmias subsequently appear, then diag-
nostic angiography should be performed. (Level of Evidence: A)
(188,251) Either an IV GP IIb/IIIa inhibitor (eptifibatide or
tirofiban. [Level of Evidence: A]), (135,137,387) clopidogrel
(loading dose followed by daily maintenance dose [Level of
Evidence: B]), (249) or ticagrelor‡ (loading dose followed by
daily maintenance dose [Level of Evidence: B]) (381) should be
added to aspirin and anticoagulant therapy before diagnostic
angiography (upstream). (Level of Evidence: C)
A loading dose of P2Y12 receptor inhibitor therapy is recom-
mended for UA/NSTEMI patients for whom PCI is planned.§
One of the following regimens should be used:
a. Clopidogrel 600 mg should be given as early as possible before
or at the time of PCI (Level of Evidence: B) (389–391) or
b. Prasugrel† 60 mg should be given promptly and no later than 1
hour after PCI once coronary anatomy is defined and a decision
is made to proceed with PCI (Level of Evidence: B) (380) or
c. Ticagrelor‡ 180 mg should be given as early as possible
before or at the time of PCI. (Level of Evidence: B) (381)
The duration and maintenance dose of P2Y12 receptor inhibitor
therapy should be as follows:
a. In UA/NSTEMI patients undergoing PCI, either clopidogrel
75 mg daily, (249,382) prasugrel† 10 mg daily, (380) or
ticagrelor‡ 90 mg twice daily (381) should be given for at
least 12 months. (Level of Evidence: B)
b. If the risk of morbidity because of bleeding outweighs the
anticipated benefits afforded by P2Y12 receptor inhibitor ther-
apy, earlier discontinuation should be considered. (Level of
Evidence: C)
ASS IIa
For UA/NSTEMI patients in whom an initial conservative strategy is
selected and who have recurrent ischemic discomfort with aspirin, a
P2Y12 receptor inhibitor (clopidogrel or ticagrelor), and anticoagu-
lant therapy, it is reasonable to add a GP IIb/IIIa inhibitor before
diagnostic angiography. (Level of Evidence: C)
For UA/NSTEMI patients in whom an initial invasive strategy is
selected, it is reasonable to omit administration of an IV GP
IIb/IIIa inhibitor if bivalirudin is selected as the anticoagulant
and at least 300 mg of clopidogrel was administered at least 6pplies to patients who were not treated chronically with these medications. anhours earlier than planned catheterization or PCI. (Level of
Evidence: B) (392–394)
ASS IIb
For UA/NSTEMI patients in whom an initial conservative (i.e.,
noninvasive) strategy is selected, it may be reasonable to add
eptifibatide or tirofiban to anticoagulant and oral antiplatelet
therapy. (Level of Evidence: B) (135,137)
Prasugrel† 60 mg may be considered for administration
promptly upon presentation in patients with UA/NSTEMI for
whom PCI is planned, before definition of coronary anatomy if
both the risk for bleeding is low and the need for CABG is
considered unlikely. (Level of Evidence: C) (380,395,396)
The use of upstream GP IIb/IIIa inhibitors may be considered in
high-risk UA/NSTEMI patients already receiving aspirin and a
P2Y12 receptor inhibitor (clopidogrel or ticagrelor) who are
selected for an invasive strategy, such as those with elevated
troponin levels, diabetes, or significant ST-segment depres-
sion, and who are not otherwise at high risk for bleeding. (Level
of Evidence: B) (135,137,188,250,397)
In patients with definite UA/NSTEMI undergoing PCI as part of
an early invasive strategy, the use of a loading dose of
clopidogrel of 600 mg, followed by a higher maintenance
dose of 150 mg daily for 6 days, then 75 mg daily may be
reasonable in patients not considered at high risk for bleed-
ing. (Level of Evidence: B) (389)
ASS III: NO BENEFIT
Abciximab should not be administered to patients in whom PCI
is not planned. (Level of Evidence: A) (386,387)
InUA/NSTEMI patientswhoare at low risk for ischemic events (e.g.,
TIMI risk score <2) or at high risk of bleeding and who are already
receiving aspirin and a P2Y12 receptor inhibitor, upstreamGP IIb/IIIa
inhibitors are not recommended. (Level of Evidence: B)
(392,396,397)
ASS III: HARM
In UA/NSTEMI patients with a prior history of stroke and/or TIA for
whom PCI is planned, prasugrel† is potentially harmful as part of a
dual antiplatelet therapy regimen. (Level of Evidence: B) (380)
atients weighing 60 kg have an increased exposure to the active metabolite of
asugrel and an increased risk of bleeding on a 10-mg once-daily maintenance
se. Consideration should be given to lowering the maintenance dose to 5 mg in
tients who weigh 60 kg, although the effectiveness and safety of the 5-mg dose
ve not been studied prospectively. For post-PCI patients, a daily maintenance
se should be given for at least 12 months for patients receiving DES and up to
months for patients receiving BMS unless the risk of bleeding outweighs the
ticipated net benefit afforded by a P2Y12 receptor inhibitor. Do not use prasugrel
patients with active pathological bleeding or a history of TIA or stroke. In
tients age 75 years, prasugrel is generally not recommended because of the
creased risk of fatal and intracranial bleeding and uncertain benefit except in
gh-risk situations (patients with diabetes or a history of prior myocardial
farction), in which its effect appears to be greater and its use may be
nsidered. Do not start prasugrel in patients likely to undergo urgent CABG.
hen possible, discontinue prasugrel at least 7 days before any surgery (395).
dditional risk factors for bleeding include body weight 60 kg, propensity to
eed, and concomitant use of medications that increase the risk of bleeding
.g., warfarin, heparin, fibrinolytic therapy, or chronic use of nonsteroidal
ti-inflammatory drugs) (395).
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ASS I
Anticoagulant therapy should be added to antiplatelet ther-
apy in UA/NSTEMI patients as soon as possible after
presentation.
a. For patients in whom an invasive strategy is selected,
regimens with established efficacy at a Level of Evidence:
A include enoxaparin and UFH (Appendix 9 has replaced
Figure 7), and those with established efficacy at a Level of
Evidence: B include bivalirudin and fondaparinux (Appendix
9 has replaced Figure 7).
b. For patients in whom a conservative strategy is selected,
regimens using either enoxaparin or UFH (Level of Evi-
dence: A) or fondaparinux (Level of Evidence: B) have
established efficacy. (Appendix 9 has replaced Figure 8)
See also Class IIa recommendation below.
c. In patients in whom a conservative strategy is selected and
who have an increased risk of bleeding, fondaparinux is
preferable. (Level of Evidence: B) (Appendix 9 has replaced
Figure 8)
ASS IIa
For UA/NSTEMI patients in whom an initial conservative
strategy is selected, enoxaparin or fondaparinux is preferable
to UFH as anticoagulant therapy, unless CABG is planned
within 24 h. (Level of Evidence: B)
gure 7. Algorithm for Patients With UA/NSTEMI Man-
ged by an Initial Invasive Strategy. Deleted—Not Cur-
nt. Replaced by Appendix 9.
gure 8. Algorithm for Patients With UA/NSTEMI Man-
ged by an Initial Conservative Strategy. Deleted—Not
urrent. Replaced by Appendix 9.
gure 9. Management After Diagnostic Angiography in
atients With UA/NSTEMI. Deleted—Not Current. Re-
laced by Appendix 9.
.2.3. Additional Management Considerations
r Antiplatelet and Anticoagulant Therapy: Recommen-
ations (UPDATED)
ee Appendixes 7, 8, 9 and the Online Data Supplement)
ASS I
For UA/NSTEMI patients in whom an initial conservative
strategy is selected and no subsequent features appear that
would necessitate diagnostic angiography (recurrent symp-
toms/ischemia, heart failure, or serious arrhythmias), a stress
test should be performed. (Level of Evidence: B) (251)
a. If, after stress testing, the patient is classified as not at
low risk, diagnostic angiography should be performed.
(Level of Evidence: A) (188,251)
imited data are available for the use of other LMWHs (e.g., dalteparin; see
able 17 and Appendixes 7 and 8) in UA/NSTEMI. heb. If, after stress testing, the patient is classified as being at
low risk, the instructions noted below should be followed in
preparation for discharge (188,251):
i. Continue aspirin indefinitely. (Level of Evidence: A)
(372,374,375)
ii. Continue clopidogrel or ticagrelor‡ for up to 12 months.
(Level of Evidence: B) (249,381,388)
iii. Discontinue IV GP IIb/IIIa inhibitor if started previ-
ously. (Level of Evidence: A) (135,137)
iv. Continue UFH for 48 hours (Level of Evidence: A)
(377,407) or administer enoxaparin (Level of Evidence:
A) (75,186,408) or fondaparinux (Level of Evidence: B)
(409) for the duration of hospitalization, up to 8 days, and
then discontinue anticoagulant therapy.
For UA/NSTEMI patients in whom CABG is selected as a
postangiography management strategy, the instructions noted
below should be followed.
a. Continue aspirin. (Level of Evidence: A) (410–416)
b. See Class I, #3, in this section.
c. Discontinue IV GP IIb/IIIa inhibitor (eptifibatide or tiro-
fiban) 4 hours before CABG. (Level of Evidence: B)
(410,414,417)
d. Anticoagulant therapy should be managed as follows:
i. Continue UFH. (Level of Evidence: B) (175,418–420)
ii. Discontinue enoxaparin 12 to 24 hours before CABG
and dose with UFH per institutional practice. (Level of
Evidence: B) (175,418–420)
iii. Discontinue fondaparinux 24 hours before CABG and
dose with UFH per institutional practice. (Level of
Evidence: B) (421,422)
iv. Discontinue bivalirudin 3 hours before CABG and dose
with UFH per institutional practice. (Level of Evidence:
B) (423,424)
In patients taking a P2Y12 receptor inhibitor in whom CABG is
planned and can be delayed, it is recommended that the drug
be discontinued to allow for dissipation of the antiplatelet
effect (Level of Evidence: B). (249) The period of withdrawal
should be at least 5 days in patients receiving clopidogrel
(Level of Evidence: B) (249,383,425) or ticagrelor‡ (Level of
Evidence: C) (399) and at least 7 days in patients receiving
prasugrel† (Level of Evidence: C) (395) unless the need for
revascularization and/or the net benefit of the P2Y12 receptor
inhibitor therapy outweighs the potential risks of excess bleed-
ing. (Level of Evidence: C) (426)
For UA/NSTEMI patients in whom PCI has been selected as a
postangiography management strategy, the instructions noted
below should be followed:
a. Continue aspirin. (Level of Evidence: A) (372–375)
b. Administer a loading dose of a P2Y12 receptor inhibitor if
not started before diagnostic angiography. (Level of Evi-
dence: A) (379,381,391,427–429)
c. Discontinue anticoagulant therapy after PCI for uncomplicated
cases. (Level of Evidence: B) (175,186,400,430,431)
he recommended maintenance dose of aspirin to be used with ticagrelor is 81 mg
ily (398). The benefits of ticagrelor were observed irrespective of prior therapy
th clopidogrel (381). When possible, discontinue ticagrelor at least 5 d before any
rgery (399). Issues of patient compliance may be especially important. Consid-
ation should be given to the potential and as yet undetermined risk of intracranial
morrhage in patients with prior stroke or TIA.
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lected as a management strategy and in whom no significant
obstructive coronary artery disease on angiography was
found, antiplatelet and anticoagulant therapy should be
administered at the discretion of the clinician (Level of
Evidence: C). For patients in whom evidence of coronary
atherosclerosis is present (e.g., luminal irregularities or
intravascular ultrasound-demonstrated lesions), albeit with-
out flow-limiting stenoses, long-term treatment with aspirin
and other secondary prevention measures should be pre-
scribed. (Level of Evidence: C)
For UA/NSTEMI patients in whom medical therapy is selected as a
management strategy and in whom coronary artery disease was
found on angiography, the following approach is recommended:
a. Continue aspirin. (Level of Evidence: A) (372,374,375)
b. Administer a loading dose of clopidogrel or ticagrelor‡ if
not given before diagnostic angiography. (Level of Evi-
dence: B) (249,381)
c. Discontinue IV GP IIb/IIIa inhibitor if started previously.
(Level of Evidence: B) (135,137,392,432)
d. Anticoagulant therapy should be managed as follows:
i. Continue IV UFH for at least 48 hours or until discharge
if given before diagnostic angiography (Level of Evi-
dence: A) (175,377,407)
ii. Continue enoxaparin for duration of hospitalization, up
to 8 days, if given before diagnostic angiography.
(Level of Evidence: A) (175,186,408,422)
iii. Continue fondaparinux for duration of hospitalization,
up to 8 days, if given before diagnostic angiography.
(Level of Evidence: B) (409)
iv. Either discontinue bivalirudin or continue at a dose of
0.25 mg/kg per hour for up to 72 hours at the
physician’s discretion if given before diagnostic an-
giography. (Level of Evidence: B) (394,433,434)
For UA/NSTEMI patients in whom a conservative strategy is
selected and who do not undergo angiography or stress test-
ing, the instructions noted below should be followed:
a. Continue aspirin indefinitely. (Level of Evidence: A)
(372,374,375)
b. Continue clopidogrel or ticagrelor‡ for up to 12 months.
(Level of Evidence: B) (249,378,381,435)
c. Discontinue IV GP IIb/IIIa inhibitor if started previously.
(Level of Evidence: A) (135,137)
d. Continue UFH for 48 hours (Level of Evidence: A)
(377,407) or administer enoxaparin (Level of Evidence: A)
(75,186,408) or fondaparinux (Level of Evidence: B) (409)
for the duration of hospitalization, up to 8 days, and then
discontinue anticoagulant therapy.
For UA/NSTEMI patients in whom an initial conservative
strategy is selected and in whom no subsequent features
appear that would necessitate diagnostic angiography (re-
current symptoms/ischemia, heart failure, or serious ar-
rhythmias), LVEF should be measured. (Level of Evidence: B)
(188,436–439)
ASS IIa
For UA/NSTEMI patients in whom PCI has been selected as a
postangiography management strategy, it is reasonable to
administer an IV GP IIb/IIIa inhibitor (abciximab, eptifibatide, ceor tirofiban) if not started before diagnostic angiography,
particularly for troponin-positive and/or other high-risk pa-
tients. (Level of Evidence: A) (188,250)
For UA/NSTEMI patients in whom PCI is selected as a manage-
ment strategy, it is reasonable to omit administration of an IV GP
IIb/IIIa inhibitor if bivalirudin was selected as the anticoagulant
and at least 300 mg of clopidogrel was administered at least 6
hours earlier. (Level of Evidence: B) (188,392)
If LVEF is less than or equal to 0.40, it is reasonable to perform
diagnostic angiography. (Level of Evidence: B) (436–439)
If LVEF is greater than 0.40, it is reasonable to perform a stress
test. (Level of Evidence: B) (436)
ASS IIb
Platelet function testing to determine platelet inhibitory response
in patients with UA/NSTEMI (or, after ACS and PCI) on P2Y12
receptor inhibitor therapy may be considered if results of testing
may alter management. (Level of Evidence: B) (440–444)
Genotyping for a CYP2C19 loss of function variant in patients with
UA/NSTEMI (or, after ACS and with PCI) on P2Y12 receptor
inhibitor therapy might be considered if results of testing may alter
management. (Level of Evidence: C) (445–451)
ASS III: NO BENEFIT
IV fibrinolytic therapy is not indicated in patients without acute
ST-segment elevation, a true posterior MI, or a presumed new
left bundle-branch block. (Level of Evidence: A) (452)
Antithrombotic therapy is essential to modify the disease
ocess and its progression to death, MI, or recurrent MI in the
ajority of patients who have ACS due to thrombosis on a
aque. A combination of ASA, an anticoagulant, and additional
tiplatelet therapy represents the most effective therapy. The
tensity of treatment is tailored to individual risk, and triple-
tithrombotic treatment is used in patients with continuing
chemia or with other high-risk features and in patients oriented
an early invasive strategy (Appendix 6; Appendix 9 has
placed Figures 7, 8, and 9). Appendixes 7 and 8 show the
commended doses of the various agents. A problematic group
patients are those who present with UA/NSTEMI but who are
erapeutically anticoagulated with warfarin. In such patients,
inical judgment is needed with respect to initiation of the
tiplatelet and anticoagulant therapy recommended in this
ction. A general guide is not to initiate anticoagulant therapy
til the international normalized ratio (INR) is less than 2.0.
owever, antiplatelet therapy should be initiated even in patients
erapeutically anticoagulated with warfarin, especially if an
vasive strategy is planned and implantation of a stent is
ticipated. In situations where the INR is supratherapeutic, the
eeding risk is unacceptably high, or urgent surgical treatment
necessary, reversal of the anticoagulant effect of warfarin may
considered with either vitamin K or fresh-frozen plasma as
emed clinically appropriate on the basis of physician judg-
ent.
.2.3.1. ANTIPLATELET/ANTICOAGULANT THERAPY IN
TIENTS FOR WHOM DIAGNOSIS OF UA/NSTEMI IS LIKELY
R DEFINITE (NEW SECTION)
.2.3.1.1. Newer P2Y12 Receptor Inhibitors. P2Y12 re-
ptor inhibitor therapy is an important component of anti-
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June 11, 2013:e179–347 UA/NSTEMI Guideline: 2012 Update Incorporatedatelet therapy in patients with UA/NSTEMI and has been
sted in several large trial populations with UA/NSTEMI.
he last version of the guideline recommended the use of
opidogrel in patients with UA/NSTEMI because it was the
ly US Food and Drug Administration (FDA)–approved
2Y12 receptor inhibitor in this patient population at that time
). Since the publication of the last guideline (1), the FDA has
proved 2 additional P2Y12 receptor inhibitors for use in
tients with UA/NSTEMI. The FDA approved the use of
asugrel and ticagrelor based on data from head-to-head com-
rison trials with clopidogrel, in which prasugrel and ticagrelor
ere respectively superior to clopidogrel in reducing clinical
ents but at the expense of an increased risk of bleeding.
The pivotal trial for prasugrel, TRITON–TIMI 38 (Trial
Assess Improvement in Therapeutic Outcomes by Op-
mizing Platelet Inhibition with Prasugrel–Thrombolysis
Myocardial Infarction) (380), focused on patients with
ute coronary syndrome (ACS) who were referred for
rcutaneous coronary intervention (PCI). TRITON–TIMI
randomly assigned 13,608 patients with moderate- to
gh-risk ACS, of whom 10,074 (74%) had UA/NSTEMI,
receive prasugrel (a 60-mg loading dose and a 10-mg
ily maintenance dose) or clopidogrel (a 300-mg loading
se and a 75-mg daily maintenance dose) for a median
llow-up of 14.5 months. Acetylsalicylic acid (aspirin)
as prescribed within 24 hours of PCI. Clinical endpoints
ere assessed at 30 and 90 days and then at 3-month
tervals for 6 to 15 months. Among patients with UA/
STEMI undergoing PCI, a prasugrel loading dose was
ministered before, during, or within 1 hour after PCI but
ly after coronary anatomy had been defined. Patients
king any thienopyridine within 5 days of randomization
ere excluded.
Prasugrel was associated with a significant 2.2% absolute
duction and a 19% relative reduction in the primary efficacy
dpoint, a composite of the rate of death due to cardiovas-
lar causes (including arrhythmia, congestive heart failure,
ock, and sudden or unwitnessed death), nonfatal myocar-
al infarction (MI), or nonfatal stroke during the follow-up
riod (see Online Data Supplement). The primary efficacy
dpoint occurred in 9.9% of patients receiving prasugrel and
.1% of patients receiving clopidogrel (HR for prasugrel
rsus clopidogrel: 0.81; 95% CI: 0.73 to 0.90; p0.001)
80), Prasugrel decreased cardiovascular death, MI, and
roke by 138 events (number needed to treat46). The
fference in the primary endpoint was largely related to the
fference in rates of non-fatal MI (7.3% for prasugrel versus
5% for clopidogrel; HR: 0.76; 95% CI: 0.67 to 0.85;
0.001). Rates of cardiovascular death (2.1% versus 2.4%;
0.31) and nonfatal stroke (1.0% versus 1.0%; p0.93)
ere not reduced by prasugrel relative to clopidogrel. Rates
stent thrombosis were significantly reduced from 2.4% to
1% (p0.001) by prasugrel.
Prasugrel was associated with a significant increase in
e rate of bleeding, notably TIMI (Thrombolysis In
yocardial Infarction) major hemorrhage, which was ob-
rved in 2.4% of patients taking prasugrel and in 1.8% of
tients taking clopidogrel (HR for prasugrel versus clopi-
grel: 1.32; 95% CI: 1.03 to 1.68; p0.03). Prasugrel was resociated with a significant increase in fatal bleeding
mpared with clopidogrel (0.4% versus 0.1%; p0.002).
rom the standpoint of safety, prasugrel was associated
ith an increase of 35 TIMI major and non– coronary
tery graft bypass (CABG) bleeds (number needed to
rm167) (380), Also, greater rates of life-threatening
eeding were evident in the prasugrel group than in the
opidogrel group: 1.4% versus 0.9%, respectively (HR for
asugrel: 1.52; 95% CI: 1.08 to 2.13; p0.01). In the few
tients who underwent CABG, TIMI major bleeding
rough 15 months was also greater with prasugrel than
ith clopidogrel (13.4% versus 3.2%, respectively; HR for
asugrel: 4.73; 95% CI: 1.90 to 11.82; p0.001) (380),
he net clinical benefit in the TRITON–TIMI 38 study
monstrated a primary efficacy and safety endpoint rate of
.9% in the clopidogrel group versus 12.2% in the prasugrel group
R: 0.87; 95% CI: 0.79 to 0.95; p0.004).
A post hoc analysis suggested there were 3 subgroups of
CS patients who did not have a favorable net clinical benefit
efined as the rate of death due to any cause, nonfatal MI,
nfatal stroke, or non–CABG-related nonfatal TIMI major
eeding) from the use of prasugrel or who had net harm:
atients with a history of stroke or transient ischemic attack
fore enrollment had net harm from prasugrel (HR: 1.54;
% CI: 1.02 to 2.32; p0.04); patients age 75 years had
net benefit from prasugrel (HR: 0.99; 95% CI: 0.81 to
21; p0.92); and patients with a body weight of 60 kg
d no net benefit from prasugrel (HR: 1.03; 95% CI: 0.69 to
53; p0.89). In both treatment groups, patients with at least
of these risk factors had higher rates of bleeding than those
ithout them (380).
The FDA approved prasugrel on July 10, 2009, and cited a
ntraindication against its use in patients with a history of
ansient ischemic attack or stroke or with active pathological
eeding (395). The FDA labeling information includes a
neral warning against the use of prasugrel in patients age
75 years because of concerns of an increased risk of fatal
d intracranial bleeding and uncertain benefit except in
gh-risk situations (patients with diabetes or a history of
ior MI), in which case the net benefit appears to be greater
d its use may be considered (395). In focusing specifically
patients with UA/NSTEMI, the rate of the primary efficacy
dpoint was significantly reduced in favor of prasugrel
.9% versus 12.1%; adjusted HR: 0.82; 95% CI: 0.73 to
93; p0.002) (380).
The pivotal trial for ticagrelor, PLATO (Study of Platelet
hibition and Patient Outcomes) (381), was a multicenter,
ternational, randomized controlled trial comparing ticagre-
r with clopidogrel (on a background of aspirin therapy) to
termine whether ticagrelor is superior to clopidogrel for the
evention of vascular events and death in a broad population
patients with ACS (see Online Data Supplement). A total
18,624 patients hospitalized with an ACS were randomized
862 centers (from 2006 through 2008). Of those, 11,598
tients had UA/NSTEMI (patients with UA and NSTEMI
ade up 16.7% and 42.7% of the overall population, respec-
vely), whereas 7,026 patients had STEMI.
The primary efficacy endpoint was the time to first occur-nce of the composite of vascular death, MI, or stroke. The
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eeding event. The randomized treatment was scheduled to
ntinue for 12 months; however, patients were allowed to
ave the trial at 6 to 9 months if the event-driven study
hieved its targeted number of primary events. Overall, the
edian duration of study drug administration was 277 days.
sing a double-blind, double-dummy design, ticagrelor
80-mg loading dose followed by 90 mg twice daily) was
mpared with clopidogrel (300- to 600-mg loading dose
llowed by 75 mg daily) (381). At 24 hours after random-
ation, 79% of patients treated with clopidogrel received at
ast 300 mg, and nearly 20% received at least 600 mg.
verall, 64.3% of patients underwent PCI during the index
spitalization and 60.6% had stent implantation. Median
mes from the start of hospitalization to initiation of study
eatment were 4.9 and 5.3 hours for ticagrelor and clopi-
grel, respectively.
At 12 months, ticagrelor was associated with a 1.9%
solute reduction and 16% relative reduction in the primary
mposite outcome compared with clopidogrel (9.8% versus
.7%; HR: 0.84; 95% CI: 0.77 to 0.92), which was driven by
wer rates of MI (5.8% versus 6.9%; HR: 0.84; 95% CI: 0.75
0.95) and vascular death (4.0% versus 5.1%; HR: 0.79;
% CI: 0.69 to 0.91) (381). The benefits of ticagrelor
peared consistent across most subgroups studied, with no
gnificant interaction being observed between the treatment
fect and type of ACS. In focusing specifically on patients
ith UA/NSTEMI, ticagrelor was associated with a signifi-
nt reduction in the primary efficacy endpoint among
STEMI patients (n7,955 patients; 11.4% versus 13.9%;
R: 0.83; 95% CI: 0.73 to 0.94) but not among UA patients
3,112 patients; 8.6% versus 9.1%; HR: 0.96; 95% CI:
75 to 1.22), although caution is urged against overinterpret-
g subgroup analyses. The benefits of ticagrelor in PLATO
peared within the first 30 days, persisted for up to 360 days,
d were evident irrespective of clopidogrel pre-treatment
d whether patients had invasive or medical management
anned. Notably, ticagrelor was associated with a 1.4%
solute reduction in all-cause mortality (4.5% versus 5.9%;
R: 0.78; 95% CI: 0.69 to 0.89) and with lower rates of
finite stent thrombosis (1.3% versus 1.90%; HR: 0.67; 95%
I: 0.50 to 0.91).
There were no significant differences between the ticagre-
r and clopidogrel groups in rates of major bleeding (the
imary safety endpoint: composite of major life-threatening
d other major bleeding events, PLATO study criteria;
.6% versus 11.2%; HR: 1.04; 95% CI: 0.95 to 1.13), TIMI
ajor bleeding (7.9% versus 7.7%; HR: 1.03; 95% CI: 0.93
1.15), or fatal bleeding (0.3% versus 0.3%; HR: 0.87; 95%
I: 0.48 to 1.59) (381). There were also no differences in
ajor bleeding in patients undergoing CABG, in whom
opidogrel and ticagrelor were discontinued before the
ocedure for 5 days and 24 to 72 hours, respectively, per
udy protocol. Ticagrelor, however, was associated with a
gher rate of non–CABG-related major bleeding (4.5%
rsus 3.8%, p0.03). In addition, ticagrelor caused a
gher incidence of dyspnea (13.8% versus 7.8%; HR:
84; 95% CI: 1.68 to 2.02; although not necessitating drug
scontinuation except in a few cases), mild increases in Featinine and uric acid levels, and a higher rate of
ntricular pauses 3 seconds in the first week (5.8%
rsus 3.6%, p0.01; but without causing differences in
ncope or pacemaker implantation). Overall, discontinu-
ion of the study drug due to adverse events occurred
ore frequently with ticagrelor than with clopidogrel
.4% versus 6.0%; p0.001). Patients with a history of
eeding were excluded in PLATO, and 4% of patients
d a prior history of nonhemorrhagic stroke (381). The
ficacy and safety of ticagrelor in patients with prior
ansient ischemic attack or stroke were not reported in
LATO (381), and the balance of risks and benefits of
cagrelor in this patient population remains unclear.
A separate analysis was performed for the 5,216 patients in
LATO admitted with ACS and prespecified as planned for
ninvasive management (constituting 28% of the overall
LATO study population) (388). Compared with clopidogrel,
agrelor was associated with a lower incidence of the primary
dpoint (12.0% versus 14.3%; HR: 0.85; 95% CI: 0.73 to 1.00;
0.04) and overall mortality without increasing major bleed-
g. These results indicate the benefits of intensified P2Y12 inhibi-
n with ticagrelor applied broadly for patients regardless of the
tended or actualized management strategy (388).
The benefits of ticagrelor in PLATO appeared to be
tenuated in patients weighing less than the median weight
r their sex and those not taking lipid-lowering therapies at
ndomization (381). There was a significant interaction
tween treatment and geographic region, with patients
rolled in North America having no statistically significant
fferences between ticagrelor and clopidogrel with respect to
e primary efficacy endpoint (381). Extensive additional
alyses were conducted to explore potential explanations for
is interaction between treatment effect in PLATO and
ographic region and whether this could be explained by
ecific patient characteristics or concomitant therapies (398).
ahaffey and colleagues (398) noted that a significantly
gher proportion of patients in the United States received a
edian aspirin dose of300 mg daily compared with the rest of
e world (53.6% versus 1.7%). Indeed, of all 37 baseline and
strandomization variables explored, only aspirin maintenance
se appeared to explain a substantial fraction of the regional
teraction. Of note, subgroup analysis consistently showed the
me aspirin-dose effect outside the United States. Without
ing able to fully rule out the play of chance or other factors
lated to clinical care in North America as explanations for the
gional interaction, PLATO concluded that a low aspirin
aintenance dose (100 mg daily) is likely to be associated
ith the most favorable outcomes when using the potent P2Y12
hibitor ticagrelor in patients with ACS (398).
Because of its reversible inhibition of the P2Y12 recep-
r, ticagrelor is associated with more rapid functional
covery of circulating platelets and, consequently, a faster
fset of effect than clopidogrel. Although this may repre-
nt a potential advantage for patients with ACS undergo-
g early CABG, it may theoretically pose a problem for
ncompliant patients (especially given its twice-daily
sing regimen).
The FDA approved ticagrelor on July 20, 2011 (399). TheDA also issued a “Boxed Warning” indicating that aspirin
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fectiveness of ticagrelor, cautioned against its use in
tients with active bleeding or a history of intracranial
morrhage, and advocated a Risk Evaluation and Mitiga-
on Strategy, a plan to help ensure that the benefits of
cagrelor outweigh its risks. As part of that plan, the
anufacturer is mandated to conduct educational outreach
ograms to alert physicians about the risk of using higher
ses of aspirin.
Dual antiplatelet therapy with aspirin and either clopi-
grel or prasugrel has increased the risk of intracranial
morrhage in several clinical trials and patient populations
specially in those with prior stroke) (380,453–455). In
LATO, the number of patients with prior stroke was small,
miting the power to detect treatment differences in intracra-
al bleeding in this subgroup (456). Patients with prior stroke
TIA have been excluded from PEGASUS (Prevention of
ardiovascular Events in Patients With Prior Heart Attack
sing Ticagrelor Compared to Placebo on a Background of
spirin) (457), an ongoing trial of ticagrelor versus placebo
addition to aspirin in patients with stable coronary artery
sease. Until further data become available, it seems prudent
weigh the possible increased risk of intracranial bleeding
hen considering the addition of ticagrelor to aspirin in
tients with prior stroke or TIA (458).
.2.3.1.2. Choice of P2Y12 Receptor Inhibitors for PCI
UA/NSTEMI. The 2012 writing group cautions that
ta on the use of prasugrel and ticagrelor come solely from
e TRITON–TIMI 38 and PLATO trials, respectively, and
eir use in clinical practice should carefully follow how they
ere tested in these studies (380,381). Prasugrel was admin-
tered only after a decision to proceed to PCI was made,
hereas ticagrelor was studied in “all-comer” patients with
A/NSTEMI, including invasively and medically managed
tients. The 2012 writing group does not recommend that
asugrel be administered routinely to patients with UA/
STEMI before angiography, such as in an emergency
partment, or used in patients with UA/NSTEMI who have
t undergone PCI. The FDA package label suggests that it is
asonable to consider selective use of prasugrel before
theterization in subgroups of patients for whom a decision
proceed to angiography and PCI has already been estab-
shed for any reason (395). The 2012 writing group acknowl-
ges this flexibility, but it is not its intention to make more
ecific recommendations about which subgroups of patients
ight benefit from prasugrel or ticagrelor instead of clopi-
grel. The 2012 writing group does wish to caution clini-
ans about the potential increased bleeding risks associ-
ed with prasugrel and ticagrelor compared with
opidogrel in specific settings and especially among the
bgroups identified in the package insert and clinical trials
80,381,395,399). This guideline explicitly does not endorse
e of the P2Y12 receptor inhibitors over the other. There
ere several reasons for this decision. Although the compos-
e efficacy endpoint in TRITON–TIMI 38 favored prasugrel,
iven predominantly by a difference in nonfatal MIs (mostly
ymptomatic), with deaths and nonfatal strokes being simi-
r, bleeding was increased in the prasugrel group (380). On toe other hand, the composite efficacy endpoint in PLATO
voring ticagrelor over clopidogrel was driven by differences
both vascular death and nonfatal MIs, with stroke rates
ing similar. Ticagrelor was also associated with a notable
duction in all-cause mortality in PLATO. Compared with
opidogrel, ticagrelor was associated with a higher rate of
n–CABG-related major bleeding and slightly more fre-
ent discontinuation of the study drug due to adverse events
81). On the other hand, prasugrel was associated with a
gnificant increase in the rate of TIMI major hemorrhage,
IMI major and non-CABG bleeding, as well as higher fatal
d life-threatening bleeding. There was a significant inter-
tion between the treatment effect in PLATO and the
ographic region, with lack of benefit in the United States
r ticagrelor versus clopidogrel (with the explanation de-
nding on a post hoc analysis of aspirin maintenance dose,
noted in the preceding text) (398) (see Online Data
upplement).
It must be recognized, however, that the 2 newer P2Y12
ceptor inhibitors were studied in different patient popu-
tions and that there is no head-to-head comparative trial
these agents. Also, the loading dose of clopidogrel in
RITON–TIMI 38 was lower than is currently recommended
this guideline (380). Furthermore, some emerging studies
ggest there may be some patients who are resistant to
opidogrel, but there is little information about the use of
rategies to select patients who might do better with newer
2Y12 receptor inhibitors. Considerations of efficacy in the
evention of thrombosis and risk of an adverse effect related
bleeding and experience with a given medication may best
ide decisions about the choice of P2Y12 receptor inhibitor
r individual patients (459) (Appendix 8).
.2.3.1.2.1. Timing of Discontinuation of P2Y12 Receptor
hibitor Therapy for Surgical Procedures. The 2012 writing
oup weighed the current data on the use of P2Y12
ceptor inhibitor therapy in patients who remain hospi-
lized after UA/NSTEMI and are candidates for CABG
d retained the 2007 recommendation (7) of empirical
iscontinuation of clopidogrel therapy for at least 5 days
49) and advocated a period of at least 7 days in patients
ceiving prasugrel and a period of at least 5 days in
atients receiving ticagrelor for their respective discontin-
ation before planned CABG (395,399). Ultimately, the
atient’s clinical status will determine the risk-to-benefit
tio of CABG compared with awaiting restoration of
latelet function.
It is the opinion of the 2012 writing group that
hysicians and patients should be cautioned against
rly discontinuation of P2Y12 receptor inhibitors for
ective noncardiac procedures. Given the increased
azard of recurrent cardiovascular events from prema-
re discontinuation of P2Y12 inhibitors and the in-
eased bleeding risk in patients undergoing procedures
n therapy (e.g., colonoscopy with biopsy, dental pro-
dures), it is advisable to consult a cardiologist and
referably defer elective noncardiac procedures until the
atient finishes the appropriate course of P2Y12 recep-
r inhibition therapy, especially in UA/NSTEMI pa-
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ith dual antiplatelet therapy after deployment of a
rug-eluting stent (DES) (460).
.2.3.1.3. Interindividual Variability in Responsiveness
Clopidogrel. Although clopidogrel in combination with
pirin has been shown to reduce recurrent coronary events in
e posthospitalized ACS population (249,382), the response
clopidogrel varies among patients, and diminished re-
onsiveness to clopidogrel has been observed (461,462).
lopidogrel is a pro-drug and requires conversion to
130964, its active metabolite, through a 2-step process in
e liver that involves several CYP450 isoenzymes (445);
these, the CYP2C19 isoenzyme is responsible for almost
lf of the first step formation (446). At least 3 major genetic
lymorphisms of the CYP2C19 isoenzyme are associated with
ss of function: CYP2C19*1, *2, and *3 (446–448). The
YP2C19*2 and *3 variants account for 85% and 99% of the
ss-of-function alleles in Caucasians and Asians, respectively
46). There are racial and ethnic differences in the prevalence of
ese loss-of-function alleles among Caucasians, African Amer-
ans, Asians, and Latinos, but all of these groups have some
pression of them.
Data from a number of observational studies have demon-
rated an association between an increased risk of adverse
rdiovascular events and the presence of more than or equal
1 of the nonfunctioning alleles (446,447,449,450,461–465)
d are well delineated in the ACCF/AHA Clopidogrel
linical Alert (446).
Prasugrel, the second FDA-approved P2Y12 receptor in-
bitor for use in ACS, is also a prodrug that requires
nversion to its active metabolite. Prasugrel requires a single
YP-dependent step for its oxidation to the active metabolite,
d at least 2 observational studies have demonstrated no
gnificant decrease in plasma concentrations or platelet
hibition activity in carriers of at least 1 loss-of-function
lele of the CYP2C19 isoenzyme (466,467). On the other
nd, ticagrelor, the latest FDA-approved P2Y12 receptor
hibitor, is a nonthienopyridine, reversible, direct-acting oral
tagonist of the P2Y12 receptor that does not require
ansformation to an active metabolite (468).
Since the FDA announced a “Boxed Warning” on March 12,
10, about the diminished effectiveness of clopidogrel in
tients with an impaired ability to convert the drug into its
tive form (459), there has been much interest in whether
inicians should perform routine testing in patients being treated
ith clopidogrel. The routine testing could be for genetic
riants of the CYP2C19 allele and/or for overall effectiveness
r inhibition of platelet activity. The ACCF/AHA Clopidogrel
linical Alert expertly summarizes the issues surrounding clopi-
grel and the use of genotype testing, as well as the potential
r routine platelet function testing (446).
The FDA label revision does not mandate testing for
YP2C19 genotypes or overall platelet function (459). The
vision serves to warn clinicians that certain patient subgroups
ay exhibit reduced clopidogrel-mediated platelet inhibition and
phasizes that clinicians should be aware of alternative treat-ent strategies to tailor alternative therapies when appropriate. unA number of commercially available genetic test kits will
entify the presence of more than or equal to 1 of the
ss-of-function CYP2C19 alleles, but these tests are expen-
ve and not routinely covered by most insurance policies.
dditionally, there are no prospective studies that demon-
rate that the routine use of these tests coupled with modi-
cation of anti-platelet therapy improves clinical outcomes or
duces subsequent clinical events. A recent meta-analysis
monstrated an association between the CYP2C19 genotype
d clopidogrel responsiveness but no significant association
genotype with cardiovascular events (469). Several ongo-
g studies are examining whether genotype assessment with
tendant alteration in antiplatelet therapy for those with
ss-of-function alleles can improve clinical outcomes. On
e basis of the current evidence, it is difficult to strongly
commend genotype testing routinely in patients with ACS,
t it might be considered on a case-by-case basis, especially
patients who experience recurrent ACS events despite
going therapy with clopidogrel.
Some argue that clinicians should consider routine testing
platelet function, especially in patients undergoing high-
sk PCI (446), to maximize efficacy while maintaining
fety. Again, no completed prospective studies have exam-
ed such an approach to guide such a sweeping change in
inical management. At least 4 randomized clinical evalua-
on studies being conducted now are testing the hypothesis
at routine platelet function testing should be used to tailor
tiplatelet therapy, and any strong recommendation regard-
g more widespread use of such testing must await the
sults of these trials. The lack of evidence does not mean
ck of efficacy or potential benefit, but the prudent physician
ould maintain an open yet critical mind-set about the
ncept until data are available from 1 of the ongoing
ndomized clinical trials examining this strategy.
Our recommendations for the use of genotype testing and
atelet function testing seek to strike a balance between not
posing an undue burden on clinicians, insurers, and society
implement these strategies in patients with UA or NSTEMI
d that of acknowledging the importance of these issues to
tients with UA/NSTEMI. Our recommendations that the
e of either strategy may have some benefit should be taken
the context of the remarks in this update, as well as the
ore comprehensive analysis in the ACCF/AHA Clopi-
grel Clinical Alert (446). The Class IIb recommendation
these strategies suggests that a selective, limited ap-
oach to platelet genotype assessment and platelet func-
on testing is the more prudent course until better clinical
idence exists for us to provide a more scientifically
rived recommendation.
.2.3.1.4. Optimal Loading and Maintenance Dosages
f Clopidogrel. Some have suggested that the loading and
aintenance doses of clopidogrel should be altered to ac-
unt for potential reduced responsiveness to clopidogrel
erapy or that some subgroups of high-risk patients should
treated preferentially with prasugrel (446). Accordingly,
e optimal loading and short-term maintenance dosing for
opidogrel in patients with UA/NSTEMI undergoing PCI is
certain.
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grel were studied in CURRENT–OASIS 7 (Clopidogrel
timal loading dose Usage to Reduce Recurrent Events–
rganization to Assess Strategies in Ischemic Syndromes),
ith published data demonstrating a potential benefit of
gher-dose clopidogrel in patients with definite UA/
STEMI undergoing an invasive management strategy
89,470). The CURRENT–OASIS 7 trial randomized
,086 patients with ACS who were intended for PCI and
ho were not considered to be at high risk for bleeding to
ceive higher-dose clopidogrel (600 mg loading, 150 mg
ily for 6 days, 75 mg daily thereafter) versus standard-
se clopidogrel (300 mg loading, 75 mg daily) as part of
22 design that also compared maintenance higher-dose
pirin (300 to 325 mg daily) with low-dose aspirin (75 to
0 mg daily). All patients received more than or equal to
0 mg of aspirin on Day 1 regardless of randomization
ter Day 1. The primary endpoint of the trial was the
mbination of cardiovascular death, myocardial (re)in-
rction, or stroke at 30 days. Although the overall trial
70) failed to demonstrate a significant difference in the
imary endpoint between the clopidogrel and aspirin
oups (4.2% versus 4.4%), the PCI subset (n17,263) did
ow significant differences in the clopidogrel arm (389).
he primary outcome was reduced in the PCI subgroup
ndomized to higher-dose clopidogrel (3.9% versus 4.5%;
0.035), and this was largely driven by a reduction in
yocardial (re)infarction (2.0% versus 2.6%; p0.017).
efinite stent thrombosis was reduced in the higher-dose
opidogrel group (0.7% versus 1.3%; p0.0001), with
nsistent results across DES versus non-DES subtypes.
igher-dose clopidogrel therapy increased major bleeding
the entire group (2.5% versus 2.0%; p0.012) and the
CI subgroup (1.1% versus 0.7%; p0.008). The benefit
higher-dose clopidogrel loading was offset by an in-
ease in major bleeding (389). The findings from the
especified PCI subgroup analysis (389) should be inter-
eted with caution and considered hypothesis generating,
cause the primary endpoint of the CURRENT–OASIS 7
ial was not met and given that the p value for interaction
0.026) between treatment effect and PCI was of
rderline statistical significance.
As noted in the dosing table (Appendix 7), the current
commended loading dose for clopidogrel is uncertain. In
dition, several hours are required to metabolize clopidogrel
its active metabolite, leaving a window of time where there
a reduced level of effectiveness even in patients who
spond to clopidogrel.
.2.3.1.5. Proton Pump Inhibitors and Dual Antiplatelet
herapy for ACS. Proton pump inhibitor (PPI) medica-
ons have been found to interfere with the metabolism of
opidogrel. When clopidogrel is started, PPIs are often
escribed prophylactically to prevent gastrointestinal (GI)
mplications such as ulceration and related bleeding (471)
e to dual antiplatelet therapy, in particular aspirin and
opidogrel (461). Coupled with concern about the GI pre-
utions, there has been increased emphasis on the prevention inpremature discontinuation of dual antiplatelet therapy,
rticularly in patients who have received a DES for whom
months of antiplatelet therapy is recommended (460).
There have been retrospective reports of adverse cardio-
scular outcomes (e.g., readmission for ACS) when the
tiplatelet regimen of clopidogrel and aspirin is accompa-
ed by PPIs assessed as a group compared with use of this
gimen without a PPI (461,472,473). In a retrospective
hort study from the Veterans Affairs’ medical records and
armacy database, concomitant clopidogrel and PPI therapy
ith omeprazole, rabeprazole, lansoprazole, or pantopra-
le) at any time during follow-up of 8,205 patients dis-
arged for ACS was associated with an increased risk of
ath or rehospitalization for ACS (461). Other post hoc
udy analyses (449). and a retrospective data analysis from
e National Heart, Lung, and Blood Institute Dynamic
egistry, in which PPIs were assessed as a class in combi-
tion with a clopidogrel and an aspirin regimen, have not
und an effect of PPI therapy on the clinical effect of
opidogrel in ACS patients, post-ACS patients, and a general
st-PCI population, respectively (449).
Some studies have suggested that adverse cardiovascular
tcomes with the combination of clopidogrel and a PPI are
plained by the individual PPI, in particular, the use of a PPI
at inhibits CYP450 2C19, including omeprazole, lansopra-
le, or rabeprazole. Notably, the PPI omeprazole has been
ported to significantly decrease the inhibitory effect of
opidogrel on platelet aggregation (474,475). One study
ported that the PPI pantoprazole was not associated with
current MI among patients receiving clopidogrel, possibly due
pantoprazole’s lack of inhibition of CYP450 2C19 (472).
Other studies have examined the P2Y12 receptor inhibitor
escribed with the PPI. One open-label drug study evaluated
e effects of the PPI lansoprazole on the pharmacokinetics
d pharmacodynamics of prasugrel and clopidogrel in
althy subjects given single doses of prasugrel 60 mg and
opidogrel 300 mg with and without concurrent lansoprazole
mg per day. The data suggest that inhibition of platelet
gregation was reduced in patients who took the combina-
on of clopidogrel and lansoprazole, whereas platelet aggre-
tion was unaffected after a prasugrel dose (476).
Another study (473) assessed the association of PPIs with
e pharmacodynamics and clinical efficacy of clopidogrel
d prasugrel, based on populations from 2 randomized trials,
e PRINCIPLE (Prasugrel In Comparison to Clopidogrel for
hibition of Platelet Activation and Aggregation) TIMI-44
ial (477) and the TRITON–TIMI 38 trial (380). The findings
dicated that first, PPI treatment attenuated the pharmaco-
namic effects of clopidogrel and, to a lesser extent, those of
asugrel. Second, PPI treatment did not affect the clinical
tcome of patients given clopidogrel or prasugrel. This
nding was true for all PPIs that were studied, including
eprazole and pantoprazole.
Observational trials may be confounded by selection bias.
the COGENT (Clopidogrel and the Optimization of Gas-
ointestinal Events) study (478), omeprazole was compared
ith placebo in 3,627 patients starting dual antiplatelet
erapy with aspirin and clopidogrel. No difference was found
the primary composite cardiovascular endpoint between
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R: 1.02), but GI bleeding complications were reduced
78). COGENT had several shortcomings (see Online Data
upplement), and more controlled, randomized clinical trial
ta are needed to address the clinical impact of conjunctive
erapy with clopidogrel and PPIs.
The FDA communication on an ongoing safety review of
opidogrel bisulfate (459) advises that healthcare providers
ould reevaluate the need for starting or continuing treat-
ent with a PPI, including omeprazole, in patients taking
opidogrel. The FDA notes there is no evidence that other
ugs that reduce stomach acid, such as H2 blockers or
tacids, interfere with the antiplatelet activity of clopidogrel.
ealthcare providers should continue to prescribe and pa-
ents should continue to take clopidogrel as directed, because
opidogrel has demonstrated benefits in preventing blood clots
at could lead to a heart attack or stroke. Healthcare providers
ould reevaluate the need for starting or continuing treatment
ith a PPI, including omeprazole (over the counter), in patients
king clopidogrel. Patients taking clopidogrel should consult
eir healthcare provider if they are currently taking or consid-
ing taking a PPI, including omeprazole (459). The ACCF has
leased a statement on the use of PPI agents in combination
ith clopidogrel. The expert consensus statement does not
ohibit the use of PPI agents in appropriate clinical settings, yet
ghlights the potential risks and benefits from use of PPI agents
combination with clopidogrel (479).
.2.3.1.6. Glycoprotein IIb/IIIa Receptor Antagonists
pdated to Incorporate Newer Trials and Evidence).
he efficacy of glycoprotein (GP) IIb/IIIa inhibitor therapy
s been well established during PCI procedures and in
tients with UA/NSTEMI, particularly among high-risk
tients such as those with elevated troponin biomarkers,
ose with diabetes, and those undergoing revascularization
35,137,246,247,383,387,480–484). The preponderance of
e evidence supporting the use of GP IIb/IIIa inhibitor
erapy predated the trials that established the benefits of
opidogrel, early invasive therapy, and contemporary medi-
l treatments in patients with UA/NSTEMI. These studies
pported the upstream use of a GP IIb/IIIa inhibitor as a
cond agent in combination with aspirin for dual antiplatelet
erapy in patients with UA/NSTEMI, especially in high-risk
bsets such as those with an initial elevation in cardiac
oponins, those with diabetes, and in those undergoing
vascularization (135,137,188,246,247,482). These studies
d not directly test in a randomized fashion the selection of
oral thienopyridine versus an intravenous (IV) GP IIb/IIIa
hibitor as the second antiplatelet agent in UA/NSTEMI.
Contemporary clinical trials have therefore been needed to
fine the optimal timing of initiation of GP IIb/IIIa inhibitor
erapy in patients with UA/NSTEMI, whether “upstream” (at
esentation and before angiography) or “deferred” (at the time
angiography/PCI), and its optimal application (whether rou-
e, selective, or provisional) and to clarify the relative benefit
d risk of GP IIb/IIIa inhibitor therapy as a third antiplatelet
ent in combination with aspirin and a thienopyridine.
The EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition
Patients With Non–ST-Segment Elevation Acute Coronary (3yndrome) trial (397) tested the hypothesis that a strategy of
rly routine administration of the GP IIb/IIIa inhibitor
tifibatide would be superior to delayed provisional admin-
tration in reducing ischemic complications among high-risk
tients with UA/NSTEMI. The study investigators enrolled
492 patients who presented within 24 hours of an episode of
chemic rest discomfort of at least 10 minutes’ duration. The
udy subjects were randomized within 8 to 12 hours after
esentation and assigned to an invasive treatment strategy no
oner than the next calendar day. To qualify as having
gh-risk UA/NSTEMI, the subjects were required to have at
ast 2 of the following: ST-segment depression or transient
T-segment elevation, elevated biomarker levels (creatine
nase–myocardial band or troponin), or age 60 years. The
udy subjects were randomized in a double-blind design to
ceive either early routine administration of eptifibatide
ouble bolus followed by standard infusion) or delayed
ovisional eptifibatide at the time of PCI. Eptifibatide
fusion was given for 18 to 24 hours after PCI in both
oups. For patients who underwent PCI, the total duration of
e infusion was less than or equal to 96 hours. For patients
ho did not receive PCI for whatever reason, the duration of
fusion was less than or equal to 96 hours. The study
fusion was stopped 2 hours before surgery for those
dergoing CABG. Early clopidogrel was allowed at the
vestigators’ discretion (75% intended early use), and if
ed, a loading dose of 300 mg was recommended. For
tients beginning clopidogrel during PCI (intended in 25%
study subjects, but actually implemented in 11%), a dose
600 mg was permitted. Randomization to 1 of 3 antithrom-
tic regimens was stratified according to the intention of the
vestigator to administer early clopidogrel (i.e., at or before
ndomization) (397).
The primary endpoint (a 30-day composite of all-cause
ath, MI, recurrent ischemia requiring urgent revasculariza-
on, or thrombotic bailout at 96 hours) occurred in 9.3% of
tients in the early therapy arm versus 10.0% of patients in
e provisional GP IIb/IIIa inhibitor therapy arm (OR: 0.92;
% CI: 0.80 to 1.06; p0.23). Secondary endpoint (all-
use death or MI within 30 days) event rates were 11.2%
rsus 12.3% (OR: 0.89; 95% CI: 0.79 to 1.01; p0.08).
arly routine eptifibatide administration was associated with
greater risk of TIMI major hemorrhage (2.6% versus 1.8%;
0.02). Severe or moderate bleeding, as defined by the
USTO (Global Utilization of Streptokinase and t-PA for
ccluded Coronary Arteries) criteria, also occurred more
mmonly in the early eptifibatide group (7.6% versus
1%; p0.001). Rates of red blood cell transfusion were
6% and 6.7% in the early-eptifibatide and delayed-
tifibatide groups, respectively (p0.001). There were no
gnificant interactions with respect to prespecified base-
ne characteristics, including early clopidogrel adminis-
ation, and the primary or secondary efficacy endpoints. In
subgroup analysis, early administration of eptifibatide in
tients who underwent PCI was associated with numeri-
lly fewer ischemic events.
A second contemporary study, the ACUITY (Acute Cath-
erization and Urgent Intervention Triage Strategy) trial
92), examined in part the optimal strategy for the use of GP
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dergoing early invasive therapy. A total of 9,207 patients
ere randomized to 1 of 3 antithrombin regimens: unfrac-
onated heparin (UFH) or enoxaparin plus GP IIb/IIIa inhib-
or therapy; bivalirudin plus GP IIb/IIIa inhibitor therapy; or
valirudin alone. Patients assigned to the heparin (UFH or
oxaparin) plus GP IIb/IIIa inhibitor therapy or to the
valirudin plus GP IIb/IIIa inhibitor therapy were also
ndomized to immediate upstream routine GP IIb/IIIa inhib-
or therapy or deferred selective use of GP IIb/IIIa inhibitor
erapy at the time of PCI. A clopidogrel loading dose of
300 mg was required in all cases no later than 2 hours after
CI, and provisional GP IIb/IIIa inhibitor use was permitted
fore angiography in the deferred group for severe break-
rough ischemia. The composite ischemic endpoint occurred
7.1% of the patients assigned to upstream administration
d in 7.9% of patients assigned to deferred selective admin-
tration (RR: 1.12; 95% CI: 0.97 to 1.29; p0.13) (392), and
us the noninferiority hypothesis was not achieved. Major
eeding was lower in the deferred-use group versus the
stream group (4.9% to 6.1%; p0.001 for noninferiority
d p0.009 for superiority).
Although early GP IIb/IIIa inhibitor therapy as dual anti-
atelet therapy also reduced complications after PCI, sup-
rting its continued role in patients undergoing PCI
50,397,481,483,484), these 2 most recent studies (392,397)
ore strongly support a strategy of selective rather than
utine upstream use of GP IIb/IIIa inhibitor therapy as part
triple antiplatelet therapy. Data from EARLY ACS (397)
ghlight the potential bleeding risks of upstream use of a GP
b/IIIa inhibitor as part of triple anti-platelet therapy. The use
a GP IIb/IIIa inhibitor should be undertaken when the
sk-benefit ratio suggests a potential benefit for the patient.
he use of these agents as part of triple antiplatelet therapy
ay therefore not be supported when there is a concern for
creased bleeding risk or in non–high-risk subsets such as
ose with a normal baseline troponin level, those without
abetes, and those aged 75 years, in whom the potential
nefit may be significantly offset by the potential risk of
eeding (Refer to Sections 3.2.1 and 3.2.3).
.2.4. Older Antiplatelet Agents and Trials
spirin, Ticlopidine, Clopidogrel)
.2.4.1. ASPIRIN (REFER TO UPDATED SECTIONS 3.2.1 AND
2.3, AND NEW SECTION 3.2.3.1)
ome of the strongest evidence available about the long-term
ognostic effects of therapy in patients with coronary disease
rtains to ASA (370). By irreversibly inhibiting COX-1
ithin platelets, ASA prevents the formation of thromboxane
2, thereby diminishing platelet aggregation promoted by
is pathway but not by others. This platelet inhibition is the
ausible mechanism for the clinical benefit of ASA, both
cause it is fully present with low doses of ASA and because
atelets represent one of the principal participants in throm-
s formation after plaque disruption. Alternative or addi-
onal mechanisms of action for ASA are possible, such as an
ti-inflammatory effect (375), but they are unlikely to be
portant at the low doses of ASA that are effective in stA/NSTEMI. Among all clinical investigations with ASA,
ials in UA/NSTEMI have consistently documented a strik-
g benefit of ASA compared with placebo independent of the
fferences in study design, such as time of entry after the
ute phase, duration of follow-up, and dose used
72,374,376,377) (Figure 10).
No trial has directly compared the efficacy of different
ses of ASA in patients who present with UA/NSTEMI;
wever, information can be gleaned from a collaborative
eta-analysis of randomized trials of antiplatelet therapy for
evention of death, MI, and stroke in high-risk patients (i.e.,
ute or previous vascular disease or other predisposing
nditions) (416). This collaborative meta-analysis pooled
ta from 195 trials involving more than 143,000 patients and
monstrated a 22% reduction in the odds of vascular death,
I, or stroke with antiplatelet therapy across a broad spec-
um of clinical presentations that included patients present-
g with UA/NSTEMI. Indirect comparisons of the propor-
onal effects of different doses of ASA ranging from less than
mg to up to 1,500 mg daily showed similar reductions in
e odds of vascular events with doses between 75 and 1,500
g daily; when less than 75 mg was administered daily, the
oportional benefit of ASA was reduced by at least one half
mpared with the higher doses. An analysis from the CURE
ial suggested that there was no difference in the rate of
rombotic events according to ASA dose, but there was a
se-dependent increase in bleeding in patients receiving
SA (plus placebo): the major bleeding rate was 2.0% in
tients taking less than 100 mg of ASA, 2.3% with 100 to
0 mg, and 4.0% with greater than 200 mg per d (249,488).
The prompt action of ASA and its ability to reduce
ortality rates in patients with suspected MI enrolled in the
econd International Study of Infarct Survival (ISIS-2) trial
d to the recommendation that ASA be initiated immediately
the ED once the diagnosis of ACS is made or suspected.
spirin therapy also can be started in the prehospital setting
hen ACS is suspected. On the basis of prior randomized
ial protocols and clinical experience, the initial dose of ASA
ould be between 162 and 325 mg. Although some trials
ve used enteric-coated ASA for initial dosing, more rapid
ccal absorption occurs with non–enteric-coated formula-
ons (489). After stenting, a higher initial maintenance dose
ASA of 325 mg per d has been recommended for 1 month
ter bare-metal stent implantation and 3 to 6 months after
ug-eluting stent (DES) implantation (9). This was based
imarily on clinical trials that led to approval of these stents,
hich used the higher doses initially. However, after PCI, a
ily aspirin dose of 81 mg per day is an accepted regimen in
eference to higher maintenance doses based on risk of
cess bleeding and an update of current evidence for ASA
sing (Appendixes 7 and 8).
In patients who are already receiving ASA, it should be
ntinued. The protective effect of ASA has been sustained
r at least 1 to 2 years in clinical trials in UA/NSTEMI.
onger term follow-up data in this population are lacking.
ong-term efficacy can be extrapolated from other studies of
SA therapy in CAD. Studies in patients with prior MI,
roke, or transient ischemic attack have shown statistically
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t not statistically significant benefit during the third year
70). In the absence of large comparison trials of different
rations of antiplatelet treatment in patients with CVD or in
imary prevention, it seems prudent to continue ASA indef-
itely unless side effects are present (8,11,374). Thus, pa-
ents should be informed of the evidence that supports the
e of ASA in UA/NSTEMI and CAD in general and
structed to continue the drug indefinitely, unless a contra-
dication develops. It is important to emphasize to patients
at there is a sound rationale for concomitant use of ASA even
other antithrombotic drugs, such as clopidogrel, prasugrel,
agrelor or warfarin, are administered concurrently and that
ithdrawal or discontinuation of ASA or P2Y12 receptor inhi-
tion therapy has been associated with recurrent episodes of
CS, including stent thrombosis (490–492) (Figure 11 deleted).
inally, because of a drug interaction between ibuprofen and
SA, patients should be advised to use an alternative NSAID or
take their ibuprofen dose at least 30 min after ingestion of
mediate-release ASA or at least 8 h before ASA ingestion to
oid any potential diminution of the protective effects of ASA.
gure 10. Older Trials of Antiplatelet and Anticoagulant Therapy i
ials except PRISM compared GP IIb-IIIa with UFH versus UFH. M
SA with placebo, the combination of UFH and ASA with ASA alo
mbination of a platelet GP IIb/IIIa antagonist, UFH, and ASA wit
lue for each trial are shown. The timing of the end point (death o
rted at the 30-d time point. Incremental gain is observed from s
iple antithrombotic therapy with ASA, UFH, and a platelet GP IIb/
CI after 20 to 24 h per study design. Data are taken from PURSU
éroux et al. (367), RISC group (368), ATACS group (369), Gurfink
d PRISM (374). anta.  antagonist; ASA  aspirin; ATACS  An
E3 Fab AntiPlatelet Therapy in Unstable REfractory angina; CI 
tery disease; GP  glycoprotein; hep.  heparin; LMWH  low-
icable; PARAGON  Platelet IIb/IIIa Antagonism for the Reductio
ork; PCI  percutaneous coronary intervention; PRISM  Platele
LUS  Platelet Receptor Inhibition in ischemic Syndrome Manag
URSUIT  Platelet glycoprotein IIb/IIIa in Unstable angina: Recep
tability in Coronary artery disease; UA/NSTEMI  unstable angin
in; VA  Veterans Affairs.o recommendations about the concomitant use of ibuprofen pod enteric-coated low-dose ASA can be made on the basis of
ailable data (493).
gure 11. Deleted—Not Current.
Contraindications to ASA include intolerance and allergy
rimarily manifested as asthma with nasal polyps), active
eeding, hemophilia, active retinal bleeding, severe un-
eated hypertension, an active peptic ulcer, or another serious
urce of gastrointestinal or genitourinary bleeding. Gastro-
testinal side effects such as dyspepsia and nausea are
frequent with the low doses. Primary prevention trials have
ported a small excess in intracranial bleeding, which is
fset in secondary prevention trials by the prevention of
chemic stroke. It has been proposed that there is a negative
teraction between ACE inhibitors and ASA, with a reduc-
on in the vasodilatory effects of ACE inhibitors, presumably
cause ASA inhibits ACE inhibitor–induced prostaglandin
nthesis. This interaction does not appear to interfere im-
STEMI. *Best results group. †GPIIb/IIIa with no heparin. ‡All
alysis of randomized trials in UA/NSTEMI that have compared
combination of an LMWH and ASA with ASA alone, and the
plus ASA. The risk ratio values, 95% CIs, and probability
aried. Results with the platelet GP IIb/IIIa antagonists are re-
erapy with ASA to double therapy with ASA and UFH and to
tagonist. In the CAPTURE trial, nearly all patients underwent
), PRISM-PLUS (130), Lewis et al. (365), Cairns et al. (366),
l. (370), FRISC group (371), CAPTURE (372), PARAGON (373),
botic Therapy in Acute Coronary Syndromes; CAPTURE 
ence interval; FRISC  FRagmin during InStability in Coronary
lar-weight heparin; MI  myocardial infarction; NA  not ap-
cute coronary syndrome events in a Global Organization Net-
ptor Inhibition in ischemic Syndrome Management; PRISM-
in Patients Limited by Unstable Signs and symptoms;
ppression Using Integrilin Therapy; RISC  Research on In-
ST-elevation myocardial infarction; UFH  unfractionated hep-n UA/N
eta-an
ne, the
h UFH
r MI) v
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tions, ASA should be administered to all patients with
A/NSTEMI.
.2.4.2. ADENOSINE DIPHOSPHATE RECEPTOR
NTAGONISTS AND OTHER ANTIPLATELET AGENTS (REFER
O UPDATED SECTIONS 3.2.1 AND 3.2.3, AND NEW SECTION
2.3.1)
everal P2Y12 receptor inhibitors are approved for antiplate-
t therapy in patients with UA/NSTEMI (380,381,495).
etailed discussion of the newer P2Y12 receptor inhibitors
rasugrel and ticagrelor) and trials is available in Section
2.3.1. The older ADP receptor antagonists (ticlopidine and
opidogrel), which are discussed in the current section, exert
reversible antiplatelet effects but take several days to
hieve maximal effect in the absence of a loading dose. The
ministration of a loading dose can shorten the time to
hievement of effective levels of antiplatelet therapy. Be-
use the mechanisms of the antiplatelet effects of ASA and
2Y12 receptor inhibitors differ, a potential exists for additive
nefit with the combination.
Ticlopidine has been used successfully for the secondary
evention of stroke and MI and for the prevention of stent
osure and graft occlusion (496). The adverse effects of
clopidine limit its usefulness: gastrointestinal problems
iarrhea, abdominal pain, nausea, and vomiting), neutrope-
a in approximately 2.4% of patients, severe neutropenia in
8% of patients, and, rarely, thrombotic thrombocytopenia
rpura (497). Neutropenia usually resolves within 1 to 3
eeks of discontinuation of therapy but very rarely may be
tal. Thrombotic thrombocytopenia purpura, which is a very
common, life-threatening complication, requires immedi-
e plasma exchange. Monitoring of ticlopidine therapy
quires a complete blood count that includes a differential
unt every 2 weeks for the first 3 months of therapy.
Extensive clinical experience with clopidogrel is derived in
rt from the Clopidogrel versus Aspirin in Patients at Risk of
chaemic Events (CAPRIE) trial (378). A total of 19,185
tients were randomized to receive ASA 325 mg per d or
opidogrel 75 mg per d. Entry criteria consisted of athero-
lerotic vascular disease manifested as recent ischemic
roke, recent MI, or symptomatic peripheral arterial disease.
ollow-up extended for 1 to 3 years. The RR of ischemic
roke, MI, or vascular death was reduced by 8.7% in favor of
opidogrel from 5.8% to 5.3% (p0.04). The benefit was
eatest for patients with peripheral arterial disease. This
oup had a 24% relative risk reduction (p0.03). There was
slightly increased, but minimal, incidence of rash and
arrhea with clopidogrel treatment and slightly more bleed-
g with ASA. There was no excess neutropenia with clopi-
grel, which contrasts with ticlopi-dine. The results provide
idence that clopidogrel is at least as effective as ASA and
pears to be modestly more effective. In 1 report, 11 severe
ses of thrombotic thrombocytopenia purpura were de-
ribed as occurring within 14 d after the initiation of
opidogrel; plasma exchange was required in 10 of the
tients, and 1 patient died (498). These cases occurred
ong more than 3 million patients treated with clopidogrel. clClopidogrel is reasonable antiplatelet therapy for second-
y prevention, with an efficacy at least similar to that of
SA. Clopidogrel is indicated in patients with UA/NSTEMI
ho are unable to tolerate ASA due to either hypersensitivity
major gastrointestinal contraindications, principally recent
gnificant bleeding from a peptic ulcer or gastritis. When
eatment with thienopyridines is considered during the acute
ase, it should be recognized that there is a delay before
tainment of the full antiplatelet effect. Clopidogrel is pre-
rred to ticlopidine because it more rapidly inhibits platelets
d appears to have a more favorable safety profile.
An oral loading dose (300 mg) of clopidogrel is typically
ed to achieve more rapid platelet inhibition. The optimal
ading dose with clopidogrel has not been rigorously estab-
shed. The greatest amount of general clinical experience and
ndomized trial data exist for a clopidogrel loading dose of
0 mg, which is the approved loading dose. Higher loading
ses (600 to 900 mg) have been evaluated (391,428). They
pear to be safe and more rapidly acting; however, it must be
cognized that the database for such higher loading doses is
t sufficiently robust to formulate definitive recommenda-
ons. Most studies to date with higher loading doses of
opidogrel have examined surrogates for clinical outcomes,
ch as measurements of 1 or more markers of platelet
gregation or function. When groups of patients are studied,
general dose response is observed with increasing magni-
de and speed of onset of inhibition of platelet aggregation in
sponse to agonists such as ADP as the loading dose
creases. However, considerable interindividual variation in
tiplatelet effect also is observed with all loading doses of
opidogrel, which makes it difficult to predict the impact of
fferent loading doses of clopidogrel in a specific patient.
mall to moderatesized trials have reported favorable out-
mes with a 600-mg versus a 300-mg loading dose in
tients undergoing PCI (427) (Appendixes 7 and 8).
Two randomized trials compared clopidogrel with
clopi-dine. In 1 study, 700 patients who successfully
ceived a stent were randomized to receive 500 mg of
clopidine or 75 mg of clopidogrel, in addition to 100 mg
ASA, for 4 weeks (499). Cardiac death, urgent target-
ssel revascularization, angio-graphically documented
rombotic stent occlusion, or nonfatal MI within 30 d
curred in 3.1% of patients who received clopidogrel and
7% of patients who received ticlopidine (p0.24),
d noncardiac death, stroke, severe peripheral vascular
morrhagic events, or any adverse event that resulted in
e discontinuation of the study medication occurred in
5% and 9.6% of patients, respectively (p0.01). The
Lopidogrel ASpirin Stent International Cooperative
tudy (CLASSICS) (500) was conducted in 1,020 patients.
loading dose of 300 mg of clopidogrel followed by 75
g per d was compared to a daily dose of 75 mg without
loading dose and with a loading dose of 150 mg of
clopidine followed by 150 mg twice per day (patients in
ch of the 3 arms also received ASA). The first dose was
ministered 1 to 6 h after stent implantation; the treatment
ration was 28 d. The trial showed better tolerance toopidogrel with or without a loading dose than to ticlopi-
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e same frequency in the 3 groups.
The CURE trial randomized 12,562 patients with UA and
STEMI presenting within 24 h to placebo or clopidogrel
oading dose of 300 mg followed by 75 mg daily) and
llowed them for 3 to 12 months (249). All patients received
SA. Cardiovascular death, MI, or stroke occurred in 11.5%
patients assigned to placebo and 9.3% assigned to clopi-
grel (RR  0.80, p0.001). In addition, clopidogrel was
sociated with significant reductions in the rate of in-hospital
vere ischemia and revascularization, as well as the need for
brinolytic therapy or intravenous GP IIb/IIIa receptor antag-
ists. These results were observed across a wide variety of
bgroups. A reduction in recurrent ischemia was noted
ithin the first few hours after randomization.
There was an excess of major bleeding (2.7% in the
acebo group vs 3.7% in the clopidogrel group, p0.003)
d of minor bleeding but not of life-threatening bleeding.
he risk of bleeding was increased in patients undergoing
ABG surgery within the first 5 d of stopping clopidogrel.
he CURE study was conducted at centers in which there was
routine policy regarding early invasive procedures; revas-
larization was performed during the initial admission in
ly 23% of the patients. Although the addition of a platelet
P IIb/IIIa inhibitor in patients receiving ASA, clopidogrel,
d heparin in CURE was well tolerated, fewer than 10% of
tients received this combination. Therefore, additional
formation on the safety of an anticoagulant and a GP
b/IIIa inhibitor in patients already receiving ASA and
opidogrel should be obtained. Accurate estimates of the
eatment benefit of clopidogrel in patients who received GP
b/IIIa antagonists remain ill-defined.
The CURE trial also provides strong evidence for the
dition of clopidogrel to ASA on admission in the manage-
ent of patients with UA and NSTEMI in whom a noninter-
ntional approach is intended, an especially useful approach
hospitals that do not have a routine policy about early
vasive procedures. The event curves for the 2 groups
parate early. The optimal duration of therapy with clopi-
grel in patients who have been managed exclusively
edically has not been determined, but the favorable results
CURE were observed over a period averaging 9 months
d for up to 1 year.
The PCI-CURE study was an observational substudy of the
tients undergoing PCI within the larger CURE trial (382).
the PCI-CURE study, 2,658 patients had previously been
ndomly assigned to double-blind treatment with clopidogrel
 1,313) as per the CURE protocol or placebo (n1,345).
atients were pretreated with ASA and the study drug for a
edian of 10 d. After PCI, most patients received open-label
opidogrel for approximately 4 weeks, after which the
inded study drug was restarted for a mean of 8 months.
ifty-nine patients (4.5%) in the clopidogrel group had the
imary end point (a composite of cardiovascular death, MI,
urgent target-vessel revascularization) within 30 d of PCI
mpared with 86 (6.4%) in the placebo group (RR  0.70,
% CI 0.50 to 0.97, p0.03). Overall, including events
fore and after PCI, there was a 31% reduction in cardio- pascular death or MI (p0.002). Thus, in patients with UA
d NSTEMI receiving ASA and undergoing PCI, a strategy
clopidogrel pretreatment followed by up to 1 year of
opidogrel use (and probably at least 1 year in those with
ES; see below) is beneficial in reducing major cardiovas-
lar events compared with placebo and appears to be
st-effective (the incremental cost-effectiveness ratio for
opidogrel plus ASA compared with ASA alone was
5,400 per quality-adjusted life-year) (501). Therefore,
opidogrel (or the newer P2Y12 receptor inhibitors) should
used routinely in patients who undergo PCI on top of
ckground ASA therapy.
Pathological and clinical evidence particularly highlights
e need for longer-term P2Y12 receptor blockade in patients
ho receive DES (502). DESs consistently have been shown
reduce stent restenosis. However, this same antiprolifera-
ve action can delay endothelialization, predisposing to stent
rombosis including late (beyond 3 to 6 months) or very late
fter 1 year) thrombosis after stent placement (502–504).
hese concerns have raised questions about the ideal duration
dual antiplatelet therapy (DAT) and the overall balance of
nefit/risk of DES compared with bare-metal stents (505). A
mber of comparisons of outcomes up to 4 years after DES
d bare-metal stent implantation, including the initial FDA
proval trials, have been published (504,506–514). These
nfirm a marked reduction in restenosis and consequent
peat revascularization procedures with DES (511). How-
er, although results have varied, they also suggest a small
cremental risk (of about 0.5%) of stent thrombosis (509–511).
eassuringly, they have not shown an overall increase in
ath or MI after DES versus bare-metal stents, suggesting
fsetting advantages of improved revascularization versus
creased stent thrombosis risk. These observations also
phasize the need for a continued search for more biocom-
tible stents that minimize restenosis without increasing the
sks of thrombosis.
In the ISAR-REACT-2 trial, patients undergoing PCI were
signed to receive either abciximab (bolus of 0.25 mg per kg
body weight, followed by a 0.125-mg per kg per min
aximum, 10 mg per min] infusion for 12 h, plus heparin 70
per kg of body weight) or placebo (placebo bolus and
fusion of 12 h, plus heparin bolus, 140 U per kg) (250). All
tients received 600 mg of clopidogrel at least 2 h before the
ocedure, as well as 500 mg of oral or intravenous ASA. Of
022 patients enrolled, 1,012 were assigned to abciximab
d 1,010 to placebo. The primary end point was reached in
patients (8.9%) assigned to abciximab versus 120 patients
1.9%) assigned to placebo, a 25% reduction in risk with
ciximab (RR  0.75, 95% CI 0.58 to 0.97, p0.03) (250).
mong patients without an elevated cTn level, there was no
fference in the incidence of primary end-point events
tween the abciximab group (23 [4.6%] of 499 patients) and
e placebo group (22 [4.6%] of 474 patients; RR  0.99,
% CI 0.56 to 1.76, p0.98), whereas among patients with
elevated cTn level, the incidence of events was signifi-
ntly lower in the abciximab group (67 [13.1%] of 513
tients) than in the placebo group (98 [18.3%] of 536
tients), which corresponds to an RR of 0.71 (95% CI
0.
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significant differences between the 2 groups with regard
the risk of major or minor bleeding or the need for
ansfusion. Thus, it appears beneficial to add an intrave-
us GP IIb/IIIa inhibitor to clopidogrel treatment if an
vasive strategy is planned in patients with high-risk
atures (e.g., elevated cTn level) (Appendix 9 has re-
aced Figures 7, 8, and 9).
The optimal timing of administration of the loading dose of
opidogrel for those who are managed with an early invasive
rategy cannot be determined with certainty from PCI-CURE
cause there was no comparison of administration of the
ading dose before diagnostic angiography (“upstream treat-
ent”) versus at the time of PCI (“in-lab treatment”). How-
er, based on the early separation of the curves, when there
delay to coronary angiography, patients should receive
opidogrel (or ticagrelor; refer to updated Sections 3.2.1 and
2.3) as initial therapy (Appendix 9 has replaced Figures 7,
and 9). The Clopidogrel for the Reduction of Events
uring Observation (CREDO) trial (384), albeit not designed
ecifically to study UA/NSTEMI patients, provides partially
levant information on the question of timing of the loading
se. Patients with symptomatic CAD and evidence of
chemia who were referred for PCI and those who were
ought to be highly likely to require PCI were randomized to
ceive clopidogrel (300 mg) or matching placebo 3 to 24 h
fore PCI. All subjects received a maintenance dose of
opidogrel (75 mg daily) for 28 d. Thus, CREDO is really a
mparison of the administration of a loading dose before
CI versus not administering a loading dose at all. There is
explicit comparison within CREDO of a pre-PCI
ading dose versus a loading dose in the catheterization
boratory. In CREDO, the relative risk for the composite
d point of death/ MI/urgent target-vessel revasculariza-
on was 0.82, in favor of the group who received a loading
se before PCI compared with the opposite arm that did
t receive a loading dose, but this did not reach statistical
gnificance (p0.23). Subgroup analyses within CREDO
ggest that if the loading dose is given at least 6 or
eferably 15 h before PCI, fewer events occur compared
ith no loading dose being administered (515). One study
om the Netherlands that compared pretreatment with
opidogrel before PCI versus administration of a loading
se at the time of PCI in patients undergoing elective PCI
owed no difference in biomarker release or clinical end
ints (516).
Thus, there now appears to be an important role for
opidogrel in patients with UA/NSTEMI, both in those who
e managed conservatively and in those who undergo PCI,
pecially stenting, or who ultimately undergo CABG surgery
17). However, it is not entirely clear how long therapy
ould be maintained (518,519). Whereas increased hazard is
early associated with premature discontinuation of dual
tiplatelet therapy after DES (384,460,520), the benefit of
tended therapy beyond 1 year is uncertain (505,512,513).
ence, the minimum requirements for DAT duration should
vigorously applied for each DES type. However, 1 year ofAT may be ideal for all UA/NSTEMI patients who are not Nhigh risk of bleeding given the secondary preventive effects
DAT, perhaps especially after DES. On the other hand, the
mited database at this point in time does not support a
commendation for DAT beyond 1 year for all DES-treated
tients (505,512,513). For patients with clinical features
sociated with an increased risk of stent thrombosis, such as
abetes or renal insufficiency or procedural characteristics
ch as multiple stents or a treated bifurcation lesion, ex-
nded DAT may be reasonable. Data on the relative merits of
ES versus bare-metal stents in “off-label” patients (such as
ultivessel disease or MI), who are at higher risk and
perience higher event rates, and of the ideal duration of
AT in these patients, are limited and are currently insuffi-
ent to draw separate conclusions (505,512,513).
Because of the importance of dual-antiplatelet therapy with
SA and a P2Y12 receptor inhibitor after implantation of a
ent, especially if a DES is being considered, clinicians
ould ascertain whether the patient can comply with 1 year
dual-antiplatelet therapy. Patients should also be instructed
contact their treating cardiologist before stopping any
ti-platelet therapy, because abrupt discontinuation of anti-
atelet therapy can put the patient at risk of stent thrombosis,
event that may result in MI or even death (460). Health
re providers should postpone elective surgical procedures
til beyond 12 months after DES implantation (460). If a
rgical procedure must be performed sooner than 12 months,
effort should be made to maintain the patient on ASA and
inimize the period of time of discontinuation of a P2Y12
ceptor inhibitor (460).
In the CURE study, which predominantly involved medi-
l management of patients with UA/NSTEMI, the relative
sk reduction in events was of a similar magnitude (approx-
ately 20%) during the first 30 d after randomization as
ring the ensuing cumulative 8 months (521). In contrast,
opidogrel was not beneficial in a large trial of high-risk
imary prevention patients (435).
Because clopidogrel, when added to ASA, increases the
sk of bleeding during major surgery, it has been recom-
ended that clopidogrel be withheld for at least 5 d (249) and
to 7 d before surgery in patients who are scheduled for
ective CABG (488,522). In many hospitals in which pa-
ents with UA/NSTEMI undergo rapid diagnostic catheter-
ation within 24 h of admission, clopidogrel is not started
til it is clear that CABG will not be scheduled within the
xt several days. However, unstable patients should receive
opidogrel (or ticagrelor; refer to updated Sections 3.2.1 and
2.3) or be taken for immediate angiography (Appendix 9
s replaced Figures 7, 8, and 9). A loading dose of
opidogrel (or one of the newer P2Y12 receptor inhibitors,
cagrelor or prasugrel) can be given to a patient on the
theterization table if a PCI is to be performed immediately.
PCI is not performed, clopidogrel or ticagrelor can be given
ter the catheterization. However, when clopidogrel is given
fore catheterization and urgent surgical intervention is
dicated, some experience suggests that “early” bypass
rgery may be undertaken by experienced surgeons at
ceptable incremental bleeding risk. Among 2,858 UA/
STEMI patients in the CRUSADE (Can Rapid Risk Strat-
ifi
O
le
R
th
“E
si
C
1.
(3
re
w
C
be
su
th
re
be
in
cl
U
sy
ha
ad
cu
ac
ti
ra
(5
is
ri
in
un
th
po
cl
H
cl
un
3
(R
A
of
tu
20
an
th
ag
to
pr
te
st
al
ra
un
th
tio
ra
an
be
(4
ph
U
to
pe
in
th
pa
im
ti
S
R
du
pr
ti
th
le
ch
of
co
on
no
as
th
th
w
ap
ac
C
pa
F
a
er
su
sh
(o
in
co
pl
re
ac
ly
an
ly
he
w
va
ar
en
or
he
e236 Anderson et al. JACC Vol. 61, No. 23, 2013
UA/NSTEMI Guideline: 2012 Update Incorporated June 11, 2013:e179–347cation of Unstable Angina Patients Suppress Adverse
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ge of Cardiology/American Heart Association Guidelines)
egistry undergoing CABG, 30% received acute clopidogrel
erapy, the majority of these (87%) within 5 d of surgery.
arly” CABG after clopidogrel was associated with a
gnificant increase in any blood transfusion (OR 1.36, 95%
I 1.10 to 1.68) and the need for 4 or more units of blood (OR
70, 95% CI 1.32 to 2.1). In-hospital rates of death were low
% to 4%), and no difference was noted in rates of death,
infarction, or stroke with “early” CABG in patients treated
ith versus without acute clopidogrel (523). The Writing
ommittee believes that more data on the overall relative
nefits versus risks of proceeding with early bypass
rgery in the presence of clopidogrel therapy (or one of
e newer P2Y12 receptor inhibitors, ticagrelor or prasug-
l) are desirable and necessary in order to formulate
tter-informed recommendations for the timing of surgery
the UA/NSTEMI patient.
Sulfinpyrazone, dipyridamole, prostacyclin, and prostacy-
in analogs have not been demonstrated to be of benefit in
A or NSTEMI and are not recommended. The thromboxane
nthase blockers and thromboxane A2 receptor antagonists
ve been evaluated in ACS and have not shown any
vantage over ASA. A number of other antiplatelet drugs are
rrently available (Appendix 8), and still others are under
tive investigation.
Evidence has emerged that there is considerable interpa-
ent variability in the response to clopidogrel, with a wide
nge of inhibition of platelet aggregation after a given dose
24) (see updated Section 3.2.3.1.3). Patients with dimin-
hed responsiveness to clopidogrel appear to be at increased
sk of ischemic events (443,525). The reasons for the large
terpatient variability in responsiveness to clopidogrel are
der investigation, but variation in absorption, generation of
e active metabolite, and drug interactions are leading
ssibilities. Maneuvers to overcome poor responsiveness to
opidogrel may involve an increase in the dose (526).
owever, techniques for monitoring for poor response to
opidogrel and the appropriate dosing strategy when it is
covered remain to be established.
.2.5. Anticoagulant Agents and Trials
efer to Updated Sections 3.2.2 and 3.2.3)
number of drugs are available to clinicians for management
patients with UA/NSTEMI. Although the medical litera-
re sometimes refers to such drugs as “antithrombins,” the
07 Writing Committee has chosen to refer to them as
ticoagulants because they often inhibit 1 or more proteins in
e coagulation cascade before thrombin. Evaluation of antico-
ulant strategies is an active area of investigation. It is difficult
draw conclusions that 1 anticoagulant strategy is to be
eferred over another given the uncertainty of whether equipo-
nt doses were administered, the different durations of treatment
udied across the trials, and the fact that many patients were
ready receiving 1 open-label anticoagulant before they were
ndomized in a trial to another anticoagulant (which makes it
certain what residual effect the open-label anticoagulant had in
e trial). Other aspects of the data set that confound interpreta- tion of the impact of specific anticoagulant strategies include a
nge of antiplatelet strategies administered concomitantly with the
ticoagulant and the addition of a second anticoagulant, either
cause of clinician preference or as part of protocol design
00,422,424) as patients moved from the medical management
ase to the interventional management phase of treatment for
A/NSTEMI.
The 2007 Writing Committee also wishes to draw attention
the fact that active-control noninferiority trials are being
rformed with increasing frequency as it becomes ethically
creasingly difficult to perform placebo-controlled trials. In
is update, for example, noninferiority (“equivalence”) com-
risons on primary or major secondary end points were
portant in the Acute Catheterization and Urgent Interven-
on Triage strategy (ACUITY) (424), Organization to Assess
trategies for Ischaemic Syndromes (OASIS-5) (422), and
andomized Evaluation of PCI Linking Angiomax to re-
ced Clinical Events (REPLACE-2) (527) studies. Although
actically useful, noninferiority analyses depend on assump-
ons not inherent in classic superiority analytical designs and
us present additional limitations and interpretative chal-
nges (528–530). Noninferiority trials require an a priori
oice of a “noninferiority margin,” typically defined in terms
a fraction of standard treatment effect to be preserved
mpared with a putative placebo (e.g., 0.5) and which rests
clinical judgment and statistical issues (529). Because
ninferiority trials do not have a placebo control, these
sumptions cannot be easily verified. Thus, whether the new
erapy indeed is therapeutically “equivalent” is less certain
an in a superiority trial. Hence, additional caution in
eighing and applying the results of noninferiority trials is
propriate.
The 2007 Writing Committee believes that a number of
ceptable anticoagulant strategies can be recommended with a
lass I status but emphasizes the fact that a preference for a
rticular strategy is far from clear (Appendix 9 has replaced
igures 7, 8, and 9). It is suggested that each institution agree on
consistent approach to minimize the chance of medication
rors and double anticoagulation when personal preferences are
perimposed on an already-initiated treatment plan. Factors that
ould be weighed when one considers an anticoagulant strategy
r set of strategies to cover the range of patient scenarios)
clude established efficacy, risk of bleeding in a given patient,
st, local familiarity with dosing regimens (particularly if PCI is
anned), anticipated need for surgery, and the desire to promptly
verse the anticoagulant effect if bleeding occurs.
Unfractionated heparin exerts its anticoagulant effect by
celerating the action of circulating antithrombin, a proteo-
tic enzyme that inactivates factor IIa (thrombin), factor IXa,
d factor Xa. It prevents thrombus propagation but does not
se existing thrombi (531). Unfractionated heparin is a
terogeneous mixture of polysaccharide chains of molecular
eights that range from 5,000 to 30,000 Daltons and have
rying effects on anticoagulant activity. Unfractionated hep-
in binds to a number of plasma proteins, blood cells, and
dothelial cells. The LMWHs are obtained through chemical
enzymatic depolymerization of the polysaccharide chains of
parin to provide chains with different molecular weight distribu-
ns. Approximately 25% to 50% of the pentasaccharide-
co
sa
an
fe
fa
m
in
U
en
lo
an
m
us
m
co
m
A
va
th
ne
bi
po
re
M
in
ri
th
am
pa
pl
cl
ab
da
ag
no
cl
fa
th
ad
of
in
pr
an
pr
re
di
fu
el
an
nu
so
m
C
ti
re
N
to
A
fu
co
in
an
no
pa
te
no
cu
de
cl
un
of
S
ag
st
th
be
3
S
w
st
w
us
fi
ei
li
m
ea
w
56
6
w
th
no
di
m
tr
da
U
(5
cr
U
U
ar
U
li
pr
tr
an
pa
li
it
a
e237JACC Vol. 61, No. 23, 2013 Anderson et al.
June 11, 2013:e179–347 UA/NSTEMI Guideline: 2012 Update Incorporatedntaining chains of LMWH preparations contain more than 18
ccharide units, and these are able to inactivate both thrombin
d factor Xa. Low-molecular-weight heparin chains that are
wer than 18 saccharide units retain their ability to inactivate
ctor Xa but not thrombin. Therefore, LMWHs are relatively
ore potent in facilitating inhibition of factor Xa than in the
activation of thrombin. Distinct advantages of LMWH over
FH include decreased binding to plasma proteins and
dothelial cells and dose-independent clearance, with a
nger half-life that results in more predictable and sustained
ticoagulation with once- or twice-a-day subcutaneous ad-
inistration. An advantage of LMWHs is that they do not
ually require laboratory monitoring of activity. The phar-
acodynamic and pharmacokinetic profiles of the different
mmercial preparations of LMWHs vary, with their mean
olecular weights ranging from 4,200 to 6,000 Daltons.
ccordingly, their ratios of anti–factor Xa to anti–factor IIa
ry, ranging from 1.9 to 3.8 (532). By contrast, the direct
rombin inhibitors specifically block thrombin without the
ed for a cofactor. Hirudin binds directly to the anion
nding site and the catalytic sites of thrombin to produce
tent and predictable anticoagulation (533).
Bivalirudin is a synthetic analog of hirudin that binds
versibly to thrombin and inhibits clot-bound thrombin.
ore upstream in the coagulation cascade are factor Xa
hibitors, such as the synthetic pentasaccharide fondapa-
nux, that act proximally to inhibit the multiplier effects of
e downstream coagulation reactions and thereby reduce the
ount of thrombin that is generated. Advantages of fonda-
rinux compared with UFH include decreased binding to
asma proteins and endothelial cells and dose-independent
earance, with a longer half-life that results in more predict-
le and sustained anticoagulation with fixed-dose, once-a-
y subcutaneous administration. An advantage of these
ents over UFH is that like the LMWHs, fondaparinux does
t require laboratory monitoring of activity. Fondaparinux is
eared renally, as is the anti–Xa activity of enoxaparin. The
ctor Xa inhibitors do not have any action against thrombin
at is already formed or that is generated despite their
ministration, which possibly contributes to the observation
an increased rate of catheter thrombosis when factor Xa
hibitors such as fondaparinux are used alone to support PCI
ocedures. In the case of both the direct thrombin inhibitors
d fondaparinux, it is not possible to reverse the effect with
otamine because they lack a protamine-binding domain;
versal of their action in the event of bleeding requires
scontinuation of their administration and, if needed, trans-
sion of coagulation factors (e.g., fresh-frozen plasma).
In summary, whereas anticoagulant therapy forms a basic
ement of UA/NSTEMI therapy, recommendation of an
ticoagulant regimen has become more complicated by a
mber of new choices suggested by contemporary trials,
me of which do not provide adequate comparative infor-
ation for common practice settings. The 2007 Writing
ommittee believes that inadequate unconfounded compara-
ve information is available to recommend a preferred
gimen when an early, invasive strategy is used for UA/
STEMI, and physician and health care system preference,
gether with individualized patient application, is advised. thdditional experience may change this viewpoint in the
ture. On the other hand, these available trials are less
nfounded for the large number of patients treated with an
itial noninvasive or delayed invasive strategy: they suggest
anticoagulant preference for these patients treated with a
ninvasive strategy in the order of fondaparinux, enoxa-
rin, and UFH (least preferred), using the specific regimens
sted in these trials. Bivalirudin has not been tested in a
ninvasive strategy and hence cannot be recommended
rrently. Even in this group, the order of preference often
pends on a single, albeit large, trial, so that additional
inical trial information will be welcomed.
The optimal duration of anticoagulation therapy remains
defined. Evidence for recurrence of events after cessation
short-duration intravenous UFH and results of studies in
TEMI patients demonstrating superiority of anticoagulant
ents that are administered for the duration of the hospital
ay suggest that anticoagulation duration of more than 2 d for
ose who are managed with a conservative strategy may be
neficial, but this requires further study (534,535).
.2.5.1. UNFRACTIONATED HEPARIN
ix relatively small randomized, placebo-controlled trials
ith UFH have been reported (536–541). The results of
udies that compared the combination of ASA and heparin
ith ASA alone are shown in (Figure 10). In the trials that
ed UFH, the reduction in the rate of death or MI during the
rst week was 54% (p0.016), and in the trials that used
ther UFH or LMWH, the reduction was 63%. Two pub-
shed meta-analyses have included different studies. In 1
eta-analysis, which involved 3 randomized trials and an
rly end point (less than 5 d) (373), the risk of death or MI
ith the combination of ASA and heparin was reduced by
% (p0.03). In the second meta-analysis, which involved
trials and end points that ranged from 2 to 12 weeks, the RR
as reduced by 33% (p0.06) (542). Most of the benefits of
e various anticoagulants are short term, however, and are
t maintained on a long-term basis. Reactivation of the
sease process after the discontinuation of anticoagulants
ay contribute to this loss of early gain among medically
eated patients that has been described with UFH (543),
lteparin (406), and hirudin (544,545). The combination of
FH and ASA appears to mitigate this reactivation in part
43,546), although there is hematologic evidence of in-
eased thrombin activity after the cessation of intravenous
FH (“rebound”) even in the presence of ASA (547).
ncontrolled observations suggested a reduction in the “hep-
in rebound” by switching from intravenous to subcutaneous
FH for several days before the drug is stopped.
Unfractionated heparin has important pharmacokinetic
mitations that are related to its nonspecific binding to
oteins and cells. These pharmacokinetic limitations of UFH
anslate into poor bioavailability, especially at low doses,
d marked variability in anticoagulant response among
tients (548). As a consequence of these pharmacokinetic
mitations, the anticoagulant effect of heparin requires mon-
oring with the activated partial thromboplastin time (aPTT),
test that is sensitive to the inhibitory effects of UFH on
rombin (factor IIa), factor Xa, and factor IXa. Many
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FH (e.g., 5,000 U bolus, 1,000 U per h initial infusion);
inical trials have indicated that a weight-adjusted dosing
gimen can provide more predictable anticoagulation than
e fixed-dose regimen (549–551). The weight-adjusted reg-
en recommended is an initial bolus of 60 U per kg
aximum 4,000 U) and an initial infusion of 12 U per kg per
(maximum 1,000 U per h). The therapeutic range of the
rious nomograms differs due to variation in the laboratory
ethods used to determine aPTT. The American College of
hest Physicians consensus conference (552) has therefore
commended dosage adjustments of the nomograms to
rrespond to a therapeutic range equivalent to heparin levels
0.3 to 0.7 U per mL by anti–factor Xa determinations,
hich correlates with aPTT values between 60 and 80 s. In
dition to body weight, other clinical factors that affect the
sponse to UFH include age and sex, which are associated
ith higher aPTT values, and smoking history and diabetes
ellitus, which are associated with lower aPTT values
48,551). At high doses, heparin is cleared renally (552).
Even though weight-based UFH dosing regimens are used,
e aPTT should be monitored for adjustment of UFH dosing.
ecause of variation among hospitals in the control aPTT
lues, nomograms should be established at each institution
at are designed to achieve aPTT values in the target range
.g., for a control aPTT of 30 s, the target range [1.5 to 2.5
mes control] would be 45 to 75 s). Delays in laboratory
rnaround time for aPPT results also can be a source of
riability in care, resulting in over- or under-anticoagulation
r prolonged time periods, and should be avoided. Measure-
ents should be made 6 h after any dosage change and used
adjust UFH infusion until the aPTT exhibits a therapeutic
vel. When 2 consecutive aPTT values are therapeutic, the
easurements may be made every 24 h and, if necessary,
se adjustment performed. In addition, a significant change
the patient’s clinical condition (e.g., recurrent ischemia,
eeding, or hypotension) should prompt an immediate aPTT
termination, followed by dose adjustment, if necessary.
Serial hemoglobin/hematocrit and platelet measurements
e recommended at least daily during UFH therapy. In
dition, any clinically significant bleeding, recurrent symp-
ms, or hemodynamic instability should prompt their imme-
ate determination. Serial platelet counts are necessary to
onitor for heparin-induced thrombocytopenia. Mild throm-
cytopenia may occur in 10% to 20% of patients who are
ceiving heparin, whereas significant thrombocytopenia
latelet count less than 100,000) occurs in 1% to 5% of
tients and typically appears after 4 to 14 d of therapy
53–557). A rare but dangerous complication (less than
2% incidence) is autoimmune UFH-induced thrombocyto-
nia with thrombosis, which can occur both shortly after
itiation of UFH or, rarely, in a delayed (i.e., after 5 to 19 d
more), often unrecognized form (558–560). A high clinical
spicion mandates the immediate cessation of all heparin
erapy (including that used to flush intravenous lines).
Most of the trials that evaluated the use of UFH in
A/NSTEMI have continued therapy for 2 to 5 d. The
timal duration of therapy remains undefined. be.2.5.2. LOW-MOLECULAR-WEIGHT HEPARIN
a pilot open-label study, 219 patients with UA were
ndomized to receive ASA (200 mg per d), ASA plus UFH,
ASA plus nadroparin (an LMWH) (486). The combination
ASA and LMWH significantly reduced the total ischemic
ent rate, the rate of recurrent angina, and the number of
tients requiring interventional procedures.
The FRISC study (406) randomized 1,506 patients with UA
non–Q-wave MI to receive subcutaneous administration of
e LMWH dalteparin (120 IU per kg twice daily) or placebo for
d and then once a day for the next 35 to 45 d. Dalteparin was
sociated with a 63% risk reduction in death or MI during the
rst 6 d (4.8% vs 1.8%, p0.001), which matched the favorable
perience observed with UFH. Although an excess of events
as observed after the dose reduction to once daily after 6 d, a
gnificant decrease was observed at 40 d with dalteparin in the
mposite outcome of death, MI, or revascularization (23.7% vs
.0%, p0.005), and a trend was noted toward a reduction in
tes of death or MI (10.7% vs 8.0%, p0.07).
Because the level of anticoagulant activity cannot be easily
easured in patients receiving LMWH (e.g., aPTT or acti-
ted clotting time [ACT]), interventional cardiologists have
pressed concern about the substitution of LMWH for UFH
patients scheduled for catheterization with possible PCI.
owever, in a study involving 293 patients with UA/
STEMI who received the usual dose of enoxaparin, Collett
al. (561) showed that PCI can be performed safely.
An alternative approach is to use LMWH during the period
initial stabilization. The dose can be withheld on the
orning of the procedure, and if an intervention is required
d more than 8 h has elapsed since the last dose of LMWH,
FH can be used for PCI according to usual practice patterns.
ecause the anticoagulant effect of UFH can be more readily
versed than that of LMWH, UFH is preferred in patients
kely to undergo CABG within 24 h.
.2.5.3. LMWH VERSUS UFH
ine randomized trials have directly compared LMWH with
FH (Table 17). Two trials evaluated dalteparin, another
aluated nadroparin, and 6 evaluated enoxaparin. Heteroge-
ity of trial results has been observed. Trials with dalteparin
d nadroparin reported similar rates of death or nonfatal MI
mpared with UFH, whereas 5 of 6 trials of enoxaparin
und point estimates for death or nonfatal MI that favored
oxaparin over UFH; the pooled OR was 0.91 (95% CI 0.83
0.99). The benefit of enoxaparin appeared to be driven
rgely by a reduction in nonfatal MI, especially in the cohort
patients who had not received any open-label anticoagulant
erapy before randomization.
There are few data to assess whether the heterogeneous
sults are explained by different populations, study designs,
rious heparin dose regimens, properties of the various
MWHs (more specifically, different molecular weights and
ti–factor Xa/anti–factor IIa ratios), concomitant therapies,
other unrecognized influences. Although it is tempting to
mpare the relative treatment effects of the different LMWH
mpounds, the limitations of such indirect comparisons mustrecognized. The only reliable method of comparing 2
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Trial
eference) LMWH/Dose UFH End Point/Drug Effect Analysis 95% CI p Major Bleeding (p)
ISC (371) 1,506 (a) 6 d*: dalteparin 120
IU per kg† SC twice
daily (maximum
10,000 IU)
(b) During first 40 d:
dalteparin 7,500 IU
SC once per day
(a) 6 d: placebo
(b) During first 40 d:
placebo
(a) Death or new MI (6
d): LMWH 1.8%,
Placebo 4.8%
(b) Death or new MI
(during first 40 d‡:
LMWH 8%, placebo
10.7%
(a) RR 0.37 ARR 3%
(b) RR 0.75 ARR 2.7%
(a) 0.20 to 0.68
(b) 0.54 to 1.03
(a) 0.001
(b) 0.07
(a) LMWH 0.8%,
placebo 0.5%;
ARR – 0.3%
(p  NR)
(b) During first 40 d:
LMWH 0.3%,
placebo 0.3%;
ARR 0%
(p  NR)
SENCE
(169)
3,171 Enoxaparin 1 mg per kg
SC twice daily
(minimum 48 h,
maximum 8 d)
UFH IV bolus (usually
5,000 units) and
continued IV
infusion
(a) Death, MI, or
recurrent angina at
14 d: LMWH 16.6%
UFH 19.8%
(b) Death, MI, or
recurrent angina at
30 d: LMWH
19.8%, UFH 23.3%
(a) OR at 14 d  0.80
ARR 3.2%
(b) OR at 30 d  0.81
ARR 3.5%
(a) 0.67 to 0.96
(b) 0.68 to 0.96
(a) 0.019
(b) 0.016
At 30 d: LMWH
6.5%, UFH 7%;
ARR 0.5%
(p  0.57)
IC (462) 1,482 (a) Days 1 to 6:
dalteparin 120 IU per
kg SC twice daily
(b) Days 6 to 45§:
dalteparin 7,500 IU
SC once per day
(a) Days 1 to 6: UFH
5,000 units IV
bolus and IV
infusion of 1,000
units per h for
48 h
(b) Days 6 to 45:
placebo SC once
daily
(a) Death, MI, or
recurrence of
angina (Days 1 to
6): LMWH 9.3%,
UFH 7.6%
(b) Death, MI, or
recurrence of
angina (Days 6 to
45): 12.3% in both
the LMWH and UFH
groups
(a) Death or MI (Days
1 to 6): LMWH
3.9%, UFH 3.6%
(b) Death or MI (Days
6 to 45): LMWH
4.3%, placebo
4.7%
(a) RR 1.18
ARR –1.7%
(b) RR 1.01
ARR 0%
(a) RR 1.07
ARR –0.3%
(b) RR 0.92
ARR 0.4%
(a) 0.84 to 1.66
(b) 0.74 to 1.38
(a) 0.63 to 1.80
(b) 0.54 to 1.57
(a) 0.33
(b) 0.96
(a) 0.80
(b) 0.76
(a) Days 1 to 6:
LMWH 1.1%,
UFH 1.0%; ARR
0.1%
(p  NR)
(b) Days 6 to 45:
LMWH 0.5%,
placebo 0.4%;
ARR 0.1%
(p  NR)
AX.I.S.
(463)
3,468 (a) Nadroparin 6 d:
nadroparin 86 anti-
Xa IU per kg IV
bolus, followed by
nadroparin 86 anti-
Xa IU per kg SC
twice daily for 6 d
(b) Nadroparin 14 d:
nadroparin 86 anti-
Xa IU per kg IV
bolus, followed by
nadroparin 86 anti-
Xa IU per kg SC
twice daily for 14 d
(a)  (b) UFH 5,000
units IV bolus
and UFH infusion
at 1,250 units
per h IV for 6 d
(plus or minus
2 d)
Cardiac death, MI,
refractory angina,
recurrence of UA at
Day 14: LMWH
17.8%, LMWH 14 d
20.0% UFH 18.1%
(a) ARR 0.3%
(b) ARR 1.9%
(a) 2.8 to 3.4
(b) 5.1 to 1.3
(a) 0.85
(b) 0.24
At 6 d:
UFH 1.6%,
LMWH 1.5%,
ARR 0.1%
At 14 d:
UFH 1.6%
LMWH 3.5%,
ARR 1.9%
(p  0.0035)
I 11B
(180)
3,910 (a) Inpatient: enoxaparin
30 mg IV bolus
immediately followed
by 1 mg per kg SC
every
12 h
(b) Outpatient:
enoxaparin 40 mg
SC twice per day
(patients weighing
less than 65 kg) or
60 mg SC twice per
day (patients
weighing at least
65 kg)
(a) Inpatient: UFH 70
units per kg
bolus and
infusion at 15
units per h
titrated to aPTT
(treatment
maintained for a
minimum of 3
and maximum of
8 d at physician’s
discretion)
(b) Outpatient:
placebo SC twice
per day
Death, MI, urgent
revascularization
(a) At 48 h: LMWH
5.5%, UFH 7.3%
(b) 8 d: LMWH
12.4%, UFH
14.5%
(c) 14 d: LMWH
14.2%, UFH
16.7%
(d) 43 d: LMWH
17.3%, UFH
19.7%
(a) OR 0.75
ARR 1.8%
(b) OR 0.83
ARR 2.1%
(c) OR 0.82
ARR 2.5%
(d) OR 0.85
ARR 2.4%
(a) 0.58 to 0.97
(b) 0.69 to 1.00
(c) 0.69 to 0.98
(d) 0.72 to 1.00
(a) 0.026
(b) 0.048
(c) 0.029
(d) 0.048
At 48 h: LMWH
0.8% UFH 0.7%
ARR –0.1%
(p  0.14)
End of initial
hospitalization:
LMWH 1.5%
UFH 1%
ARR –0.5%
(p  0.143)
Between Day 8 and
Day 43: LMWH
2.9%, placebo
2.9%, ARR 0%
(p  0.021)(Continued on next page)
Ta
(R
AC
IN
A
SY
A
de
bl
of
bl
he
ac
of
bl
ad
ris
FR
in
in
In
e240 Anderson et al. JACC Vol. 61, No. 23, 2013
UA/NSTEMI Guideline: 2012 Update Incorporated June 11, 2013:e179–347ble 17. Continued
Trial
eference) LMWH/Dose UFH End Point/Drug Effect Analysis 95% CI p Major Bleeding (p)
UTE II
(464)
525 Enoxaparin 1 mg per kg
SC every 12 h
UFH 5,000 units IV
bolus and
maintenance
infusion at 1,000
units per h IV
adjusted to aPTT
(a) Death or (b) MI at
30 d
(a) LMWH 2.5%, UFH
1.9%
(b) LMWH 6.7%, UFH
7.1%
(a) RR 1.3 ARR
0.6%
(b) RR 0.94 ARR 0.4%
(a) 0.06 to 3.93
(b) 0.45 to 2.56
(a) 0.77
(b) 0.86
LMWH 0.3%; UFH
1%; ARR 0.7%
(p  0.57)
TERACT,
(465)¶
746 Enoxaparin 1 mg per kg
SC every 12 h
UFH 70 units per kg
IV bolus followed
by continuous
infusion at 15
units per kg per
h
Death or MI at 30 d:
LMWH 5.0%,
UFH 9.0%
RR 0.55
ARR 4%
0.30 to 0.96 0.031 At 96 h:
LMWH 1.8%; UFH
4.6%; ARR 2.8%
(p  0.03)
to Z**
(466)
3,987 Enoxaparin 1 mg per kg
SC every 12 h
UFH 4,000 units IV
bolus followed by
900 units per h
IV infusion for
patients weighing
equal to or
greater than
70 kg
UFH 60 units per kg
(maximum 4,000
units) IV bolus
followed by 12
units per h kg
per IV infusion for
patients weighing
less than 70 kg
All-cause death, MI, or
refractory ischemia
within 7 d of
tirofiban initiation:
LMWH 8.4%,
UFH 9.4%
HR 0.88 ARR 1% 0.71 to 1.08 NR LMWH 0.9%; UFH
0.4%; ARR
0.5%
(p  0.05)
NERGY††
(423)
9,978 Enoxaparin 1 mg per kg
SC every 12 h
UFH 60 units per kg
IV bolus
(maximum of
5,000 units) and
followed by IV
infusion of
12 units per kg
per h (maximum
of 1,000 units
per h initially
Death or nonfatal MI
during first 30 d
after randomization
LMWH 14.0%,
UFH 14.5%,
HR 0.96 ARR 0.5% 0.86 to 1.06 0.40 TIMI minor: LMWH
12.5%, UFH
12.3%; ARR
0.2%
(p  0.80)
TIMI major: LMWH
9.1%, UFH 7.6%;
ARR 1.5%
(p  0.008)
GUSTO severe: LMWH
2.7%, UFH 2.2%;
ARR 0.5%
(p  0.08)
For specific interventions and additional medications during the study, see individual study references. Major bleeding was classified as follows in the various trials:
to Z: decrease in hemoglobin of more than 5 mg per dL or intracranial or pericardial bleeding. ESSENCE: Major hemorrhage was defined as bleeding resulting in
ath, transfusion of at least 2 U of blood, a fall in hemoglobin of 30 g per liter or more, or a retroperitoneal, intracranial, or intraocular hemorrhage. TIMI 11B: Overt
eed resulting in death; a bleed in a retroperitoneal, intracranial, or intraocular location; a hemoglobin drop of greater than or equal to 3 g per dL; or the requirement
transfusion of at least 2 U of blood. SYNERGY: TIMI and GUSTO criteria. ACUTE II: Severity was recorded on the basis of the TIMI trial bleeding criteria. TIMI major
eeding involved a hemoglobin drop greater than 5 g per dL (with or without an identified site, not associated with coronary artery bypass grafting) or intracranial
morrhage or cardiac tamponade. INTERACT: Major bleeding included bleeding resulting in death, or retroperitoneal hemorrhage, or bleeding at a specific site
companied by a drop in hemoglobin greater than or equal to 3g per dL. FRIC: A bleeding event was classified as major if it led to a fall in the hemoglobin level
at least 20 g per liter, required transfusion, was intracranial, or caused death or cessation of the study treatment.
*Primary study end point was first 6 d.
†Initial trial dose of 150 IU per kg SC twice daily decreased to 120 IU per kg SC twice daily due to increased bleeding during first 6 d (4 patients or 6% major
eeding episodes and 9 patients or 14% minor episodes among 63 actively treated patients).
‡Follow-up incomplete in 13 patients (8 dalteparin, 5 placebo) at their request.
§Primary study outcome was Days 6 to 45.
All patients in ACUTE II received a tirofiban loading dose of 0.4 mcg per kg per min over 30 min, followed by a maintenance infusion at 0.1 mcg per kg per min.
¶All patients in INTERACT received eptifibatide 180 mcg per kg bolus followed by a 2.0 mcg per kg per min infusion for 48 h.
**All patients enrolled in the A to Z Trial received aspirin and tirofiban.
††Patients also received glycoprotein IIb/IIIa inhibitors, aspirin, clopidogrel; patients eligible for enrollment even if LMWH or UFH given before enrollment,
justments made to enoxaparin and UFH during percutaneous coronary intervention.
A to Z Aggrastat to Zocor study; ACUTE II Antithrombotic Combination Using Tirofiban and Enoxaparin; aPTT activated partial thromboplastin time; ARR absolute
k reduction; CI  confidence interval; ESSENCE  Efficacy and Safety of Subcutaneous Enoxaparin in Unstable Angina and Non-Q-Wave Myocardial Infarction; FRIC 
agmin In unstable Coronary disease; HR  hazard ratio; INTERACT  Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment; IU 
ternational units; IV  intravenous; LD  loading dose; MD  maintenance dose; N  number of patients; LMWH  low-molecular-weight heparin; MI  myocardial
farction; NR not reported; RR relative risk; SC subcutaneous; SYNERGY Superior Yield of the New strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIA
hibitors; TIMI 11B  Thrombolysis In Myocardial Infarction 11B; U  unit; UA  unstable angina; UFH  unfractionated heparin.
tr
cl
th
(e
be
L
ex
di
ti
at
in
L
w
pa
an
B
su
m
th
he
tr
ti
bl
T
an
bl
st
da
bl
of
re
L
of
E
di
li
an
du
th
R
(S
PC
M
ti
(9
G
an
an
bl
ov
va
re
du
m
ph
co
re
pl
U
w
ad
fi
3
F
(F
In
ev
ti
F
6
th
ad
6
Is
us
al
su
ad
A
sh
po
p
co
tr
p
ti
an
th
in
an
pr
fr
an
3
H
be
G
su
hi
th
(4
en
oc
hi
S
ti
si
in
H
M
e241JACC Vol. 61, No. 23, 2013 Anderson et al.
June 11, 2013:e179–347 UA/NSTEMI Guideline: 2012 Update Incorporatedeatments is through a direct comparison in a well-designed
inical trial or series of trials. The comparison of different
erapies (e.g., different LMWHs) with a common therapy
.g., UFH) in different trials does not allow a conclusion to
made about the relative effectiveness of the different
MWHs because of the variability in both control group and
perimental group event rates due to protocol differences,
fferences in concomitant therapies due to geographic and
me variability, and the play of chance. Similar consider-
ions apply to comparisons among platelet GP IIb/IIIa
hibitors.
In the Enoxaparin Versus Tinzaparin (EVET) trial, 2
MWHs, enoxaparin and tinzaparin, administered for 7 d,
ere compared in 436 patients with UA/NSTEMI. Enoxa-
rin was associated with a lower rate of death/MI/recurrent
gina at 7 and 30 d compared with tinzaparin (562,563).
leeding rates were similar with the 2 LMWHs.
The advantages of LMWH preparations are the ease of
bcutaneous administration and the absence of a need for
onitoring. Furthermore, the LMWHs stimulate platelets less
an UFH (564) and are less frequently associated with
parin-induced thrombocytopenia (556). In the ESSENCE
ial, minor bleeding occurred in 11.9% of enoxaparin pa-
ents and 7.2% of UFH patients (p0.001), and major
eeding occurred in 6.5% and 7.0%, respectively (175). In
IMI 11B, the rates of minor bleeding in hospital were 9.1%
d 2.5%, respectively (p0.001), and the rates of major
eeding were 1.5% and 1.0% (p0.14) (186). In the FRISC
udy, major bleeding occurred in 0.8% of patients given
lteparin and in 0.5% of patients given placebo, and minor
eeding occurred in 61 (8.2%) of 746 patients and 2 (0.3%)
760 patients, respectively (406).
The anticoagulant effect of LMWH is less effectively
versed with protamine than that of UFH. In addition,
MWH administered during PCI does not permit monitoring
the ACT to titrate the level of anticoagulation. In the
SSENCE and TIMI 11B trials, special rules were set to
scontinue enoxaparin before PCI and CABG. Because of
mited experience with enoxaparin at the time the ESSENCE
d TIMI 11B trials were conducted, UFH was administered
ring PCI to achieve ACT values of greater than 350 s. In
e Superior Yield of the New Strategy of Enoxaparin,
evascularization and Glycoprotein IIb/IIIa Inhibitors
YNERGY) trial, enoxaparin was compared to UFH during
I in patients with high-risk UA/NSTEMI (400) (Figure 12).
ore bleeding was observed with enoxaparin, with a statis-
cally significant increase in TIMI-defined major bleeding
.1% vs 7.6%, p0.008) but a nonsignificant excess in
USTO-defined severe bleeding (2.7% vs 2.2%, p0.08)
d transfusions (17.0% vs 16.0%, p0.16). A post hoc
alysis from SYNERGY suggested that some of the excess
eeding seen with enoxaparin could be explained by cross-
er to UFH at the time of PCI (431). This remains to be
lidated prospectively, but at the present time, it appears
asonable to minimize the risk of excessive anticoagulation
ring PCI by avoiding crossover of anticoagulants (i.e.,
aintain consistent anticoagulant therapy from the pre-PCI
ase throughout the procedure itself). tiAn economic analysis of the ESSENCE trial suggested
st savings with enoxaparin (565). For patients who are
ceiving subcutaneous LMWH and in whom CABG is
anned, it is recommended that LMWH be discontinued and
FH be used during the operation. Additional experience
ith regard to the safety and efficacy of the concomitant
ministration of LMWHs with GP IIb/IIIa antagonists and
brinolytic agents is currently being acquired.
.2.5.3.1. Extended Therapy with LMWHs. The
RISC, Fragmin in unstable coronary artery disease study
RIC), TIMI 11B, and Fast Revascularization during
Stability in Coronary artery disease-II (FRISC-II) trials
aluated the potential benefit of the prolonged administra-
on of LMWH after hospital discharge (Table 17). In the
RISC trial, doses of dalteparin were administered between
d and 35 to 45 d; in FRIC, patients were rerandomized after
e initial 6-d treatment period to receive dalteparin for an
ditional 40 d, and the outpatient treatment period lasted 5 to
weeks in TIMI 11B and 1 week in the FRAXiparine in
chaemic Syndromes (FRAXIS) trial. The FRISC-II trial
ed a different study design. Dalteparin was administered to
l patients for a minimum of 5 d (566). Patients were
bsequently randomized to receive placebo or the continued
ministration of dalteparin twice per day for up to 90 d.
nalysis of the results from the time of randomization
owed a significant reduction with dalteparin in the com-
site end point of death or MI at 30 d (3.1% vs 5.9%,
0.002) but not at 3 months (6.7% vs 8.0%, p0.17). The
mposite of death, MI, or revascularization during the total
eatment period was reduced at 3 months (29.1% vs 33.4%,
0.031). The benefits of prolonged dalteparin administra-
on were limited to patients who were managed medically
d to those with elevated TnT levels at baseline. Although
ese results make a case for the prolonged use of an LMWH
selected patients who are managed medically or in whom
giography is delayed, their relevance to contemporary
actice is less clear now that clopidogrel is used more
equently and there is a much greater tendency to proceed to
early invasive strategy.
.2.5.4. DIRECT THROMBIN INHIBITORS
irudin, the prototype of the direct thrombin inhibitors, has
en extensively studied but with mixed results. The
USTO-IIb trial randomly assigned 12,142 patients with
spected MI to 72 h of therapy with either intravenous
rudin or UFH (567). Patients were stratified according to
e presence of ST-segment elevation on the baseline ECG
,131 patients) or its absence (8,011 patients). The primary
d point of death, non-fatal MI, or reinfarction at 30 d
curred in 9.8% of the UFH group versus 8.9% of the
rudin group (OR 0.89, p0.058). For patients without
T-segment elevation, the rates were 9.1% and 8.3%, respec-
vely (OR 0.90, p0.22). At 24 h, the risk of death or MI was
gnificantly lower in the patients who received hirudin than
those who received UFH (2.1% vs 1.3%, p0.001).
owever, the Thrombolysis and Thrombin Inhibition in
yocardial Infarction (TIMI) 9B trial of hirudin as adjunc-ve therapy to thrombolytic therapy in patients with STEMI
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ug infusion or later (568). The GUSTO-IIb and TIMI 9B
ials used hirudin doses of 0.1 mg per kg bolus and 0.1 mg
r kg per h infusion for 3 to 5 d after the documentation of
cess bleeding with higher doses used in the GUSTO-IIA
d TIMI 9A trials (0.6 mg per kg bolus and 0.2 mg per kg
r h infusion) (567,569).
The OASIS program evaluated hirudin in patients with
A/NSTEMI. OASIS 1 (570) was a pilot trial of 909 patients
at compared the low hirudin dose of 0.1 mg per kg per h
fusion and the medium hirudin dose of 0.15 mg per h
fusion with UFH. The latter dose provided the best results,
ith a reduction in the rate of death, MI, or refractory angina
7 d (6.5% with UFH vs 3.3% with hirudin, p0.047). This
edium dose was used in the large OASIS 2 (571) trial that
nsisted of 10,141 patients with UA/NSTEMI who were
ndomized to receive UFH (5,000 IU bolus plus 15 U per kg
r h) or recombinant hirudin (0.4 mg per kg bolus and 0.15
g per kg per h) infusion for 72 h. The primary end point of
rdiovascular death or new MI at 7 d occurred in 4.2% in the
FH group versus 3.6% patients in the hirudin group (RR
84, p0.064). A secondary end point of cardiovascular
ath, new MI, or refractory angina at 7 d was significantly
duced with hirudin (6.7% vs 5.6%, RR 0.83, p0.011).
here was an excess of major bleeding incidents that required
ansfusion with hirudin (1.2% vs 0.7% with heparin,
0.014) but no excess in life-threatening bleeding incidents
strokes. A meta-analysis of the GUSTO-IIB, TIMI 9B,
ASIS 1, and OASIS 2 trials showed a relative risk of death
MI of 0.90 (p0.015) with hirudin compared with UFH at
d after randomization; RR values were similar for patients
ceiving thrombolytic agents (0.88) and not receiving throm-
gure 12. SYNERGY Primary Outcomes at 30 d. CI  confidence
e New strategy of Enoxaparin, Revascularization and Glycoprotelytic agents (0.90) (571). deThe relative benefits of hirudin versus UFH in ACS
tients undergoing PCI were evaluated in the 1,410-patient
bset in GUSTO-IIb who underwent PCI during the initial
ug infusion. A reduction in nonfatal MI and the composite
death and MI was observed with hirudin that was associ-
ed with a slightly higher bleeding rate (430).
Hirudin (lepirudin) is presently indicated by the US Food
d Drug Administration only for anticoagulation in patients
ith heparin-induced thrombocytopenia (556) and for the
ophylaxis of deep vein thrombosis in patients undergoing
p replacement surgery. It should be administered as a 0.4
g per kg IV bolus over 15 to 20 s followed by a continuous
travenous infusion of 0.15 mg per kg per h, with adjustment
the infusion to a target range of 1.5 to 2.5 times the control
TT values. Argatroban is another direct thrombin inhibitor
at is approved for the management of patients with heparin-
duced thrombocytopenia (572). However, in ACS, the
onovalent direct thrombin inhibitors (including argatro-
n) are ineffective antithrombotic agents compared with
FH, and thus, argatroban should generally not be used in
anagement of ACS (573). The recommended initial dose
argatroban is an intravenous infusion of 2 mcg per kg
r min, with subsequent adjustments to be guided by the
TT (medical management) or ACT (interventional man-
ement).
The REPLACE 2 investigators compared bivalirudin (bo-
s 0.75 mg per kg followed by infusion of 1.75 mg per kg per
with provisional GP IIb/IIIa inhibition) with UFH 65 U per
bolus with planned GP IIb/IIIa inhibition in patients
dergoing urgent or elective PCI (527). Only 14% had been
eated for UA within 48 h before enrollment. Prespecified
al; MI  myocardial infarction; SYNERGY  Superior Yield of
Ia Inhibitors (423); UFH unfractionated heparin.intervfinitions of noninferiority were satisfied for bivalirudin,
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ollow-up through 1 year also suggested similar mortality for
e 2 approaches (434).
Bivalirudin was investigated further in the ACUITY trial
24) (Figures 13 and 14). The ACUITY trial used a 2  2
ctorial design to compare a heparin (UFH or enoxaparin)
ith or without upstream GP IIb/IIIa inhibition versus bivali-
din with or without upstream GP IIb/IIIa inhibition; a third
m tested bivalirudin alone and provisional GP IIb/IIIa
hibition. The study was randomized but open-label (un-
inded). The main comparisons in the ACUITY trial were of
parin with GP IIb/IIIa inhibition versus bivalirudin with GP
b/IIIa inhibition versus bivalirudin with provisional GP
b/IIIa inhibition. Three primary 30-d end points were
especified: composite ischemia, major bleeding, and net
inical outcomes (composite ischemia or major bleeding).
ivalirudin plus GP IIb/IIIa inhibitors compared with heparin
us GP IIb/IIIa inhibitors resulted in noninferior 30-d rates
composite ischemia (7.7% vs 7.3%), major bleeding (5.3%
5.7%), and net clinical outcomes (11.8% vs 11.7%)
igure 13). Bivalirudin alone compared with heparin GB
us IIb/IIIa inhibitors resulted in noninferior rates of com-
site ischemia (7.8% vs 7.3%, p0.32, RR 1.08, 95% CI
93 to 1.42), significantly reduced major bleeding (3.0% vs
7%, p0.001, RR 0.53, 95% CI 0.43 to 0.65), and superior
gure 13. ACUITY Clinical Outcomes at 30 d. p for noninferiority
rategY; CI  confidence interval; GP  glycoprotein; UFH  unf-d net clinical outcomes (10.1% vs 11.7% respectively, in0.015, RR 0.86, 95% CI 0.77 to 0.97). For the subgroup of
753 patients who did receive clopidogrel before angiogra-
y or PCI, the composite ischemic end point occurred in
0% in the bivalirudin-alone group versus 7.3% in the group
at received heparin plus GP IIb/IIIa inhibition (RR 0.97,
% CI 0.80 to 1.17), whereas in the 3,304 patients who did
t receive clopidogrel before angiography or PCI, the
mposite ischemic event rate was 9.1% in the bivalirudin-
one group versus 7.1% in the heparin plus GP IIb/IIIa
hibition group (RR 1.29, 95% CI 1.03 to 1.63; p for
teraction 0.054) (Figure 14) (424). The 2007 Writing
ommittee believes that this observation introduces a note of
ution about the use of bivalirudin alone, especially when
ere is a delay to angiography when high-risk patients who
ay not be represented by the ACUITY trial population are
ing managed, or if early ischemic discomfort occurs after
e initial antithrombotic strategy has been implemented
ppendix 9 has replaced Figures 7, 8, and 9). The 2007
riting Committee therefore recommends that patients meeting
ese criteria be treated with concomitant GP IIb/IIIa inhibitors
clopidogrel, administered before angiography to optimize
tcomes whether a bivalirudin-based or heparin-based antico-
ulant strategy is used. This approach is also supported by the
ndings of the ACUITY timing study that showed a trend
ward higher rates of ischemic events, which did not meet
ITY  Acute Catheterization and Urgent Intervention Triage
ated heparin.. ACUferiority criteria, in the deferred GP IIb/IIIa inhibitor group
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planned revascularization for ischemia occurred in 7.1% of
utine upstream GP IIb/IIIa inhibitor group versus 7.9% of
ferred selective inhibitor group; RR 1.12 (95% CI 0.97 to
29) (392,575). Similarly, in the ACUITY PCI substudy
94,576), subjects who did not receive clopidogrel pre-PCI had
gher rates of the composite ischemic end point in the
valirudin-alone group compared with the heparin plus GP
b/IIIa group. In both the REPLACE 2 and ACUITY trials,
valirudin with provisional GP IIb/IIIa blockade was associated
ith a lower risk of bleeding, whereas this was not the case in
CUITY with the combination of bivalirudin and planned GP
b/IIIa blockade, suggesting that dosing regimens and concom-
nt GP IIb/IIIa blockade plays an important role in bleeding
sk (433). The impact of switching anticoagulants after random-
ation, which has been associated with excess bleeding
00,577), is unclear for bivalirudin. It should be noted that the
CUITY protocol called for angiography within 24 to 48 h of
ndomization and that the median time to catheterization (from
e time the study drug was started) was approximately 4 h; thus,
e study results of this trial cannot be extrapolated beyond the
oup of patients treated in an early invasive fashion.
.2.5.5. FACTOR XA INHIBITORS
he OASIS 5 investigators evaluated the use of fondaparinux
UA/NSTEMI (422) (Figure 15). OASIS 5 compared 2
ticoagulant strategies given for a mean of 6 d; one of which
as amended during the conduct of the trial. In OASIS 5,
tients with UA/NSTEMI were randomized to a control
rategy of enoxaparin 1.0 mg per kg SC twice daily (reduced
1.0 mg per kg once daily for patients with an estimated
eatinine clearance less than 30 ml per min) coupled with
gure 14. ACUITY Composite Ischemia and Bleeding Outcomes.
rategY; CI  confidence interval; GP  glycoprotein; PCI  percFH when PCI was performed (no additional UFH if the thst dose of enoxaparin was less than 6 h before). If the last
se of enoxaparin was given more than 6 h before, the
commendation was that an intravenous bolus of UFH 65
per kg be administered if a GP IIb/IIIa inhibitor was to
used and 100 U per kg if no GP IIb/IIIa inhibitor was to
used. The opposite arm was a strategy of fondaparinux
5 mg SC once daily to be supplemented as follows if PCI
as performed: within 6 h of the last subcutaneous dose of
ndaparinux, no additional study drug was given if a GP
b/IIIa inhibitor was used, and 2.5 mg of fondaparinux
as given intravenously if no GP IIb/IIIa inhibitor was
ed; more than 6 h since the last dose of fondaparinux, an
ditional intravenous dose of fondaparinux 2.5 mg was
commended if a GP IIb/IIIa inhibitor was used or 5.0 mg
if no GP IIb/IIIa inhibitor was used. As explained by
e OASIS 5 investigators, the rationale for the recommen-
tion to use UFH during PCI in the enoxaparin arm was
sed on lack of approval for enoxaparin for PCI in the
.S. by the Food and Drug Administration, lack of
ailable trial data on the use of enoxaparin during PCI
hen OASIS 5 was designed, and lack of any recommen-
tions about the use of enoxaparin in the available
CC/AHA or ESC PCI guidelines (personal communica-
on, OASIS 5 Investigators, July 7, 2006). The UFH
sing recommendation in the enoxaparin arm was formu-
ted in consultation with the maker of enoxaparin and was
t altered when the SYNERGY trial did not show
periority of enoxaparin over UFH (400). Of note, during
e conduct of the trial, catheter-associated thrombus was
ported 3 times more frequently with the fondaparinux
rategy (0.9% vs 0.3%). After approximately 12,000 of
Y  Acute Catheterization and Urgent Intervention Triage
us coronary intervention; UFH unfractionated heparin.ACUITe 20,078 patients ultimately enrolled in the trial had been
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vestigators to be certain that the intravenous dose of
ndaparinux was properly flushed in the line and to permit
e use of open-label UFH. As described by the OASIS 5
vestigators (personal communication, OASIS 5 Investi-
tors, July 7, 2006), investigators gave open-label UFH
th before and during PCI, with the dose being deter-
ined at their discretion.
The number of patients with primary outcome events at
d (death, MI, or refractory ischemia) was similar in the
groups (579 with fondaparinux [5.8%] vs 573 with
oxaparin [5.7%]; HR in the fondaparinux group 1.01;
% CI 0.90 to 1.13), which satisfied prespecified nonin-
riority criteria. The number of events that met this
mbined primary efficacy outcome showed a nonsignifi-
nt trend toward a lower value in the fondaparinux group
30 d (805 vs 864, p0.13) and at the end of the study
80 d; 1,222 vs 1,308, p0.06; Figure 12). The rate of
ajor bleeding at 9 d was lower with fondaparinux than
ith enoxaparin (217 events [2.2%] vs 412 events [4.1%];
R 0.52; p0.001). The composite of the primary out-
me and major bleeding at 9 d favored fondaparinux (737
ents [7.3%] vs 905 events [9.0%]; HR 0.81; p0.001)
igure 15). Fondaparinux was associated with a signifi-
ntly reduced number of deaths at 30 d (295 vs 352,
0.02) and at 180 d (574 vs 638, p0.05). Fondaparinux
so was associated with significant reductions in death,
I, and stroke (p0.007) at 180 d.
Thus, fondaparinux is another anticoagulant that has been
ven a Class I recommendation in the management of
A/NSTEMI (Appendix 9 has replaced Figures 7, 8, and 9). As
sted in OASIS 5, the fondaparinux (plus UFH) strategy was
sociated with lower bleeding rates, clearly an attractive feature
gure 15. OASIS 5 Cumulative Risks of Death, MI, or Refractory
terval; MI  myocardial infarction; OASIS 5  Fifth Organizationven the relationship between bleeding events and increased risk of poath and ischemic events (578). The excess bleeding in the
oxaparin arm may have been in part a result of the combination
enoxaparin and UFH during PCI.
At present, based on experience in both OASIS 5 and OASIS
(534), it appears that patients receiving fondaparinux before
CI should receive an additional anticoagulant with anti–IIa
tivity to support PCI (see Appendixes 7 and 8). To date, the
ly anticoagulant that has been evaluated with fondaparinux
ring PCI is UFH, and based on limited experience, the
ASIS investigators recommend an UFH dose of 50 to 60 U
r kg IV when fondaparinux-treated patients are taken to
CI (personal communication, OASIS 5 Investigators, July 7,
06). However, a cautionary note is that this UFH recom-
endation is not fully evidence-based, given its inconsistent
d uncontrolled use in OASIS 5. Hence, additional clinical
ial information is needed to establish more rigorously the
fety of intravenous UFH at the time of PCI in patients
ceiving fondaparinux as initial medical treatment. Because
e anticoagulant effect of UFH can be more readily reversed
an that of fondaparinux, UFH is preferred over fondapa-
nux in patients likely to undergo CABG within 24 h.
.2.5.6. LONG-TERM ANTICOAGULATION
EFER TO UPDATED SECTION 5.2.6)
he long-term administration of warfarin has been evaluated
a few, mostly small studies. Williams et al. (537) random-
ed 102 patients with UA to UFH for 48 h followed by
en-label warfarin for 6 months and reported a 65% risk
duction in the rate of MI or recurrent UA. The Antithrom-
tic Therapy in Acute Coronary Syndromes (ATACS) trial
73) randomized 214 patients with UA/NSTEMI to ASA
one or to the combination of ASA plus UFH followed by
arfarin. At 14 d, there was a reduction in the composite end
ia. p for noninferiority. †p for superiority. CI  confidence
ess Strategies for Ischemic Syndromes.Ischemint of death, MI, and recurrent ischemia with the combi-
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ndomized pilot study of 57 patients allocated to warfarin or
acebo in addition to ASA, less evidence was noted of
giographic progression in the culprit lesion after 10 weeks
treatment with warfarin (33% for placebo vs 4% for
arfarin) and more regression was observed (579). The
ASIS pilot study (580) compared a fixed dosage of warfarin
mg per d or a moderate dose titrated to an INR of 2.0 to 2.5
197 patients and given for 7 months after the acute phase.
ow-intensity warfarin had no benefit, whereas the moderate-
tensity regimen reduced the risk of death, MI, or refractory
gina by 58% and the need for rehospitalization for UA by
%. However, these results were not reproduced in the
rger OASIS 2 trial (571) of 3,712 patients randomized to the
oderate-intensity regimen of warfarin or standard therapy,
ith all patients receiving ASA. The rate of cardiovascular
ath, MI, or stroke after 5 months was 7.7% with the
ticoagulant and 8.4% without (p0.37) (581). Thus, the
le, if any, of long-term warfarin in patients with UA/
STEMI remains to be defined.
The Coumadin Aspirin Reinfarction Study (CARS) con-
cted in post-MI patients was discontinued prematurely
ing to a lack of evidence of a benefit of reduced-dose ASA
0 mg per d) combined with either 1 or 3 mg of warfarin
ily compared with 160 mg per d of ASA alone (582). The
ombination Hemotherapy And Mortality Prevention study
und no benefit to the use of warfarin (to an INR of 1.5 to
5) plus 81 mg per d of ASA versus 162 mg per d of ASA
one with respect to total mortality (the primary end point),
rdiovascular mortality, stroke, or nonfatal MI (mean
llow-up of 2.7 years) after an index MI (583). Low- or
oderate-intensity anticoagulation with fixed-dose warfarin
us is not recommended for routine use after hospitalization
r UA/NSTEMI. Warfarin should be prescribed, however,
r UA/NSTEMI patients with established indications for
arfarin, such as atrial fibrillation, left ventricular thrombus,
d mechanical prosthetic heart valves.
The Antithrombotics in the Secondary Prevention of
vents in Coronary Thrombosis-2 (ASPECT-2) open-label
ial randomized 999 patients after ACS to low-dose ASA,
gh-intensity oral anticoagulation (INR 3.0 to 4.0), or
mbined low-dose ASA and moderate intensity oral antico-
ulation (INR 2.0 to 2.5) (584). After a median of 12
onths, the primary end point of MI, stroke, or death was
ached in 9% receiving ASA, 5% given anticoagulants
0.048), and 5% receiving combination therapy (p0.03).
ajor and minor bleeding events occurred in 1% and 5%, 1%
d 8%, and 2% and 15% of patients, respectively.
Similarly, a large (n  3,630) Norwegian open-label study
ARIS-2) compared ASA (160 mg per d), high-intensity
arfarin (INR target 2.8 to 4.2), or ASA (75 mg per d)
mbined with moderate-intensity warfarin (INR 2.0 to 2.5)
er a mean of 4 years after MI (41% with non–Q-wave MI)
85). One third of patients underwent an intervention over
e study period. The primary outcome of death, nonfatal MI,
thromboembolic stroke occurred in 20% of ASA patients,
.7% of warfarin patients, and 15% of combination therapy
tients (p0.03). The annual major bleeding rate was 0.62% reboth warfarin arms and 0.17% with ASA alone (p0.001).
hus, moderate-intensity warfarin with low-dose ASA ap-
ars to be more effective than ASA alone when applied to
I patients treated primarily with a noninterventional ap-
oach, but it is associated with a higher bleeding risk.
An indication for warfarin (e.g., for atrial fibrillation,
echanical prosthetic valve, or left ventricular thrombus) in
dition to ASA and P2Y12 receptor inhibitor therapy, which
e indicated for most high-risk patients, arises occasionally
ter UA/NSTEMI. There are no prospective trials and few
servational data to establish the benefit and risk of such
riple antithrombotic” therapy (586,587). In the 2004
TEMI guidelines (8), a Class IIb, Level of Evidence: C
commendation was given for the use of warfarin (INR 2.0
3.0) in combination with ASA (75 to 162 mg) and
opidogrel (75 mg per d) for patients with a stent implanted
d concomitant indications for anticoagulation. Similarly,
e 2005 PCI guidelines (9) stated that warfarin in combina-
on with clopidogrel and low-dose ASA should be used with
eat caution and only when INR is carefully regulated (2.0 to
0). Despite a limited amount of subsequent observational
ta (587), the evidence base remains small, which leaves this
a Class IIb recommendation. When triple-combination
erapy is selected for clear indications and is based on
inical judgment that benefit will outweigh the incremental
sk of bleeding, then therapy should be given for the
inimum time and at the minimally effective doses necessary
achieve protection. An expanded evidence base on this
sue is strongly needed.
.2.6. Platelet GP IIb/IIIa Receptor Antagonists
efer to Updated Sections 3.2.1, 3.2.3, and 3.2.3.1.6)
he GP IIb/IIIa receptor is abundant on the platelet surface.
hen platelets are activated, this receptor undergoes a
ange in conformation that increases its affinity for binding
fibrinogen and other ligands. The binding of molecules of
brinogen to receptors on different platelets results in platelet
gregation. This mechanism is independent of the stimulus
r platelet aggregation and represents the final and obliga-
ry pathway for platelet aggregation (588). The platelet GP
b/IIIa receptor antagonists act by occupying the receptors,
eventing fibrinogen from binding, and thereby preventing
atelet aggregation. Experimental and clinical studies have
ggested that occupancy of at least 80% of the receptor
pulation and inhibition of platelet aggregation to ADP (5 to
micromoles per liter) by at least 80% results in potent
tithrombotic effects (589). The various GP IIb/IIIa antag-
ists, however, possess significantly different pharmacoki-
tic and pharmacodynamic properties (590).
Abciximab is a Fab fragment of a humanized murine
tibody that has a short plasma half-life but strong affinity
r the receptor, which results in some receptor occupancy
at persists in part for weeks. Platelet aggregation gradually
turns to normal 24 to 48 h after discontinuation of the drug.
bciximab also inhibits the vitronectin receptor (alphavbeta3)
endothelial cells and the MAC-1 receptor on leukocytes
91,592). The clinical relevance of occupancy of these
ceptors is unknown.
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ys-Gly-Asp) sequence; tirofiban is a nonpeptide mimetic of
e RGD (Arg-Gly-Asp) sequence of fibrinogen (590,593–595).
eceptor occupancy with these 2 synthetic antagonists is, in
neral, in equilibrium with plasma levels. They have half-
ves of 2 to 3 h and are highly specific for the GP IIb/IIIa
ceptor. Platelet aggregation returns to normal in 4 to 8 h
ter discontinuation of these drugs, a finding that is consis-
nt with their relatively short half-lives (596). Glycoprotein
b/IIIa antagonists can bind to different sites on the receptor,
hich results in somewhat different binding properties that
n modify their platelet effects and, potentially and paradox-
ally, activate the receptor (597). Oral antagonists to the
ceptor, previously under investigation, have been aban-
ned because of negative results of 5 large trials of 4 of these
mpounds (598–601).
The efficacy of GP IIb/IIIa antagonists in prevention of the
mplications associated with percutaneous interventions has
en documented in numerous trials, many of them composed
tally or largely of patients with UA (387,483,484,602)
able 18). Two trials with tirofiban and 1 trial with eptifi-
tide have also documented their efficacy in UA/NSTEMI
tients, only some of whom underwent interventions
35,137). Two trials were completed with the experimental
ug lamifiban (487,608) and 1 with abciximab (385). Few
rect comparative data are available for these various anti-
atelet agents. The TARGET study (Do Tirofiban and
eoPro Give Similar Efficacy Trial) assessed differences in
fety and efficacy of tirofiban and abciximab in 4,809
tients undergoing PCI with intended stenting (609). The
mposite of death, nonfatal MI, or urgent target-vessel
vascularization at 30 d occurred more frequently in the
rofiban group (7.6% vs 6.0%). The advantage of abciximab
as observed exclusively among patients presenting with
A/NSTEMI (63% of the population) (609). A possible
planation for the inferior performance of in-laboratory
itiation of tirofiban for PCI in the setting of ACS was an
sufficient loading dose of tirofiban to achieve optimal early
eriprocedural) antiplatelet effect (610).
Abciximab has been studied primarily in PCI trials, in
hich its administration consistently resulted in reductions in
tes of MI and the need for urgent revascularization (Table
). In subgroups of patients within those trials who had
CS, the risk of ischemic complications within the first 30 d
ter PCI was reduced by 60% to 80% with abciximab
erapy. Two trials with abciximab specifically studied pa-
ents with acute ischemic syndromes. The CAPTURE trial
rolled patients with refractory UA (387). After angio-
aphic identification of a culprit lesion suitable for angio-
asty, patients were randomized to either abciximab or
acebo administered for 20 to 24 h before angioplasty and
r 1 h thereafter. The rate of death, MI, or urgent revascu-
rization within 30 d (primary outcome) was reduced from
.9% with placebo to 11.3% with abciximab (RR 0.71,
0.012). At 6 months, death or MI had occurred in 10.6%
the placebo-treated patients versus 9.0% of the abciximab-
eated patients (p0.19). Abciximab is approved for the
eatment of UA/NSTEMI as an adjunct to PCI or when PCI
planned within 24 h. CThe GUSTO IV-ACS trial (385) enrolled 7,800 patients
ith UA/NSTEMI who were admitted to the hospital with
ore than 5 min of chest pain and either ST-segment
pression and/or elevated TnT or TnI concentration. All
ceived ASA and either UFH or LMWH. They were ran-
mized to an abciximab bolus and a 24-h infusion, an
ciximab bolus and a 48-h infusion, or placebo. In contrast
other trials with GP IIb/IIIa antagonists, GUSTO IV-ACS
rolled patients in whom early (less than 48 h) revascular-
ation was not intended. At 30 d, death or MI occurred in
0% of patients taking placebo, 8.2% of patients taking 24-h
ciximab, and 9.1% of patients taking 48-h abciximab,
fferences that were not statistically significant. At 48 h,
ath occurred in 0.3%, 0.7%, and 0.9% of patients in these
oups, respectively (placebo vs abciximab 48 h, p0.008).
he lack of benefit of abciximab was observed in most
bgroups, including patients with elevated concentrations of
oponin who were at higher risk. Although the explanation
r these results is not clear, they indicate that abciximab at
e dosing regimen used in GUSTO IV-ACS is not indicated
the management of patients with UA or NSTEMI in whom
early invasive management strategy is not planned.
Tirofiban was studied in the Platelet Receptor Inhibition in
chemic Syndrome Management (PRISM) (485) and Platelet
eceptor Inhibition in Ischemic Syndrome Management in
atients Limited by Unstable Signs and Symptoms (PRISM-
LUS) (137) trials. PRISM directly compared tirofiban with
parin in 3232 patients with accelerating angina or angina at
st and ST-segment or T-wave changes and with cardiac
arker elevation, a previous MI, or a positive stress test or
giographically documented coronary disease (485). The
imary composite outcome (death, MI, or refractory isch-
ia at the end of a 48-h infusion period) was reduced from
6% with UFH to 3.8% with tirofiban (RR 0.67, p0.01). At
d, the frequency of the composite outcome was similar in
e 2 groups (17.1% for UFH vs 15.9% for tirofiban,
0.34), but a trend toward reduction in the rate of death
MI was present with tirofiban (7.1% vs 5.8%, p0.11),
d a significant reduction in mortality rates was observed
.6% vs 2.3%, p0.02). The benefit of tirofiban was
ainly present in patients with an elevated TnI or TnT
ncentration at baseline.
The PRISM-PLUS trial enrolled 1,915 patients with clin-
al features of UA/NSTEMI within the previous 12 h and the
esence of ischemic ST-T changes or CK and CK-MB
evation (137). Patients were randomized to tirofiban alone,
FH alone, or the combination for a period varying from 48
108 h. The tirofiban-alone arm was dropped during the trial
cause of an excess mortality rate. The combination of
rofiban and UFH compared with UFH alone reduced the
imary composite end point of death, MI, or refractory
chemia at 7 d from 17.9% to 12.9% (RR 0.68, p0.004).
his composite outcome also was significantly reduced at
d (22%, p0.03) and at 6 months (19%, p0.02). The end
int of death or nonfatal MI was reduced at 7 d (43%,
0.006), at 30 d (30%, p0.03), and at 6 months (22%,
0.06). A high rate of angiography in this trial could have
ntributed to the important reduction in event rates.
omputer-assisted analysis of coronary angiograms obtained
Table 18. UA/NSTEMI Outcome of Death or Myocardial Infarction in Clinical Trials of GP IIb/IIIa Antagonists Involving More Than 1,000 Patients
Results
Placebo GP IIb/IIIa
Trial (Year) Study Population Drugs n % n % ARR, % RR 95% CI p
PCI trials
EPIC (1994) (510) High-risk PTCA Abciximab 72/696 10.3 49/708 6.9* 3.4 0.68 0.47 to 0.95 0.022
EPILOG (1997) (511) All PTCA Abciximab 85/939 9.1 35/935 3.7* 5.4 0.41 0.28 to 0.61 Less than 0.001
CAPTURE (1997) (372) UA Abciximab 57/635 9.0 30/630 4.8 4.2 0.53 0.35 to 0.81 0.003
IMPACT II (1997) (517) All PTCA Eptifibatide 112/1,328 8.4 93/1,349 6.9* 1.5 0.83 0.63 to 1.06 0.134
RESTORE (1997) (518) UA Tirofiban 69/1,070 6.4 54/1,071 5.0 1.4 0.78 0.55 to 1.10 0.162
EPISTENT (1998) (512) Elective stenting Abciximab 83/809 10.2 38/794 4.8* 5.4 0.46 0.32 to 0.68 Less than 0.001
ESPRIT (2000) (519) Elective stenting Eptifibatide 104/1,024 10.2 66/1,040 6.3 3.9 0.62 0.46 to 0.84 0.0016
ISAR-REACT (2004) (520) Elective stenting with
clopidogrel pretreatment
Abciximab 42/1,080 3.9 43/1,079 4.0 0.1 1.02 0.68 to 1.55 0.91
ACS trials
PRISM-PLUS (1998) (130) UA/NQWMI Tirofiban 95/797 11.9 67/733* 9.1* 2.8 0.70 0.51 to 0.96 0.03
PRISM (1998) (374) UA/NQWMI Tirofiban 115/1,616 7.1 94/1,616 5.8† 1.3 0.82 0.61 to 1.05 0.11
PURSUIT (1998) (128) UA/NQWMI Eptifibatide 744/4,739 15.7 670/4,722 14.2* 1.5 0.90 0.82 to 1.00 0.04
PARAGON A (1998) (373) UA/NQWMI Lamifiban 89/758 11.7 80/755 10.6*† 1.1 0.90 0.68 to 1.20 0.48
GUSTO IV ACS (2001) (514) UA/NQWMI Abciximab 209/2,598 8.0 450/5,202‡ 8.7 0.7 1.08 0.92 to 1.26 0.36
PARAGON B (2002) (521) UA/NQWMI Lamifiban 296/2,597 11.4 278/2,628 10.6 0.8 0.94 0.77 to 1.09 0.32
ISAR-REACT (2006) (244) UA/NSTEMI§ Abciximab 116/1,010 11.5 87/1,012 8.6 2.9 0.75 0.57 to 0.97 0.03
All PCI trials 624/7,581 8.2 408/7,606 5.4 2.8 0.65 0.58 to 0.74 Less than 0.0001
All ACS trials 1,664/14,115 11.7 1,726/16,668 10.4 1.3 0.86 0.81 to 0.93 Less than 0.0001
All PCI and ACS trials 2,288/21,696 10.5 2,134/24,274 8.8 1.7 0.83 0.83 to 0.84 Less than 0.0001
*Best treatment group selected for analysis.
†Platelet GP IIb/IIIa antagonist without heparin.
‡Pooled results for 24- and 48-h infusion arms.
§Used an invasive (PCI) strategy; all patients received clopidogrel.
ACS  acute coronary syndrome; CAPTURE  c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina; CI  confidence interval; EPIC  Evaluation of c7E3 for the Prevention of Ischemic Complications; EPILOG 
Evaluation of PTCA and Improve Long-term Outcome by c7E3 GP IIb/IIIa receptor blockade; EPISTENT  Evaluation of Platelet IIb/IIIa Inhibitor for STENTing; ESPRIT  Enhanced Suppression of Platelet Receptor GP IIb/IIIa using
Integrilin Therapy; GUSTO IV ACS  Global Use of Strategies to Open Occluded Coronary Arteries IV; IMPACT II  Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis II; ISAR-REACT  Intracoronary Stenting
and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment; NQWMI  non–Q-wave myocardial infarction; PARAGON  Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global
Organization Network; PCI  percutaneous coronary intervention; PRISM  Platelet Receptor Inhibition in Ischemic Syndrome Management; PRISM-PLUS  Platelet Receptor Inhibition in Ischemic Syndrome Management in
Patients Limited by Unstable Signs and Symptoms; PTCA  percutaneous transluminal coronary angioplasty; PURSUIT  Platelet Glycoprotein IIb/IIIa in Unstable 16 Angina: Receptor Suppression Using Integrilin Therapy;
RESTORE  Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis; RR  risk ratio; UA  unstable angina; UA/NSTEMI  unstable angina/non–ST-elevation myocardial infarction.
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June 11, 2013:e179–347 UA/NSTEMI Guideline: 2012 Update Incorporatedter 48 h of treatment in PRISM-PLUS also showed a
duction in the thrombus load at the site of the culprit lesion
d improved coronary flow in patients who received the
mbination of tirofiban and UFH (141). Tirofiban, in com-
nation with heparin, has been approved for the treatment of
tients with ACS, including patients who are managed
edically and those undergoing PCI.
Eptifibatide was studied in the PURSUIT trial, which
rolled 10,948 patients who had chest pain at rest within the
evious 24 h and ST-T changes or CK-MB elevation (135).
he study drug was added to standard management until
spital discharge or for 72 h, although patients with
rmal coronary arteries or other mitigating circumstances
d shorter infusions. The infusion could be continued for
additional 24 h if an intervention was performed near
e end of the 72-h infusion period. The primary outcome
te of death or nonfatal MI at 30 d was reduced from
.7% to 14.2% with eptifibatide (RR 0.91, p0.042).
ithin the first 96 h, a substantial treatment effect was
en (9.1% vs 7.6%, p0.01). The benefits were main-
ined at 6-month follow-up. Eptifibatide has been ap-
oved for the treatment of patients with ACS (UA/
STEMI) who are treated medically or with PCI. It is
ually administered with ASA and heparin.
The cumulative event rates observed during the phase of
edical management and at the time of PCI in the
APTURE, PRISM-PLUS, and PURSUIT trials are shown
(Figure 16) (611). By protocol design, almost all patients
derwent PCI in CAPTURE. In PRISM-PLUS, angiography
as recommended. A percutaneous revascularization was
rformed in 31% of patients in PRISM-PLUS and in 13% of
tients in PURSUIT. Each trial showed a statistically sig-
ficant reduction in the rate of death or MI during the phase
medical management; the reduction in event rates was
agnified at the time of the intervention.
Although it is tempting to evaluate the drug effect by
mparing patients who had intervention with those who did
t, such an analysis is inappropriate. Patients who do not
dergo intervention include many low-risk patients, patients
ho died before having the opportunity for intervention,
tients with contraindications, and patients with uncompli-
ted courses in countries and practices that use the ischemia-
ided approach; there is no way to adjust for these imbal-
ces. Accordingly, the analysis in Figure 16 includes the
ent rates for all patients during the time when they were
eated medically. It then begins the analysis anew in patients
ho underwent PCI at the time of angiography while taking
ug or placebo. In the PRISM-PLUS trial, 1,069 patients did
t undergo early PCI. Although tirofiban treatment was
sociated with a lower incidence of death, MI or death, or MI
refractory ischemia at 30 d, these reductions were not
atistically significant (137). In a high-risk subgroup of these
tients not undergoing PCI (TIMI risk score greater than or
ual to 4) (166), tirofiban appeared to be beneficial whether
tients underwent PCI (OR 0.60, 95% CI 0.35 to 1.01) or not
R 0.69, 95% CI 0.49 to 0.99); however, no benefit was
served in patients at lower risk (187,612). In the PURSUIT
ial, the impact of eptifibatide on the incidence of death or
I in the subgroup of patients who did not undergo revas- colarization within the first 72 h was modest and consistent
ith the overall trial result, although not individually signif-
ant (15.6% vs 14.5%, p0.23) (135).
Boersma et al. performed a meta-analysis of GP IIb/IIIa
tagonists of all 6 large, randomized, placebo-controlled
ials (including GUSTO IV (385)) involving 31,402 patients
ith UA/NSTEMI not routinely scheduled to undergo coro-
ry revascularization (383). In the overall population, the
sk of death or MI by 30 d was modestly reduced in the
tive treatment arms (11.8% vs 10.8%, OR 0.91, 95% CI
84 to 0.98, p0.015). Treatment effect appeared to be
eater among higher-risk patients with troponin elevations or
CG ST-segment depressions. Unexpectedly, no benefit was
served in women, but there was no evidence of a sex
fference in treatment effect once patients were stratified by
oponin concentrations (a risk reduction was seen in both
en and women with elevated cTn levels). These and other
ta have elevated troponin level to a major factor in decision
aking for the use of these agents in UA/NSTEMI. Major
eeding complications were increased in the GP IIb/IIIa
tagonist-treated group compared with those who received
acebo (2.4% vs 1.4%, p0.0001). For special consider-
ions about the use of GP IIb/IIIa antagonists in women, see
ection 6.1.2.1.
A relationship was observed between revascularization
ocedures and the apparent treatment effect of GP IIb/IIIa
ockade in the meta-analysis by Boersma et al. (383).
evascularization strategies were not specified by trial pro-
cols or randomized, but 5847 (19%) of the 31,402 patients
derwent PCI or CABG within 5 d, and 11,965 patients
8%) did so within 30 d. Significant reductions in the risk
death or MI with GP IIb/IIIa blockade were observed in
ese subgroups (OR 0.79, 95% CI 0.68 to 0.91 for patients
vascularized within 5 d; OR  0.89, 95% CI 0.80 to 0.98
r patients revascularized within 30 d), whereas no
gnificant treatment effect was present in the other 19,416
tients who did not undergo coronary revascularization
ithin 30 d (OR for death or MI 0.95, 95% CI 0.86 to
05). The authors concluded that the benefit of GP IIb/IIIa
ockade in patients with UA/NSTEMI was “clinically
ost meaningful in patients at high risk of thrombotic
mplications” (383). The findings of this meta-analysis in
e context of other trials of GP IIb/IIIa blockade during
CI suggest that GP IIb/IIIa inhibitors are of substantial
nefit in patients with UA/NSTEMI who undergo PCI, are
modest benefit in patients who are not routinely sched-
ed to undergo revascularization (but who may do so),
d are of questionable benefit in patients who do not
dergo revascularization.
Although there is a temptation to use the comparison of
ch of these GP IIb/IIIa inhibitors with placebo to draw
nclusions about relative efficacy, such an exercise could be
isleading. Each trial had different entry criteria, different
proaches to angiographic evaluation, and different criteria
r end-point measurement and took place in different loca-
ons in different time periods. The effects of these differences
nnot be accounted for in an indirect comparison. Head-to-
ad (direct) comparisons are required to draw reliable
nclusions about the relative efficacy of these different
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advantage to in-laboratory initiation of abciximab over
rofiban for UA/NSTEMI patients undergoing PCI with
enting (609). An explanation offered for this difference was
insufficient loading dose of tirofiban to achieve optimal
ri-procedural antiplatelet effect (610).
Treatment with a GP IIb/IIIa antagonist increases the risk
gure 16. Kaplan-Meier Curves Showing Cumulative Incidence of
atelet GP IIb/IIIa receptor antagonist (bold line) or placebo. Data
ft: events during the initial period of medical treatment until the
inistered for 18 to 24 h before the PCI was performed in almost
r the intervention. In PURSUIT, a PCI was performed in 11.2% o
sted 72 h and for 24 h after the intervention. In PRISM-PLUS, an
medical therapy with tirofiban, and the drug infusion was mainta
e time of PCI and the next 48 h, with the event rates reset to 0%
tions exceeding 2 times the upper limit of normal were consider
e upper limit of normal for PCI-related events. Adapted from Boe
ceptor inhibition in non–ST-elevation acute coronary syndromes.
d PRISM-PLUS (134). © Lippincott, Williams & Wilkins. CABG 
erapy in Unstable REfractory angina; GP  glycoprotein; MI  m
CI  percutaneous coronary intervention; PRISM-PLUS  Platele
mited by Unstable Signs and symptoms; PURSUIT  Platelet gly
tegrilin Therapy.bleeding, which is typically mucocutaneous or involves the thcess site of vascular intervention. Unfortunately, each trial
so used a different definition of bleeding and reported
eeding related to CABG differently. In the PRISM trial,
ith no interventions (including CABG) on treatment, major
eeding (excluding CABG) occurred in 0.4% of patients who
ceived tirofiban and 0.4% of patients who received UFH
85). In the PRISM-PLUS trial, major bleeding according to
or MI. Incidence is shown in patients randomly assigned to
rived from the CAPTURE, PURSUIT, and PRISM-PLUS trials.
t of PCI or CABG. In the CAPTURE trial, abciximab was ad-
ents as per study design; abciximab was discontinued 1 h af-
ts during a period of medical therapy with eptifibatide that
ention was performed in 30.2% of patients after a 48-h period
r 12 to 24 h after an intervention. Right: events occurring at
e the intervention. Creatine kinase or creatine kinase-MB ele-
nfarction during medical management and exceeding 3 times
, Akkerhuis KM, Théroux P, et al. Platelet glycoprotein IIb/IIIa
ation 1999;100:2045–8 (523), CAPTURE (240), PURSUIT (172),
ary artery bypass graft; CAPTURE  c7E3 Fab AntiPlatelet
dial infarction; N  number of patients; OR  odds ratio;
ptor Inhibition in ischemic Syndrome Management in Patients
ein IIb/IIIa in Unstable angina: Receptor Suppression UsingDeath
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0.23), whereas PURSUIT reported major bleeding in
.6% of patients who received eptifibatide and 9.1% of
tients who received placebo (p0.02) (141,178). In the
URSUIT trial, with the exclusion of patients who underwent
ABG, the rates were 3.0% with eptifibatide and 1.3% with
acebo (p0.001). No trials have shown an excess of
tracranial bleeding with a GP IIb/IIIa inhibitor. As with the
ficacy data, the temptation to make indirect comparisons
ould be tempered by the variability in protocol, circum-
ances, and definitions of the trial.
Aspirin has been used with the intravenous GP IIb/IIIa
ceptor blockers in all trials. A strong case also can be made
r the concomitant use of heparin with GP IIb/IIIa receptor
ockers. The tirofiban arm without UFH in the PRISM-
LUS trial was discontinued early because of an excess of
aths. In addition, the PURSUIT trial reported a higher
ent rate in the 11% of patients who were not treated with
ncomitant heparin (135). In a randomized comparison, a
wer-dose regimen of the GP IIb/IIIa inhibitor lamifiban
ve a more favorable outcome trend when combined with
parin than when administered without heparin (487). Cur-
nt recommendations call for the concomitant use of heparin
ith GP IIb/IIIa inhibitors. Glycoprotein IIb/IIIa inhibitors
n increase the ACT when combined with heparin, which
eans that lower doses of heparin are required to achieve a
rget level of anticoagulation. Moreover, trial data indicate
at lower heparin doses diminish the bleeding risk associated
ith GP IIb/IIIa blockade in the setting of PCI, findings that
kely can be extrapolated to the medical phase of manage-
ent in patients with UA/NSTEMI.
Blood hemoglobin and platelet counts should be moni-
red and patient surveillance for bleeding should be
rformed daily during the administration of GP IIb/IIIa
ceptor blockers. Thrombocytopenia is an unusual com-
ication of this class of agents. Severe thrombocytopenia,
fined by nadir platelet counts of less than 50,000 per mL,
observed in 0.5% of patients, and profound thrombocy-
penia, defined by nadir platelet counts of less than
,000 per mL, is observed in 0.2% of patients. Although
versible, thrombocytopenia is associated with an in-
eased risk of bleeding (613,614).
Several trials have demonstrated that GP IIb/IIIa inhibitors
n be used with LMWH among patients with unstable
chemic syndromes. In the Antithrombotic Combination
sing Tirofiban and Enoxaparin (ACUTE II) study (403),
FH and enoxaparin were compared in patients with UA/
STEMI receiving tirofiban. The incidence of major and
inor bleeding was similar, and there was a trend to fewer
verse events in patients receiving enoxaparin. More re-
ntly, 2 large-scale, randomized trials have examined the
lative efficacy of enoxaparin versus UFH among patients
ith ACS. One of these, the A to Z Trial (Aggrastat to
ocor), randomized 3,987 patients who were treated with
ncomitant ASA and tirofiban (405). Coronary angiography
as performed in 60% of patients. Nonsignificant trends
ward fewer ischemic end points but more frequent bleeding
ents were observed with enoxaparin than with UFH therapy
05). In the larger SYNERGY trial, 10,027 patients withgh-risk ACS were randomized to receive either UFH or
oxaparin (400) (Figure 12). Glycoprotein IIb/IIIa antago-
sts were administered to 57% of patients, and 92% under-
ent coronary angiography. No advantage of enoxaparin over
parin was observed for the primary end point of death or
yocardial infarction by 30 d (14.0% vs 14.5%), but the 2
ndomized therapies offered similar protection against isch-
ic events during PCI. Enoxaparin was associated, how-
er, with an excess risk of TIMI major bleeding (9.1% vs
6%, p0.008) (400).
The ACUITY trial investigated the combination of a GP
b/IIIa inhibitor with bivalirudin, a direct thrombin inhibitor
ee Section 3.2.2.43.2.2.4 and Figure 13) (424). Glycopro-
in IIb/IIIa inhibition with bivalirudin resulted in similar
oninferior) clinical outcomes compared with GP IIb/IIIa
hibition with UFH or enoxaparin.
A challenge for the current guidelines is integrating the GP
b/IIIa studies from the 1990s with more recent studies using
eangiography clopidogrel loading, newer anticoagulants,
d varying degrees of patient acuity and risk/benefit. The
rrent evidence base and expert opinion suggest that for
A/NSTEMI patients in whom an initial invasive strategy is
lected, either an intravenous GP IIb/IIIa inhibitor or an
propriate P2Y12 receptor inhibitor should be added to ASA
d anticoagulant therapy before diagnostic angiography
pstream) and that both may be considered before angiog-
phy for high-risk patients. For UA/NSTEMI patients in
hom an initial conservative (i.e., noninvasive) strategy is
lected, the evidence for benefit is less.
.2.7. Fibrinolysis
he failure of intravenous fibrinolytic therapy to improve
inical outcomes in the absence of MI with ST-segment
evation or bundle-branch block was clearly demonstrated in
e TIMI 11B, ISIS-2, and GISSI 1 trials (136,615,616). A
eta-analysis of fibrinolytic therapy in UA/NSTEMI pa-
ents showed no benefit of fibrinolysis versus standard
erapy (452). Fibrinolytic agents had no significant ben-
cial effect and actually increased the risk of MI (452).
onsequently, such therapy is not recommended for the
anagement of patients with an ACS without ST-segment
evation, a posterior-wall MI, or a presumably new left
ndle-branch block (see ACC/AHA Guidelines for the
anagement of Patients With ST-Elevation Myocardial
farction (8).
.3. Initial Conservative Versus Initial
vasive Strategies (UPDATED)
efer to Appendixes 6 and 9 for
upplemental Information)
ASS I
An early invasive strategy (i.e., diagnostic angiography with
intent to perform revascularization) is indicated in UA/NSTEMI
patients who have refractory angina or hemodynamic or elec-
trical instability (without serious comorbidities or contraindi-
cations to such procedures). (Level of Evidence: B) (617,618)
An early invasive strategy (i.e., diagnostic angiography with
intent to perform revascularization) is indicated in initially
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or contraindications to such procedures) who have an elevated
risk for clinical events (see Appendix 6 and Sections 2.2.6
and 3.4.3). (Level of Evidence: A) (188,251,436)
ASS IIa
It is reasonable to choose an early invasive strategy (within 12
to 24 hours of admission) over a delayed invasive strategy for
initially stabilized high-risk patients with UA/NSTEMI.¶ For
patients not at high risk, a delayed invasive approach is also
reasonable. (Level of Evidence: B) (432)
ASS IIb
In initially stabilized patients, an initially conservative (i.e., a
selectively invasive) strategy may be considered as a treat-
ment strategy for UA/NSTEMI patients (without serious comor-
bidities or contraindications to such procedures) who have an
elevated risk for clinical events (see Appendix 6 and Sections
2.2.6 and 3.4.3), including those who are troponin positive.
(Level of Evidence: B) (436,619). The decision to implement
an initial conservative (vs initial invasive) strategy in these
patients may be made by considering physician and patient
preference. (Level of Evidence: C)
ASS III: NO BENEFIT
An early invasive strategy (i.e., diagnostic angiography with
intent to perform revascularization) is not recommended in
patients with extensive comorbidities (e.g., liver or pulmonary
failure, cancer), in whom the risks of revascularization and
comorbid conditions are likely to outweigh the benefits of
revascularization. (Level of Evidence: C)
An early invasive strategy (i.e., diagnostic angiography with
intent to perform revascularization) is not recommended in
patients with acute chest pain and a low likelihood of ACS.
(Level of Evidence: C)
An early invasive strategy (i.e., diagnostic angiography with
intent to perform revascularization) should not be performed in
patients who will not consent to revascularization regardless of
the findings. (Level of Evidence: C)
.3.1. General Principles
addition to aggressive medical therapy, 2 treatment path-
ays have emerged for treating ACS patients. The “initial” or
arly” invasive strategy, now known simply as the “inva-
ve” strategy, triages patients to undergo an invasive diag-
stic evaluation without first getting a noninvasive stress test
without failing medical treatment (i.e., an initial conserva-
ve diagnostic strategy, or sometimes now known as the
elective invasive strategy”; see below and de Winter et al.
36). Patients treated with an invasive strategy generally will
dergo coronary angiography within 4 to 24 h of admission;
wever, these patients also are treated with the usual
A/NSTEMI medications, including appropriate anti-
chemic, antiplatelet, and anticoagulant therapy, as outlined
Sections 3.1 and 3.2. These drugs generally are not
ithheld until after angiography. Within the invasive strat-
y, there is a subgroup of patients presenting to the ED who
quire urgent catheterization and revascularization in theremmediate catheterization/angiography is recommended for unstable patients.sence of ST deviation because of ongoing ischemic
mptoms or hemodynamic or rhythm instability. These
tients are often rushed off to the catheterization labora-
ry within minutes to a few hours of arrival and are not
nsidered appropriate candidates for a conservative strat-
y. Even here, appropriate medical therapy is considered;
wever, with these patients, the administration of GP
b/IIIa inhibitors or P2Y12 receptor inhibitor therapy may
delayed until the time of angiography, at a physician’s
scretion (Appendix 9 has replaced Figures 7, 8, and 9).
n the other hand, the longer the interval between presen-
tion and angiography in patients, the greater the incre-
ental benefit of “upstream” antiplatelet therapy. In sum-
ary, the invasive strategy can be subdivided into: 1) those
tients requiring urgent angiography/revascularization
ry soon after arrival at the ED, and 2) those with a
A/NSTEMI presentation who are designated either by
tient/physician discretion or after risk assessment to
enefit from “early” but nonurgent angiography/
tervention.
In contrast, the “initial conservative strategy” (also referred
as “selective invasive management”) calls for proceeding
ith an invasive evaluation only for those patients who fail
edical therapy (refractory angina or angina at rest or with
inimal activity despite vigorous medical therapy) or in
hom objective evidence of ischemia (dynamic ECG
anges, high-risk stress test) is identified. Estimating the risk
r an adverse outcome is paramount for determining which
rategy is best applied to an individual ACS patient. Several
sk tools have been validated that are useful in guiding the
pe and intensity of therapy by identifying patients most
kely to benefit from aggressive treatment.
One such valuable tool for risk determination is based on
ta from the TIMI 11B and ESSENCE trials (166) and is
scussed in Section 2.2.6 and Table 8. The TIMI risk
lculator is available at http://www.timi.org/.
Another simple risk-prediction tool has been validated
data from GRACE (122) (Figure 4; Section 2.2.6). The
RACE calculator can estimate short and intermediate
ortality and is useful when making diagnostic and
eatment decisions for ACS patients. The GRACE clinical
plication tool can be downloaded to a handheld PDA to
used at the bedside and is available at http://www.
tcomes-umassmed.org/grace.
The PURSUIT, TIMI, and GRACE risk scores demon-
rate good predictive accuracy for death and MI. They
ovide valuable information that can be used to identify
tients likely to benefit from early, aggressive therapy,
cluding intravenous GP platelet inhibitors and early coro-
ry revascularization (180).
.3.2. Rationale for the Initial Conservative Strategy
few multicenter trials have shown similar outcomes with
itial conservative and invasive therapeutic strategies
36,620,621). Some trials (621,622) have emphasized the
rly risk associated with revascularization procedures.
he conservative strategy seeks to avoid the routine early
e of invasive procedures unless patients experience
fractory or recurrent ischemic symptoms or develop
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chosen, a plan for noninvasive evaluation is required to
tect severe ischemia that occurs spontaneously or at a
w threshold of stress and to promptly refer these patients
r coronary angiography and revascularization when pos-
ble. In addition, as in STEMI (438), an early echocar-
ogram should be considered to identify patients with
gnificant LV dysfunction (e.g., LVEF less than 0.40).
uch a finding prompts consideration for angiography to
entify left main or multivessel CAD, because patients
ith multivessel disease and LV dysfunction are at high
sk and could accrue a survival benefit from CABG
37,623). In addition, a stress test (e.g., exercise or
armacological stress) for the assessment of ischemia is
commended before discharge or shortly thereafter to
entify patients who may also benefit from revasculariza-
on. The use of aggressive anticoagulant and antiplatelet
ents has reduced the incidence of adverse outcomes in
atients managed conservatively (see Section 3.3)
35,141,175,186,387,408,485,611). An advantage offered
the conservative strategy is that many patients stabilize
medical therapy and will not require coronary angiog-
phy. Consequently, the conservative strategy limits the
e of in-hospital cardiac catheterization and may avoid
stly and possibly unnecessary invasive procedures.
.3.3. Rationale for the Invasive Strategy
or patients with UA/NSTEMI without recurrent ischemia in
e first 24 h, the use of angiography provides an invasive
proach to risk stratification. It can identify the 10% to 20%
patients with no significant coronary stenoses and the
proximately 20% with 3-vessel disease with LV dysfunc-
on or left main CAD. This latter group can derive a survival
nefit from CABG (see Section 4). In addition, PCI of the
lprit lesion has the potential to reduce the risk for subse-
ent hospitalization and the need for multiple antianginal
ugs compared with the early conservative strategy (TIMI
IB) (136). Just as the use of improved anticoagulant therapy
d/or a platelet GP IIb/IIIa receptor blocker has improved
e outcome in patients managed according to the conserva-
ve strategy, the availability of these agents also makes the
vasive approach more attractive, particularly because the
rly hazard of PCI is lessened. The availability of GP
b/IIIa receptor blockers also has led to 2 alternatives for
e routine invasive approach: immediate angiography or
ferred angiography.
.3.3.1. TIMING OF INVASIVE THERAPY (NEW SECTION)
mong initially stabilized patients with UA/NSTEMI for
hom an early invasive strategy of coronary angiography is
osen, optimal timing of angiography has not been well
fined. Early or immediate catheterization with revascular-
ation of unstable coronary lesions may prevent ischemic
ents that would otherwise occur during medical therapy.
onversely, pretreatment with intensive antithrombotic ther-
y may diminish thrombus burden and “passivate” unstable
aques, improving the safety of percutaneous revasculariza-
on and reducing the risk of periprocedural ischemic com-
ications. Three trials have compared different strategies of eaarly” versus “delayed” intervention in patients with UA/
STEMI and form the basis of the updated recommendations
this guideline.
The ISAR-COOL (Intracoronary Stenting with Antithrom-
tic Regimen Cooling-Off) trial (624) carried out at 2
spitals between 2000 and 2002 randomized 410 patients
ith unstable chest pain and either electrocardiographic
T-segment depression or elevated troponin levels to undergo
ronary angiography within 6 hours of presentation (median
4 hours) or after 3 to 5 days (median 86 hours) of
tithrombotic pretreatment (624). Patients with “large MI,”
fined by ST-segment elevation or creatine kinase– myocar-
al band isoenzyme activity 3 times normal, were ex-
uded. Underlying medical therapy in both treatment arms
cluded aspirin, clopidogrel, UFH, and tirofiban. By 30
ys’ follow-up, the primary endpoint of death or large MI
efined by new electrocardiographic Q waves, left bundle-
anch block, or creatine kinase–myocardial band elevation
5 times normal) occurred in 11.6% of patients randomized
delayed catheterization versus 5.9% of those in the early
giography group (p0.04). Differences between treatment
oups were observed exclusively in the period before cath-
erization, with identical event rates in the 2 arms after
giography. Although providing evidence that a strategy of
ooling-off” for 3 to 5 days before angiography does not
prove outcome in this setting, the findings of this trial were
mited because of the small sample size and the prolonged
lay before angiography in the medical pretreatment arm.
Information more relevant to contemporary practice pat-
rns was provided in the 2009 publication of the large-scale
ulticenter TIMACS (Timing of Intervention in Acute Cor-
ary Syndromes) trial (432), which compared early versus
layed angiography and intervention in patients with non–
T-segment elevation ACS. Patients were included if they
esented within 24 hours of onset of unstable ischemic
mptoms with advanced age (60 years), elevated cardiac
omarkers, or ischemic electrocardiographic changes, and
ere randomized to undergo angiography as rapidly as
ssible and within 24 hours of randomization (median 14
urs) versus after a minimum delay of 36 hours (median 50
urs). Anticoagulation included aspirin, clopidogrel in
80% of patients, heparin or fondaparinux, and GP IIb/IIIa
hibitors in 23% of patients. Although the trial was initially
wered for enrollment of 4,000 patients to detect a 25%
duction in the primary endpoint of death, new MI, or stroke
6 months, the steering committee chose to terminate
rollment at 3,031 patients because of recruitment chal-
nges. Among the overall trial population, there was only a
nsignificant trend toward a reduced incidence of the pri-
ary clinical endpoint, from 11.3% in the delayed interven-
on group to 9.6% in the early intervention arm (HR for early
tervention: 0.85; 95% CI: 0.68 to 1.06; p0.15). However,
prospectively defined secondary endpoint of death, MI, or
fractory ischemia was significantly reduced by early inter-
ntion from 12.9% to 9.5% (HR: 0.72; 95% CI: 0.58 to 0.89;
0.003), mainly because of a difference in the incidence of
fractory ischemia (3.3% versus 1.0% in the delayed versus
rly intervention arms, respectively; p0.001). The occur-
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fold increase in risk of subsequent MI. Moreover, signifi-
nt heterogeneity was observed in the primary endpoint
hen stratified according to a prespecified estimation of
seline risk according to the GRACE (Global Registry of
cute Coronary Events) score. Patients in the highest tertile
the GRACE risk score (140) experienced a sizeable and
gnificant reduction in the incidence of the primary ischemic
dpoint, from 21.0% to 13.9% (HR: 0.65; 95% CI: 0.48 to
89; p0.006), whereas no difference in outcome (6.7%
rsus 7.6% in the delayed and early groups, respectively;
R: 1.12; 95% CI: 0.81 to 1.56; p0.48) was observed
ong patients in the lower 2 risk tertiles (GRACE score
140) (432).
Results of the TIMACS trial suggested superior outcome
ong patients managed by early rather than delayed inter-
ntion in the setting of UA/NSTEMI, although the reduction
the primary endpoint did not reach statistical significance
r the overall trial population. Nevertheless, refractory isch-
ia was reduced by an early approach, as were the risks of
ath, MI, and stroke among patients at the highest tertile of
chemic risk as defined by the GRACE risk score (432).
To assess whether a more aggressive strategy of very early
tervention, analogous to the standard of primary PCI for
TEMI, would lead to improved outcomes in patients with
n–ST-elevation ACS, the ABOARD (Angioplasty to Blunt
e Rise of Troponin in Acute Coronary Syndromes) study
vestigators (625) compared angiography and intervention
rformed immediately on presentation with intervention
rried out on the next working day. A total of 352 patients
ith unstable ischemic symptoms, ECG changes, or troponin
evation were randomized at 13 hospitals to immediate (at a
edian 70 minutes after enrollment) versus delayed (at a
edian 21 hours) angiography and revascularization. Back-
ound anti-thrombotic therapy consisted of aspirin, clopi-
grel with a loading dose of more than or equal to 300 mg,
ciximab during PCI, and the anticoagulant of the investi-
tor’s choice. The primary trial endpoint was peak troponin
value during the hospitalization period. Immediate interven-
on conferred no advantage with regard to the primary
dpoint (median troponin I value 2.1 versus 1.7 ng/mL in the
mediate and delayed intervention groups, respectively),
r was there even a trend toward improved outcome in the
especified clinical secondary endpoint of death, MI, or
gent revascularization by 1 month (13.7% versus 10.2% in
e immediate and delayed intervention groups, respectively;
0.31) (625).
These 3 trials (432,624,625), taken together with earlier
udies, do provide support for a strategy of early angiogra-
y and intervention to reduce ischemic complications in
tients who have been selected for an initial invasive strategy,
rticularly among those at high risk (defined by a GRACE
ore140), whereas a more delayed approach is reasonable in
w- to intermediate-risk patients. The “early” time period in this
ntext is considered to be within the first 24 hours after hospital
esentation, although there is no evidence that incremental
nefit is derived by angiography and intervention performed
ithin the first few hours of hospital admission. The advantage reearly intervention was achieved in the context of intensive
ckground antithrombotic therapy.
.3.4. Immediate Angiography
xcluding those in need of urgent intervention, 2 alternatives
r the invasive approach have emerged: early (“immediate”)
deferred angiography (i.e., with respect to a 12- to 48-h
indow). Some may argue that proceeding immediately to
giography is an efficient approach for the ACS patient.
atients found not to have CAD may be discharged rapidly or
ifted to a different management strategy. Patients with
vious culprit lesions amenable to PCI can have a procedure
rformed immediately, hastening discharge. Patients with
ft main CAD and those with multivessel disease and LV
sfunction can be sent expeditiously to undergo bypass
rgery, thereby avoiding a risky waiting period. Earlier
pport for immediate angiography came from the Intracoro-
ry Stenting with Antithrombotic Regimen Cooling-off
tudy (ISAR-COOL) (624). All ACS patients were treated
ith intensive medical therapy (including oral and intravenous
tiplatelet therapy). They were randomized to immediate an-
ography (median time 2.4 h) or a prolonged “cooling off”
riod for a median of 86 h before undergoing catheterization.
atients randomized to immediate angiography had significantly
wer deaths or MIs at 30 d. Importantly, this difference in
tcome was attributed to events that occurred before catheter-
ation in the “cooling off” group, which supports the rationale
r intensive medical therapy and very early angiography.
owever, the more contemporary ABOARD study (625), which
mpared angiography and intervention performed immediately
presentation with intervention carried out on the next working
y, found no evidence of incremental benefit derived by a
rategy of immediate angiography and intervention for UA/
STEMI (see Section 3.3.3.1).
.3.5. Deferred Angiography
efer to New Section 3.3.3.1.)
most reports that involve use of the invasive strategy,
giography has been deferred for 12 to 48 h while antithrom-
tic and anti-ischemic therapies are intensified. Several
servational studies, as summarized in Smith et al. (626)
ve found a lower rate of complications in patients under-
ing PCI more than 48 h after admission, during which
parin and ASA were administered, than with early inter-
ntion; however, the value of prolonged medical stabiliza-
on before angiography has not proven in the contemporary
a. The TIMACS trial (432) compared early versus delayed
giography and intervention in patients with UA/NSTEMI
ee Section Section 3.3.3.1), and demonstrated that a strat-
y of early angiography and intervention reduced ischemic
mplications, particularly among patients at high risk (de-
ned by a GRACE score 140).
.3.6. Comparison of Early Invasive and Initial
onservative Strategies (Refer to New Section 3.3.3.1.)
rior meta-analyses have concluded that routine invasive
erapy is better than an initial conservative or selectively
vasive approach (627–629). Mehta et al. (628) concluded
at the routine invasive strategy resulted in an 18% relative
duction in death or MI, including a significant reduction in
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June 11, 2013:e179–347 UA/NSTEMI Guideline: 2012 Update IncorporatedI alone. The routine invasive arm was associated with
gher in-hospital mortality (1.8% vs 1.1%), but this disad-
ntage was more than compensated for by a significant
duction in mortality between discharge and the end of
llow-up (3.8% vs 4.9%). The invasive strategy also was
sociated with less angina and fewer rehospitalizations than
ith the conservative pathway. Patients undergoing routine
vasive treatment also had improved quality of life.
In contrast to these finding, other studies, most recently
TUS (Invasive versus Conservative Treatment in Unstable
ronary Syndromes) (436), have favorably highlighted a
rategy of selective invasive therapy (436). In ICTUS, 1,200
gh-risk ACS patients were randomized to routine invasive
rsus selective invasive management and followed up for 1
ar with respect to the combined incidence of death, MI, and
chemic rehospitalization. All patients were treated with
timal medical therapy that included ASA, clopidogrel,
MWH, and lipid-lowering therapy; abciximab was given to
ose undergoing revascularization. At the end of 1 year,
ere was no significant difference in the composite end point
tween groups. This study suggests that a selective invasive
rategy could be reasonable in ACS patients. A possible
planation for the lack of benefit of the invasive approach in
is trial (and other trials) (630) could be related to the
latively high rate of revascularization actually performed in
tients treated in the selective invasive arm (47%), thereby
ducing observed differences between treatment strategies
80), and to the lower event rate (lower-risk population) than in
her studies. Results were unchanged during longer term
llow-up (631,632). Nevertheless, ICTUS required troponin
sitivity for entry. Thus troponin alone might no longer be an
equate criterion for strategy selection, especially with increas-
gly sensitive troponin assays. The degree of troponin
evation and other high-risk clinical factors taken together
ould be considered in selecting a treatment strategy.
Other criticisms of ICTUS have included that it was
latively underpowered for hard end points and that it used
controversial definition for postprocedural MI (ie even
inimal, asymptomatic CK-MB elevation) (436,631,632).
Additionally, 1-year follow-up may be inadequate to fully
alize the long-term impact and benefit of the routine
vasive strategy. In the RITA-3 trial (Third Randomized
tervention Treatment of Angina), 5-year but not 1-year
ent rates favored the early invasive arm (see Figure 17 and
xt below) (633). In ICTUS, however, results were main-
ined during a 3-year follow-up (634).
Thus, these guidelines recommend that in initially stabi-
zed UA/NSTEMI patients, an initial conservative (selective
vasive) strategy may be considered as a treatment option.
he 2007 Writing Committee also believes that additional
mparative trials of the selective invasive with the routine
itial invasive strategies are indicated using aggressive
ntemporary medical therapies in both arms, including
utine dual antiplatelet therapy in medically treated patients
s recommended in Section 5.2.1) as well as aggressive lipid
wering and other updated secondary prevention measures
s summarized in Section 5.2). Further study could provide
stronger evidence base for an initial conservative/selective thvasive strategy in initially stabilized patients, as it has for
able angina patients (634).
Nevertheless, a meta-analysis of contemporary randomized
ials in NSTEMI, including ICTUS, currently supports a
ng-term mortality and morbidity benefit of an early invasive
compared with an initial conservative strategy (635).
onfatal MI at 2 years (7.6% vs 9.1%, respectively; RR 0.83,
% CI 0.72 to 0.96, p0.012) and hospitalization (at 13
onths; RR  0.69, 95% CI 0.65 to 0.74, p0.0001) also
ere reduced by an early invasive strategy (Figure 18). A
parate review of contemporary randomized trials in the
ent era using the Cochrane database arrived at similar
nclusions (636). Details of selected contemporary trials of
vasive versus conservative strategies follow.
In the FRISC-II study, 3,048 ACS patients were treated
ith dalteparin for 5 to 7 d (251). Of these patients, 2,457
ho qualified were then randomized (2  2 factorial design)
continue to receive dalteparin or placebo (double blind)
d to receive either a noninvasive or an invasive treatment
rategy, with coronary angiography and revascularization, if
propriate, performed within 7 d of admission. At 6 months,
gure 17. Cumulative Risk of Death or Myocardial Infarction or
eath in RITA-3. Cumulative risk of death or myocardial infarc-
n (top) or of death (bottom) in the RITA 3 trial of patients with
n–ST acute coronary syndromes. Reprinted from The Lancet,
66), Fox KAA, Poole-Wilson P, Clayton TC, et al. 5-year out-
me of an interventional strategy in non–ST-elevation acute
ronary syndrome: the British Heart Foundation RITA 3 ran-
mised trial, 914–20. Copyright 2005, with permission from
sevier (546). RITA-3  Third Randomized Intervention Treat-
ent of Angina trial.ere were no differences between continued dalteparin com-
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UA/NSTEMI Guideline: 2012 Update Incorporated June 11, 2013:e179–347gure 18. Relative Risk of Outcomes With Early Invasive Versus Conservative Therapy in UA/NSTEMI. A: Relative risk of all-cause
ortality for early invasive therapy compared with conservative therapy at a mean follow-up of 2 years. B: Relative risk of recurrent
nfatal myocardial infarction for early invasive therapy compared with conservative therapy at a mean follow-up of 2 years. C: Relative
k of recurrent unstable angina resulting in rehospitalization for early invasive therapy compared with conservative therapy at a mean
llow-up of 13 months. Modified from the Journal of the American College of Cardiology, 48, Bavry AA, Kumbhani DJ, Rassi AN, Bhatt
L, Askari AT. Benefit of early invasive therapy in acute coronary syndromes a meta-analysis of contemporary randomized clinical tri-
s, 1319–25. Copyright 2006, with permission from Elsevier (547). CI  confidence interval; FRISC-II  FRagmin and fast Revascular-
ation during InStability in Coronary artery disease; ICTUS  Invasive versus Conservative Treatment in Unstable coronary Syndromes;
AR-COOL  Intracoronary Stenting with Antithrombotic Regimen COOLing-off study; RITA-3  Third Randomized Intervention Treat-
ent of Angina trial; RR  relative risk; TIMI-18  Thrombolysis In Myocardial Infarction-18; TRUCS  Treatment of Refractory Unsta-
e angina in geographically isolated areas without Cardiac Surgery; UA/NSTEMI  unstable angina/non–ST-elevation myocardial in-
rction; VINO  Value of first day angiography/angioplasty In evolving Non–ST-segment elevation myocardial infarction: Open
ulticenter randomized trial.
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June 11, 2013:e179–347 UA/NSTEMI Guideline: 2012 Update Incorporatedred with placebo. However, death or MI occurred in 9.4%
patients assigned to the invasive strategy versus 12.1% of
ose assigned to the noninvasive strategy (p0.03). At 1
ar, the mortality rate in the invasive strategy group was
2% compared with 3.9% in the noninvasive strategy group
0.016) (637). It may be concluded from FRISC-II that
tients with UA/NSTEMI who are not at very high risk for
vascularization and who first receive an average of 6 d of
eatment with LMWH, ASA, nitrates, and beta blockers have
better outcome at 6 months with a (delayed) routine
vasive approach than with a routine conservative approach,
ith very low revascularization rates. Long-term outcomes of
e FRISC-II trial have been published recently (638). At 5
ars, the invasive strategy was favored for the primary end
int of death or nonfatal MI (HR 0.81, p0.009). Benefit
as confined to men, nonsmokers, and patients with 2 or
ore risk factors.
In the TACTICS-TIMI 18 trial (188), 2,220 patients with
A or NSTEMI were treated with ASA, heparin, and the GP
b/IIIa inhibitor tirofiban. They were randomized to an early
vasive strategy with routine coronary angiography within
h followed by revascularization if the coronary anatomy
as deemed suitable or to a more conservative strategy. In the
tter group, catheterization was performed only if the patient
d recurrent ischemia or a positive stress test. Death, MI, or
hospitalization for ACS at 6 months occurred in 15.9% of
tients assigned to the invasive strategy versus 19.4%
signed to the more conservative strategy (p0.025). Death
MI (188) was also reduced at 6 months (7.3% vs 9.5%,
0.05). The beneficial effects on outcome were observed in
edium- and high-risk patients, as defined by an elevation of
nT greater than 0.01 ng per mL, the presence of ST-segment
viation, or a TIMI risk score greater than 3 (166). In the
sence of these high-risk features, outcomes in patients
signed to the 2 strategies were similar, which emphasizes
e critical importance of appropriate risk stratification. Rates
major bleeding were similar, and lengths of hospital stay
ere reduced in patients assigned to the invasive strategy.
he benefits of the invasive strategy were achieved at no
gnificant increase in the costs of care over the 6-month
llow-up period.
Thus, both the FRISC-II (251) and TACTICS-TIMI 18
88) trials showed a benefit in patients assigned to the
vasive strategy. In contrast to earlier trials, a large majority
patients undergoing PCI in these 2 trials received coronary
enting as opposed to balloon angioplasty alone. Also, there
as a differential rate of clopidogrel use between the 2 arms;
ly stented patients were treated. In FRISC-II, the invasive
rategy involved treatment for an average of 6 d in the
spital with LMWH, ASA, nitrates, and beta blockers before
ronary angiography, an approach that would be difficult to
opt in US hospitals. In TACTICS-TIMI 18, treatment
cluded the GP IIb/IIIa antagonist tirofiban, which was
ministered for an average of 22 h before coronary angiog-
phy. The routine use of the GP IIb/IIIa inhibitor in this trial
ay have eliminated the excess risk of early (within 7 d) MI
the invasive arm, an excess risk that was observed in
RISC-II and other trials in which there was no routine
pstream” use of a GP IIb/IIIa blocker. Therefore, an revasive strategy is associated with a better outcome in
A/NSTEMI patients at high risk as defined in (Appendix 6)
d as demonstrated in TACTICS-TIMI 18 when a GP
b/IIIa inhibitor is used (188). In the PURSUIT trial (135), in
tients with UA/NSTEMI who were admitted to community
spitals, the administration of eptifibatide was associated
ith a reduced need for transfer to tertiary referral centers and
proved outcomes (639).
The RITA-3 trial (633) compared early and conservative
erapy in 1,810 moderate-risk patients with ACS. Patients
ith positive cardiac biomarkers (CK-MB greater than 2
mes the upper limit of normal at randomization) were
cluded from randomization, as were those with new Q
aves, MI within 1 month, PCI within 1 year, and any prior
ABG. The combined end point of death, nonfatal MI, and
fractory angina was reduced from 14.5% to 9.6% by early
vasive treatment. The benefit was driven primarily by a
duction in refractory angina. There was a late divergence of
e curves, with reduced 5-year death and MI in the early
vasive arm (Figure 17).
In the VINO trial (Value of first day angiography/
gioplasty In evolving Non–ST-segment elevation myocar-
al infarction: Open multicenter randomized trial) (640), 131
tients with NSTEMI were randomized to cardiac catheter-
ation on the day of admission versus conservative therapy.
espite the fact that 40% of the conservatively treated
tients crossed over to revascularization by the time of the
month follow-up, there was a significant reduction in death
reinfarction for patients assigned to early angiography and
vascularization (6% vs 22%).
The ISAR-COOL trial (624) randomized 410 intermediate-to
gh-risk patients to very early angiography and revascular-
ation versus a delayed invasive strategy. All patients were
eated with intensive medical therapy that included ASA,
parin, clopidogrel (600-mg loading dose), and the intrave-
us GP IIb/IIIa receptor inhibitor tirofiban. In the very early
m, patients underwent cardiac catheterization at a mean
me of 2.4 h versus 86 h in the delayed invasive arm. The
ry early invasive strategy was associated with significantly
tter outcome at 30 d, measured by reduction in death and
rge MI (5.9% vs 11.6%). More importantly, the benefit seen
as attributable to a reduction in events before cardiac
theterization, which raises the possibility that there is a
zard associated with a “cooling-down” period.
.3.7. Subgroups
ACTICS-TIMI 18 demonstrated a reduction in the 6-month
d point of death or MI in older adult ACS patients. With
spect to gender, controversy exists over revascularization
eatment differences between men and women with ACS.
he FRISC-II trial showed a benefit of early revascularization
men for death or MI that was not observed for women
41). In contrast, death, MI, or rehospitalization rates were
duced for both men and women in TACTICS-TIMI 18
88). Furthermore, an observational study reported that
omen actually did better than men with early interventional
erapy for UA/NSTEMI (642). Finally, RITA-3 (633)
owed that the routine strategy of invasive evaluation
sulted in a beneficial effect in men that was not seen in
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ese diverse observations (643).
.3.8. Care Objectives
he objective is to provide a strategy that has the most
tential to yield the best clinical outcome and improve
ng-term prognosis. The purpose of coronary angiography is
provide detailed information about the size and distribution
coronary vessels, the location and extent of atherosclerotic
struction, and the suitability for revascularization. The LV
giogram, which is usually performed along with coronary
giography, provides an assessment of the extent of focal
d global LV dysfunction and of the presence and severity
coexisting disorders (e.g., valvular or congenital lesions).
detailed discussion of revascularization is presented in
ection 4 of these guidelines, as well as in the ACC/AHA
uidelines for Percutaneous Coronary Intervention (9) and
e ACC/AHA Guideline Update for Coronary Artery Bypass
raft Surgery (644). Although general guidelines can be
fered, the selection of appropriate procedures and the
cision to refer patients for revascularization require both
inical judgment and counseling with the patient and the
tient’s family regarding expected risks and benefits.
Although not conducted in patients with UA/NSTEMI, the
llowing studies have addressed the value of stress testing in
iding therapy. The DANish trial in Acute Myocardial
farction (DANAMI) studied 503 patients with inducible
chemia (i.e., a positive exercise stress test) after fibrinolytic
erapy for first MI and compared an ischemia-guided invasive
rategy with a conservative strategy (645). The invasive strategy
the post-MI patients with inducible ischemia resulted in a
duction in the incidence of reinfarction, hospitalizations for
A, and stable angina. Similarly, in the Asymptomatic Cardiac
chemia Pilot (ACIP) study (646,647), 558 clinically stable
tients with ischemia on stress testing and during daily life
T-segment depression on exercise treadmill testing or perfu-
on abnormality on radionuclide pharmacological stress test if
able to exercise, in addition to ST-segment depression on
bulatory ECG monitoring), most of whom had angina in the
evious 6 weeks, were randomized to 1 of 3 initial treatment
rategies: symptom-guided medical care, ischemia-guided med-
al care, or revascularization. More than one third of these
tients had “complex” stenoses on angiography. Those ran-
mized to early revascularization experienced less ambulatory
chemia at 12 weeks than did those randomized to initial
edical care in whom revascularization was delayed and symp-
m driven.
After either STEMI or NSTEMI, the SWISSI II (Swiss
terventional Study of Silent Ischemia Type II) study, which
ndomized 201 patients with silent ischemia, demonstrated
stress imaging, to either revascularization with PCI or
ti-ischemic drug therapy and followed them for an average
10 years. Survival free of cardiac death, nonfatal MI, or
mptom-driven revascularization was significantly reduced
the PCI group. Though relatively small, the study supports
e use of stress testing after UA/NSTEMI for guiding the
lection of invasive evaluation in UA/NSTEMI patients
eated with an initial conservative strategy (648). saIn ACS patients with UA/NSTEMI, the purpose of
ninvasive testing is both to identify ischemia and to
entify candidates at high risk for adverse outcomes and
direct them to coronary angiography and revasculariza-
on when possible. However, neither randomized trials
36,251,620,621) nor observational data (649) uniformly
pport an inherent superiority for the routine use of coronary
giography and revascularization (see Section 4). Accord-
gly, the decision regarding which strategy to pursue for a
ven patient should be based on the patient’s estimated
tcome risk assisted by clinical and noninvasive test results,
ailable facilities, previous outcome of revascularization by
e team available in the institution in which the patient is
spitalized, and patient preference.
Coronary angiography can enhance prognostic stratifica-
on. This information can be used to guide medical therapy
d to plan revascularization therapy, but it is important to
phasize that an adverse outcome in ACS is very time
pendent and that after 1 to 2 months, the risk for adverse
tcome is essentially the same as that for low-risk chronic
able angina (Figure 17). Several older studies in patients
ith stable angina, including the Second Randomized Interven-
n Treatment of Angina (RITA-2) trial (622), have found a
gher early risk of death or MI with an interventional strategy
an with medical management alone. Thus, the timing of
ronary angiography and revascularization is critically impor-
nt if patients at high risk are to benefit. Unfortunately, the total
mber of operative complications is increased when revascu-
rization procedures are performed routinely, because some
tients who are not in need of revascularization will be exposed
its hazards. However, contemporary use of aggressive medi-
l therapy in UA/NSTEMI, including oral and intravenous
tiplatelet agents and anticoagulant agents, has lessened the
rly hazard and risk for ischemic complications in patients
dergoing early invasive procedures.
Patients with UA/NSTEMI often can be divided into
fferent risk groups on the basis of their initial clinical
esentation. The TIMI, PURSUIT, and GRACE scores are
eful clinical tools for assigning risk to patients presenting
ith UA/NSTEMI (Table 8; Figure 4; see Section 2.2.6).
Risk stratification in turn identifies patients who are most
ely to benefit from subsequent revascularization. For example,
tients with left main disease or multivessel CAD with reduced
V function are at high risk for adverse outcomes and are likely
benefit from surgical bypass. Clinical evaluation and nonin-
sive testing will aid in the identification of most patients in the
gh-risk subset, because they often have 1 or more of the
llowing high-risk features: advanced age (greater than 70
ars), prior MI, revascularization, ST-segment deviation, HF or
pressed resting LV function (i.e., LVEF less than or equal to
40) on noninvasive study, or noninvasive stress test findings.
he presence of any of these risk factors or of diabetes mellitus
ds in the identification of high-risk patients who could benefit
om an invasive strategy.
The majority of patients presenting with UA/NSTEMI,
wever, do not fall into the very high-risk group and do not
ve findings that typically portend a high risk for adverse
tcomes. Accordingly, they are not likely to receive the
me degree of benefit from routine revascularization af-
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r those at lower risk and can be safely deferred pending
rther clinical developments. Decisions regarding coronary
giography in patients who are not high risk according to
ndings on clinical examination and noninvasive testing can
individualized on the basis of patient preferences and the
gree to which they are affected by clinical symptoms.
The data on which recommendations for invasive or
nservative strategy recommendations are based come from
veral randomized trials. Older trials included TIMI IIIB
36,650), Veterans Affairs Non-Q-Wave Infarction Strate-
es in Hospital (VANQWISH) (621), and Medicine versus
ngiography in Thrombolytic Exclusion (MATE) (620).
ore recent trials, relevant to contemporary practice, include
RISC-II (251), TACTICS-TIMI 18 (188), VINO (640),
ITA-3 (633), ISAR-COOL (624), and ICTUS (436); a large,
ospective, multinational registry, the OASIS registry (649);
d several meta-analyses (627–629). See Section 3.3.1.5 for
detailed description of these trials and the more recent
eta-analyses (628,635). See Section 3.3.3.1 for updated
ials on the timing of invasive angiography.
Some selected areas require additional comment. In a patient
ith UA, a history of prior PCI within the past 6 months
ggests the presence of restenosis, which often can be treated
fectively with repeat PCI. Coronary angiography without
eceding functional testing is generally indicated. Patients with
ior CABG represent another subgroup for whom a strategy of
rly coronary angiography is usually indicated. The complex
terplay between the progression of native coronary disease and
e development of graft atherosclerosis with ulceration and
bolization is difficult to untangle noninvasively; these consid-
ations argue for early coronary angiography. In addition,
tients with known or suspected reduced LV systolic function,
cluding patients with prior anterior Q-wave MIs, those with
own depressed LV function, and those who present with HF,
ve sufficient risk that the possibility of benefit from revascu-
rization procedures merits early coronary angiography without
eceding functional testing.
In patients with UA/NSTEMI, coronary angiography typi-
lly shows the following profile: 1) no severe epicardial
enosis in 10% to 20% with a sex differential, 2) 1-vessel
enosis in 30% to 35%, 3) multivessel stenosis in 40% to 50%,
d 4) significant (greater than 50%) left main stenosis in 4% to
%. In the early invasive strategy in TIMI IIIB, no critical
struction (less than 60% diameter stenosis) was found in 19%
patients, 1-vessel stenosis in 38%, 2-vessel stenosis in 29%,
vessel stenosis in 15%, and left main stenosis (greater than
%) in 4% (651). Complex plaques are usually believed to be
sponsible for the culprit lesions. These usually are eccentric
d sometimes have irregular borders and correlate with intra-
ronary thrombi and an increased risk of recurrent ischemia at
st, MI, and cardiac death (652). Similar findings were noted in
ore than 80% of the patients in the VANQWISH trial, and
ore than 1 complex lesion was found in most patients (621).
terestingly, in TIMI IIIB, many of the patients without severe
enosis had reduced contrast clearance, which suggests micro-
scular dysfunction (651), which can contribute to impaired
yocardial perfusion. MAppropriate treatment for women presenting with ACS
ight be different from that in men (see also Section 6.1). In
RISC-II and RITA-3, an improved outcome in the early
vasive arm was seen only in men, whereas the benefit of
rly revascularization was equivalent in men and women in
e TACTICS-TIMI 18 (188) trial provided that the troponin
vel was elevated. In contrast, low-risk women tended to have
orse outcomes, including a higher risk of major bleeding, with
rly revascularization therapy, whereas low-risk men were
ither harmed nor benefited by this strategy (653). Most studies
owed that women were more likely than men to have either
rmal vessels or noncritical stenoses. High-risk women also
ere more likely to have elevation of CRP and BNP and less
ten had elevated troponin (188,653). Women with any positive
omarker benefited from invasive therapy, whereas those with-
t elevated CRP, BNP, or troponin did better with a conserva-
e approach (see Section 6.1).
Patients with severe 3-vessel stenosis and reduced LV func-
n and those with left main stenosis should be considered for
rly CABG (see Section 4). In low-risk patients, quality of life
d patient preferences should be given considerable weight in
e selection of a treatment strategy. Low-risk patients whose
mptoms do not respond well to maximal medical therapy and
ho experience poor quality of life and functional status and are
epared to accept the risks of revascularization should be
nsidered for revascularization.
The discovery that a patient does not have significant obstruc-
e CAD should prompt consideration of whether the symptoms
present another cause of cardiac ischemia (e.g., syndrome X,
ronary spasm, coronary embolism, or coronary artery dissec-
n; see Section 6) or pericarditis/myocarditis or are noncardiac
origin. There is a distinction between normal coronaries and
ssels with less than 50% stenoses but with atherosclerotic
aque present, which might be demonstrated to be extensive on
ronary intravascular ultrasound. The latter can include visual-
ation of a culprit ulcerated plaque. Noncardiac syndromes
ould prompt a search for the true cause of symptoms. Unfor-
nately, many such patients continue to have recurrent symp-
ms, are readmitted to the hospital, can become disabled, and
ntinue to consume health care resources even with repeated
ronary angiography (654,655).
It is not presently possible to define the extent of comor-
dity that would, in every case, make referral for coronary
giography and revascularization inappropriate. The high-
sk patient with significant comorbidities requires thoughtful
scussion among the physician, patient, and family and/or
tient advocate. A decision for or against revascularization
ust be made on a case-by-case basis.
Examples of extensive comorbidity that usually preclude
vascularization include 1) advanced or metastatic malig-
ncy with a projected life expectancy of 1 year or less,
intracranial pathology that contraindicates the use of
stemic anticoagulation or causes severe cognitive distur-
nce (e.g., Alzheimer’s disease) or advanced physical limita-
ns, 3) end-stage cirrhosis with symptomatic portal hyperten-
on (e.g., encephalopathy, visceral bleeding), and 4) CAD that
known from previous angiography not to be amenable to
vascularization. This list is not meant to be all-inclusive.
ore diffi-cult decisions involve patients with significant
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amples include patients who have moderate or severe renal
ilure but are stable with dialysis.
Consultation with an interventional cardiologist and a
rdiac surgeon before coronary angiography is advised to
fine technical options and likely risks and benefits. The
erators who perform coronary angiography and revascular-
ation and the facility in which these procedures are per-
rmed are important considerations, because the availability
interventional cardiologists and cardiac surgeons who are
perienced in high-risk and complex patients is essential. As
general principle, the potential benefits of coronary angiog-
phy and revascularization must be carefully weighed
ainst the risks and the conflicting results of the clinical
ials and registries. The 2007 Writing Committee endorses
rther research into techniques that could reduce bleeding
.g., radial access and smaller sheath sizes) (656) and the
oper selection and dosing of drugs to minimize bleeding in
tients with UA/NSTEMI.
.4. Risk Stratification Before Discharge
ecommendations
ASS I
Noninvasive stress testing is recommended in low-risk patients
Table 7 who have been free of ischemia at rest or with low-level
activity and of HF for aminimum of 12 to 24 h. (Level of Evidence: C)
Noninvasive stress testing is recommended in patients at
intermediate risk (Table 7) who have been free of ischemia at
rest or with low-level activity and of HF for a minimum of 12 to
24 h. (Level of Evidence: C)
Choice of stress test is based on the resting ECG, ability to
perform exercise, local expertise, and technologies available.
Treadmill exercise is useful in patients able to exercise in
whom the ECG is free of baseline ST-segment abnormalities,
bundle-branch block, LV hypertrophy, intraventricular conduc-
tion defect, paced rhythm, pre-excitation, and digoxin effect.
(Level of Evidence: C)
An imaging modality should be added in patients with resting
ST-segment depression (greater than or equal to 0.10 mV), LV
hypertrophy, bundle-branch block, intraventricular conduction
defect, preexcitation, or digoxin who are able to exercise. In
patients undergoing a low-level exercise test, an imaging
modality can add sensitivity. (Level of Evidence: B)
Pharmacological stress testing with imaging is recommended
when physical limitations (e.g., arthritis, amputation, severe
peripheral vascular disease, severe chronic obstructive pulmo-
nary disease, or general debility) preclude adequate exercise
stress. (Level of Evidence: B)
Prompt angiography without noninvasive risk stratification
should be performed for failure of stabilization with intensive
medical treatment. (Level of Evidence: B)
A noninvasive test (echocardiogram or radionuclide angio-
gram) is recommended to evaluate LV function in patients with
definite ACS who are not scheduled for coronary angiography
and left ventriculography. (Level of Evidence: B)
The management of ACS patients requires continuous risk
ratification. Important prognostic information is derived
om careful initial assessment, the patient’s course during the isrst few days of management, and the patient’s response to
ti-ischemic and antithrombotic therapy. The Braunwald
assification (21,266) has been validated prospectively and
presents an appropriate clinical instrument to help predict
tcome (657). Angina at rest, within 48 h in the absence of
extracardiac condition (primary UA; Braunwald Class III),
d UA in the early postinfarction period (Braunwald class
), along with age, male sex, hypertension, and maximal
travenous antianginal/anti-ischemic therapy, were indepen-
nt predictors for death or nonfatal MI. The baseline ECG
presentation was also found to be extremely useful for risk
ratification in the TIMI III registry (205) as discussed in
ection 2.2.6.2, and in the RISC (Research on InStability in
oronary artery disease) study group (658). In a more recent
tabase of 12,142 patients presenting within 12 h of the
set of ischemic symptoms, the ECG at presentation allowed
dividualized risk stratification across the spectrum of ACS
34) (Figure 19). In many cases, noninvasive stress testing
ovides a very useful supplement to such clinically based
sk assessment. In addition, as pointed out previously,
oponins are very helpful in risk assessment. Some patients,
wever, are at such high risk for an adverse outcome that
ninvasive risk stratification would not be likely to identify
subgroup with sufficiently low risk to avoid coronary
giography to determine whether revascularization is possi-
e. These patients include those who, despite intensive
edical therapy, manifest recurrent rest angina, hemody-
mic compromise, or severe LV dysfunction. Such patients
ould be considered directly for early coronary angiography
ithout noninvasive stress testing; however, referral for
ronary angiography is not reasonable if they are unwilling
consider revascularization or have severe complicating
lnesses that preclude revascularization. Other patients may
ve such a low likelihood of CAD after initial clinical
aluation that even an abnormal test finding is unlikely to
ompt additional therapy that would further reduce risk (e.g.,
35-year-old woman without CAD risk factors). Such
tients would ordinarily not be considered for coronary
giography and revascularization unless the diagnosis of
A/NSTEMI is unclear. The majority of patients presenting
ith UA/NSTEMI do not fall into these categories and are
cordingly reasonable candidates for risk stratification with
ninvasive testing.
Determination of patient risk on the basis of a validated
oring algorithm (e.g., from the TIMI, GRACE, or PUR-
UIT trial data) can be valuable for identifying high-risk
tients (see Section 2.2.6 and Table 8). They also can assist
selecting those who can benefit most from more aggressive
erapies, such as LMWH or an invasive treatment strategy
ee Section 3.4.1).
.4.1. Care Objectives
he goals of noninvasive testing are to 1) determine the
esence or absence of ischemia in patients with a low or
termediate likelihood of CAD and 2) estimate prognosis.
his information is key for the development of further
agnostic steps and therapeutic measures.
A detailed discussion of noninvasive stress testing in CAD
presented in the ACC/AHA Guidelines for Exercise Test-
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adionuclide Imaging, and ACC/AHA Guidelines for the
linical Application of Echocardiography (11,659 – 661)
ables 19, 20, and 21). Briefly, the provocation of ischemia
a low workload (664) or a high-risk treadmill score (i.e.,
eater than or equal to 11) (665) implies severe limitation in
e ability to increase coronary blood flow. This is usually the
sult of severe coronary artery obstruction and is associated
ith a high risk for an adverse outcome and/or severe angina
ter discharge. Unless there are contraindications to revas-
larization, such patients generally merit referral for early
ronary angiography to direct a revascularization procedure,
gure 19. Kaplan-Meier Estimates of Probability of Death
ased on Admission Electrocardiogram. Modified with permis-
on from Savonitto S, Ardissino D, Granger CB, et al. Prognos-
value of the admission electrocardiogram in acute coronary
ndromes. JAMA 1999;281:707–13 (127). Copyright © 1999
merican Medical Association.appropriate. On the other hand, the attainment of a higherorkload (e.g., greater than 6.5 metabolic equivalents
ETS]) without evidence of ischemia (low-risk treadmill
ore greater than or equal to 5) (665) is associated with
nctionally less severe coronary artery obstruction. Such
tients have a better prognosis and can often be safely
anaged conservatively. Ischemia that develops at greater
an 6.5 METS can be associated with severe coronary
tery obstruction, but unless other high-risk markers are
esent (greater than 0.2-mV ST-segment depression or
evation, fall in blood pressure, ST-segment shifts in
ultiple leads reflecting multiple coronary regions, or
olonged ST-segment shifts [greater than 6 min] in
covery), these patients also may be safely managed
nservatively (Table 20).
Stress radionuclide ventriculography or stress echocardi-
raphy (Table 20) provides an important alternative to
ercise electrocardiography testing. Myocardial perfusion
aging with pharmacological stress (Table 21) is particu-
rly useful in patients who are unable to exercise. The
ble 19. Noninvasive Risk Stratification
gh risk (greater than 3% annual mortality rate)
Severe resting LV dysfunction (LVEF less than 0.35)
High-risk treadmill score (score –11 or less)
Severe exercise LV dysfunction (exercise LVEF less than 0.35)
Stress-induced large perfusion defect (particularly if anterior)
Stress-induced multiple perfusion defects of moderate size
Large, fixed perfusion defect with LV dilation or increased lung uptake
(thallium-201)
Stress-induced moderate perfusion defect with LV dilation or increased
lung uptake (thallium-201)
Echocardiographic wall-motion abnormality (involving more than 2
segments) developing at low dose of dobutamine (10 mcg per kg per
min or less) or at a low heart rate (less than 120 beats per min)
Stress echocardiographic evidence of extensive ischemia
termediate risk (1% to 3% annual mortality rate)
Mild/moderate resting LV dysfunction (LVEF  0.35 to 0.49)
Intermediate-risk treadmill score (–11 to 5)
Stress-induced moderate perfusion defect without LV dilation or increased
lung intake (thallium-201)
Limited stress echocardiographic ischemia with a wall-motion abnormality
only at higher doses of dobutamine involving less than or equal to 2
segments
w risk (less than 1% annual mortality rate)
Low-risk treadmill score (score 5 or greater)
Normal or small myocardial perfusion defect at rest or with stress*
Normal stress echocardiographic wall motion or no change of limited
resting wall-motion abnormalities during stress*
*Although the published data are limited, patients with these findings will
obably not be at low risk in the presence of either a high-risk treadmill
ore or severe resting LV dysfunction (LVEF less than 0.35). Reproduced
m (Table 23) in Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002
ideline update for the management of patients with chronic stable angina: a
port of the American College of Cardiology/American Heart Association Task
rce on Practice Guidelines (Committee to Update the 1999 Guidelines for the
anagement of Patients With Chronic Stable Angina). 2002. Available at:
ww.acc.org/qualityandscience/clinical/statements.htm (4).LV  left ventricular; LVEF  left ventricular ejection fraction.
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milar to that of exercise testing with imaging, although there
e few direct comparisons.
As noted earlier (Section 2.3.2.), CMR is a newer imaging
odality that can effectively assess cardiac function, per-
sion (e.g., with adenosine stress), and viability at the same
udy. The combination of these features has been reported to
eld excellent predictive information in suspected CAD/
CS patients (303).
.4.2. Noninvasive Test Selection
here are no conclusive data that either LV function or
yocardial perfusion at rest and during exercise or pharma-
logical stress is superior in the assessment of prognosis.
oth the extent of CAD and the degree of LV dysfunction are
portant in the selection of the appropriate therapy. Studies
at directly compare prognostic information from multiple
ninvasive tests for ischemia in patients after the stabiliza-
on of UA/NSTEMI are hampered by small sample size.
obutamine stress echocardiography measures both resting
V function and the functional consequences of a coronary
enosis (659). An ischemic response is characterized by
itially improved LV function at low-stress doses, followed
deterioration with increasing dobutamine doses (659).
owever, UA and MI are listed as contraindications for
butamine stress echocardiography (666).
The RISC study evaluated predischarge symptom-limited
cycle exercise testing in 740 men with UA/NSTEMI (667).
ultivariate analysis showed that the extent of ST-segment
pression, expressed as the number of leads with ischemic
anges at a low maximal workload, was negatively corre-
ted independently with infarct-free survival rates at 1 year.
his and other smaller studies permit a comparison of the
fectiveness of exercise ECG with exercise or dipyridamole
allium-201 study for risk stratification. All of these nonin-
sive tests show similar accuracy in dichotomization of the
tal population into low- and high-risk subgroups.
Selection of the noninvasive stress test should be based
imarily on patient characteristics, local availability, and
pertise in interpretation (668). Because of simplicity, lower
st, and widespread familiarity with performance and inter-
etation, the standard low-level exercise ECG stress test
ble 20. Noninvasive Test Results That Predict High Risk for
dverse Outcome (Left Ventricular Imaging)
Stress Radionuclide
Ventriculography Stress Echocardiography
ercise EF 0.50 or less Rest EF 0.35 or less
st EF 0.35 or less Wall-motion score index greater than 1
ll in EF 0.10 or greater
Adapted from O’Rourke RA, Chatterjee K, Dodge HT, et al. Guidelines for
inical use of cardiac radionuclide imaging, December 1986: a report of the
erican College of Cardiology/American Heart Association Task Force on
sessment of Cardiovascular Procedures (Subcommittee on Nuclear Imaging).
Am Coll Cardiol 1986;8:1471–83 (576); and Cheitlin MD, Alpert JS,
mstrong WF, et al. ACC/AHA guidelines for the clinical application of
hocardiography. Circulation 1997;95:1686 –744 (577).
EF  ejection fraction.mains the most reasonable test in patients who are able to Jercise and who have a resting ECG that is interpretable for
T-segment shifts. Patients with an ECG pattern that would
terfere with interpretation of the ST segment should have an
ercise test with imaging. Patients who are unable to exercise
ould have a pharmacological stress test with imaging. Low-
d intermediate-risk patients admitted with ACS may undergo
mptom-limited stress testing provided they have been asymp-
matic and clinically stable for 12 to 24 h.
The optimal testing strategy in women is less well defined
an in men (see Section 6.1), but there is evidence that
aging studies are superior to exercise ECG evaluation in
omen (668,669). Exercise testing has been reported to be
ss accurate for diagnosis in women. At least a portion of the
wer reported accuracy derives from a lower pretest likeli-
od of CAD in women than in men; the higher prevalence of
chemia secondary to vascular dysfunction (coronary endo-
elial and/or microvascular dysfunction) in the absence of
structive CAD also is a likely contributor to this.
Results of a symptom-limited exercise test performed 3 to
d after UA/NSTEMI were compared with results of a test
nducted 1 month later in 189 patients (621,670). The
agnostic and prognostic values of the tests were similar, but
e earlier test identified patients who developed adverse
ents during the first month, and this represented approxi-
ately one half of all events that occurred during the first
ar. These data illustrate the importance of early noninva-
ve testing for risk stratification.
The VANQWISH trial used symptom-limited thallium
ercise treadmill testing at 3 to 5 d to direct the need for
giography in the 442 non–Q-wave MI patients randomized
an early conservative strategy (621). Among subjects in
e conservative arm meeting VANQWISH stress test
iteria to cross over to coronary angiography, 51% were
und to have surgical CAD and showed favorable out-
mes after revascularization (671). These findings sup-
rt the concept that noninvasive stress testing can be used
ccessfully to identify a high-risk subset of patients who
n be directed to coronary angiography. It is unlikely that
y angiographically directed early revascularization strat-
y could alter the very low early event rates observed in
tients without a high-risk stress test.
Noninvasive tests are most useful for management
cisions when risk can be stated in terms of events over
me. A large population of patients must be studied to
rive and test the equations needed to accurately predict
ble 21. Noninvasive Test Results That Predict High Risk for
dverse Outcome on Stress Radionuclide Myocardial Perfusion
aging
normal myocardial tracer distribution in more than 1 coronary artery
region at rest or with stress or a large anterior defect that reperfuses
normal myocardial distribution with increased lung uptake
rdiac enlargement
Adapted from O’Rourke RA, Chatterjee K, Dodge HT, et al. Guidelines for
inical use of cardiac radionuclide imaging, December 1986: a report of the
erican College of Cardiology/American Heart Association Task Force on
sessment of Cardiovascular Procedures (Subcommittee on Nuclear Imaging).
Am Coll Cardiol 1986;8:1471–83 (576).
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ported in a sufficient number of patients after the
abilization of UA/NSTEMI to develop and test the
curacy of a multivariable equation to report test results
terms of absolute risk. Therefore, data from studies of
able angina patients must be used for risk, reported as
ents over time. Although the pathological process that
okes ischemia may be different in the 2 forms of angina,
is likely that the use of prognostic nomograms derived
om patients with stable angina also are predictive of risk
patients with recent UA/NSTEMI after stabilization.
ith this untested assumption, the much larger literature
rived from populations that include patients with both
able angina and UA/NSTEMI provides equations for risk
ratification that convert physiological changes observed
ring noninvasive testing into statements of risk ex-
essed as events over time.
.4.3. Selection for Coronary Angiography
contrast to the noninvasive tests, coronary angiography
ovides detailed structural information to allow an assessment
prognosis and to provide direction for appropriate manage-
ent. When combined with LV angiography, it also allows an
sessment of global and regional LV function. Indications for
ronary angiography are interwoven with indications for pos-
ble therapeutic plans, such as PCI or CABG.
Coronary angiography is usually indicated in patients with
A/NSTEMI who either have recurrent symptoms or isch-
ia despite adequate medical therapy or are at high risk as
tegorized by clinical findings (HF, serious ventricular
rhythmias) or noninvasive test findings (significant LV
sfunction: ejection fraction less than 0.35, large anterior or
ultiple perfusion defects; Tables 19, 20, and 21), as dis-
ssed in Section 3.4.2. Patients with UA/NSTEMI who have
d previous PCI or CABG also should generally be consid-
ed for early coronary angiography, unless prior coronary
giography data indicate that no further revascularization is
kely to be possible. The placement of an IABP may allow
ronary angiography and revascularization in those with
modynamic instability (see Section 3.1.2.7). Patients with
spected Prinzmetal’s variant angina also are candidates for
ronary angiography (see Section 6.7).
In all cases, the general indications for coronary angiogra-
y and revascularization are tempered by individual patient
aracteristics and preferences. Patient and physician judg-
ents regarding risks and benefits are particularly important
r patients who might not be candidates for coronary
vascularization, such as very frail older adults and those
ith serious comorbid conditions (i.e., severe hepatic, pul-
onary, or renal failure; active or inoperable cancer).
.4.4. Patient Counseling
esults of testing should be discussed with the patient, the
tient’s family, and/or the patient’s advocate in a language
at is understood by them. Test results should be used to help
termine the advisability of coronary angiography, the need
r adjustments in the medical regimen, and the need for
condary prevention measures (see Section 5).. Coronary Revascularization
.1. Recommendations for Revascularization
ith PCI and CABG in Patients With UA/NSTEMI
ables A and B are excerpted from the “2011 ACCF/AHA/
CAI Guideline for Percutaneous Coronary Intervention”
72) and “2011 ACCF/AHA Guideline for Coronary Artery
ypass Graft Surgery” (673) and are included to provide a
mprehensive and concordant set of recommendations for
vascularization. See the respective guidelines for supportive
ferences and supplemental text.
ASS I
The selection of PCI or CABG as the means of revascularization
in the patient with ACS should generally be based on the same
considerations as those without ACS. (Level of Evidence: B)
. Late Hospital Care, Hospital
ischarge, and Post-Hospital
ischarge Care
he acute phase of UA/NSTEMI is usually over within 2 months.
he risk of progression to MI or the development of recurrent MI or
ath is highest during that period. At 1 to 3 months after the acute
ase, most patients resume a clinical course similar to that in
tients with chronic stable coronary disease.
The broad goals during the hospital discharge phase are
fold: 1) to prepare the patient for normal activities to the
tent possible and 2) to use the acute event as an opportunity
reevaluate the plan of care, particularly lifestyle and risk
ctor modification. Aggressive risk factor modifications that
n prolong survival should be the main goals of long-term
anagement of stable CAD. Patients who have undergone
ccessful PCI with an uncomplicated course are usually dis-
arged the next day, and patients who undergo uncomplicated
ABG are generally discharged 4 to 7 d after CABG. Medical
anagement of low-risk patients after noninvasive stress testing
d coronary angiography can typically be accomplished rap-
ly, with discharge soon after testing. Medical management of
high-risk group of patients who are unsuitable for or unwilling
undergo revascularization could require vigilant inpatient
onitoring in order to achieve adequate ischemic symptom
ntrol with medical therapy that will minimize future morbidity
d mortality and improve quality of life.
.1. Medical Regimen and
se of Medications
ecommendations
ASS I
Medications required in the hospital to control ischemia
should be continued after hospital discharge in patients with
UA/NSTEMI who do not undergo coronary revascularization,
patients with unsuccessful revascularization, and patients
with recurrent symptoms after revascularization. Upward or
downward titration of the doses may be required. (Level of
Evidence: C)
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Anatomic
Setting COR LOE
UPLM or complex CAD
CABG and PCI I—Heart Team approach recommended C
CABG and PCI IIa—Calculation of STS and SYNTAX scores B
UPLM*
CABG I B
PCI IIa—For SIHD when both of the following are present:
● Anatomic conditions associated with a low risk of PCI procedural complications and a high likelihood of good long-
term outcome (e.g., a low SYNTAX score of 22, ostial or trunk left main CAD)
● Clinical characteristics that predict a significantly increased risk of adverse surgical outcomes (e.g., STS-predicted risk
of operative mortality 5%)
B
IIa—For UA/NSTEMI if not a CABG candidate B
IIa—For STEMI when distal coronary flow is TIMI flow grade 3 and PCI can be performed more rapidly and safely
than CABG
C
IIb—For SIHD when both of the following are present:
● Anatomic conditions associated with a low to intermediate risk of PCI procedural complications and an intermediate to
high likelihood of good long-term outcome (e.g., low-intermediate SYNTAX score of 33, bifurcation left main CAD)
● Clinical characteristics that predict an increased risk of adverse surgical outcomes (e.g., moderate- severe COPD,
disability from prior stroke, or prior cardiac surgery; STS-predicted risk of operative mortality 2%)
B
III: Harm—For SIHD in patients (versus performing CABG) with unfavorable anatomy for PCI and who are good
candidates for CABG
B
3-vessel disease with or without proximal LAD artery disease*
CABG I B
IIa—It is reasonable to choose CABG over PCI in patients with complex 3-vessel CAD (e.g., SYNTAX score
22) who are good candidates for CABG.
B
PCI IIb—Of uncertain benefit B
2-vessel disease with proximal LAD artery disease*
CABG I B
PCI IIb—Of uncertain benefit B
2-vessel disease without proximal LAD artery disease*
CABG IIa—With extensive ischemia B
IIb—Of uncertain benefit without extensive ischemia C
PCI IIb—Of uncertain benefit B
1-vessel proximal LAD artery disease
CABG IIa—With LIMA for long-term benefit B
PCI IIb—Of uncertain benefit B
1-vessel disease without proximal LAD artery involvement
CABG III: Harm B
PCI III: Harm B
LV dysfunction
CABG IIa—EF 35% to 50% B
CABG IIb—EF 35% without significant left main CAD B
PCI Insufficient data
Survivors of sudden cardiac death with presumed ischemia-mediated VT
CABG I B
PCI I C
No anatomic or physiologic criteria for revascularization
CABG III: Harm B
PCI III: Harm B
*In patients with multivessel disease who also have diabetes, it is reasonable to choose CABG (with LIMA) over PCI (Class IIa; LOE: B).
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; COR, class of recommendation; EF,
ection fraction; LAD, left anterior descending; LIMA, left internal mammary artery; LOE, level of evidence; LV, left ventricular; N/A, not applicable; PCI, percutaneous
ronary intervention; SIHD, stable ischemic heart disease; STEMI, ST-elevation myocardial infarction; STS, Society of Thoracic Surgeons; SYNTAX, Synergy between
rcutaneous Coronary Intervention with TAXUS and Cardiac Surgery; TIMI, Thrombolysis In Myocardial Infarction; UA/NSTEMI, unstable angina/non–ST-elevation
yocardial infarction; UPLM, unprotected left main disease; and VT, ventricular tachycardia.
2.
3.
4.
5.
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spray NTG and instructed in its use. (Level of Evidence: C)
Before hospital discharge, patients with UA/NSTEMI should
be informed about symptoms of worsening myocardial isch-
emia and MI and should be instructed in how and when to
seek emergency care and assistance if such symptoms
occur. (Level of Evidence: C)
Before hospital discharge, post-UA/NSTEMI patients and/or
designated responsible caregivers should be provided with
supportable, easily understood, and culturally sensitive instruc-
tions with respect to medication type, purpose, dose, fre-
quency, and pertinent side effects. (Level of Evidence: C)
In post-UA/NSTEMI patients, anginal discomfort lasting more
than 2 or 3 min should prompt the patient to discontinue
physical activity or remove himself or herself from any stressful
event. If pain does not subside immediately, the patient should
be instructed to take 1 dose of NTG sublingually. If the chest
discomfort/pain is unimproved or worsening 5 min after 1 NTG
dose has been taken, it is recommended that the patient or a
family member/friend call 9-1-1 immediately to access EMS.
While activating EMS access, additional NTG (at 5-min inter-
vals 2 times) may be taken while lying down or sitting. (Level
of Evidence: C)
If the pattern or severity of anginal symptoms changes, which
suggests worsening myocardial ischemia (e.g., pain is more
frequent or severe or is precipitated by less effort or now
occurs at rest), the patient should contact his or her physician
without delay to assess the need for additional treatment or
testing. (Level of Evidence: C)
In most cases, the inpatient anti-ischemic medical regimen
ed in the nonintensive phase (other than intravenous NTG)
ould be continued after discharge, and the antiplatelet/antico-
ulant medications should be changed to an outpatient regimen.
he goals for continued medical therapy after discharge relate to
tential prognostic benefits (primarily shown for antiplatelet
ents, beta blockers, low-density cholesterol (LDL-C)–lower-
g agents, and inhibitors of the renin-angiotensin aldosterone
stem, especially for ejection fraction of 0.40 or less), control of
ble B. Revascularization to Improve Symptoms With Significan
ysiological (FFR<0.80) Coronary Artery Stenoses
Clinical Setting
1 significant stenoses amenable to revascularization and unacceptable
angina despite GDMT
1 significant stenoses and unacceptable angina in whom GDMT cannot b
implemented because of medication contraindications, adverse effects, o
patient preferences
Previous CABG with 1 significant stenoses associated with ischemia and
unacceptable angina despite GDMT
Complex 3-vessel CAD (e.g., SYNTAX score 22) with or without
involvement of the proximal LAD artery and a good candidate for CABG
Viable ischemic myocardium that is perfused by coronary arteries that are
not amenable to grafting
No anatomic or physiologic criteria for revascularization
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; CO
edical therapy; LOE, level of evidence; N/A, not applicable; PCI, percutaneous c
ith TAXUS and Cardiac Surgery; and TMR, transmyocardial laser revascularizachemic symptoms (nitrates, beta blockers, and CCBs), and apeatment of major risk factors such as hypertension, smoking,
slipidemia, physical inactivity, and diabetes mellitus (see
ection 5.2). Thus, the selection of a medical regimen is
dividualized to the specific needs of each patient based on the
-hospital findings and events, the risk factors for CAD, drug
lerability, and recent procedural interventions. The mnemonic
BCDE (Aspirin, antianginals, and ACE inhibitors; Beta block-
s and blood pressure; Cholesterol and cigarettes; Diet and
abetes; Education and exercise) has been found to be useful in
iding treatment (11,719).
An effort by the entire multidisciplinary team with special
ills (physicians, nurses, dietitians, pharmacists, rehabilita-
on specialists, care managers, and physical and occupational
erapists) is often necessary to prepare the patient for
scharge. Both the patient and family should receive instruc-
ons about what to do if ischemic symptoms occur in the
ture (80). Face-to-face patient instruction is important and
ould be reinforced and documented with written instruction
eets. Enrollment in a cardiac rehabilitation program after
scharge can enhance patient education and compliance with
e medical regimen (see Section 5.4).
Telephone follow-up can serve to reinforce in-hospital
struction, provide reassurance, and answer the patient’s
estions (720). If personnel and budget resources are avail-
le, the health care team should establish a follow-up system in
hich personnel specially trained to support and assist clinicians
CAD management call patients on the telephone. For exam-
e, calls might occur weekly for the first 4 weeks after
scharge. This structured program can gauge the progress of the
tient’s recovery, reinforce the CAD education taught in the
spital, address patient questions and concerns, and monitor
ogress in meeting risk factor modification goals.
.2. Long-Term Medical Therapy and
econdary Prevention
or the non-updated subsections on long-term medical ther-
omic (>50% Left Main or >70% Non–Left Main CAD) or
COR LOE
I–CABG
I–PCI
A
IIa–CABG
IIa–PCI
C
IIa–PCI C
IIb–CABG C
IIa–CABG preferred
over PCI
B
IIb–TMR as an adjunct
to CABG
B
III: Harm–CABG
III: Harm–PCI
C
s of recommendation; FFR, fractional flow reserve; GDMT, guideline-directed
intervention; SYNTAX, Synergy between Percutaneous Coronary Interventiont Anat
e
r
R, clas
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e 2012 Stable Ischemic Heart Disease Guideline (722).
Patients with UA/NSTEMI require secondary preven-
on for CAD at discharge. The management of the patient
ith stable CAD is of relevance, as detailed in the
CC/AHA/ACP Guidelines for the Management of Pa-
ents With Chronic Stable Angina (11), as are the second-
y prevention guidelines (10) outlined in the more recent
CC/AHA Guidelines for the Management of Patients
ith ST-Elevation MI (8) and Secondary Prevention
0,45).
A health care team with expertise in aggressively
anaging CAD risk factors should work with patients and
eir families to educate them in detail regarding specific
rgets for LDL-C and high-density lipoprotein cholesterol
DL-C), blood pressure, body mass index (BMI), physi-
l activity, and other appropriate lifestyle modifications
1). These health care teams can be hospital-, office-, or
mmunity-based and may include chronic disease man-
ement or cardiac rehabilitation/secondary prevention
ograms. The family should be instructed on how best to
rther support the patient by encouraging reasonable
anges in risk behavior (e.g., cooking AHA, Mediterra-
an, or DASH [Dietary Approach to Stop Hypertension]
et meals for the entire family; exercising together). This
particularly important when screening of family mem-
rs reveals common risk factors, such as dyslipidemia,
pertension, secondhand smoke, and obesity. Of recent concern is
e national trend to obesity, which has increased over the past
cade in all 50 states, and its risk consequences (723). The
mbination of evidence-based therapies provides complementary,
ded morbidity and mortality reductions (724,725); prescription of
d compliance with these combination therapies should be
ressed.
.2.1. Convalescent and Long-Term Antiplatelet
herapy (UPDATED)
ASS I
For UA/NSTEMI patients treated medically without stenting,
aspirin# should be prescribed indefinitely (Level of Evidence: A)
(371,372,374,375); clopidogrel (75 mg per day) or ticagrelor‡
(90 mg twice daily) should be prescribed for up to 12 months.
(Level of Evidence: B) (381,388,459)
For UA/NSTEMI patients treated with a stent (BMS or DES),
aspirin should be continued indefinitely. (Level of Evidence: A)
The duration and maintenance dose of P2Y12 receptor inhibitor
therapy should be as follows:
or aspirin-allergic patients, use either clopidogrel or ticagrelor alone (indefinitely)
try aspirin desensitization. Note that there are no data for therapy with 2
ncurrent P2Y12 receptor inhibitors, and this is not recommended in the case of
pirin allergy.
‡The recommended maintenance dose of aspirin to be used with ticagrelor is 81
g daily (398). Ticagrelor’s benefits were observed irrespective of prior therapy with
pidogrel (381). When possible, discontinue ticagrelor at least 5 d before any
rgery (399). Issues of patient compliance may be especially important. Consid-
ation should be given to the potential and as yet undetermined risk of intracranial
morrhage in patients with prior stroke or TIA. sha. Clopidogrel 75 mg daily, (382) prasugrel† 10 mg daily
(380), or ticagrelor‡ 90 mg twice daily (381) should be
given for at least 12 months in patients receiving DES and
up to 12 months for patients receiving BMS. (Level of
Evidence: B) (249,381,382)
b. If the risk of morbidity because of bleeding outweighs the
anticipated benefits afforded by P2Y12 receptor inhibitor ther-
apy, earlier discontinuation should be considered. (Level of
Evidence: C)
Clopidogrel 75 mg daily (Level of Evidence: B) (249,378),
prasugrel† 10 mg daily (in PCI-treated patients) (Level of
Evidence: C) (380), or ticagrelor‡ 90 mg twice daily (Level of
Evidence: C) (381) should be given to patients recovering from
UA/NSTEMI when aspirin is contraindicated or not tolerated
because of hypersensitivity or GI intolerance (despite use of
gastroprotective agents such as PPIs) (379,478).
ASS IIa
After PCI, it is reasonable to use 81 mg per day of aspirin in
preference to higher maintenance doses. (Level of Evidence: B)
(389,416,470,726,727)
ASS IIb
For UA/NSTEMI patientswho have an indication for anticoagulation,
the addition of warfarin** may be reasonable to maintain an INR of
2.0 to 3.0.†† (Level of Evidence: B) (728–737)
Continuation of a P2Y12 receptor inhibitor beyond 12 months
may be considered in patients following DES placement. (Level
of Evidence: C)
ASS III: NO BENEFIT
Dipyridamole is not recommended as an antiplatelet agent in
post-UA/NSTEMI patients because it has not been shown to be
effective. (Level of Evidence: B) (416,738,739)
.2.2. Beta Blockers
ASS I
Beta blockers are indicated for all patients recovering from
UA/NSTEMI unless contraindicated. (For those at low risk, see
†Patients weighing 60 kg have an increased exposure to the active
etabolite of prasugrel and an increased risk of bleeding on a 10-mg once-daily
aintenance dose. Consideration should be given to lowering the maintenance
se to 5 mg in patients who weigh 60 kg, although the effectiveness and
fety of the 5-mg dose have not been studied prospectively. For post-PCI
tients, a daily maintenance dose should be given for at least 12 mo for patients
ceiving DES and up to 12 mo for patients receiving BMS unless the risk of
eeding outweighs the anticipated net benefit afforded by a P2Y12 receptor
hibitor. Do not use prasugrel in patients with active pathological bleeding or
history of TIA or stroke. In patients age 75 y, prasugrel is generally not
commended because of the increased risk of fatal and intracranial bleeding and
certain benefit except in high-risk situations (patients with diabetes or a
story of prior myocardial infarction), in which its effect appears to be greater
d its use may be considered. Do not start prasugrel in patients likely to
dergo urgent CABG. When possible, discontinue prasugrel at least 7 d before
y surgery (395). Additional risk factors for bleeding include body weight 60
, propensity to bleed, and concomitant use of medications that increase the
k of bleeding (e.g., warfarin, heparin, fibrinolytic therapy, or chronic use of
nsteroidal anti-inflammatory drugs) (395).
**Continue aspirin indefinitely and warfarin longer term as indicated for specific
nditions such as atrial fibrillation; LV thrombus; or cerebral, venous, or pulmonary emboli.
††An INR of 2.0 to 2.5 is preferable while given with aspirin and a P2Y12
ceptor inhibitor, especially in older patients and those with other risk factors for
eeding. For UA/NSTEMI patients who have mechanical heart valves, the INR
ould be at least 2.5 (based on type of prosthesis).
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within a few days of the event, if not initiated acutely, and
should be continued indefinitely. (Level of Evidence: B)
Patients recovering from UA/NSTEMI with moderate or severe
LV failure should receive beta-blocker therapy with a gradual
titration scheme. (Level of Evidence: B)
ASS IIa
It is reasonable to prescribe beta blockers to low-risk patients
(i.e., normal LV function, revascularized, no high-risk features)
recovering from UA/NSTEMI in the absence of absolute con-
traindications. (Level of Evidence: B)
.2.3. Inhibition of the Renin-Angiotensin-
ldosterone System
ASS I
Angiotensin-converting enzyme inhibitors should be given
and continued indefinitely for patients recovering from UA/
NSTEMI with HF, LV dysfunction (LVEF less than 0.40),
hypertension, or diabetes mellitus, unless contraindicated.
(Level of Evidence: A)
An angiotensin receptor blocker should be prescribed at dis-
charge to those UA/NSTEMI patients who are intolerant of an
ACE inhibitor and who have either clinical or radiological signs
of HF and LVEF less than 0.40. (Level of Evidence: A)
Long-term aldosterone receptor blockade should be pre-
scribed for UA/NSTEMI patients without significant renal
dysfunction (estimated creatinine clearance should be
greater than 30 mL per min) or hyperkalemia (potassium
should be less than or equal to 5 mEq per liter) who are
already receiving therapeutic doses of an ACE inhibitor, have
an LVEF less than or equal to 0.40, and have either symp-
tomatic HF or diabetes mellitus. (Level of Evidence: A)
ASS IIa
Angiotensin-converting enzyme inhibitors are reasonable for
patients recovering from UA/NSTEMI in the absence of LV
dysfunction, hypertension, or diabetes mellitus unless contra-
indicated. (Level of Evidence: A)
Angiotensin-converting enzyme inhibitors are reasonable for patients
with HF and LVEF greater than 0.40. (Level of Evidence: A)
In UA/NSTEMI patients who do not tolerate ACE inhibitors, an
angiotensin receptor blocker can be useful as an alternative to
ACE inhibitors in long-term management provided there are
either clinical or radiological signs of HF and LVEF less than 0.40.
(Level of Evidence: B)
ASS IIb
The combination of an ACE inhibitor and an angiotensin recep-
tor blocker may be considered in the long-term management of
patients recovering from UA/NSTEMI with persistent symp-
tomatic HF and LVEF less than 0.40‡‡ despite conventional
therapy including an ACE inhibitor or an angiotensin receptor
blocker alone. (Level of Evidence: B)
Data on the utility of ACE inhibitors in stable CAD in the
esence of HF and LV dysfunction have been compelling,
hereas data in their absence have been conflicting. A
The safety of this combination has not been proven in patients also aldosterone
tagonist and is not recommended. §§duction in the rates of mortality and vascular events was
ported in the Heart Outcomes Prevention Evaluation
OPE) Study (349) with the long-term use of an ACE
hibitor (ramipril) in moderate-risk patients with CAD,
any of whom had preserved LV function, as well as patients
high risk of developing CAD. Similar but smaller benefits
ere reported in the EUROPA study (EUropean trial on
eduction Of cardiac events with Perindopril in patients with
able coronary Artery disease), which observed a significant
duction in incidence of cardiovascular death, MI, or cardiac
rest among moderate-risk patients with known coronary
sease without apparent HF randomized to perindopril ver-
s placebo (740). Conflicting results, however, were ob-
rved in the Prevention of Events with Angiotensin Convert-
g Enzyme Inhibition (PEACE) trial, which found no
gnificant difference in the risk of cardiovascular death, MI,
coronary revascularization among low-risk patients with
able CAD and preserved LV function when an ACE
hibitor (trandolapril) was added to modern conventional
erapy (741); however, a subsequent meta-analysis of these
major trials supported benefit across the risk spectrum
udied (742). These and other data may be harmonized by
stulating that ACE inhibitors provide general benefit in
able CAD but that the absolute benefit is proportional to
sease-related risk, with those at lowest risk benefiting least
42,743). These and other agents that may be used in
tients with chronic CAD are listed in (Table 22) and are
scussed in detail in the ACC/AHA Guidelines for the
anagement of Patients With Chronic Stable Angina (11).
.2.4. Nitroglycerin
ASS I
Nitroglycerin to treat ischemic symptoms is recommended.
(Level of Evidence: C)
.2.5. Calcium Channel Blockers
ASS I
Calcium channel blockers§§ are recommended for ischemic
symptoms when beta blockers are not successful. (Level of Evi-
dence: B)
Calcium channel blockers§§ are recommended for ischemic
symptoms when beta blockers are contraindicated or cause
unacceptable side effects. (Level of Evidence: C)
.2.6. Warfarin Therapy (UPDATED)
ASS I
Use of warfarin in conjunction with aspirin and/or P2Y12
receptor inhibitor therapy is associated with an increased risk
of bleeding, and patients and clinicians should watch for
bleeding, especially GI, and seek medical evaluation for evi-
dence of bleeding. (Level of Evidence: A) (249,380,381,
459,583–585,744)
ASS IIb
Warfarin either without (INR 2.5 to 3.5) or with low-dose
aspirin (81 mg per day; INR 2.0 to 2.5) may be reasonable for
patients at high coronary artery disease risk and low bleedingShort-acting dihydropyridine calcium channel antagonists should be avoided.
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inhibitor therapy. (Level of Evidence: B) (745,746)
Targeting oral anticoagulant therapy to a lower INR (e.g.,
2.0 to 2.5) might be reasonable in patients with UA/NSTEMI
managed with aspirin and a P2Y12 inhibitor. (Level of Evi-
dence: C)
.2.7. Lipid Management
ASS I
The following lipid recommendations are beneficial:
a. Lipid management should include assessment of a fasting
lipid profile for all patients, within 24 h of hospitalization.
(Level of Evidence: C)
b. Hydroxymethyl glutaryl-coenzyme A reductase inhibitors
(statins), in the absence of contraindications, regardless of
baseline LDL-C and diet modification, should be given to
post-UA/NSTEMI patients, including postrevascularization
patients. (Level of Evidence: A)
c. For hospitalized patients, lipid-lowering medications should
be initiated before discharge. (Level of Evidence: A)
d. For UA/NSTEMI patients with elevated LDL-C (greater than
or equal to 100 mg per dL), cholesterol-lowering therapy
ble 22. Medications Used for Stabilized UA/NSTEMI Patients
Anti-Ischemic and
Antithrombotic/Antiplatelet Agents Drug Action
pirin Antiplatelet
opidogrel or prasugrel (in PCI-treated
patients) or ticagrelor
Antiplatelet
ta blockers Anti-ischemic
EI EF less than 0.40 or HF EF greate
than 0.40
trates Antianginal
lcium channel blockers (short-acting
dihydropyridine antagonists should
be avoided)
Antianginal
pyridamole Antiplatelet
gents for Secondary Prevention and
Other Indications Risk Factor
G-CoA reductase inhibitors LDL cholesterol greater than 70 m
brates HDL cholesterol less than 40 mg p
acin HDL cholesterol less than 40 mg p
acin or fibrate Triglycerides 200 mg per dL
tidepressant Treatment of depression
eatment of hypertension Blood pressure greater than 140/90 m
greater than 130/80 mm Hg if k
disease or diabetes present
rmone therapy (initiation)* Postmenopausal state
eatment of diabetes HbA1C greater than 7%
rmone therapy (continuation)* Postmenopausal state
X-2 inhibitor or NSAID Chronic pain
tamins C, E, beta-carotene; folic
acid, B6, B12
Antioxidant effect; homocysteine lo
*For risk reduction of coronary artery disease.
ACEI  angiotensin-converting enzyme inhibitor; CHF  congestive heart
oprotein; HMG-CoA  hydroxymethyl glutaryl coenzyme A; INR  intern
ti-inflammatory drug; NSTEMI  non–ST-segment elevation myocardial infarshould be initiated or intensified to achieve an LDL-C of less 20than 100 mg per dL. (Level of Evidence: A) Further titration
to less than 70 mg per dL is reasonable. (Class IIa, Level of
Evidence: A)
e. Therapeutic options to reduce non–HDL-C 
f. Dietary therapy for all patients should include reduced
intake of saturated fats (to less than 7% of total calories),
cholesterol (to less than 200 mg per d), and trans fat (to
less than 1% of energy). (Level of Evidence: B)
g. Promoting daily physical activity and weight management
are recommended. (Level of Evidence: B)
Treatment of triglycerides and non-HDL-C is useful, including
the following:
a. If triglycerides are 200 to 499 mg per dL, non-HDLC 
should be less than 130 mg per dL. (Level of Evidence: B)
b. If triglycerides are greater than or equal to 500 mg per
dL,¶¶ therapeutic options to prevent pancreatitis are fi-
Non-HDL-C  total cholesterol minus HDL-C.
¶¶Patients with very high triglycerides should not consume alcohol. The use of
le acid sequestrants is relatively contraindicated when triglycerides are greater than
Class/Level of Evidence
I/B
I/B
I/B
I/A IIa/A
I/C for ischemic symptoms
I for ischemic symptoms; when beta blockers are not successful (B)
or contraindicated, or cause unacceptable side effects (C)
III/A
Class/Level of Evidence
Ia
IIa/B
IIa/B
IIa/B
IIb/B
I/A
III/A
I/B
III/B
IIa/C, IIb/C or III/C
III/A
COX-2  cyclooxygenase 2; EF  ejection fraction; HDL  high-density
normalized ratio; LDL  low-density lipoprotein; NSAID  nonsteroidal
 unstable angina.r
g per dL
er dL
er dL
m Hg or
idney
wering
failure;
ational0 mg per dL.
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mended. It is also recommended that LDL-C be treated to
goal after triglyceride-lowering therapy. Achievement of a
non-HDL-C  less than 130 mg per dL (i.e., 30 mg per dL
greater than LDL-C target) if possible is recommended.
(Level of Evidence: C)
ASS IIa
The following lipid management strategies can be beneficial:
a. Further reduction of LDL-C to less than 70 mg per dL is
reasonable. (Level of Evidence: A)
b. If baseline LDL cholesterol is 70 to 100 mg per dL, it is
reasonable to treat LDL-C to less than 70 mg per dL. (Level
of Evidence: B)
c. Further reduction of non-HDL-C  to less than 100 mg per
dL is reasonable; if triglycerides are 200 to 499 mg per dL,
non-HDL-C target is less than 130 mg per dL. (Level of
Evidence: B)
d. Therapeutic options to reduce non-HDL-C  (after LDL-C
lowering) include niacin## or fibrate¶¶ therapy.
e. Nicotinic acid (niacin)## and fibric acid derivatives (feno-
fibrate, gemfibrozil)¶¶ can be useful as therapeutic options
(after LDL-C–lowering therapy) for HDL-C less than 40 mg
per dL. (Level of Evidence: B)
f. Nicotinic acid (niacin)## and fibric acid derivatives (fenofi-
brate, gemfibrozil)¶¶ can be useful as therapeutic options
(after LDL-C–lowering therapy) for triglycerides greater than
200 mg per dL. (Level of Evidence: B)
g. The addition of plant stanol/sterols (2 g per d) and viscous
fiber (more than 10 g per d) is reasonable to further lower
LDL-C. (Level of Evidence: A)
ASS IIb
Encouraging consumption of omega-3 fatty acids in the form of
fish*** or in capsule form (1 g per d) for risk reduction may be
reasonable. For treatment of elevated triglycerides, higher doses (2
to 4 g per d) may be used for risk reduction. (Level of Evidence: B)
There is a wealth of evidence that cholesterol-lowering
erapy for patients with CAD and hypercholesterolemia
47) or with mild cholesterol elevation (mean 209 to 218 mg
r dL) after MI and UA reduces vascular events and death
48,749). Moreover, recent trials have provided mounting
idence that statin therapy is beneficial regardless of
hether the baseline LDL-C level is elevated (750–752).
ore aggressive therapy has resulted in suppression or
versal of coronary atherosclerosis progression and lower
rdiovascular event rates, although the impact on total
ortality remains to be clearly established (753). These data
e discussed more fully elsewhere (10,24,46).
For patients with CHD or CHD equivalents (i.e., athero-
lerosis in other vascular territories, diabetes mellitus, or
-year estimated cardiovascular risk greater than 20%), the
CEP Adult Treatment Panel III recommended a target
DL-C level less than 100 mg per dL (24). Therapeutic
##The combination of high-dose statin plus fibrate can increase risk for severe
yopathy. Statin doses should be kept relatively low with this combination. Dietary
pplement niacin must not be used as a substitute for prescription niacin.
***Pregnant and lactating women should limit their intake of fish to minimizenoposure to methylmercury.festyle changes are recommended as well. Therapeutic
festyle changes include diet, weight management, and in-
eased physical activity. Specific diet recommendations
clude restriction of calories from saturated fat to less than
of total caloric intake and of cholesterol to less than 200
g per d. Additionally, increased soluble fiber (10 to 25 g per
and plant stanols/sterols (2 g per d) are noted as therapeutic
festyle change dietary options to enhance LDL-C lowering.
eduction in trans fat (to less than 1% of caloric intake)
bsequently has been added to prevention guidelines
0,45). These guidelines also recommend consideration of
ug therapy if LDL-C is above goal range, either simulta-
ously with therapeutic lifestyle changes or sequentially,
ter 3 months of therapeutic lifestyle changes.
An update to the Adult Treatment Panel III guidelines was
blished in mid 2004 (23). The major change recommended
this update is an LDL-C treatment goal of less than 70 mg
r dL as a reasonable option in very-high-risk patients (such
after UA/NSTEMI). Furthermore, if a high-risk patient has
gh triglycerides (greater than 200 mg per dL) or low
DL-C (less than 40 mg per dL), consideration can be given
combining a fibrate or nicotinic acid with an LDL-lowering
ug. For moderately high-risk patients (2 or more risk factors
d 10-year risk of 10% to 20%), the recommended LDL-C
al is less than 130 mg per dL, but an LDL-C goal of less
an 100 mg per dL is a reasonable option. When drug therapy
utilized in moderate- to high-risk patients, it is advised that the
tensity of the treatment be sufficient to achieve a reduction in
DL-C levels of at least 30% to 40%. Therapeutic lifestyle
anges to modify existing lifestyle-based risk factors are
rongly urged regardless of LDL-C levels.
Two trials further support early intensive lipid lowering
ter ACS. In the PROVE-IT TIMI 22 study (PRavastatin Or
orVastatin Evaluation and Infection Therapy–Thrombolysis
Myocardial Infarction 22), 4,162 patients within 10 d of
CS were randomized to 40 mg of pravastatin or 80 mg of
orvastatin daily (752). The median LDL-C achieved in the
oderately intensive (standard-dose) pravastatin group was
mg per dL compared with a median of 62 mg per dL in the
gressive, high-dose atorvastatin group. A 16% reduction in
e HR for the primary composite end point of all-cause
ath, MI, UA requiring rehospitalization, revascularization
erformed at least 30 d after randomization), and stroke was
served in favor of the high-dose regimen. The second trial,
ase Z of the A to Z Trial (751), compared early initiation of
intensive statin regimen (simvastatin 40 mg per d for 1
onth followed by 80 mg per d thereafter) with a delayed
itiation of a less-intensive regimen (placebo for 4 months
llowed by simvastatin 20 mg per d) in patients with ACS.
o difference was observed between the groups during the
rst 4 months of follow-up for the primary end point
omposite of cardiovascular death, nonfatal MI, readmission
r ACS, and stroke). However, from 4 months through the
d of the study, the primary end point was significantly
duced in the aggressive treatment arm, which represented a
vorable trend toward a reduction of major cardiovascular
ents with the early, aggressive statin regimen. The incidence
myopathy (CK greater than 10 times the upper limit ofrmal, with muscle symptoms) occurred more frequently in the
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reful monitoring and follow-up with aggressive treatment.
Observational studies have generally supported initiation of
id-lowering therapy before discharge after ACS both for safety
d for early efficacy (event reduction) (754). In contrast, a meta-
alysis of randomized trials of early (less than 14 d) initiation of
id lowering after ACS, although supporting its safety, suggests
at efficacy is generally delayed beyond 4 months (755).
Short- and long-term compliance is a clear benefit of
hospital initiation of lipid lowering (756). In a demonstra-
on project, the Cardiovascular Hospitalization Atheroscle-
sis Management Program, the in-hospital initiation of
pid-lowering therapy increased the percentage of patients
eated with statins 1 year later from 10% to 91%, and for those
ith an LDL-C less than 100 mg per dL, the percentage
creased from 6% to 58% (757), which suggests that predis-
arge initiation of lipid-lowering therapy enhances long-term
mpliance. Thus, there appear to be no adverse effects and
bstantial advantages to the initiation of lipid-lowering therapy
fore hospital discharge (756,758). Such early initiation of
erapy also has been recommended in the update of the third
port of the NCEP (23). Adherence to statin therapy was shown
be associated with improved survival in a large, population-based
ngitudinal observational study (759).
.2.8. Blood Pressure Control
ASS I
Blood pressure control according to JNC 7 guidelines††† is
recommended (i.e., blood pressure less than 140/90 mm Hg or
less than 130/80 mm Hg if the patient has diabetes mellitus or
chronic kidney disease). (Level of Evidence: A) Additional
measures recommended to treat and control blood pressure
include the following:
a. Patients should initiate and/or maintain lifestyle modifica-
tions, including weight control, increased physical activity,
alcohol moderation, sodium reduction, and emphasis on
increased consumption of fresh fruits, vegetables, and
low-fat dairy products. (Level of Evidence: B)
b. For patients with blood pressure greater than or equal to
140/90 mm Hg (or greater than or equal to 130/80 mm Hg
for individuals with chronic kidney disease or diabetes
mellitus), it is useful to add blood pressure medication as
tolerated, treating initially with beta blockers and/or ACE
inhibitors, with addition of other drugs such as thiazides as
needed to achieve target blood pressure. (Level of Evi-
dence: A)
All patients with elevated systolic or diastolic blood
essures should be educated and motivated to achieve
rgeted hypertensive control according to JNC 7 guide-
nes (760) adapted to patients with ischemic heart disease
61). Systolic and diastolic blood pressures should be in
e normal range (i.e., less than 140/90 mm Hg; 130/80
m Hg if the patient has diabetes mellitus or chronic
dney disease).
†Chobanian AV, Bakris GL, Black HR, et al., for the National High Blood
essure Education Program Coordinating Committee. The seventh report of the
int National Committee on Prevention, Detection, Evaluation, and Treatment ofwigh Blood Pressure: the JNC 7 report. JAMA 2003;289:2560–72 (760)..2.9. Diabetes Mellitus
ASS I
Diabetes management should include lifestyle and pharmaco-
therapy measures to achieve a near-normal HbA1c level of less
than 7%. (Level of Evidence: B) Diabetes management should
also include the following:
a. Vigorous modification of other risk factors (e.g., physical
activity, weight management, blood pressure control, and
cholesterol management) as recommended should be initi-
ated and maintained. (Level of Evidence: B)
b. It is useful to coordinate the patient’s diabetic care with
the patient’s primary care physician or endocrinologist.
(Level of Evidence: C)
Glycemic control during and after ACS is discussed in
ection 6.2.1.
Overweight patients should be instructed in a weight
ss regimen, with emphasis on the importance of regular
ercise and a lifelong prudent diet to maintain ideal body
ass index. Patients should be informed and encouraged
at even small reductions in weight can have positive
nefits. This can be reassuring to severely obese patients.
the Diabetes Prevention Program study, 3,234 over-
eight subjects with elevated fasting and postload plasma
ucose concentrations were randomized to treatment with
etformin or a lifestyle modification program (762). The
als of the lifestyle modification program were targeted
at least a 7% weight loss and at least 150 min of physical
tivity per week. The incidence of diabetes mellitus was
duced by 58% in the lifestyle modification group and
% in the metformin group compared with placebo. The
udy supports the substantial positive effects of even
odest changes in weight and physical activity on the
velopment of diabetes, a major risk factor for cardiovas-
lar events (762–764).
.2.10. Smoking Cessation
ASS I
Smoking cessation and avoidance of exposure to environmen-
tal tobacco smoke at work and home are recommended.
Follow-up, referral to special programs, or pharmacotherapy
(including nicotine replacement) is useful, as is adopting a
stepwise strategy aimed at smoking cessation (the 5 A’s
are: Ask, Advise, Assess, Assist, and Arrange). (Level of
Evidence: B)
For patients who smoke, persistent smoking cessation
unseling is often successful and has substantial potential to
prove survival. Daly et al. (765) quantified the long-term
fects of smoking on patients with ACS. Men less than 60
ars old who continued to smoke had a risk of death due to
l causes that was 5.4 times that of men who stopped
oking (p0.05). Referral to a smoking cessation program
d the use of pharmacological agents including nicotine
tches or gum are recommended (766).
Bupropion, an anxiolytic agent and weak inhibitor of
uronal uptake of neurotransmitters, has been effective when
ded to brief regular counseling sessions in helping patients
quit smoking. The treatment of 615 study subjects for 7eeks resulted in smoking cessation rates of 28.8% for the
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ith 19.6% for placebo-assigned patients (p0.001) (766).
he abstinence rate at 1 year was 23.0% for those treated with
propion 300 mg per d versus 12.4% for those receiving
acebo (766).
Recently, another nonnicotine replacement therapy, va-
nicline, was approved to assist in smoking cessation.
arenicline is a first-in-class nicotine acetylcholine receptor
rtial agonist, designed to provide some nicotine effects
asing withdrawal symptoms) and to block the effects of
cotine from cigarettes, discouraging smoking. Approval
as based on demonstrated effectiveness in 6 clinical trials
volving a total of 3,659 chronic cigarette smokers
9 – 41). In 2 of the 5 placebo-controlled trials, vareni-
ine also was compared to buproprion and found to be
ore effective. Varenicline is given for an initial 12-week
urse. Successfully treated patients may continue treatment for
additional 12 weeks to improve the chances of long-term
stinence. Family members who live in the same household should
so be encouraged to quit smoking to help reinforce the patient’s
fort and to decrease the risk of secondhand smoke for everyone.
.2.11. Weight Management
ASS I
Weight management, as measured by body mass index and/or
waist circumference, should be assessed on each visit. A body
mass index of 18.5 to 24.9 kg per m2 and a waist circumfer-
ence (measured horizontally at the iliac crest) of less than 40
inches for men and less than 35 inches for women is recom-
mended. (Level of Evidence: B) Additional weight management
practices recommended include the following:
a. On each patient visit, it is useful to consistently encourage
weight maintenance/reduction through an appropriate bal-
ance of physical activity, caloric intake, and formal behav-
ioral programs when indicated to maintain/achieve a body
mass index between 18.5 and 24.9 kg per m2. (Level of
Evidence: B)
b. If waist circumference is 35 inches or more in women or 40
inches or more in men, it is beneficial to initiate lifestyle
changes and consider treatment strategies for metabolic
syndrome as indicated. (Level of Evidence: B)
c. The initial goal of weight loss therapy should be to reduce
body weight by approximately 10% from baseline. With
success, further weight loss can be attempted if indicated
through further assessment. (Level of Evidence: B)
.2.12. Physical Activity
ASS I
The patient’s risk after UA/NSTEMI should be assessed on the
basis of an in-hospital determination of risk. A physical activity
history or an exercise test to guide initial prescription is
beneficial. (Level of Evidence: B)
Guided/modified by an individualized exercise prescription,
patients recovering from UA/NSTEMI generally should be en-
couraged to achieve physical activity duration of 30 to 60 min
per d, preferably 7 (but at least 5) d per week of moderate
aerobic activity, such as brisk walking, supplemented by an
increase in daily lifestyle activities (e.g., walking breaks at
work, gardening, and household work). (Level of Evidence: B) isCardiac rehabilitation/secondary prevention programs are rec-
ommended for patients with UA/NSTEMI, particularly those
with multiple modifiable risk factors and/or those moderate-
to high-risk patients in whom supervised exercise training is
particularly warranted. (Level of Evidence: B)
ASS IIb
The expansion of physical activity to include resistance train-
ing on 2 d per week may be reasonable. (Level of Evidence: C)
Federal and ACC/AHA guidelines recommend that all
mericans strive for at least 30 to 60 min of moderate
ysical activity most days of the week, preferably daily
67). The 30 to 60 min can be spread out over 2 or 3
gments during the day. For post-UA/NSTEMI patients,
ily walking can be encouraged immediately after discharge.
xcellent resource publications on exercise prescription in
rdiovascular patients are available (52,768). Physical
tivity is important in efforts to lose weight because it
creases energy expenditure and plays an integral role in
eight maintenance. Regular physical activity reduces
mptoms in patients with CVD, improves functional
pacity, and improves other cardiovascular risk factors
ch as insulin resistance and glucose intolerance (52).
eyond the instructions for daily exercise, patients require
ecific instruction on those strenuous activities (e.g.,
avy lifting, climbing stairs, yard work, and household
tivities) that are permissible and those they should avoid.
everal activity questionnaires or nomograms, specific to
e cardiac population and general population, have been
veloped to help guide the patient’s exercise prescription
an exercise test is not available (769 –772). As empha-
zed by the US Public Health Service, comprehensive
rdiac rehabilitation services include long-term programs
volving medical evaluation, prescribed exercise, cardiac
sk factor modification, education, and counseling (773).
hese programs are designed to limit the physiological and
ychological effects of cardiac illness, reduce the risk for
dden death or reinfarction, control cardiac symptoms,
d enhance the psychosocial and vocational status of
lected patients. Enrollment in a cardiac rehabilitation
ogram after discharge can enhance patient education and
mpliance with the medical regimen and assist with the
plementat ion of a regular exercise program
2,54,661,774,775). In addition to aerobic training, mild-
moderate-resistance training may be considered. This
n be started 2 to 4 weeks after aerobic training has begun
76). Expanded physical activity is an important treat-
ent component for the metabolic syndrome, which is
coming increasingly prevalent.
Exercise training can generally begin within 1 to 2
eeks after UA/NSTEMI treated with PCI or CABG to
lieve ischemia (768). Unsupervised exercise may target a
art rate range of 60% to 75% of maximum predicted;
pervised training (see Section 5.4) may target a some-
hat higher heart rate (70% to 85% of maximum pre-
cted) (768). Additional restrictions apply when residual
chemia is present.
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ASS I
Beyond the detailed instructions for daily exercise, patients
should be given specific instruction on activities (e.g., heavy
lifting, climbing stairs, yard work, and household activities)
that are permissible and those that should be avoided.
Specific mention should be made regarding resumption of
driving, return to work, and sexual activity. (Level of Evi-
dence: C) Specific recommendations for physical activity
follow in Section 5.4.
Patients should be educated and motivated to achieve
propriate target LDL-C and HDL-C goals. Patients who
ve undergone PCI or CABG derive benefit from cholesterol
wering (777) and deserve special counseling lest they
istakenly believe that revascularization obviates the need
r significant lifestyle changes. The NHLBI “Your Guide to
etter Health” series provides useful educational tools for
tients (http://hp2010.nhlbihin.net/yourguide/).
.2.14. Influenza
ASS I
An annual influenza vaccination is recommended for patients
with cardiovascular disease. (Level of Evidence: B)
.2.15. Depression
ASS IIa
It is reasonable to consider screening UA/NSTEMI patients
for depression and refer/treat when indicated. (Level of
Evidence: B)
.2.16. Nonsteroidal Anti-inflammatory Drugs
ASS I
At the time of preparation for hospital discharge, the patient’s
need for treatment of chronic musculoskeletal discomfort
should be assessed, and a stepped-care approach to treatment
should be used for selection of treatments (Figure 20). Pain
relief should begin with acetaminophen, small doses of narcot-
ics, or nonacetylated salicylates. (Level of Evidence: C)
ASS IIa
It is reasonable to use nonselective NSAIDs, such as
naproxen, if initial therapy with acetaminophen, small doses
of narcotics, or nonacetylated salicylates is insufficient.
(Level of Evidence: C)
ASS IIb
Nonsteroidal anti-inflammatory drugs with increasing degrees
of relative COX-2 selectivity may be considered for pain relief
only for situations in which intolerable discomfort persists
despite attempts at stepped-care therapy with acetamino-
phen, small doses of narcotics, nonacetylated salicylates, or
nonselective NSAIDs. In all cases, the lowest effective
doses should be used for the shortest possible time. (Level
of Evidence: C)
ASS III
Nonsteroidal anti-inflammatory drugs with increasing degrees
of relative COX-2 selectivity should not be administered to
UA/NSTEMI patients with chronic musculoskeletal discomfort bewhen therapy with acetaminophen, small doses of narcotics,
nonacetylated salicylates, or nonselective NSAIDs provides
acceptable levels of pain relief. (Level of Evidence: C)
The selective COX-2 inhibitors and other nonselective
SAIDs have been associated with increased cardiovascular
sk. The risk appears to be amplified in patients with
tablished CVD (8,366–369). In a large Danish observa-
onal study of first-time MI patients (n  58,432), the HRs
d 95% CIs for death were 2.80 (2.41 to 3.25) for
fecoxib, 2.57 (2.15 to 3.08) for celecoxib, 1.50 (1.36 to
67) for ibuprofen, 2.40 (2.09 to 2.80) for diclofenac, and
29 (1.16 to 1.43) for other NSAIDS (368). There were
se-related increases in risk of death and non– dose-
pendent trends for rehospitalization for MI for all drugs
67,368). An AHA scientific statement on the use of
SAIDS concluded that the risk of cardiovascular events
proportional to COX-2 selectivity and the underlying
sk in the patient (778). Nonpharmacological approaches
ere recommended as the first line of treatment, followed
the stepped-care approach to pharmacological therapy,
shown in (Figure 20).
.2.17. Hormone Therapy
ASS III
Hormone therapy with estrogen plus progestin, or estrogen
alone, should not be given de novo to postmenopausal women
after UA/NSTEMI for secondary prevention of coronary events.
(Level of Evidence: A)
Postmenopausal women who are already taking estrogen plus
progestin, or estrogen alone, at the time of UA/NSTEMI in
general should not continue hormone therapy. However,
women who are more than 1 to 2 years past the initiation of
hormone therapy who wish to continue such therapy for another
compelling indication should weigh the risks and benefits, recog-
nizing the greater risk of cardiovascular events and breast cancer
(combination therapy) or stroke (estrogen). Hormone therapy
should not be continued while patients are on bedrest in the
hospital. (Level of Evidence: B)
Although prior observational data suggested a protective
fect of hormone therapy for coronary events, a randomized
ial of hormone therapy for secondary prevention of death and
I (Heart and Estrogen/progestin Replacement Study [HERS])
iled to demonstrate a beneficial effect (779). Disturbingly,
ere was an excess risk for death and MI early after hormone
erapy initiation. The Women’s Health Initiative included
ndomized primary prevention trials of estrogen plus progestin
d estrogen alone. Both trials were stopped early owing to an
served increased risk related to hormone therapy that was
lieved to outweigh the potential benefits of further study
80–782). It is recommended that post-menopausal women
ceiving hormone therapy at the time of a cardiovascular
ent discontinue its use. Likewise, hormone therapy
ould not be initiated for secondary prevention of coro-
ry events. However, there may be other permissible
dications for hormone therapy in postmenopausal women
.g., prevention of perimenopausal symptoms such as
ushing, or prevention of osteoporosis) if the benefits are
lieved to outweigh the increased cardiovascular risk).
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ASS III
Antioxidant vitamin supplements (e.g., vitamins E, C, or beta
carotene) should not be used for secondary prevention in
UA/NSTEMI patients. (Level of Evidence: A)
Folic acid, with or without B6 and B12, should not be used for
secondary prevention in UA/NSTEMI patients. (Level of Evidence: A)
Although there is an association of elevated homocysteine
ood levels and CAD, a reduction in homocysteine levels
ith routine folate supplementation was not demonstrated to
duce the risk of CAD events in 2 trials (Norwegian Vitamin Trial
ORVIT] and HOPE) that included post-MI or high risk, stable
tients (783–786). Similarly, a large clinical trials experience with
tioxidant vitamins has failed to demonstrate benefit for primary or
condary prevention (45,787).
.3. Postdischarge Follow-Up
ecommendations
ASS I
Detailed discharge instructions for post-UA/NSTEMI patients
should include education on medications, diet, exercise, and
smoking cessation counseling (if appropriate), referral to a
cardiac rehabilitation/secondary prevention program (when
appropriate), and the scheduling of a timely follow-up appoint-
ment. Low-risk medically treated patients and revascularized
patients should return in 2 to 6 weeks, and higher risk patients
should return within 14 d. (Level of Evidence: C)
Patients with UA/NSTEMI managed initially with a conserva-
tive strategy who experience recurrent signs or symptoms of
UA or severe (Canadian Cardiovascular Society class III)
chronic stable angina despite medical management who are
suitable for revascularization should undergo timely coronary
angiography. (Level of Evidence: B)
gure 20. Stepped-Care Approach to Pharmacological Therapy f
isk Factors for Ischemic Heart Disease. Addition of ASA may no
rmission. American Heart Association Scientific Statement on th
r Clinicians © 2007, American Heart Association, Inc. (674). ASA
flammatory drugs; PPI  proton-pump inhibitor.Patients with UA/NSTEMI who have tolerable stable angina or
no anginal symptoms at follow-up visits should be managed
with long-term medical therapy for stable CAD. (Level of
Evidence: B)
Care should be taken to establish effective communication be-
tween the post-UA/NSTEMI patient and health care team mem-
bers to enhance long-term compliance with prescribed therapies
and recommended lifestyle changes. (Level of Evidence: B)
The risk of death within 1 year can be predicted on the
sis of clinical information and the ECG (see also Section
3). In a study of 515 survivors of hospitalization for
STEMI, risk factors included persistent ST-segment depres-
on, HF, advanced age, and ST-segment elevation at dis-
arge (788). Patients with all high-risk markers present had
14-fold greater mortality rate than did patients with all
arkers absent. Elevated cardiac TnT levels have also been
monstrated to provide independent prognostic information
r cardiac events at 1 to 2 years. For patients with ACS in a
USTO-IIa substudy, age, ST-segment elevation on admis-
on, prior CABG, TnT, renal insufficiency, and severe
ronic obstructive pulmonary disease were independently
sociated with risk of death at 1 year (789,790). For
A/NSTEMI patients, prior MI, TnT positivity, accelerated
gina before admission, and recurrent pain or ECG changes
ere independently associated with risk of death at 2 years.
atients managed with an initial conservative strategy (see
ection 3) should be reassessed at the time of return visits for
e need for cardiac catheterization and revascularization.
pecifically, the presence and severity of angina should be
certained. Rates of revascularization during the first year
ve been reported to be high (791). Long-term (7 years)
llow-up of 282 patients with UA demonstrated high event
tes during the first year (MI 11%, death 6%, PTCA 30%,
d CABG 27%); however, after the first year, event rates
culoskeletal Symptoms With Known Cardiovascular Disease or
fficient protection against thrombotic events. Reproduced with
of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)-An Update
irin; COX-2  cyclooxygenase-1; NSAIDs  nonsteroidal anti-or Mus
t be su
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e greater than 70 years, diabetes, and male sex. A predic-
ve model for the risk of death from discharge to 6 months
ter an ACS has been developed and validated using the
,142-patient GRACE registry database (122). Mortality aver-
ed 4.8%. Nine predictive variables were identified: older age,
story of MI, history of HF, increased pulse rate at presentation,
wer systolic blood pressure at presentation, elevated initial
rum creatinine level, elevated initial serum cardiac biomarker
vels, ST-segment depression on presenting ECG, and not
ving a PCI performed in the hospital. The C statistic for the
lidation cohort was 0.75. The GRACE tool was suggested to be
simple, robust tool for clinical use.
Certain patients at high risk of ventricular tachyarrhythmia
ter UA/NSTEMI may be candidates for an implantable
rdioverter defibrillator. Indications and timing of an im-
antable cardioverter defibrillator in this setting are pre-
nted in the STEMI guidelines (8) and more recently the
entricular Arrhythmias and Sudden Cardiac Death guide-
nes (792). Indications for testing for atherosclerotic disease
other vascular beds (i.e., carotid, peripheral arterial) are
so covered elsewhere in recent guidelines (793).
Major depression has also been reported to be an indepen-
nt risk factor for cardiac events after MI and occurs in up
25% of such patients (794). Antidepressant therapy (with
rtra-line) was safe and effective for relief of depressive
mptoms in a controlled trial in 369 depressed patients with
CS, but it did not conclusively demonstrate a beneficial
fect on cardiovascular end points, perhaps because of
mited sample size (795). Cognitive therapy and, in some
ses, sertraline did not affect late survival after MI in another
ndomized study (Enhancing Recovery in Coronary Heart
isease [ENRICHD]), but those whose depression did not
prove were at higher risk of late mortality (796). The
REATE trial evaluated interpersonal psychotherapy (IPT)
mpared with clinical management and the selective sero-
nin reuptake inhibitor citalopram compared with placebo in
2  2 factorial design among patients with CAD and
ajor depression (797). The primary end point of Hamil-
n Depression Rating Scale score was improved in the
talopram group versus placebo (mean reduction 14.9 vs
.6, p0.005) but did not differ for IPT versus clinical
anagement (mean reduction 12.1 vs 14.4, p0.06).
ikewise, the secondary end point of reduction in mean
eck Depression Inventory score was improved in the
talopram group but did not differ for IPT.
Patients recognized to be at high risk for a cardiac event after
scharge for any of the above reasons should be seen for follow-up
rlier and more frequently than lower-risk patients.
The overall long-term risk for death or MI 2 months after
episode of UA/NSTEMI is similar to that of other CAD
tients with similar characteristics. Van Domburg et al.
91) reported a good long-term outcome even after a
mplicated early course. Based on a median follow-up of
most 8 years, mortality in the first year was 6%, then 2% to
annually in the following years (791). When the patient
s returned to the baseline level, typically 6 to 8 weeks after
spitalization, arrangements should be made for long-term
gular follow-up visits, as for stable CAD. Cardiac catheter- faation with coronary angiography is recommended for any of
e following situations: 1) significant increase in anginal
mptoms, including recurrent UA; 2) high-risk pattern
.g., at least 2 mm of ST-segment depression, systolic
ood pressure decline of at least 10 mm Hg) on exercise
st (see Section 3.4); 3) HF; 4) angina with mild exertion
nability to complete stage 2 of the Bruce protocol for
gina); and 5) survivors of sudden cardiac death. Revas-
larization is recommended based on the coronary anat-
y and ventricular function (see Section 4, ACC/AHA
uidelines for the Management of Patients With Chronic
table Angina (11), and ACC/AHA 2004 Guideline Up-
te for Coronary Artery Bypass Graft Surgery (644).
Minimizing the risk of recurrent cardiovascular events
quires optimizing patients’ compliance with prescribed
erapies and recommended lifestyle modifications. Many
udies exploring predictors of compliance have failed to find
edictive value in simple demographic or socioeconomic
riables. More reliable predictors are the patients’ beliefs
d perceptions about their vulnerability to disease and the
ficacy of the prescribed treatments and, importantly, various
pects of the relationship with their health care provider
98–800). Development of a therapeutic relationship with
e patient and family is likely to enhance compliance. Care
ould be taken to ensure that there is adequate time spent
ith the family focused on explanation of the disease and
oposed treatments, the importance of adhering to the
escribed treatment plan, and exploration of patient-specific
rriers to compliance. Participation in cardiac rehabilitation/
condary prevention programs can help reinforce patient-
ecific secondary prevention issues and can address barriers
compliance. Close communication between the treating
ysician and the cardiac rehabilitation team is important to
aximize effectiveness (10,54,801,802).
.4. Cardiac Rehabilitation
ASS I
Cardiac rehabilitation/secondary prevention programs, when
available, are recommended for patients with UA/NSTEMI,
particularly those with multiple modifiable risk factors and
those moderate- to high-risk patients in whom supervised or
monitored exercise training is warranted. (Level of Evidence: B)
Cardiac rehabilitation programs are designed to limit the
ysiological and psychological effects of cardiac illness,
duce the risk for sudden death or reinfarction, control
rdiac symptoms, stabilize or reverse the atherosclerotic pro-
ss, and enhance the psychosocial and vocational status of
lected patients (773,801,803). Cardiac rehabilitation is a com-
ehensive long-term program that involves medical evaluation,
escribed exercise, cardiac risk factor modification, education,
d counseling (773,804). Cardiac rehabilitation may occur in a
riety of settings, including medically supervised groups in a
spital, physician’s office, or community facility (802). Exer-
se may involve a stationary bicycle, treadmill, calisthenics,
alking, or jogging, and monitoring may include ECG teleme-
y, depending on a patient’s risk status and the intensity of
ercise training. Education and counseling concerning risk
ctor modification are individualized, and close communication
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ay promote long-term behavioral change (801,802). Alterna-
e delivery approaches, including home exercise, internet-
sed, and transtelephonic monitoring/supervision, can be im-
emented effectively and safely for carefully selected clinically
able patients (773,805).
Witt et al. (806) examined the association of participation
cardiac rehabilitation with survival in Olmstead County,
innesota, and found that participants had a lower risk of
ath and recurrent MI at 3 years (p0.001 and p0.049,
spectively). The survival benefit associated with participa-
on was stronger in more recent years (806). In this study,
lf of the eligible patients participated in cardiac rehabilita-
on after MI, although women and older adult patients were
ss likely to participate, independent of other characteristics.
A pooled-effect estimate for total mortality for the exercise-
ly intervention demonstrated a reduction in all-cause mortality
andom effects model OR 0.73 [95% CI 0.54 to 0.98]) com-
red with usual care. Comprehensive cardiac rehabilitation
duced all-cause mortality, although to a lesser degree (OR 0.87
5% CI 0.71 to 1.05]). Neither of the interventions had an effect
the occurrence of nonfatal MI. The authors concluded that
ercise-based cardiac rehabilitation appeared to be effective in
ducing cardiac deaths but that it was still unclear whether an
ercise-only or a comprehensive cardiac rehabilitation inter-
ntion was more beneficial. The population studied was pre-
minantly male, middle-aged, and low risk. The authors sug-
sted that those who could have benefited from the intervention
ight have been excluded owing to age, gender, or comorbidity.
he authors cautioned that the results were of limited reliability
cause the quality of reporting in the studies was generally poor,
d there were high losses to follow-up (804).
Cardiac rehabilitation comprising exercise training and edu-
tion, counseling, and behavioral interventions yielded im-
ovements in exercise tolerance with no significant cardiovas-
lar complications, improvements in symptoms (decreased
ginal pain and improved symptoms of HF such as shortness of
eath and fatigue), and improvements in blood lipid levels;
duced cigarette smoking in conjunction with a smoking ces-
tion program; decreased stress; and improved psychosocial
ell-being (773). In addition to reductions in total cholesterol
d LDL-C, increases in HDL-C levels occur (807).
Cardiac rehabilitation has been reported to improve prognosis
ter MI in a cost-effective manner (808,809). In current practice,
ferrals for cardiac rehabilitation are more frequent after bypass
rgery and less frequent after PCI for UA/NSTEMI (810).
enefits of rehabilitation after uncomplicated UA/NSTEMI with
vascularization and modern medical therapy are less clear in
mparison with STEMI or complicated NSTEMI.
Existing community studies reveal that fewer than one
ird of patients with MI receive information or counseling
out cardiac rehabilitation before being discharged from the
spital (773,811). Only 16% of patients in a study of 5
spitals in 2 Michigan communities were referred to a
rdiac rehabilitation program at discharge, and only 26% of
e patients later interviewed in the community reported
tual participation in such a program; however, 54% of the
tients referred at discharge did participate at the time of
eir follow-up interview (811). Physician referral was the riost powerful predictor of patient participation in a cardiac
habilitation program. In a longitudinal study of the use of
patient cardiac rehabilitation in 5,204 Worcester, Mass,
sidents hospitalized with MI in seven 1-year periods be-
een 1986 and 1997, patients not referred to inpatient
rdiac rehabilitation were less likely to be prescribed effec-
ve cardiac medications and to undergo risk factor modifi-
tion counseling before discharge (812).
Patient reasons for nonparticipation and noncompliance
clude affordability of service, insurance coverage/noncov-
age, social support from a spouse or other caregiver,
nder-specific attitudes, patient-specific internal factors such
anxiety or poor motivation, and logistical and financial
nstraints, or a combination of these factors (794,811).
omen and the elderly are referred less frequently to cardiac
habilitation programs, even though they derive benefit from
em (45,813–816). Health care systems should consider
stituting processes that encourage referral of appropriate pa-
nts to cardiac rehabilitation/secondary prevention programs
or example, the use of standardized order sets that facilitate
is, such as the AHA “Get with the Guidelines” tools). In
dition, it is important that referring health care practitioners
d cardiac rehabilitation teams communicate in ways that
omote patient participation. Of note, Medicare coverage for
habilitation recently was expanded beyond post-MI, post-
ABG, and stable angina to include PCI (817).
.5. Return to Work and Disability
eturn-to-work rates after MI, which currently range from 63%
18) to 94% (819), are difficult to influence because they are
nfounded by factors such as job satisfaction, financial stability,
d company policies (820). In PAMI (Primary Angioplasty in
yocardial Infarction)-II, a study of primary PTCA in low-risk
tients with MI (i.e., age less than 70 years, ejection fraction
eater than 0.45, 1- or 2-vessel disease, and good PTCA result),
tients were encouraged to return to work at 2 weeks (821). The
tual timing of return to work was not reported, but no adverse
ents occurred as a result of this strategy.
Cardiac rehabilitation programs after MI can contribute to
ductions of mortality and improved physical and emotional
ell-being (see Section 5.4). Patients whose expectations for
turn to work were addressed in rehabilitation returned to
ork at a significantly faster rate than the control group in a
ospective study (822).
Lower or absent levels of depressive symptoms before MI
creases the odds of recovery of functional status (823). Patients
ith high pre-event functional independence measurement have
shorter length of stay and a greater likelihood of discharge to
me (824). Pre-event peak aerobic capacity and depression
ore are the best independent predictors of postevent physical
nction. Women tend to have lower physical function scores
an men of similar age, depression score, and comorbidity.
esting LVEF is not a predictor of physical function score.
Patients’ cardiac functional states are not a strong
edictor of their probability of returning to work. Diabe-
s, older age, Q-wave MI, and preinfarction angina are
sociated with failure to resume full employment (825).
owever, psychological variables such as trust, job secu-
ty, patient feelings about disability, expectations of
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matizing are more predictive (826,827). Physical re-
irements of the job play a role as well (825,827).
To aid occupational physicians in making return-to-
ork decisions, Froom et al. (825) studied the incidence of
st-MI events at 1, 2, 4, 6, 9, and 12 months. Events
cluded cardiac death, recurrent infarction, CHF, and UA.
hey found that the incidence of events reached a low
eady state at 10 weeks.
Return to work can be determined by employer regulations
ther than by the patient’s medical condition. It behooves the
ysician to provide data to prove that the patient’s job does
t impose a prohibitive risk for a cardiac event. An example
the case of Canadian bus drivers reported by Kavanagh et
. (828). These patients were evaluated with a stress test. The
ysician and technologist studied the drivers at work and
owed that the cardiac stress values during driving were
ly half of the average values obtained in the stress
boratory. The calculated risk of sudden cardiovascular
cidents causing injury or death to passengers, other road
ers, and the drivers themselves in the first year after
ble 23. Energy Levels Required to Perform Some Common Act
Less Than 3 METS 3–5 METS 5–7 M
Se
ashing
aving
essing
sk work
ashing dishes
iving auto
ght housekeeping
Cleaning windows
Raking
Power lawn mowing
Bed making/stripping
Carrying objects (15 to 30 lb)
Easy digging in
Level hand lawn
Climbing stairs (
Carrying objects
Occu
tting (clerical/assembly)
ping
sk work
anding (store clerk)
Stocking shelves (light
objects)
Auto repair
Light welding/carpentry
Carpentry (exteri
Shoveling dirt
Sawing wood
Operating pneum
Recr
lf (cart)
itting
nd sewing
Dancing (social)
Golf (walking)
Sailing
Tennis (doubles)
Volleyball (6 persons)
Table tennis
Marital sex
Badminton (com
Tennis (singles)
Snow skiing (dow
Light backpackin
Basketball
Football
Stream Fishing
Physical
alking (2 mph)
ationary bike
ry light calisthenics
Level walking (3–4 mph)
Level biking (6–8 mph)
Light calisthenics
Level walking (4
Bicycling (9–10
Swimming, brea
Adapted with permission from Haskell WL. Design and implementation of ca
e Coronary Patient. New York, NY: Churchill Livingstone, 1978 (725).
METS  metabolic equivalents; mph  miles per hour.covery from an MI was 1 in 50,000 driving-years. The bus vaivers were allowed to return to work after they satisfied the
anadian Cardiovascular Society guidelines.
Covinsky et al. (829) performed a mail survey study of
tients with MIs. Three months after discharge, women re-
rted worse physical and mental health and were more likely to
ork less than before the MI. Similarly, women were less likely
return to work than men. Contemporary information specific to
A/NSTEMI on return to work by gender is needed.
The current aggressive interventional treatment of ACS will
ve an impact on mortality, morbidity, and hospital length of
ay (830). It remains to be determined whether earlier improve-
ent in cardiac condition after ACS will have an effect on the
te of return to work because of the multiple noncardiac factors
at influence disability and return to work.
.6. Other Activities
patients who desire to return to physically demanding
tivities early, the safety of the activity can be determined by
mparing performance on a graded exercise test with the
ET level required for the desired activity. Table 23 presents
ergy levels, expressed in METS, required to perform a
7–9 METS More Than 9 METS
0 lb)
Sawing wood
Heavy shoveling
Climbing stairs (moderate speed)
Carrying objects (60 to 90 lb)
Digging vigorously
Carrying loads upstairs (objects
more than 90 lb)
Climbing stairs (quickly)
Shoveling heavy snow
l
ls
Digging ditches (pick and shovel)
Forestry
Farming
Lumber jack
Heavy laborer
Shoveling (heavy)
Canoeing
Mountain climbing
Paddle ball
Walking (5 mph)
Running (12 min. mile)
Mountain or rock climbing
Soccer
Handball
Football (competitive)
Squash
Ski touring
Vigorous basketball (game)
ning
ph) Level jogging (5 mph)
Swimming (crawl stroke)
Rowing machine
Heavy calisthenics
Bicycling (12 mph)
Running (more than 6 mph)
Bicycling (more than
13 mph)
Rope jumping
Walking uphill (5 mph)
nditioning program. In: Wenger NL, Hellerstein HK, editors. Rehabilitation ofivities
ETS
lf-Care
garden
mowing
slowly)
(30 to 6
pationa
or)
atic too
eational
petitive)
nhill)
g
Conditio
.5–5.0 m
mph)
st stroke
rdiac coriety of common activities (831). This and similar tables
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aded exercise test into daily activities that can be under-
ken with reasonable safety.
The health care provider should provide explicit advice
out when to return to previous levels of physical activity,
xual activity, and employment. Daily walking can be
couraged immediately (832). In stable patients without
mplications (Class I), sexual activity with the usual partner
n be resumed within 1 week to 10 d. Driving can begin 1
eek after discharge if the patient is judged to be in
mpliance with individual state laws. Each state’s Depart-
ent of Motor Vehicles or its equivalent has mandated
rtain criteria, which vary from state to state and must be
et before operation of a motor vehicle after serious illness
33). These include such caveats as the need to be accompa-
ed and to avoid stressful circumstances such as rush hour,
clement weather, night driving, heavy traffic, and high speeds.
or patients who have experienced a complicated MI (one that
quired CPR or was accompanied by hypotension, serious
rhythmias, high-degree block, or CHF), driving should be
layed 2 to 3 weeks after symptoms have resolved.
Most commercial aircraft are pressurized to 7,500 to 8,000
et and therefore could cause hypoxia due to the reduced
veolar oxygen tension. The maximum level of pressuriza-
on is limited to 8,000 feet (2440 m) by Federal Aviation
dministration regulation (834). Therefore, air travel within
e first 2 weeks of MI should be undertaken only if there is
angina, dyspnea, or hypoxemia at rest or fear of flying. The
dividual must have a companion, must carry NTG, and must
quest airport transportation to avoid rushing and increased
rdiac demands. Availability of an emergency medical kit and
tomated external defibrillator has been mandated as of April
, 2004 (835), in all aircraft that carry at least approximately 30
ssengers and have at least 1 flight attendant.
Patients with UA (i.e., without infarction) who are revascularized
d otherwise stable may accelerate return to work, driving, flying,
d other normal activities (often, within a few days).
.7. Patient Records and
ther Information Systems
ffective medical record systems that document the course
d plan of care should be established or enhanced. Both
per-based and electronic systems that incorporate
idence-based guidelines of care, tools for developing cus-
mized patient care plans and educational materials, and
pture of data for appropriate standardized quality measure-
ents should be implemented and used routinely. Examples
such tools are the ACC’s “Guidelines Applied in Practice”
d the AHA’s “Get With the Guidelines.” All computerized
ovider order entry (CPOE) systems should incorporate
ese attributes as well. In some settings, the regular and
nsistent use of such systems and tools has been shown to
gnificantly improve quality of care and patient safety. The
tient’s medical record from the time of hospital discharge
ould indicate the discharge medical regimen, the major
structions about postdischarge activities and rehabilitation,
d the patient’s understanding and plan for adherence to the
commendations. After resolution of the acute phase of
A/NSTEMI, the medical record should summarize cardiac syents, current symptoms, and medication changes since
spital discharge or the last outpatient visit and should
cument the plan for future care. Processes for effective and
mely transfer of relevant prehospital and postdischarge
tient information between all participating caregivers
ould be continuously enhanced in accordance with existing
gulatory standards. This should include providing all pa-
ents with the tools to facilitate access to and understanding
the nature and importance of their most current plan of
re. With the increasing numbers of patients who have
gular access to the Internet, awareness of online informa-
on reflecting current evidence-based and professionally
veloped standards of care should be encouraged and
omoted. Several sites with reliable health care information
levant to UA/NSTEMI are available to patients (http://
ww.heartauthority.com/; http://www.nhlbi.nih.gov/health/
i/index.html; http://www.nlm.nih.gov/medlineplus/tutorial.
ml; http://www.fda.gov/hearthealth/index.html).
. Special Groups
.1. Women
ecommendations
ASS I
Women with UA/NSTEMI should be managed with the same
pharmacological therapy as men both in the hospital and for
secondary prevention, with attention to antiplatelet and anti-
coagulant doses based on weight and renal function; doses of
renally cleared medications should be based on estimated
creatinine clearance. (Level of Evidence: B)
Recommended indications for noninvasive testing in women with
UA/NSTEMI are similar to those for men. (Level of Evidence: B)
For women with high-risk features, recommendations for inva-
sive strategy are similar to those of men. See Section 3.3.
(Level of Evidence: B)
In women with low-risk features, a conservative strategy is
recommended. (Level of Evidence: B)
Although at any age, women have a lower incidence of
AD than men, they account for a considerable proportion of
A/NSTEMI patients, and UA/NSTEMI is a serious and
mmon condition among women. It is important to over-
me long-held notions that severe coronary manifestations
e uncommon in this population; however, women can
anifest CAD somewhat differently than men (784). Women
ho present with chest discomfort are more likely than men to
ve non-cardiac causes and cardiac causes other than fixed
structive coronary artery stenosis. Other cardiac causes
clude coronary vasospasm, abnormal vasodilator reserve,
d other mechanisms (784,836–838). Women with CAD
e, on average, older than men and are more likely to have
morbidities such as hypertension, diabetes mellitus, and HF
ith preserved systolic function; to manifest angina rather
an MI; and, among angina and MI patients, to have atypical
mptoms (157,839–841).
6
C
w
re
w
m
m
pr
a
ti
du
an
sy
ch
ha
pr
co
of
an
el
in
Im
si
bo
w
C
de
cr
fr
S
no
fi
un
m
ch
er
so
ou
ra
to
re
pe
S
6
6
In
re
(3
of
th
(1
w
le
sa
an
(6
de
w
ev
sa
an
in
an
fu
co
th
bl
sh
in
cl
de
re
II
st
si
ag
F
w
D
in
an
th
ba
in
of
re
in
m
w
di
6
C
be
m
ag
of
la
so
w
w
de
w
li
re
to
st
fa
S
U
e278 Anderson et al. JACC Vol. 61, No. 23, 2013
UA/NSTEMI Guideline: 2012 Update Incorporated June 11, 2013:e179–347.1.1. Profile of UA/NSTEMI in Women
onsiderable clinical information about UA/NSTEMI in
omen has emerged from many randomized trials and
gistries (157,641,643,839,842). As in other forms of CAD,
omen are older and have more comorbidities (diabetes
ellitus and hypertension) and stronger family histories than
en (157,839–841). Women are less likely to have had a
evious MI or cardiac procedures (839), more likely to have
history of HF, but less likely to have LV systolic dysfunc-
on. Women present with symptoms of similar frequency,
ration, and pattern, but more often than men, they have
ginal-equivalent symptoms such as dyspnea or atypical
mptoms (78,148,843). The frequency of ST-segment
anges is similar to that for men, but women more often
ve T-wave inversion. There are notable differences in the
ofiles of cardiac biomarkers for women and men, with a
nsistent finding in trials and registries that women less
ten have elevated levels of troponin (641,643,653,842). In
analysis of TACTICS-TIMI 18, women also less often had
evation of CK-MB; however, women more often had
creased levels of high-sensitivity CRP or BNP than men.
portantly, the prognostic value of elevated biomarkers is
milar in men and women (844). Coronary angiograms in
th trials and registries revealed less extensive CAD in
omen, as well as a higher proportion with nonobstructive
AD. The rate of nonobstructive CAD can be as high as 37%
spite selection of women according to strict inclusion
iteria in clinical trials (157,643).
A differing symptom pattern in women than men, the lower
equency of positive cardiac biomarkers despite high rates of
T-T abnormalities on the ECG, and the higher frequency of
nobstructive CAD in women make it challenging to con-
rm the diagnosis of UA/NSTEMI. This is a likely cause of
derutilization of several therapies in women compared with
en (842). There are important mechanisms of ischemic
est pain other than platelet/thrombus aggregates on plaque
osion or ulceration in women (see Section 6.8). Although
me studies report that female sex is a risk factor for poor
tcome in UA/NSTEMI on the basis of unadjusted event
tes (78,842), multivariate models have not found female sex
be an independent risk factor for death, reinfarction, or
current ischemia. This is in contrast to an apparent inde-
ndent risk of death for women compared with men with
TEMI, particularly for younger women.
.1.2. Management
.1.2.1. PHARMACOLOGICAL THERAPY
studies that span the spectrum of CAD, women tend to
ceive less intensive pharmacological treatment than men
9,842,845), perhaps in part because of a general perception
lower frequency and severity of CAD in women. Although
e specifics vary regarding beta blockers and other drugs
57,839,846), a consistent (and disturbing) pattern is that
omen are prescribed ASA and other antithrombotic agents
ss frequently than men (157,842,845). Women derive the
me treatment benefit as men from ASA, clopidogrel (61),
ticoagulants, beta blockers, ACE inhibitors, and statins
1,847). A meta-analysis of GP IIb/IIIa antagonists in ACS eamonstrated an interaction between sex and treatment effect,
ith an apparent lack of efficacy in women (383); how-
er, women with elevated troponin levels received the
me beneficial effect as men treated with GP IIb/IIIa
tagonists. The findings of a beneficial effect of a direct
vasive strategy in women treated with a GP IIb/IIIa
tagonist in TACTICS-TIMI 18 (see Section 6.1.2.3)
rther supports the similar efficacy of these agents in this
hort of women and men.
Despite the clear benefit of antiplatelet and anticoagulant
erapy for women with ACS, women are at increased risk of
eeding. A low maintenance dose of ASA (75 to 162 mg)
ould be used to reduce the excess bleeding risk, especially
combination with clopidogrel (61). Estimated creatinine
earance instead of serum creatinine levels should guide
cisions about dosing and the use of agents that are
nally cleared, eg, LMWHs and the small-molecule GP
b/IIIa antagonists. In a large community-based registry
udy, 42% of patients with UA/NSTEMI received exces-
ve initial dosing of at least 1 antiplatelet or anticoagulant
ent (UFH, LMWH, or GP IIb/IIIa inhibitor) (738).
emale sex, older age, renal insufficiency, low body
eight, and diabetes were predictors of excessive dosing.
osing errors predicted an increased risk of major bleed-
g (738). The formula used to estimate creatinine clear-
ce for dose adjustment in clinical studies and labeling
at defines adjustments for several medications have been
sed on the Cockroft-Gault formula for estimating creat-
ine clearance, which is not identical to the Modification
Diet and Renal Disease (MDRD) formula recently
commended for screening for renal disease (848), either
units or cut points for adjustment. Weight-based adjust-
ent of medication doses also should be applied carefully
here recommended.
The use of hormone therapy in postmenopausal women is
scussed in Section 5.2.17.
.1.2.2. CORONARY ARTERY REVASCULARIZATION
ontemporary studies have cast doubt on the widely held
lief that women fare worse with PCI and CABG than do
en because of technical factors (e.g., smaller artery size, greater
e, and more comorbidities) (157,840,847,849–853). In the case
PCI, it has been suggested that angiographic success and
te outcomes are similar in women and men, although in
me series, early complications occurred more frequently in
omen (849,850,854 – 857). However, the outlook for
omen undergoing PCI appears to have improved, as evi-
nced by the NHLBI PTCA registry (858). Earlier studies of
omen undergoing CABG showed that women were less
kely to receive internal mammary arteries or complete
vascularization and had a higher mortality rate (RR 1.4
4.4) than men (852,853,859). However, more recent
udies of CABG in patients with ACS show a more
vorable outlook for women than previously thought (see
ection 6.3) (860 – 862).
A Mayo Clinic review of 3,014 patients (941 women) with
A who underwent PCI reported that women had similar
rly and late results as men (840). The BARI trial of 1829
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ith UA, and showed that the results of revascularization
ere, if anything, better in women than men when corrected
r other factors. At an average 5.4-year follow-up, mortality
tes for men and women were 12% and 13%, respectively,
t when adjusted for baseline differences (e.g., age, diabetes,
d other comorbidities), there was a lower risk of death (RR
60, 95% CI 0.43 to 0.84, p0.003) but a similar risk of
ath or MI (RR 0.84, 95% CI 0.66 to 1.07, p0.16) in
omen compared with men (859). The NHLBI Dynamic
egistry has reported improved outcomes for women who
derwent PCI in 1997 to 1998 compared with 1985 to 1986.
ompared with men, women had similar procedural success,
-hospital death, MI, and CABG (858). Although the 1-year
ent rate was higher for women, female sex was not
dependently associated with death or MI because women
nded to be older and had more comorbidities. A prospective
udy of 1,450 patients with UA/NSTEMI who underwent an
direct or direct invasive strategy with coronary stenting
ported that female sex was independently associated with a
wer rate of death and MI (HR 0.51, 95% CI 0.28 to 0.95)
42).
.1.2.3. INITIAL INVASIVE VERSUS
ITIAL CONSERVATIVE STRATEGY
the modern era, clinical trials assessing a direct invasive
rategy compared with an initial conservative strategy for the
anagement of UA/NSTEMI have consistently demonstrated
benefit for men (641,643,653). Approximately one third of
e cohorts in these trials were women (n2,179), and the
sults on the efficacy and safety of a direct invasive strategy
women have been conflicting. Each trial was underpow-
ed to evaluate the subgroup of women, and there were
bstantial differences among the trials (Table 24). A meta-
alysis of trials in the era of stents and GP IIb/IIIa antago-
sts has failed to show a survival benefit of a direct invasive
rategy in women at 6 to 12 months (OR for women 1.07,
% CI 0.82 to 1.41; OR for men 0.68, 95% CI 0.57 to 0.81)
27).
In TACTICS-TIMI 18, there was a significant reduction in
e primary end point of death, nonfatal MI, or rehospitaliza-
on for an ACS with a direct invasive strategy (OR 0.45, 95%
I 0.24 to 0.88, p0.02) (188). All subjects in this trial (n 
4) were treated with an early GP IIb/IIIa antagonist
irofiban). A similar overall reduction in the primary com-
site end point of death, MI, or rehospitalization for ACS at
months was observed for women and men (adjusted OR
72, 95% CI 0.47 to 1.11 and adjusted OR 0.64, 95% CI 0.47
0.88, respectively). Women were older, more frequently
d hypertension, and less frequently had previous MI,
ABG, and elevated cardiac biomarkers (p0.001 for all),
t there was no significant difference in TIMI risk score
stribution by sex (p0.76) (653). A similar reduction in
mposite risk was observed in women with intermediate (3
4) or high (5 to 7) TIMI risk scores as in men. However,
contrast to men with a low TIMI risk score who had similar
tcomes with an invasive and conservative strategy, low-
sk women had an OR for events of 1.59 (95% CI 0.69 to
67) for the invasive compared with the conservative strat- diy (653). However, the number of events was small (n  26
ents), and the p value for interaction between strategy,
IMI risk score, and sex on outcome did not achieve
gnificance (p0.09). An elevated biomarker, including
NP, CRP, CK-MB, and troponin, also identified women
nd men) who benefited differentially from a direct invasive
rategy. The reduction in risk was enhanced in women with
evated TnT levels (adjusted OR 0.47, 95% CI 0.26 to 0.83),
ith a similar reduction in the primary end point noted for
omen and men with elevated troponin. However, in contrast
the similar outcome for the invasive versus conservative
rategy in men with a negative TnT marker (OR 1.02, 95%
I 0.64 to 1.62, p0.04), the primary end point of death, MI,
d rehospitalization occurred significantly more frequently
women with negative troponin randomized to an invasive
rategy (OR 1.46, 95% CI 0.78 to 2.72) (653).
The RITA-3 trial enrolled 682 women (38% of 1,810
tients) (863). There was a significant interaction between
x and treatment strategy (invasive versus conservative) on
tcome in RITA-3 (p0.042). In contrast to a reduction in
ath or MI for men assigned to an invasive strategy, the HR
r women was 1.09. Women assigned to an initial conser-
tive strategy had a lower rate of death and MI (5.1%) at 1
ar than the women enrolled in TACTICS-TIMI 18 (9.7% at
months). Consistent with this difference, 37% of women in
ITA-3 had no significant obstructive CAD, compared with
% of women in TACTICS-TIMI 18 (188). Other notable
fferences between RITA-3 and TACTICS-TIMI 18 include
utine use of GP IIb/IIIa antagonist in TACTICS-TIMI 18
d different criteria for the MI end point in both the
nservative and the invasive treatment groups. The RITA-3
vestigators have reported that the rates of death and MI for
omen are 11.1% and 12.7% in the conservative versus
vasive strategy, respectively, that is, not significantly dif-
rent, when there was a lower threshold for cardiac marker
agnosis of MI among the conservatively treated group
43).
In the only trial that showed an overall survival benefit for
invasive strategy, FRISC-II, there was a significant inter-
tion in outcome between treatment strategy, which included
systematic but delayed interventional approach within 7 d
symptom onset, and sex (637,641). Thirty percent of the
457 enrolled patients were women, and the death and MI
te at 1 year was nonsignificantly higher for invasively
eated versus conservatively treated women, in contrast to a
rge reduction in death and MI for men. Female sex was
dependently associated with events in the invasively as-
gned patients. However, the poor outcome of women was
rgely driven by a 9.9% death rate at 1 year in women who
derwent CABG. In contrast, the death rate for women who
derwent PCI in the invasive strategy group was similar to
at of men (1.5% vs 1.0%; RR 1.50, 95% CI 0.27 to 8.28;
 nonsignificant [NS]).
In summary, women with UA/NSTEMI and high-risk
atures, including elevated cardiac biomarkers, appear to
nefit from an invasive strategy with early intervention and
junctive GP IIb/IIIa antagonist use. There is no benefit of a
rect invasive strategy for low-risk women, and the weight
Table 24. Invasive Versus Conservative Strategy Results for UA/NSTEMI by Gender
Study (Reference) Timing End Point Overall Result Results in Men Results in Women Comment
TACTICS-TIMI 18 (182,565)
2002
n 2,220
34% female
Angiography 4 to 48 h Death, MI 30 d
Inv: 4.7%
Cons: 7.0%
p  0.02
ARR  2.3%
6 months
Inv: 7.3%
Cons: 9.5%
OR  0.74 (95% CI 0.54 to 1.00)
ARR  2.2%
6 months
Inv: 7.6%
Cons: 9.4%
OR  0.68 (95% CI 0.43 to 1.05)
ARR  1.8%
6 months
Inv: 6.6%
Cons: 9.7%
OR  0.45 (95% CI 0.24 to 0.88)
ARR  3.1%
Benefit greater in women with
high cTnT; OR  0.47
(95% CI 0.26 to 0.83) for
death, MI, and
rehospitalization
RITA-(758) 2002
n  1,810
38% female
Angiography within 48 h Death, MI, refractory
angina
Death, MI
4 months
Inv: 9.6%
Cons: 14.5%
p  0.001
RR  0.66 (95% CI 0.51 to 0.85)
ARR  4.9%
1 year
Inv: 7.0%
Cons: 8.3% p  0.58
RR 0.91 (95% CI 0.67 to 1.25)
ARR  0.7%
4 months
Inv: 8.8%
Cons: 17.3%
ARR  8.5%
1 year
Inv: 7.0%
Cons: 10.1%
Arr 3.1%
4 months
Inv: 10.9%
Cons: 9.6%, p  NS
ARR  1.3%
1 year
Inv: 8.6%
Cons: 5.1%
ARR 3.5%
Angina reduced with invasive
strategy
FRISC II (245,549,552)
1999
n  2,457
30% female
Revascularization within 7d Death, MI 6 months
Inv: 9.4%
Cons: 12.1%
p  0.3
ARR  2.7%
1 year
Inv: 10.4%
Cons: 14.1%
p  0.005
ARR  3.7%
1 year
Inv: 9.6%
Cons: 15.8% p less than 0.001
ARR  6.2%
6 months
Inv: 10.5%
Cons: 8.3%, RR  1.26 (95% CI
0.80 to 1.97)
ARR 1.9%
1 year
Inv: 12.4%
Cons: 10.5%, p  NS
ARR  1.9%
Mortality benefit at year (2.2%
vs. 3.9%
ARR  1.7% p  0.02, not
seen in women (4% vs.
3.3%
ARR  0.7%
TIMI-IIIB (150) 1997
n  1,423
34% female
Angiography 1 to 48 h Death, MI 1 year
Inv: 10.8%
Cons: 12.2%
p  0.42
ARR  1.4%
Death at 6 weeks
Inv: 2.6%
Cons: 1.4%
ARR  1.2%
MI at 6 weeks
Inv: 5.5%
Cons: 6.0%
ARR  0.5%
Death at weeks
Inv: 2%
Cons: 4.4%
ARR  2.4%
MI at weeks
Inv: 4.4%
Cons: 5.2%
ARR  0.8%
Invasively treated patients had
less angina and fewer
rehospitalizations for
ischemia
Reproduced with permission from Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women: A Statement for Healthcare professionals from the American Heart Association © 2005, American Heart
Association, Inc. (742).
ACS  acute coronary syndrome; ARR  absolute risk reduction; CI  confidence interval; Cons  conservative; cTnT  cardiac troponin T; FRISC II  Fast Revascularization during InStability in Coronary artery disease-II;
Inv  invasive; MI  myocardial infarction; n  number of patients; NS  nonsignificant; NSTEMI  non–ST-segment elevation MI; OR  odds ratio; PTCA  percutaneous transluminal coronary angioplasty; RITA-3  Third
Randomized Intervention Treatment of Angina; RR  risk ratio; TACTICS-TIMI 18  Treat Angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy–Thrombolysis In Myocardial Infarction 18;
TIMI IIIB  Thrombolysis In Myocardial Infarction III; UA  unstable angina.
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sts that there may be excess risk associated with a direct
vasive strategy in this group. The challenges in the diagno-
s of UA/NSTEMI and the varied pathophysiology of isch-
ic pain in women who present with rest discomfort suggest
at perhaps the excess risk of a direct invasive strategy
served in low-risk women could be due to intervention on
stable incidental coronary lesion in a woman with another
echanism for rest pain.
.1.3. Stress Testing
general, ECG exercise testing is less predictive in women
an in men, primarily because of the lower pretest probabil-
y of CAD (669,864–866). Perfusion studies using sestamibi
ve good sensitivity and specificity in women (867). Breast
tenuation is less of a problem than previously with thallium-
1 stress testing with new tissue software. Stress echocar-
ography (dobutamine or exercise) is therefore an accurate
d cost-effective technique for CAD detection in women
69). Newer perfusion methods such as adenosine-stress
MR also appear to be promising in women. Cardiac mag-
tic resonance imaging (for function, perfusion, and viabil-
y) and multislice CCTA are 2 new diagnostic modalities that
uld prove particularly useful in women because of their
omise of both greater sensitivity and specificity (improved
agnostic accuracy). Evidence of ischemia by objective
easures without obstructive CAD carries an adverse prog-
sis (11,868) and is suggestive of vascular dysfunction
oronary endothelial or microvascular dysfunction) as an
iological mechanism.
Recommendations for noninvasive testing in women are
e same as in men (see Section 3.4) (838,868). A report of
6 women who underwent treadmill exercise suggests that
e Duke Treadmill Score provides accurate diagnostic and
ognostic estimates in both women and men (869). The
uke Treadmill Score actually performed better for women
an for men in the exclusion of CAD. There were fewer
w-risk women than men with any significant CAD (at least
vessel with greater than 75% stenosis; 20% in women vs
% in men, p0.001).
Regarding dobutamine stress echocardiography, pilot
ase data from the Women’s Ischemia Syndrome Evaluation
ISE) indicated that in women, the test reliably detects
ultivessel disease (sensitivity 81.8%, similar to that in men)
t not 1-vessel disease (870). Several studies have indicated
at women with positive stress tests tend not to be evaluated
aggressively as men (846), which is inappropriate given
e adverse prognosis of ischemia as demonstrated in WISE
d other studies (838,871–878).
In the TIMI IIIB registry, women underwent exercise testing
a similar proportion as men (157,839). The frequencies of
ress test positivity were also similar, although women were less
ely to have a high-risk stress test result. Moreover, women
ere less likely to undergo angiography (RR 0.71, p0.001),
rhaps because of the lower percentage with high-risk test
sults on noninvasive testing.
.1.4. Conclusions
omen with UA/NSTEMI are older and more frequently
ve comorbidities compared with men but have more anypical presentations and appear to have less severe and less
tensive obstructive CAD. Women receive ASA less fre-
ently than do men, but patients with UA/NSTEMI of either
x benefit from and should receive this agent, as well as
her Class I recommended agents. Doses should be adjusted
the basis of weight and estimated creatinine clearance for
nally cleared drugs for all recommended agents when
propriate. Image-enhanced stress testing has similar prog-
stic value in women as in men.
.2. Diabetes Mellitus (UPDATED)
ASS I
Medical treatment in the acute phase of UA/NSTEMI and
decisions on whether to perform stress testing, angiogra-
phy, and revascularization should be similar in patients with
and without diabetes mellitus. (Level of Evidence: A)
(188,251,408,879)
ASS IIa
For patients with UA/NSTEMI and multivessel disease, CABG
with use of the internal mammary arteries can be beneficial
over PCI in patients being treated for diabetes mellitus. (Level
of Evidence: B) (880)
PCI is reasonable for UA/NSTEMI patients with diabetes
mellitus with single-vessel disease and inducible ischemia.
(Level of Evidence: B) (188)
It is reasonable to use an insulin-based regimen to achieve and
maintain glucose levels less than 180 mg/dL while avoiding
hypoglycemia‡‡‡ for hospitalized patients with UA/NSTEMI
with either a complicated or uncomplicated course. (Level of
Evidence: B) (881–884)
.2.1. Profile and Initial Management of Diabetic
d Hyperglycemic Patients With UA/NSTEMI
oronary artery disease accounts for 75% of all deaths in
tients with diabetes mellitus (57,58), and approximately
% to 25% of all patients with UA/NSTEMI have diabetes
97,839,885–888). Patients with UA/NSTEMI and diabetes
ve more severe CAD (886,889,890), and diabetes is an
portant independent predictor for adverse outcomes (death,
I, or readmission with UA at 1 year; RR 4.9) (891–894). In
dition, many patients with diabetes who present with
A/NSTEMI have already undergone CABG (895).
Patients with diabetes tend to have more extensive non-
ronary vascular comorbidities, hypertension, LV hypertro-
y, cardiomyopathy, and HF. In addition, autonomic dys-
nction, which occurs in approximately one third of patients
ith diabetes, influences heart rate and blood pressure, raises
e threshold for the perception of angina, and may be
companied by LV dysfunction (896–898). On coronary
giography, patients with diabetes and UA have a greater
oportion of ulcerated plaques (94% vs 60%, p0.01) and
tracoro-nary thrombi (94% vs 55%, p0.004) than patients
ithout diabetes (899). These findings suggest a higher risk
plaque instability.
‡There is uncertainty about the ideal target range for glucose necessary to achieve
optimal risk-benefit ratio.
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re (900), the relationship of controlled blood glucose levels
d reduced mortality in the setting of MI has been demon-
rated. The American College of Endocrinology has also
phasized the importance of careful control of blood glu-
se targets in the range of 110 mg per dL preprandially to a
aximum of 180 mg per dL. In 1 study (901), admission blood
ucose values were analyzed in consecutive patients with MI.
nalysis revealed an independent association of admission
ood glucose and mortality. The 1-year mortality rate was
gnificantly lower in subjects with admission plasma glucose
ss than 101 mg per dL (5.6 mmol per liter) than in those with
asma glucose 200 mg per dL (11 mmol per liter). In the first
iabetes and Insulin-Glucose Infusion in Acute Myocardial
farction (DIGAMI) study (902,903), insulin-glucose infusion
llowed by subcutaneous insulin treatment in diabetic patients
ith MI was examined. Mean blood glucose in the intensive
sulin intervention arm was 172.8 mg per dL (9.5 mmol per
er) compared with 211 mg per dL (11.6 mmol per liter) in the
onventional” group. Overall, the intensive approach reduced
ng-term relative mortality (at 3.4 years of follow-up) by 25%
the insulin-treated group. The broad range of blood glucose
vels within each arm limits the ability to define specific blood
ucose target thresholds.
In the second DIGAMI study (904), 3 treatment strategies
ere compared in a randomized trial among 1,253 patients
ith type 2 diabetes mellitus and suspected MI: acute
sulin-glucose infusion followed by insulin-based long-term
ucose control, insulin-glucose infusion followed by stan-
rd glucose control, and routine metabolic management
cording to local practice. Blood glucose was reduced more
24 h in those receiving insulin-glucose infusions, but
ng-term glucose control, assessed by HbA1C, did not differ
tween the groups, and the fasting glucose in group 1 (8.0
mol per liter) did not reach target (5 to 7 mmol per liter).
he primary end point of all-cause mortality between groups
and 2 did not differ significantly (23.4% vs 22.6%) at a
edian of 2.1 years of follow-up. Morbidity also did not
ffer among the 3 groups. Although the DIGAMI-2 regimen
acutely introduced, long-term insulin treatment in the
tting of suspected acute MI was not demonstrated to
crementally reduce morbidity and mortality, epidemiologi-
l analyses still support a strong, independent relationship
tween glucose levels and long-term mortality in patients
ith ischemic heart disease (904).
Attainment of targeted glucose control in the setting of
rdiac surgery is associated with reduced mortality and risk
deep sternal wound infections in cardiac surgery patients
ith diabetes (905,906). This supports the concept that
rioperative hyperglycemia is an independent predictor of
fection in patients with diabetes mellitus, with the lowest
ortality in patients with blood glucose less than or equal to
0 mg per dL (8.3 mmol per liter) (907).
A mixed group of patients with and without diabetes
mitted to a surgical intensive care unit (ICU) were random-
ed to receive intensive insulin therapy (target blood glucose
to 110 mg per dL [4.4 to 6.1 mmol per liter]). Achieve-
ent of a mean blood glucose of 103 mg per dL (5.7 mmol
r liter) reduced mortality during the ICU stay and decreased aerall in-hospital mortality (908). Subsequent analysis dem-
strated that for each 20-mg per dL (1.1-mmol per liter)
ucose elevation above 100 mg per dL (5.5 mmol per liter),
e risk of death during the ICU stay increased. Hospital and
U survival were linearly associated with ICU glucose
vels, with the highest survival rates occurring in patients
hieving an average blood glucose less than or equal to 110
g per dL (6.1 mmol per liter).
Although beta blockers can mask the symptoms of hypo-
ycemia or lead to it by blunting the hyperglycemic re-
onse, they nevertheless should be used with appropriate
ution in patients with diabetes mellitus and UA/NSTEMI.
iuretics that cause hypokalemia can inhibit insulin release
d thereby worsen glucose intolerance.
Elevated blood glucose among critically ill patients even in
e absence of clinical diabetes mellitus has received recent
tention as an important risk factor for mortality (909). A
ndomized trial in the surgical ICU setting (910) found that
rict glycemic control with insulin reduced both morbidity
d in-hospital mortality (910). More recently, the role of
tensive insulin therapy in the medical ICU setting has been
udied (884) in 1,200 medical ICU patients (some with
VD) randomized to conventional therapy (insulin adminis-
red when glucose exceeded 215 mg per dL, tapering
fusion when glucose fell below 180 mg per dL) or to
tensive insulin therapy (targeting a glucose of 80 to 110 mg
r dL). Overall, intensive insulin did not significantly reduce
-hospital mortality, the primary end point (37.3% in the
tensive therapy arm, 40% in the conventional arm,
0.33), but secondary outcomes of acquired kidney injury,
me to ventilator weaning, and ICU and hospital discharge
ays were reduced. Hypoglycemia was more common but
ten consisted of a single, asymptomatic episode. However,
hen analysis was restricted to the intended population of
7 patients whose ICU stay was at least 3 d, in-hospital
ath was reduced from 52.5% to 43% (p0.009) and ICU
ath from 38.1% to 31.3% (p0.005). In addition, second-
y outcomes of time to ventilator weaning, days to ICU
scharge and to hospital discharge, acquired kidney injury,
perbilirubinemia, and CRP levels were reduced. Newer
idence has emerged which led the 2012 writing group to
commend treatment for hyperglycemia 180 mg/ dL while
oiding hypoglycemia (see Section 6.2.1.1).
.2.1.1. INTENSIVE GLUCOSE CONTROL (NEW SECTION)
s detailed in the 2004 STEMI guideline (8), 2007 UA/
STEMI guideline revision (7), and 2009 STEMI and PCI
cused update (911), randomized trial evidence supported
e of insulin infusion to control hyperglycemia. A clinical
ial of intensive versus conventional glucose control in
itically ill patients raised uncertainty about the optimal level
target when achieving glucose control. NICE-SUGAR
ormoglycaemia in Intensive Care Evaluation–Survival Us-
g Glucose Algorithm Regulation), a large international
ndomized trial (n6,104) of adults admitted to the inten-
ve care unit with either medical or surgical conditions,
mpared intensive glucose control (target glucose range, 81
108 mg/dL) with conventional glucose control (to achieveglucose level of 180 mg/dL, with reduction and discon-
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4 mg/dL) (881). Time-weighted glucose levels achieved
ere 11518 mg/dL in the intensive group versus 14423
g/dL in the conventional group. The risk of death was
creased at 90 days in the intensive group by 2.6% (27.5%
rsus 24.9%; OR: 1.14; 95% CI: 1.02 to 1.08; p0.02;
mber needed to harm38). The result remained the same
ter adjusting for potential confounders. There were signif-
antly more episodes of treatment-related hypoglycemia in
e intensely managed group (6.8% versus 0.5%; p0.001),
though the contribution of hypoglycemia to excess mortal-
y is uncertain (881,882). Overall, the hospital course and
oximate causes of death were similar in the 2 groups.
xcess deaths in the intensive management group were
edominantly of cardiovascular causes (absolute difference:
8%; p0.02). More patients in the intensive group than in
e conventional group were treated with corticosteroids.
Because NICE-SUGAR (881) enrolled critically ill medi-
l and surgical patients, the degree to which its results can be
trapolated to the management of patients with UA/
STEMI is unclear. Although recent data from a small,
echanistic clinical trial (912) suggest that glucose control
ay reduce inflammation and improve left ventricular ejec-
on fraction in patients with acute MI, it remains uncertain
hether acute glucose control will improve patient outcomes.
A consensus statement by the American Association of
linical Endocrinologists and the American Diabetes Asso-
ation (913) summarized that “although hyperglycemia is
sociated with adverse outcomes after acute MI, reduction of
ycemia per se and not necessarily the use of insulin is
sociated with improved outcomes. It remains unclear,
wever, whether hyperglycemia is a marker of underlying
alth status or is a mediator of complications after acute MI.
oniatrogenic hypoglycemia has also been associated with
verse outcomes and is a predictor of higher mortality.”
There is a clear need for a well-designed, definitive
ndomized trial of target-driven glucose control in UA/
STEMI patients with meaningful clinical endpoints so that
ucose treatment thresholds and glucose targets can be
termined. Until such a trial is completed, and on the basis
the balance of current evidence (913–915), the 2012
riting group concluded that it was prudent to change the
commendation for the use of insulin to control blood
ucose in UA/NSTEMI from a more stringent to a more
oderate target range in keeping with the recent 2009 STEMI
d PCI focused update (Class IIa, LOE: B) (911) and
commend treatment for hyperglycemia more than 180
g/dL while avoiding hypoglycemia. The 2012 writing group
lieved that the 2007 recommendation (7) regarding long-
rm glycemic control targets failed to reflect recent data
sting doubt on a specific ideal goal for the management of
abetes in patients with UA/NSTEMI.
Diabetes is another characteristic associated with high risk
r adverse outcomes after UA/NSTEMI. The 2007 UA/
STEMI guidelines (7) state that patients with diabetes are at
gh risk and in general should be treated similarly to patients
ith other high-risk features. However, the 2012 writing
oup noted that diabetes was not listed as a high-risk feature cor which an invasive strategy was specifically preferred, in
ntrast to the inclusion of chronic kidney disease (CKD) and
abetes mellitus as characteristics favoring an invasive
proach in the 2007 European Society of Cardiology guide-
nes for management of UA/NSTEMI (916). To revisit this
estion for diabetes, the 2012 writing group reviewed results
the published analysis of patients with diabetes in the
RISC-II (FRagmin and Fast Revascularization during
Stability in Coronary artery disease) trial (251). Overall, the
RISC-II trial demonstrated a benefit with invasive manage-
ent compared with conservative management in patients
ith UA/NSTEMI. There were similar reductions in the risk
MI/death at 1 year in the diabetic subgroup randomized to
invasive strategy (OR: 0.61; 95% CI: 0.36 to 1.04)
mpared with patients who did not have diabetes random-
ed to an invasive strategy (OR: 0.72; 95% CI: 0.54 to
95). The risk of death was also reduced by randomization
an invasive strategy among patients with diabetes (OR:
59; 95% CI: 0.27 to 1.27) and without diabetes (OR:
50; 95% CI: 0.27 to 0.94). Subgroup analysis of the
ACTICS–TIMI-18 (Treat Angina with aggrastat and
termine Cost of Therapy with Invasive or Conservative
trategy–Thrombolysis In Myocardial Infarction 18) study
patients with diabetes, available in abstract form, was
nsistent with this finding (917). Thus, diabetes, as well
the often concurrent comorbidity of CKD (Section 6.5,
hronic Kidney Disease: Recommendations), is not only a
gh-risk factor but also benefits from an invasive ap-
oach. Accordingly, diabetes has been added to the list of
aracteristics for which an early invasive strategy is
nerally preferred (Appendix 6).
.2.2. Coronary Revascularization
pproximately 20% of all patients who undergo CABG (918)
d PCI (850,851,854,855,889,890) have diabetes mellitus.
ata regarding outcomes are complex. In the Coronary
rtery Surgery Study (CASS) of CABG, patients with
abetes had a 57% higher mortality rate than patients without
abetes. A striking advantage for CABG over PCI was found
treated patients with diabetes in the BARI trial (886), a
ndomized trial of PCI versus CABG in 1,829 stable patients
ith multivessel disease, of whom 19% were patients with
abetes (see Section 4). As in other studies, patients with
abetes mellitus had increased comorbidity rates. Five years
ter randomization, patients who required treatment for
abetes had a lower survival rate than patients without
abetes (73.1% vs 91.3%, p0.0001), whereas survival rates
patients without and with diabetes who did not require
poglycemic treatment were similar (93.3% vs 91.1%,
NS). Outcomes for CABG in treated patients with diabetes
ere far better than those for PCI (80.6% vs 65.5% survival,
0.0003). An interesting finding was that the mortality rate
ring the 5.4 years of the study in patients with diabetes who
ceived SVGs (18.2%) was similar to that of patients who
derwent PCI (20.6%); whereas the mortality rate in patients
ho received internal mammary arteries was much lower
.9%). Results of the Emory Angioplasty versus Surgery
rial (EAST) at 8 years showed a similar trend but were less
nclusive (919). The increased mortality rate noted in
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s been confirmed in a registry study from Emory University
00). Uncorrected, there was little difference in long-term
ortality rates. The CABG patients had more severe disease,
d with correction for baseline differences, there was an
proved survival rate in insulin-requiring patients with
ultivessel disease who were revascularized with CABG
ther than with PCI. That the more severely diseased
tients, in a nonrandomized registry, were selectively sent
ore often for CABG than for PCI probably represents good
inical decision making.
A 9-year follow-up of the NHLBI registry showed a
milar disturbing pattern for patients with diabetes undergo-
g PCI (889). Immediate angiographic success and com-
eteness of revascularization were similar, but compared
ith patients without diabetes, patients with diabetes (who,
ain, had more severe CAD and comorbidities) had in-
eased rates of hospital mortality (3.2% vs 0.5%), nonfatal
I (7.0% vs 4.1%), death and MI (10.0% vs 4.5%), and the
mbined end point of death, MI, and CABG (11% vs 6.7%;
0.01 for all). At 9 years, rates of mortality (35.9% vs
.9%), MI (29% vs 18.5%), repeat PCI (43.0% vs 36.5%),
d CABG (37.6% vs 27.4%) were all higher in patients with
abetes than in those without (889).
However, other data point to a lesser differential effect of PCI
patients with diabetes. For example, data from the BARI
gistry varied from those of the BARI trial. In the registry, there
as no significant difference in cardiac survival for patients with
abetes undergoing PCI (92.5%) and CABG (94%; pNS)
02,920). In the Duke University registry, patients with diabetes
d PCI or CABG were matched with the BARI population
21). The outcome in patients with diabetes was worse than that
ithout diabetes with either CABG or PCI, but there was no
fferential effect by therapy. The 5-year survival rate for PCI and
ABG adjusted for baseline characteristics was 86% and 89% in
tients with diabetes and 92% and 93% without diabetes, respec-
ely (921).
Stents could improve the outcome of patients with diabetes
ho undergo PCI. In a study with historical controls, the
tcome after coronary stenting was superior to that after PTCA
patients with diabetes, and the restenosis rate after stenting
as reduced (63% vs 36%, diabetes vs no diabetes with balloon
TCA at 6 months, p0.0002, compared with 25% and 27%
ith stents, pNS) (919). On the other hand, patients with
abetes who underwent atherectomy had a substantial restenosis
te (60% over 6 months) (922). Using data derived from the
orthern New England registries, a contemporary BARI-like
mparison of long-term survival after PCI (64% with at least 1
ent) versus CABG found significantly better risk-adjusted
ng-term survival in CABG patients with 3-vessel disease
R 0.60, p0.01) (923). Similar benefits of CABG over PCI
ere demonstrated for patients with diabetes.
Three trials have shown that abciximab considerably im-
oved the outcome of PCI in patients with diabetes. In the
PILOG trial, abciximab resulted in a greater decline in
ath/MI over 6 months after PCI in patients with diabetes (HR
36, 95% CI 0.21 to 0.61) than in those without diabetes (HR
60, 95% CI 0.44 to 0.83) (924). Similar results have been
ported for tirofiban in the PRISM-PLUS trial (140). EPIS- NENT was a randomized trial that compared stent plus placebo
ith stent plus abciximab and balloon plus abciximab in 2,399
tients, of whom 20.5% had diabetes and 20.3% had UA (602).
he 30-d event rate (death, MI, and urgent revascularization)
patients with diabetes declined from 12.1% (stent plus
acebo) to 5.6% (stent plus abciximab; p0.040). At 6
onths, the drug reduced revascularization of target arter-
s in patients with diabetes (16.6% vs 8.1%, p0.02).
eath or MI was reduced to a similar degree in patients
ith diabetes as that in patients without diabetes (925).
hese benefits were maintained at 1 year (926). Thus, in
e 6-month data, initial GP IIb/IIIa therapy, as well as
enting, considerably improved the safety of PCI in
tients with diabetes. In a comparative trial of abciximab
d tirofiban (TARGET), both agents were associated with
mparable event rates, including similar rates of 6-month
rget-vessel revascularization and 1-year mortality (927).
.2.3. Conclusions
iabetes occurs in approximately one fifth of patients with
A/NSTEMI and is an independent predictor of adverse
tcomes. It is associated with more extensive CAD, unstable
sions, frequent comorbidities, and less favorable long-term
tcomes with coronary revascularization, especially with
TCA. It is unclear whether these differences are due to more
equent restenosis and/or severe progression of the underly-
g disease (889). The use of stents, particularly with abcix-
ab, appears to provide more favorable results in patients
ith diabetes, although more data are needed, including with
ES. Coronary artery bypass grafting, especially with 1 or
th internal mammary arteries, leads to more complete
vascularization and a decreased need for reintervention than
CI, even when bare-metal stents are used in diabetic patients
ith multivessel disease. Given the diffuse nature of diabetic
ronary disease, the relative benefits of CABG over PCI
ay well persist for diabetic patients, even in the era of DES.
.3. Post-CABG Patients Recommendations
ASS I
Medical treatment for UA/NSTEMI patients after CABG should
follow the same guidelines as for non–post-CABG patients with
UA/NSTEMI. (Level of Evidence: C)
Because of the many anatomic possibilities that might be
responsible for recurrent ischemia, there should be a low
threshold for angiography in post-CABG patients with UA/
NSTEMI. (Level of Evidence: C)
ASS IIa
Repeat CABG is reasonable for UA/NSTEMI patients with
multiple SVG stenoses, especially when there is significant
stenosis of a graft that supplies the LAD. Percutaneous coro-
nary intervention is reasonable for focal saphenous vein steno-
sis. (Level of Evidence: C) (Note that an intervention on a
native vessel is generally preferable to that on a vein graft that
supplies the same territory, if possible.)
Stress testing with imaging in UA/NSTEMI post-CABG patients
is reasonable. (Level of Evidence: C)
Overall, up to 20% of patients presenting with UA/
STEMI have previously undergone CABG (895). Con-
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A/NSTEMI during an interval of 7.5 years (928), with a
ghly variable postoperative time of occurrence (929). Post-
ABG patients who present with UA/NSTEMI are at higher
sk, with more extensive CAD and LV dysfunction than
ose patients who have not previously undergone surgery.
.3.1. Pathological Findings
athologically, intimal hyperplasia or atherosclerosis may
velop in SVGs, and there is a particular tendency for
rombotic lesions to develop in these vessels (in 72% of
afts resected in 1 study) (930–933). In addition, post-
ABG patients may develop atherosclerosis in their native
ssels, and this can lead to UA/NSTEMI (933,934). How-
er, obstructive lesions are more likely to occur in SVGs
3% within 5 years, 76% at 5 to 10 years, and 92% at greater
an 10 years) (935), and there is a high rate of early graft
ilure in current practice (occlusion in up to one third at 1
ar). Spasm in grafts or native vessels (936,937) and
chnical complications may also play a role in the develop-
ent of UA/NSTEMI during the early postoperative period
28,938). Both angioscopic and angiographic findings indi-
te that SVG disease is a serious and unstable process.
ngioscopically, friable plaques occur uniquely in SVGs
4% vs 0% in native coronary arteries), whereas rough and
hite plaques occur in both SVGs and native coronary
teries (939). Angiographically, the SVGs more frequently
ve complex lesions (i.e., overhanging edges, irregular
rders, ulcerations, or thrombosis), thrombi (37% vs 12%,
0.04), and total occlusions (49% vs 24%, p0.02) (935).
.3.2. Clinical Findings and Approach
ompared with UA/NSTEMI patients without prior CABG,
st-CABG patients are more often male (presumably be-
use more men than women have undergone CABG), older,
d more likely to have diabetes. They have more extensive
tive-vessel CAD and more previous MIs and LV dysfunc-
on. Symptomatically, these patients have more prolonged
est pain than ACS patients without prior CABG. More than
% of post-CABG patients have resting ECG abnormalities,
d ECG stress tests are therefore less conclusive (940);
wever, a test that becomes positive after having been
gative is helpful in the diagnosis of ischemia. Myocardial
ress perfusion imaging and dobuta-mine echocardiography
e often helpful diagnostically (941). Furthermore, a positive
aging test can help to define the area of ischemia in
st-CABG patients with complex disease.
The outcomes of UA/NSTEMI in post-CABG patients are
ss favorable than those in patients who have not undergone
ABG. There is a high rate of embolization of atherosclerotic
aterial from friable grafts at the time of intervention, which
akes these procedures more difficult and which is associated
ith higher rates of complications (942). In one matched
se-control study of UA, the initial course was similar, but
st-CABG patients had twice the incidence of adverse
ents (death, MI, or recurrent UA) during the first year. This
as attributed to a lower rate of complete revascularization,
hich was possible in only 9 of 42 post-CABG patients
mpared with 39 of 52 patients who had not previously
dergone CABG (p0.001) (928). Results were direction- thly similar in the TIMI III registry of ACS, in which 16% of
tients were post-CABG. Here again, early outcomes in
st-CABG patients and others were equivalent, but at 1 year,
e rate of adverse events (death, MI, or recurrent ischemia)
as 39.3% for those who had previously undergone CABG
rsus 30.2% for those who had not (p0.002) (943).
Revascularization with either PCI or reoperation often is
dicated and is possible in post-CABG patients with UA/
STEMI. In a randomized controlled trial that compared
ents with PTCA of obstructed SVGs, there was no statisti-
lly significant difference in restenosis during a 6-month
riod, although a trend favored stents (34% vs 46%) (944).
lthough hemorrhagic complications were higher in the stent
oup, clinical outcomes (freedom from MI or repeat revas-
larization) were better (73% vs 58%, p0.03) (944).
.3.3. Conclusions
ost-CABG patients, especially those with only SVGs, are at
gh risk of UA/NSTEMI. There is a higher likelihood of
sease in SVGs than in native arteries, and this difference
creases with postoperative time. Pathologically and angio-
aphically, disease in SVGs has characteristics associated
ith instability. There also are difficulties with treadmill ECG
sting and less favorable outcomes with repeat revascular-
ation than in patients who have not undergone previous
ABG.
.4. Older Adults
ecommendations
ASS I
Older patients with UA/NSTEMI should be evaluated for appropri-
ate acute and long-term therapeutic interventions in a similar
manner as younger patientswith UA/NSTEMI. (Level of Evidence: A)
Decisions on management of older patients with UA/NSTEMI
should not be based solely on chronologic age but should be
patient-centered, with consideration given to general health,
functional and cognitive status, comorbidities, life expectancy,
and patient preferences and goals. (Level of Evidence: B)
Attention should be given to appropriate dosing (i.e., adjusted
by weight and estimated creatinine clearance) of pharmaco-
logical agents in older patients with UA/NSTEMI, because they
often have altered pharmacokinetics (due to reduced muscle
mass, renal and/or hepatic dysfunction, and reduced volume of
distribution) and pharmacodynamics (increased risks of hypo-
tension and bleeding). (Level of Evidence: B)
Older UA/NSTEMI patients face increased early procedural risks
with revascularization relative to younger patients, yet the overall
benefits from invasive strategies are equal to or perhaps greater
in older adults and are recommended. (Level of Evidence: B)
Consideration should be given to patient and family prefer-
ences, quality-of-life issues, end-of-life preferences, and socio-
cultural differences in older patients with UA/NSTEMI. (Level
of Evidence: C)
Older adults represent a group of patients in whom baseline
sk is higher (Table 25) and who have more comorbidities
t who derive equivalent or greater benefit (e.g., invasive vs
nservative strategy) compared to younger patients. Al-
ough a precise definition of “older patients” or “elderly” has
no
ha
ol
pa
w
ag
w
pe
w
ra
yo
C
st
up
li
as
sy
tr
th
yo
an
sy
de
th
dy
ol
co
M
pe
re
bu
w
fo
al
hi
at
6
O
re
ol
re
m
tr
in
so
m
ba
er
(9
do
pi
in
an
in
th
yo
fu
vu
al
ex
re
el
ti
a
se
st
co
ye
re
do
fr
U
(7
pa
fi
ab
dr
vo
an
6
O
ex
le
it
Ta
Le
45
55
65
75
85
de
of
e286 Anderson et al. JACC Vol. 61, No. 23, 2013
UA/NSTEMI Guideline: 2012 Update Incorporated June 11, 2013:e179–347t been established in the medical literature, many studies
ve used this term to refer to those who are 75 years and
der. On the basis of a large national ACS registry, older
tients make up a substantial portion of those presenting
ith UA/NSTEMI, with 35% older than 75 years and 11%
ed more than 85 years (946). Older persons also present
ith a number of special and complex challenges. First, older
rsons who develop UA/NSTEMI are more likely to present
ith atypical symptoms, including dyspnea and confusion,
ther than with the chest pain typically experienced by
unger patients with acute myocardial ischemia (947).
onversely, noncardiac comorbidities such as chronic ob-
ructive lung disease, gastroesophageal reflux disease,
per-body musculoskeletal symptoms, pulmonary embo-
sm, and pneumonia also are more frequent and may be
sociated with chest pain at rest that can mimic classic
mptoms of UA/NSTEMI. Hence, successful recognition of
ue myocardial ischemia in the elderly is often more difficult
an in younger patients. Second, they are more likely than
unger patients to have altered or abnormal cardiovascular
atomy and physiology, including a diminished beta-
mpathetic response, increased cardiac afterload due to
creased arterial compliance and arterial hypertension, or-
ostatic hypotension, cardiac hypertrophy, and ventricular
sfunction, especially diastolic dysfunction (948). Third,
der patients typically have developed significant cardiac
morbidities and risk factors, such as hypertension, prior
I, HF, cardiac conduction abnormalities, prior CABG,
ripheral and cerebrovascular disease, diabetes mellitus,
nal insufficiency, and stroke. Fourth, because of this larger
rden of comorbid disease, older patients tend to be treated
ith a greater number of medications and are at higher risk
r drug interactions and polypharmacy. Hence, among an
ready high-risk population, older age is associated with
gher disease severity and higher disease and treatment risk
presentation (946).
.4.1. Pharmacological Management
verall, although the elderly have been generally underrep-
sented in randomized controlled trials, when examined,
der subgroups appear to have relatively similar relative risk
ductions and similar or greater absolute risk reductions in
any end points as younger patients for commonly used
eatments in the management of UA/NSTEMI. In spite of an
ble 25. Impact of Age on Outcomes of Acute Coronary Syndro
Age Group
No. of Deaths
(Hospital Mortality Rate)*
ss than 45 y 20 (1.3)
to 54 y 79 (2.0)
to 64 y 171 (3.1)
to 74 y 373 (5.5)
to 84 y 439 (9.3)
y or more 260 (18.4)
*All p less than 0.0001. The GRACE risk model includes systolic blood pressure
viation, and cardiac arrest at hospital arrival. Modified with permission from A
acute coronary syndrome: observations from the Global Registry of Acute CoCCS  Canadian Cardiovascular Society classification; UA  unstable angina.creasing number of possible relative contraindications as-
ciated with older age, the rates of serious adverse events for
ost older patients generally remain low when evidence-
sed treatment for UA/NSTEMI is provided. Despite gen-
ally similar benefits, recent studies such as CRUSADE
46), TACTICS-TIMI 18 (188), and GRACE (945) have
cumented significantly lower use of evidence-based thera-
es in the elderly, including less use of an aggressive, early
vasive strategy and of key pharmacotherapies, including
ticoagulants, beta blockers, clopidogrel, and GP IIb/IIIa
hibitors.
With this said, precautions need to be taken to personalize
ese therapies (i.e., beginning with lower doses than in
unger patients, whenever appropriate, and providing care-
l observation for toxicity). Older persons are particularly
lnerable to adverse events from cardiovascular drugs due to
tered drug metabolism and distribution, as well as to
aggerated drug effects. Reductions in cardiac output and in
nal and hepatic perfusion and function decrease the rate of
imination of drugs in the elderly. Additionally, older pa-
ents typically have lower drug distribution volumes (due to
lower body mass). As a result, drugs need to be carefully
lected and individually adjusted. Current evidence demon-
rates that older adults are frequently excessively dosed. In a
mmunity-based registry, among treated patients aged 75
ars or older, 38% received an excessive dose of UFH, 17%
ceived excessive LMWH, and 65% received an excessive
se of a GP IIb/IIIa antagonist (946). A subsequent study
om the same registry found that 15% of major bleeding in
A/NSTEMI patients could be attributed to excessive dosing
38). Mortality and length of stay also were higher in
tients receiving excessive dosing.
In the elderly, drugs such as beta blockers that undergo
rst-pass hepatic metabolism exhibit increased bioavail-
ility (949). Exaggerated pharmacodynamic responses to
ugs often resulted from lower cardiac output, plasma
lume, and vasomotor tone, as well as blunted baroreceptor
d beta-adrenergic responses.
.4.2. Functional Studies
lder persons can have difficulty performing standardized
ercise tolerance tests because of age-related medical prob-
ms, such as general deconditioning, decreased lung capac-
y, chronic pain, sensory neuropathy, osteoarthritis, and
ACE Risk Model
Crude OR (95% CI) Adjusted OR (95% CI)
Reference Reference
1.47 (0.90 to 2.41) 1.95 (1.06 to 3.61)
2.35 (1.47 to 3.74) 2.77 (1.53 to 4.99)
4.34 (2.76 to 6.83) 4.95 (2.78 to 8.79)
7.54 (4.80 to 11.8) 8.04 (4.53 to 14.3)
16.7 (10.5 to 26.4) 15.7 (8.77 to 28.3)
serum creatinine, heart rate, initial cardiac enzyme, Killip class, ST- segment
, Makdisse M, Spencer F, et al. Impact of age on management and outcome
vents (GRACE). Am Heart J 2005; 149:67–73 (835).me: GR
, initial
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eexisting resting ECG abnormalities (892), arrhythmias
47,950), and cardiac hypertrophy often make the interpre-
tion of a standard stress ECG inconclusive or impossible. In
ch patients, alternative methods for evoking evidence of
ute myocardial ischemia, such as pharmacological stress
sting with dynamic cardiac imaging, may be substituted
ee also Section 3.4).
.4.3. Percutaneous Coronary Intervention
Older Patients
ecent evidence from several major interventional trials has
monstrated a clear benefit for older patients. A collabora-
ve meta-analysis of several more recently published PCI
ials (FRISC-II, TACTICS, RITA-3, VINO, and MATE)
ve suggested that the majority of the benefit from an
vasive strategy in the elderly has accrued from contempo-
ry strategies used in trials published after 1999 and in
tients with positive troponins or their cardiac biomarkers
28). These trials indicated that compared with younger
tients, the elderly gain important absolute benefits from an
rly invasive strategy but at a cost of increased bleeding.
pecifically, a significant benefit was seen in reduction of the
mbined end point of death and recurrent MI, but only a
end to reduction in death was noted. A recent observational
alysis in a community population failed to show an early
nefit on in-hospital survival with an invasive strategy in the
der subgroup (75 years or older), which highlights the need
r continued caution in applying trial results uniformly in
der patients (951). Thus, selection of older patients for an
rly invasive strategy is complex, including risk from
sease and risk from intervention, but given the absolute
nefits observed in these trials, age should not preclude
nsideration.
Despite these potential benefits, older patients are also far
ss likely to undergo angiography (RR 0.65, p0.001 at 6
eeks) and coronary revascularization (RR 0.79, p0.002 at
weeks) after a UA/NSTEMI episode than younger patients.
his apparent underuse of potentially beneficial interventions
ight be due in part to practitioner concerns about the increased
sk of complications. Finding the appropriate balance between
nefit and risk of aggressive therapies to maximize net clinical
tcome remains a challenge in the elderly.
.4.4. Contemporary Revascularization Strategies in
lder Patients
everal studies of PCI in patients aged 65 to 75 years have
own that success rates with experienced medical profes-
onals are similar to those in younger patients, but with even
der patients, success rates decline and complication rates
se. On the other hand, a Mayo Clinic review of PCI in
tients greater than 65 years old (of whom 75% had UA)
vealed an overall success rate of 93.5%, an immediate
-hospital mortality rate of 1.4%, and a need for emergency
ABG rate of only 0.7% (952). Angiographic outcome
anged little between the 65-to-69-year-old group and the
eater than 75-year-old group, and the 1-year event rate
eath, MI, CABG, repeat PCI, or severe angina) was 45.1%
all patients greater than 65 years old (952). Predictors of
tcomes (i.e., extent and severity of CAD and comorbidi- exes) after PCI in older patients were the same as those in
unger patients (953). Similarly, a review of coronary
enting in the elderly reported that procedural success rates
ere high (95% to 98%) and periprocedural complication
tes were low (MI 1.2% to 2.8%, urgent CABG 0.9% to
8%, repeat PCI 0% to 0.6%) in the elderly, with little
fference between those greater than 75 years old and those
ss than 65 years old (954). Subgroup analyses in both TIMI
IB (136) and FRISC-II (251) showed a greater advantage of
e invasive strategy in patients older than 65 years of age.
ore contemporary studies have confirmed this advantage,
cluding TACTICS-TIMI 18 (955). Among patients older
an 75 years of age, the early invasive strategy conferred an
solute reduction of 10.8 percentage points (to 10.8% from
.6%; p0.016) and a relative reduction of 56% in death or
I at 6 months; however, benefits came with an increased
sk of major bleeding events (16.6% vs 6.5%; p0.009).
A review of 15,679 CABG procedures performed in patients
eater than 70 years old from the Toronto Hospital (956)
ported encouraging results. Operative mortality rates declined
om 7.2% in 1982 to 1986, to 4.4% in 1987 to 1991 (and from
.2% to 9.1% for high-risk patients) but showed little further
ange in the period of 1992 to 1996. Predictors of operative
ath (LV dysfunction, previous CABG, peripheral vascular
sease, and diabetes) were similar to those in younger patients.
Operative morbidity and mortality rates increase for
ABG with advanced age, but outcomes have been favorable
mpared with medical therapy, and quality of life improves
57–961). A recent retrospective review of 662,033 patients
ho underwent cardiac surgical procedures performed using
e STS National Cardiac Database (962) found a CABG
erative mortality of 2.8% for patients 50 to 79 years of age,
1% for patients 80 to 89 years of age, and 11.8% for
tients aged 90 years or more. This study included more than
000 patients over 90 years of age and 5 centenarians and
cumented that the 57% of nonagenarians without certain risk
ctors (renal failure, IABP, emergency surgery, or peripheral or
rebrovascular disease) constituted a relatively low-risk group
ith an operative mortality of only 7.2%, similar to the overall
sk in octogenarians. Thus, with appropriate selection, CABG
rgery can be an appropriate revascularization strategy in even
e oldest patient subgroups.
.4.5. Conclusions
lder patients with UA/NSTEMI tend to have atypical
esentations of disease, substantial comorbidity, ECG stress
sts that are more difficult to interpret, and different physio-
gical responses to pharmacological agents compared with
unger patients. Although they are at highest risk, guideline-
commended therapies are used less frequently. Even though
eir outcomes with interventions and surgery are not as
vorable as those of younger patients, coronary revascular-
ation should be recommended when the same group of
ognostic risk factors that play a role in the younger age
oup are taken into account. The approach to these patients
so must consider general medical and cognitive status,
eeding risk and other risk of interventions, anticipated life
pectancy, and patient or family preferences.
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ASS I
Creatinine clearance should be estimated in UA/NSTEMI pa-
tients and the doses of renally cleared medications should be
adjusted according to the pharmacokinetic data for specific
medications. (Level of Evidence: B) (963,964)
Patients undergoing cardiac catheterization with receipt of
contrast media should receive adequate preparatory hydration.
(Level of Evidence: B) (965,966)
Calculation of the contrast volume to creatinine clearance
ratio is useful to predict the maximum volume of contrast
media that can be given without significantly increasing the
risk of contrast-associated nephropathy. (Level of Evidence: B)
(967,968)
ASS IIa
An invasive strategy is reasonable in patients with mild (stage
2) and moderate (stage 3) CKD. (Level of Evidence: B)
(963,964,969,970) (There are insufficient data on benefit/
risk of invasive strategy in UA/NSTEMI patients with advanced
CKD [stages 4, 5].)
Chronic kidney disease (CKD) is not only a coronary risk
uivalent for ascertainment of coronary risk but also a risk factor
r the development and progression of CVD (848). Chronic kidney
sease constitutes a risk factor for adverse outcomes after MI (971),
cluding NSTEMI and other coronary patient subsets. In the highly
lidated GRACE risk score, serum creatinine is 1 of the 8
dependent predictors of death (945,969).
In recent study, even early CKD constituted a significant
sk factor for cardiovascular events and death (971,972).
hronic kidney disease also predicts an increase in recurrent
rdiovascular events (973). Cardiovascular death is 10 to 30
mes higher in dialysis patients than in the general popula-
on. The underrepresentation of patients with renal disease in
ndomized controlled trials of CVD is of concern (185). Most
the limited evidence available and current opinion suggest
at when appropriately monitored, cardiovascular medications
d interventional strategies can be applied safely in those with
nal impairment and provide therapeutic benefit (971). How-
er, not all recent evidence is consistent with this premise:
orvastatin did not significantly reduce the primary end point of
rdiovascular death, nonfatal MI, or stroke in a prospective
ndomized trial of patients with diabetes and end-stage CKD
ho were undergoing hemodialysis (240). The preference for
imary PCI has also been questioned (241).
Particularly in the setting of ACS, bleeding complica-
ons are higher in this patient subgroup because of platelet
s-function and dosing errors; benefits of fibrinolytic
erapy, antiplatelet agents, and anticoagulants can be
gated or outweighed by bleeding complications; and
nin-angiotensin-aldosterone inhibitors can impose a greater
sk because of the complications of hyperkalemia and worsen-
g renal function in the CKD patient. Angiography carries an
creased risk of contrast-induced nephropathy; the usual bene-
ts of percutaneous interventions can be lessened or abolished;
d PCI in patients with CKD is associated with a higher rate of
rly and late complications of bleeding, restenosis, and death
85). Thus, the identification of CKD is important in that it 95presents an ACS subgroup with a far more adverse prognosis
t for whom interventions have less certain benefit.
Coronary arteriography is a frequent component of the care
ACS patients. As such, contrast-induced nephropathy can
nstitute a serious complication of diagnostic and interven-
onal procedures (see Section 6.5.1). Identification of CKD
tients as recommended in the AHA science advisory on
tection of chronic kidney disease in patients with or at
creased risk of cardiovascular disease should guide the use
isosmolar contrast agents (848).
The advisory recommendations are that all patients with CVD
screened for evidence of kidney disease by estimating
omerular filtration rate, testing for microalbuminuria, and
easuring the albumin-to-creatinine ratio (Class IIa, Level of
vidence: C). A glomerular filtration rate less than 60 mL per
in per 1.73 square meters of body surface should be regarded
abnormal (Class I, Level of Evidence: B). Furthermore, the
bumin-to-creatinine ratio should be used to screen for the
esence of kidney damage in adult patients with CVD, with
lues greater than 30 mg of albumin per 1 g of creatinine
garded as abnormal (Class IIa, Level of Evidence: B).
A diagnosis of renal dysfunction is critical to proper
edical therapy of UA/NSTEMI. Many cardiovascular drugs
ed in UA/NSTEMI patients are renally cleared; their doses
ould be adjusted for estimated creatinine clearance (see
so Section 3). In a large community-based registry study,
% of patients with UA/NSTEMI received excessive initial
sing of at least 1 antiplatelet or antithrombin agent (UFH,
MWH, or GP IIb/IIIa inhibitor) (738). Renal insufficiency
as an independent predictor of excessive dosing. Dosing
rors predicted an increased risk of major bleeding. Clinical
udies and labeling that defines adjustments for several of
ese drugs have been based on the Cockroft-Gault formula
r estimating creatinine clearance, which is not identical to
e MDRD formula. Use of the Cockroft-Gault formula to
nerate dose adjustments is recommended. The impact of
nal dysfunction on biomarkers of necrosis (i.e., troponin) is
scussed in Section 2.2.8.2.1.
To increase the meager evidence base and to optimize care
r this growing high-risk population, the recognition of CKD
tients with or at risk of CVD and the inclusion and
porting of renal disease in large CVD trials must be
creased in the future.
.5.1. Angiography in Patients With CKD
EW SECTION)
ince the 2007 UA/NSTEMI Guidelines were published (7),
veral larger randomized trials have been published that
ported no difference in contrast-induced nephropathy (CIN)
hen iodixanol was compared with various other low-
molar contrast media (LOCM) (974–977). These and other
ndomized trials comparing isosmolar iodixanol with
OCM have been summarized in 2 mutually supportive and
mplementary meta-analyses involving 16 trials in 2,763
tients (978) and 25 trials in 3,260 patients (979), respec-
vely. When more recent trials were combined with the older
udies, the data supporting a reduction in CIN favoring
dixanol were no longer significant (summary RR: 0.79;
% CI: 0.56 to 1.12; p0.29 (978); summary RR: 0.80; 95%
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banalyses showed variations in relative renal safety by
ecific LOCM: A reduction in CIN was observed when
dixanol was compared to ioxaglate, the only ionic LOCM
R: 0.58; 95% CI: 0.37 to 0.92; p0.022) (978), and to
hexol, a nonionic LOCM (RR: 0.19; 95% CI: 0.07 to 0.56;
0.0002) (978), but no difference was noted in comparisons
iodixanol with iopamidol, iopromide, or ioversol (978),
d a single trial favored iomeprol (974). A pooled compar-
on of iodixanol with all nonionic LOCM other than iohexol
dicated equivalent safety (RR: 0.97; 95% CI: 0.72 to 1.32;
0.86) (979). Results were consistent regardless of ancil-
ry preventive therapies (hydration, acetylcysteine), route of
ministration (IV or intra-arterial), age, sex, dose, or preex-
ting CKD or diabetes. Of further interest, findings were
milar in the 8 studies (n1,793 patients) performed in the
tting of coronary angiography (978). A more recent study
mparing iodixanol versus iopamidol provides additional
pportive evidence (980). However, even these clinical
ferences must be tempered by the relative paucity of
ad-to-head trials comparing CIN rates among the various
ntrast media and the variability in results (e.g., for iohexol
rsus other low-osmolar comparators) (981–984). Further-
ore, the assumption that a transient rise in serum creatinine
ter 24 to 48 hours is a reliable predictor of the more serious
t somewhat delayed development of renal failure requiring
spitalization or dialysis has been challenged. A nationwide
wedish survey (985) of hospitalizations for renal failure
ter coronary procedures in 57,925 patients found that this
sk was paradoxically higher with iodixanol (1.7%) than
xaglate (0.8%) or iohexol (0.9%; p0.001). Although the
sult was observational, hence subject to selection bias, it
rsisted in analyses of high-risk patient subsets (patients
ith diabetes, prior history of renal failure), in multivariable
alysis, and in hospitals crossing over from ioxaglate to
dixanol. Iodixanol’s greater viscosity was speculated but
t demonstrated to be a possible mechanism for the ob-
rved effect. Thus, an overall summary of the current
tabase, updated since previous guideline recommendations
2007 (7), is that strength and consistency of relationships
tween specific isosmolar or low-osmolar agents and CIN or
nal failure are not sufficient to enable a guideline statement
selection among commonly used low-osmolar and isos-
olar media. Instead, the 2012 writing group recommends
cusing on operator conduct issues shown to be important to
otect patients, that is, 1) proper patient preparation with
dration, and 2) adjustment of maximal contrast dose to
ch patient’s renal function and other clinical characteristics.
With respect to patient preparation, the 2012 writing group
viewed several trials addressing the optimal preparatory
gimen of hydration and pharmacotherapy. The basic prin-
ple of hydration follows from experimental studies and
inical experience, with isotonic or half-normal saline alone
ing the historical gold standards (965,966,986–988). More
cently, sodium bicarbonate has been tested as the hydrating
lution. Some trials have reported superiority of sodium bicar-
nate over saline in preventing CIN (989–992). Similarly,
me have reported a benefit of N-acetylcysteine administration
adjunctive therapy to hydration (989,993), whereas others deve not (994,995). Thus, although the 2012 writing group
und the evidence compelling for adequate hydration prepara-
ry to angiography with contrast media, it found the evidence
sufficient to recommend a specific regimen.
With respect to limitation of contrast dose by renal function,
ounting evidence points to renal-function–specific limits on
aximal contrast volumes that can be given without signifi-
ntly increasing the baseline risk of provoking CIN. In a
ntemporary study, Laskey et al. studied 3,179 consecutive
tients undergoing PCI and found that a contrast volume to
eatinine clearance ratio 3.7 was a significant and indepen-
nt predictor of an early and abnormal increase in serum
eatinine (967). In an earlier trial, administration of a contrast
lume of 5 mLbody weight (kg)/serum creatinine (mg/dL),
plied to 16,592 patients undergoing cardiac catheterization,
as associated with a 6-fold increase in the likelihood of patients
veloping CIN requiring dialysis (968).
Patients with CKD are consistently underrepresented in
ndomized controlled trials of cardiovascular disease (185).
he impact of an invasive strategy has been uncertain in this
oup. The SWEDEHEART (Swedish Web-System for En-
ncement and Development of Evidence-Based Care in
eart Disease Evaluated According to Recommended Ther-
ies) study included a cohort of 23,262 patients hospitalized
r NSTEMI in Sweden between 2003 and 2006 who were
e 80 years (970). This contemporary nationwide registry
nearly all consecutive patients examined the distribution of
KD and the use of early revascularization after NSTEMI
d evaluated whether early revascularization (by either PCI
CABG) within 14 days of admission for NSTEMI altered
tcomes at all stages of kidney function.
In SWEDEHEART, all-cause mortality was assessed at 1
ar and was available in 99% of patients. Moderate or
ore advanced CKD (estimated glomerular filtration rate
GFR] 60 mL/min per 1.73 m2) was present in 5,689
tients (24.4%). After multivariable adjustment, the 1-year
ortality in the overall cohort was 36% lower with early
vascularization (HR: 0.64; 95% CI: 0.56 to 0.73; p0.001)
70). The magnitude of the difference in 1-year mortality
as similar in patients with normal eGFR (early revascular-
ation versus medically treated: 1.9% versus 10%; HR: 0.58;
% CI: 0.42 to 0.80; p0.001), mild CKD [eGFR 60 to 89
L/min per 1.73 m2] (2.4% versus 10%; HR: 0.64; 95% CI:
52 to 0.80; p0.001), and moderate CKD [eGFR 30 to 59
L/min per 1.73 m2] (7% versus 22%; HR: 0.68; 95% CI:
54 to 0.86; p0.001). The benefit of an invasive therapy
as not evident in patients with severe CKD stage 4 [eGFR
to 29 mL/min per 1.73 m2] (22% versus 41%; HR: 0.91;
% CI: 0.51 to 1.61; p0.780) or in those with CKD stage
kidney failure [eGFR15 mL/min per 1.73 m2 or receiving
alysis] (44% versus 53%; HR: 1.61; 95% CI: 0.84 to 3.09;
0.150). Early revascularization was associated with in-
eased 1-year survival in UA/NSTEMI patients with mild to
oderate CKD, but no association was observed in those with
vere or end-stage kidney disease (970).
The findings from SWEDEHEART are limited by their
n-randomized nature and the potential for selection bias
spite the intricate multivariable adjustment (970). On the other
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morbidities and is therefore more reflective of real-world patients.
Recently, a collaborative meta-analysis of randomized
ntrolled trials that compared invasive and conservative
eatments in UA/NSTEMI was conducted to estimate the
fectiveness of early angiography in patients with CKD
69). The meta-analysis demonstrated that an invasive strat-
y was associated with a significant reduction in rehospital-
ation (RR: 0.76; 95% CI: 0.66 to 0.87; p0.001) at 1 year
mpared with conservative strategy. The meta-analysis did
t show any significant differences with regard to all-cause
ortality (RR: 0.76; 95% CI: 0.49 to 1.17; p0.21), nonfatal
I (RR: 0.78; 95% CI: 0.52 to 1.16; p0.22), and the
mposite of death/nonfatal MI (RR: 0.79; 95% CI: 0.53 to
18; p0.24) (969).
Our recommendation is that an early invasive strategy (i.e.,
agnostic angiography with intent to perform revasculariza-
on) is a reasonable strategy in patients with mild and
oderate CKD. Clinicians should exercise judgment in all
pulations with impaired kidney function when considering
hether to implement an invasive strategy. Such implemen-
tion should be considered only after careful assessment of
e risks, benefits, and alternatives for each individual patient.
The observational data with regard to patients with mild to
vere CKD also support the recognition that CKD is an
derappreciated high-risk characteristic in the UA/NSTEMI
pulation. The increased risk of mortality associated with
ild, moderate, and severe CKD remains evident across
udies (963,964,969,996). Indeed, the risks of short- and
ng-term mortality are increased as the gradient of renal
sfunction worsens (963,969,996). The optimal role of early
vascularization in this heterogeneous population of patients
mains an important topic of research and investigation as
scussed earlier in this update (997).
.6. Cocaine and Methamphetamine Users
ecommendations
ASS I
Administration of sublingual or intravenous NTG and intrave-
nous or oral calcium channel blockers is recommended for
patients with ST-segment elevation or depression that accom-
panies ischemic chest discomfort after cocaine use. (Level of
Evidence: C)
Immediate coronary angiography, if possible, should be per-
formed in patients with ischemic chest discomfort after co-
caine use whose ST segments remain elevated after NTG and
calcium channel blockers; PCI is recommended if occlusive
thrombus is detected. (Level of Evidence: C)
Fibrinolytic therapy is useful in patients with ischemic chest
discomfort after cocaine use if ST segments remain elevated
despite NTG and calcium channel blockers, if there are no
contraindications, and if coronary angiography is not possible.
(Level of Evidence: C)
ASS IIa
Administration of NTG or oral calcium channel blockers can be
beneficial for patients with normal ECGs or minimal ST- aosegment deviation suggestive of ischemia after cocaine use.
(Level of Evidence: C)
Coronary angiography, if available, is probably recommended
for patients with ischemic chest discomfort after cocaine use
with ST-segment depression or isolated T-wave changes not
known to be previously present and who are unresponsive to
NTG and calcium channel blockers. (Level of Evidence: C)
Management of UA/NSTEMI patients with methamphetamine
use similar to that of patients with cocaine use is reasonable.
(Level of Evidence: C)
ASS IIb
Administration of combined alpha- and beta-blocking agents
(e.g., labetalol) may be reasonable for patients after cocaine
use with hypertension (systolic blood pressure greater than
150 mm Hg) or those with sinus tachycardia (pulse greater
than 100 beats per min) provided that the patient has received
a vasodilator, such as NTG or a calcium channel blocker, within
close temporal proximity (i.e., within the previous hour). (Level
of Evidence: C)
ASS III
Coronary angiography is not recommended in patients with
chest pain after cocaine use without ST-segment or T-wave
changes and with a negative stress test and cardiac biomark-
ers. (Level of Evidence: C)
The use of cocaine can produce myocardial ischemia,
ereby leading to UA/NSTEMI (998–1001). The widespread
e of cocaine makes it mandatory to consider this cause,
cause its recognition mandates special management. Spe-
fically, initial management recommendations for cocaine-
duced ACS include NTG and calcium channel antagonists.
ssessment for resolution of chest discomfort and ECG
anges is then undertaken before fibrinolytic therapy is
itiated or angiography is considered. The use of beta
ockers in close proximity (i.e., within 4 to 6 h) of cocaine
posure is controversial, with some evidence for harm; thus,
hen used, the guidelines recommend combination alpha and
ta blockade in addition to a vasodilator. There are no data
guide recommendations for beta blockade later after
posure, after cocaine elimination.
The action of cocaine is to block presynaptic reuptake of
urotransmitters such as norepinephrine and dopamine,
hich produces excess concentrations at the postsynaptic
ceptors that lead to sympathetic activation and the stimu-
tion of dopaminergic neurons (1002). There may also be a
rect contractile effect on vascular smooth muscle (999).
etoxification is accomplished with plasma and liver cholin-
terases, which form metabolic products that are excreted in
e urine. Infants, elderly patients, and patients with hepatic
sfunction lack sufficient plasma cholinesterase to metabo-
ze the drug (1003) and therefore are at high risk of adverse
fects with cocaine use.
.6.1. Coronary Artery Spasm With Cocaine Use
he basis for coronary spasm has been demonstrated in both
vitro (1003) and in vivo (999,1004–1008) experiments in
imals and humans. Reversible vasoconstriction of rabbit
rtic rings has been demonstrated with cocaine in concen-
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lcium channel blockers markedly inhibits cocaine-induced
soconstriction. Coronary injection of cocaine produces
soconstriction in miniswine with experimentally induced
nocclusive athero-sclerotic lesions (1009).
Nademanee et al. (1010) performed 24-h ECG monitoring
21 male cocaine users after admission to a substance abuse
eatment center and found that 8 had frequent episodes of
T-segment elevation, most during the first 2 weeks of
ithdrawal. In cocaine users with prolonged myocardial
chemia, coronary arteriography can reveal coronary artery
asm with otherwise normal-appearing coronary arteries or
ith underlying minimally obstructive coronary atheroscle-
sis (999,1001,1004). The cocaine-induced increase in cor-
ary vascular resistance is reversed with calcium channel
ockers (1005,1011). Cocaine increases the response of
atelets to arachidonic acid, thus increasing thromboxane A2
oduction and platelet aggregation (1012). In addition,
versible combined reduction in protein C and antithrombin
I has been observed in patients with cocaine-related arterial
rombosis (1013). All of these effects favor coronary throm-
sis (999,1006,1014). Coronary thrombosis can also de-
lop as a consequence of coronary spasm.
Cocaine users can develop ischemic chest discomfort that
indistinguishable from the UA/NSTEMI secondary to
ronary atherosclerosis. The patient who presents with
olonged myocardial ischemia should be questioned about
e use of cocaine. In a study by Hollander et al. (1015) the
esence or absence of cocaine use was assessed in only 13% of
tients who presented to the ED with chest pain. (Table 26) lists
e clinical characteristics of a typical patient with cocaine-
lated chest pain or MI (1001).
Most patients who present to the ED with cocaine-associated
est pain do not develop MI (1016). MI development has been
ported to occur only in 6% of such patients (1001).
Accelerated coronary atherosclerosis has been reported in
ronic users of cocaine (1017,1018); coronary artery spasm
more readily precipitated at sites of atherosclerotic plaques
004). Cocaine causes sinus tachycardia, as well as an
crease in blood pressure and myocardial contractility,
ereby increasing myocardial oxygen demand (1005). These
creases can precipitate myocardial ischemia and UA/
STEMI in both the presence and absence of obstructive
ronary atherosclerosis and coronary spasm.
Aortic dissection (1019) and coronary artery dissection
99,1019) have been reported as consequences of cocaine
e. Other reported cardiac complications are myocarditis
018) and cardiomyopathy (1020,1021).
.6.2. Treatment
hen a patient with or suspected of cocaine use is seen in the
D with chest pain compatible with myocardial ischemia and
T-segment elevation, sublingual NTG or a calcium channel
ockers (e.g., diltiazem 20 mg IV) should be administered
99,1008). If there is no response, immediate coronary
giography should be performed, if possible. Fibrinolytic
erapy has been successfully employed in patients with MI
ter cocaine use, although these patients frequently have con-
aindications to fibrinolysis, including hypertension, seizures, or pertic dissection. Thus, PCI may be a preferred method of
vascularization in this setting. However, even this therapeutic
rategy is problematic in subjects with cocaine-related MI; those
whom stents are deployed are at substantial risk of subsequent
-stent thrombosis unless double-antiplatelet therapy (ASA and
opidogrel) is ingested regularly and predictably for several
onths afterward, and those who partake in substance abuse
ten are unreliable in adhering to such a regimen. Thus,
re-metal stents, which require a shorter duration of dual-
tiplatelet therapy, generally are preferred to DES in cocaine
users. If thrombus is present and PCI is unavailable or
effective, fibrinolytic agents may be administered if there are
contraindications (1022,1023). If catheterization is not avail-
le, intravenous fibrinolytic therapy may be considered in
tients with ST-segment elevation and clinical symptoms
nsistent with MI.
If the ECG is normal or shows only minimal T-wave
anges and there is a history of chest pain compatible with
ute myocardial ischemia, the patient should receive sublin-
al NTG or an oral calcium channel blocker and be
served. After cocaine use, increased motor activity, skeletal
uscle injury, and rhabdomyolysis can occur, causing CK
d even CK-MB elevation in the absence of MI (1024).
roponin I and TnT are more specific for myocardial injury
d therefore are preferred. Blood should be drawn twice for
rum markers of myocardial necrosis at 6-h intervals. If the
CG shows ST-segment changes and the cardiac biochemical
arkers are normal, the patient should be observed in the
spital in a monitored bed for 24 h; most complications will
cur within 24 h (1025). If the patient’s clinical condition is
changed and the ECG remains unchanged after 24 h, the
tient can be discharged (1023). A shorter observation
riod of 9 to 12 h, with measurement of troponin levels at 3,
and 9 h after presentation, also has been validated (1026).
Many observers believe that beta blockers are contraindi-
ted in cocaine-induced coronary spasm because there is
idence from a single double-blind, randomized, placebo-
ntrolled trial that beta-adrenergic blockade augments
caine-induced coronary artery vasoconstriction (1027).
thers believe that if the patient has a high sympathetic state
ith sinus tachycardia and hypertension, beta blockers should
used (999). Labetalol, an alpha and beta blocker, has
en advocated, because it has been shown not to induce
ble 26. Clinical Characteristics in the Typical Patient With
caine-Related Chest Pain, Unstable Angina, or Myocardial
farction
ung age, usually less than 40 years
ale gender
garette smoker, but no other risk factors for atherosclerosis
ronic or first-time cocaine user
mptom onset minutes or even several hours after cocaine use
sociated with all routes of administration
ay occur with small or large doses
ten associated with concomitant use of cigarettes and/or alcohol
Reprinted from Progressive Cardiovascular Disease, Pitts WF, Lange RA,
garroa JE, Hillis LD. Cocaine-induced myocardial ischemia and infarction:
thophysiology, recognition, and management, 65–76. Copyright 1997, with
rmission from Elsevier (857).
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ta-adrenergic– blocking action predominates over its alpha-
renergic–blocking activity in the doses that are commonly
ed (1028). Therefore, in cocaine-induced myocardial ischemia
d vasoconstriction, NTG and calcium channel blockers are the
eferred drugs. Both NTG and verapamil have been shown to
verse cocaine-induced hypertension, coronary arterial vasocon-
riction (1008,1027), and tachycardia (verapamil).
.6.3. Methamphetamine Use and UA/NSTEMI
iven the rapid increase in methamphetamine abuse, recog-
tion of its cardiovascular risk is of mounting importance.
urrently, the evidence base for UA/NSTEMI after metham-
etamine and its treatment is limited to a few publications of
se reports and small series (1029–1032). These suggest that
CS is increasingly common in patients evaluated in the ED
r chest discomfort after methamphetamine use and that the
equency of other potentially life-threatening arrhythmias is not
gligible (1030). Clinical presentation resembles that of
caine-associated ACS. On the basis of the similarities in
thophysiology and these few clinical observations, therapy
milar to that of cocaine-induced UA/NSTEMI is recommended
nding information more specific to methamphetamine.
.7. Variant (Prinzmetal’s) Angina
ecommendations
ASS I
Diagnostic investigation is indicated in patients with a clinical
picture suggestive of coronary spasm, with investigation for
the presence of transient myocardial ischemia and ST-segment
elevation during chest pain. (Level of Evidence: A)
Coronary angiography is recommended in patients with epi-
sodic chest pain accompanied by transient ST-segment eleva-
tion. (Level of Evidence: B)
Treatment with nitrates and calcium channel blockers is rec-
ommended in patients with variant angina whose coronary
angiogram shows no or nonobstructive coronary artery lesions.
Risk factor modification is recommended, with patients with
atherosclerotic lesions considered to be at higher risk. (Level
of Evidence: B)
ASS IIb
Percutaneous coronary intervention may be considered in pa-
tients with chest pain and transient ST-segment elevation and a
significant coronary artery stenosis. (Level of Evidence: B)
Provocative testing may be considered in patients with no
significant angiographic CAD and no documentation of tran-
sient ST-segment elevation when clinically relevant symptoms
possibly explained by coronary artery spasm are present.
(Level of Evidence: C)
ASS III
Provocative testing is not recommended in patients with
variant angina and high-grade obstructive stenosis on coronary
angiography. (Level of Evidence: B)
Variant angina (Prinzmetal’s angina, periodic angina) is a
rm of UA that usually occurs spontaneously and is charac-
rized by transient ST-segment elevation that spontaneously (1solves or resolves with NTG use without progression to MI
033). The earliest stages of MI can also be associated with
clic ST-segment elevations, but MI does not possess the
ture of periodic angina. The spasm is most commonly focal
d can occur simultaneously at more than 1 site (1034).
ven coronary segments that are apparently normal on
ronary angiography often have evidence of mural athero-
lerosis on intravascular ultrasound (1035). This can result
localized endothelial dysfunction and coronary spasm.
Patients with Prinzmetal’s angina frequently have coronary
tery plaques that can be either nonobstructive or obstructive
036). Walling et al., (1037) reported that coronary arteriog-
phy showed 1-vessel disease in 81 (39%) of 217 patients
d multivessel disease in 40 (19%). Rovai et al., (1038)
und a similar high prevalence of obstructive disease in 162
tients with variant angina.
.7.1. Clinical Picture
lthough chest discomfort in the patient with variant angina
n be precipitated by exercise, it usually occurs without any
eceding increase in myocardial oxygen demand; the major-
y of patients have normal exercise tolerance, and stress
sting may be negative. Because the anginal discomfort
ually occurs at rest without a precipitating cause, it may
mulate UA/NSTEMI secondary to coronary atherosclerosis.
pisodes of Prinzmetal’s angina often occur in clusters, with
olonged asymptomatic periods of weeks to months. Attacks
n be precipitated by an emotional stress, hyperventilation
039), exercise (1040), or exposure to cold (1041). A
rcadian variation in the episodes of angina is most often
esent, with most attacks occurring in the early morning
042). Compared with patients with chronic stable angina,
tients with variant angina are younger and, except for
oking, have fewer coronary risk factors (1043,1044). Some
udies have shown an association of variant angina with
her vasospastic disorders, such as migraine headache and
aynaud’s phenomenon (1045). The presence of syncope
ring an episode of chest pain suggests severe ischemia
lated to an acute occlusion, often due to focal spasm.
Most often, the attacks of angina resolve spontaneously
ithout evidence of MI. However, a prolonged vasospasm
ay result in complications such as MI, a high degree of AV
ock, life-threatening ventricular tachycardia, or sudden
ath (1046,1047).
.7.2. Pathogenesis
he pathogenesis of focal coronary spasm in this condition is
t well understood. The probable underlying defect is the
esence of dysfunctional endothelium that exposes the me-
al smooth muscle to vasoconstrictors such as cat-
holamines, thromboxane A2, serotonin, histamine, and
dothelin (1048). Endothelial dysfunction also can impair
ronary flow-dependent vasodilatation owing to the de-
eased production and release of nitric oxide (1049) and
hanced phosphorylation of myosin light chains, an impor-
nt step in smooth muscle contraction (1050). There can be
imbalance between endothelium-produced vasodilator fac-
rs (i.e., prostacyclin, nitric oxide) and vasoconstrictor fac-
rs (i.e., endothelin, angiotensin II) that favors the latter
051). There also is evidence of involvement of the auto-
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d enhanced reactivity of the alpha-adrenergic vascular
ceptors (1049,1052,1053). Regardless of the mechanism,
e risk for focal spasm is transient but recurrent.
.7.3. Diagnosis
he key to the diagnosis of variant angina is the documen-
tion of ST-segment elevation in a patient during transient
est discomfort (which usually occurs at rest, typically in the
rly morning hours, and nonreproducibly during exercise)
d that resolves when the chest discomfort abates. Typically,
TG is exquisitely effective in relieving the spasm. ST-
gment elevation implies transmural focal ischemia associ-
ed with complete or near-complete coronary occlusion of an
icardial coronary artery in the absence of collateral circu-
tion. In variant angina, the dynamic obstruction can be
perimposed on severe or nonsevere coronary stenosis or
pervene in an angiographically normal coronary artery
gment. Hence, coronary angiography is usually part of the
orkup of these patients and can help orient treatment.
It is noteworthy that spasm often develops spontaneously
ring angiography, which aids the diagnosis in patients with
previously documented ST-segment elevation; catheter-
duced spasm is not, however, an indicator of vasospastic
sease. Diagnostic tests for Prinzmetal’s angina are based on
e recording of transient ST-segment elevation during an
isode of chest pain. Continuous 12-lead ECG monitoring
n be performed for this purpose in-hospital or as an
tpatient; recording during numerous episodes of pain im-
oves diagnostic sensitivity. A treadmill exercise test is also
eful; one third of patients will show ST-segment elevation,
other third ST-segment depression, and one third no
T-segment change. Interestingly, the results may not be
producible within the same patients and are more often
sitive when the test is performed in the early morning
urs. A 2-dimensional echocardiogram or the injection of a
clear marker at the time of chest pain may help document
e presence of transmural ischemia. A number of other
ovocative tests can be used to precipitate coronary artery
asm when the diagnosis is suspected but not objectively
cumented. Nitrates and calcium channel blockers should be
ithdrawn well before provocative testing. These tests are
ore often used during coronary angiography; the spasm can
en be visualized before the appearance of chest pain and
omptly relieved by the intracoronary injection of NTG. The
st can also be performed in a coronary care unit setting
hile the patient is monitored for ST-segment elevation, but
is is recommended only if the coronary anatomy is known.
uch nonpharmacological tests include the cold pressor test
d hyperventilation performed for 6 min in the morning,
one or after exercise (1054). Pharmacological tests in
neral provide a better diagnostic yield. Ergonovine, methy-
rgonovine, and ergometrine have been most widely studied
d used in the past, but methylergonovine and ergometrine
e no longer generally available, and the use of ergonovine
limited. Acetylcholine and methacholine are now predom-
antly used for this diagnostic purpose. Although the spasm
usually promptly relieved with NTG administered intra-
ronarily or intravenously, it may at times be refractory to werapy with NTG and other vasodilators and may be recur-
nt in the same segment or in other coronary artery seg-
ents, resulting in prolonged ischemia, MI, or occasionally,
ath (1055). For these reasons, provocative tests are now
rely used and are limited to a few indications, such as
tients with suggestive symptoms that could be helped by an
propriate diagnosis not otherwise reached, patients in
hom treatment with nitrates and calcium channel blockers
s failed, and patients with a life-threatening disease in
hom the physician wants to verify the efficacy of the
eatment. Thus, patients with a positive hyperventilation test
e more likely to have a higher frequency of attacks,
ultivessel spasm, or high degree of AV block or ventricular
chycardia than are patients with a negative hyperventilation
st (1054), and high-risk patients whose tests become nega-
ve with treatment are more likely to have a favorable
ng-term course. The investigation of coronary spasm in
tients with coronary artery lesions of borderline signifi-
nce can be complemented by other diagnostic procedures
ch as intravascular ultrasound, functional flow reverse, and
her functional testing to assess more accurately the signif-
ance of the obstruction.
.7.4. Treatment
oronary spasm is usually very responsive to NTG, long-
ting nitrates, and calcium channel blockers (1056–1058),
hich are considered first-line therapies. (Beta-blockers have
eoretical adverse potential, and their clinical effect is
ntroversial.) Smoking should be discontinued. Usually, a
lcium channel blocker in a moderate to high dose (e.g.,
rapamil 240 to 480 mg per d, diltiazem 180 to 360 mg per
or nifedipine 60 to 120 mg per d) is started; patients with
ry active disease can require a combination of nitrates and
calcium channel blockers of different classes (i.e., a
hydropyridine with verapamil or diltiazem). Alpha-receptor
ockers have been reported to be of benefit, especially in
tients who are not responding completely to calcium
annel blockers and nitrates (1050). In patients who develop
ronary spasm (with or without provocation) during coro-
ry angiography, 0.3 mg of NTG should be infused directly
to the coronary artery that is involved.
.7.5. Prognosis
he prognosis of variant angina is usually excellent in
tients with variant angina who receive medical therapy,
pecially in patients with normal or near-normal coronary
teries. Yasue et al. (1059) reported an 89% to 97% overall
year survival rate. In a 7-year follow-up in approximately
0 patients, the incidence of sudden death was 3.6% and the
cidence of MI was 6.5% (1059). Patients with coronary
tery vasospasm superimposed on a fixed obstructive CAD
ve a worse prognosis. In a study of 162 patients with
riant angina by Rovai et al. (1038), patients with normal
ronary arteries and single-vessel disease had a 5-year
rvival rate of 95% compared with a rate of 80% for those
ith multivessel disease. Almost identical survival rates were
ported in an earlier study by Walling et al. (1037). Occa-
onal patients may require instrumentation with a pacemaker
prevent transient AV block associated with ischemia or
ith a defibrillator to prevent sudden death associated with
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mes be very frustrating in the occasional patient refractory
standard medication. Cardiac denervation has been used in
ese patients with marginal benefit.
.8. Cardiovascular “Syndrome X”
ecommendations
ASS I
Medical therapy with nitrates, beta blockers, and calcium
channel blockers, alone or in combination, is recommended in
patients with cardiovascular syndrome X. (Level of Evidence: B)
Risk factor reduction is recommended in patients with cardio-
vascular syndrome X. (Level of Evidence: B)
ASS IIb
Intracoronary ultrasound to assess the extent of atherosclero-
sis and rule out missed obstructive lesions may be considered
in patients with syndrome X. (Level of Evidence: B)
If no ECGs during chest pain are available and coronary spasm
cannot be ruled out, coronary angiography and provocative
testing with acetylcholine, adenosine, or methacholine and
24-h ambulatory ECG may be considered. (Level of Evidence: C)
If coronary angiography is performed and does not reveal a
cause of chest discomfort, and if syndrome X is suspected,
invasive physiological assessment (i.e., coronary flow reserve
measurement) may be considered. (Level of Evidence: C)
Imipramine or aminophylline may be considered in patients with
syndrome X for continued pain despite implementation of Class I
measures. (Level of Evidence: C)
Transcutaneous electrical nerve stimulation and spinal cord
stimulation for continued pain despite the implementation of
Class I measures may be considered for patients with syn-
drome X. (Level of Evidence: B)
ASS III
Medical therapy with nitrates, beta blockers, and calcium
channel blockers for patients with noncardiac chest pain is not
recommended. (Level of Evidence: C)
.8.1. Definition and Clinical Picture
ardiovascular “syndrome X” refers to patients with angina
angina-like discomfort with exercise, ST-segment depres-
on on exercise testing, and normal or nonobstructed coro-
ry arteries on arteriography (1060). This entity should be
fferentiated from the metabolic syndrome X (metabolic
ndrome), which describes patients with insulin resistance,
perinsulinemia, dyslipidemia, hypertension, and abdominal
esity. It also should be differentiated from noncardiac chest
in. Syndrome X is more common in women than in men
84,1060–1062). Chest pain can vary from that of typical
gina pectoris to chest pain with atypical features to chest
in that simulates UA secondary to CAD (1061). Other
ypical features can be prolonged chest pain at rest and chest
in that is unresponsive to NTG (1063). Most often, the
est pain occurs with activity and simulates angina pectoris
e to stable CAD. However, because chest pain can accel-
ate in frequency or intensity or may occur at rest, the patient
n present with the clinical picture of UA. Therefore, this
ndrome is discussed in this guideline. wThe cause of the discomfort and ST-segment depression in
tients with syndrome X is not well understood. The most
equently proposed causes are impaired endothelium-dependent
terial vasodilatation with decreased nitric oxide production,
paired microvascular dilation (non–endothelium-dependent),
creased sensitivity to sympathetic stimulation, or coronary vaso-
nstriction in response to exercise (836,1064,1065). Increased
vels of plasma endothelin correlate with impaired coro-
ry microvascular dilation (1066). There is increasing
idence that these patients frequently also have an in-
eased responsiveness to pain and an abnormality in pain
rception.
The diagnosis of syndrome X is suggested by the triad of
ginal-type chest discomfort, objective evidence of isch-
ia, and absence of obstructive CAD. The diagnosis can be
nfirmed by provocative coronary angiographic testing with
etylcholine for coronary endothelium-dependent function
d adenosine for non–endothelium-dependent microvascu-
r function. Other causes of angina-like chest discomfort not
sociated with cardiac disease, such as esophageal dysmo-
lity, fibromyalgia, and costochondritis, must also be elimi-
ted. In addition, in patients with a clinical presentation
nsistent with variant angina, coronary spasm must be ruled
t by the absence of ST-segment elevation with the anginal
scomfort or by provocative testing. Myocardial perfusion
anning may be abnormal owing to a patchy abnormal
sponse to exercise of the microvasculature that can lead to
duced coronary flow to different regions of the myocardium
36). Magnetic resonance imaging studies also may suggest
yocardial ischemia (1067,1068).
The intermediate-term prognosis of patients with syn-
ome X has been reported to be excellent in older studies
061,1063,1069). The CASS registry reported a 96% 7-year
rvival rate in patients with anginal-type chest pain, normal
ronary arteriograms, and an LVEF greater than 0.50
070). However, testing for ischemia was not performed in
ASS. More recent data from WISE indicate that the prog-
sis in syndrome X, validated by ischemia testing, is not
tirely benign with respect to risk of cardiac death and
nfatal MI (1062,1063). The WISE data demonstrate that
e prognosis is related to the extent of angiographic disease
ross the range of 20% stenosis to obstructive lesions
062). Long-term follow-up shows that ventricular function
ually remains normal (1063), although there have been
ports of progressive LV dysfunction, and many patients
ntinue to have chest pain that requires medication (1071).
Additional data from WISE (838,871–878) suggest ad-
rse outcomes in some women with myocardial ischemia on
ninvasive testing and nonobstructive CAD. A number of
riables may be contributory. Intramural lesions, evidence
an atherosclerotic burden, are evident on intravascular
trasound. A decrease in coronary flow reserve appears to
dependently predict major coronary events. In addition,
ere is important coronary endothelial dysfunction that may
related to hormonal influences, inflammatory markers, or
idative stress and possibly to a clustering of risk factors as
seen in the metabolic syndrome. Other microvascular
sfunction may be present. Although half of the WISE
omen with myocardial ischemia documented on noninva-
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angiography, not only were there persisting symptoms, but
ere was a subsequent significant occurrence of coronary
ents. Evaluation of the 4-year risk-adjusted freedom from
ath or MI showed that women with no or minimal obstruc-
ve disease had a total rate of occurrence of these end points
9.4% by 4 years. Pending additional data, aggressive
ronary risk factor reduction appears to be appropriate.
.8.2. Treatment
ersistence of symptoms is common, and many patients do
t return to work (1063). The demonstration of normal
ronary arteries on angiography can be reassuring. In 1
udy, after a normal coronary arteriogram, there was a
duced need for hospitalization and a reduction in the
mber of hospital days for cardiac reasons (654). However,
en minimal atherosclerotic disease on angiography war-
nts risk factor modification.
Both beta blockers and calcium channel blockers have
en found to be effective in reducing the number of episodes
chest discomfort (1072,1073). Beneficial effects with
trates are seen in approximately one half of patients (1074).
he use of alpha-adrenergic blockers would appear to be a
tional therapy, but the results of small trials are inconsistent
075). Imipramine 50 mg daily has been successful in some
ronic pain syndromes, including syndrome X, reducing the
equency of chest pain by 50% (1076). Transcutaneous
ectrical nerve stimulation and spinal cord stimulation can
fer good pain control (1077,1078). Estrogen in postmeno-
usal women with angina and normal coronary arteriograms
s been shown to reverse the acetylcholine-induced coro-
ry arterial vasoconstriction, presumably by improving
dothelium-dependent coronary vasomotion (1079), and to
duce the frequency of chest pain episodes by 50% (1080).
owever, because of increased cardiovascular and other risks
cumented in randomized controlled trials of primary and
condary coronary prevention, hormone therapy is not rec-
mended for chronic conditions (36). Statin therapy and
ercise training have improved exercise capacity, endothe-
al function, and symptoms (1081,1082).
It is recommended that patients be reassured of the
cellent intermediate-term prognosis and treated with long-
ting nitrates. If the patient continues to have episodes of
est pain, a calcium channel blocker or beta blocker can be
arted (1073). Finally, 50 mg of imipramine daily has been
ccessful in reducing the frequency of chest pain episodes
076). Cognitive behavioral therapy can be beneficial
083). If symptoms persist, other causes of chest pain,
pecially esophageal dysmotility, should be ruled out.
.9. Takotsubo Cardiomyopathy
disorder, or group of disorders, with several names (stress-
duced cardiomyopathy, transient LV apical ballooning,
akotsubo cardiomyopathy, and broken heart syndrome) is an
common but increasingly reported cause of ACS. Takot-
bo cardiomyopathy is noteworthy for the absence of ob-
ructive coronary artery disease, typical precipitation by
tense psychological or emotional stress, and predominant
currence in postmenopausal women. The characteristic binding of apical LV ballooning is seen on left ventriculog-
phy or echocardiography, with transient ST elevation or
ep T-wave inversions on the surface ECG. Despite the
esence of positive cardiac biomarkers and frequent hemo-
namic compromise or even cardiogenic shock, almost all
tients recover completely, typically with normal wall mo-
on within 1 to 4 weeks (1084,1085).
. Conclusions and Future Directions
he last quarter century has witnessed enormous strides in the
derstanding of ACS pathophysiology and its management.
hese have included the critical role of coronary thrombosis
086), the novel concept and suggestion of a therapeutic
nefit of reperfusion therapy (1087–1090), and finally, the
monstration of mortality reductions with fibrinolysis in
rge, multicenter trials (452). However, these trials also
covered the paradox that fibrinolysis did not benefit or even
rmed NSTEMI patients (452). This central management
chotomy, together with other differences between STEMI and
A/NSTEMI (20), has been reflected since 2000 in separate
actice guidelines. Despite these differences, more remains in
mmon than distinct, including the discovery that atherothrom-
sis is an active, inflammatory process (1091,1092). Further
quiry has led to the concept of the vulnerable plaque and the
lnerable patient (1093,1094).
Whereas the incidence and risk of STEMI have decreased
er the past 25 years, the relative frequency of UA/NSTEMI
s increased, and its risk has remained relatively high (now
mparable to that of STEMI) (1095). Hence, improving
A/NSTEMI outcomes remains a challenge for the future.
A contemporary multinational observational study has
phasized the benefits of applying evidence-based guide-
nes in clinical practice (1096). Between 1999 and 2006,
,558 patients with UA/NSTEMI in 14 countries were
rolled and followed for 6 months after discharge. Increases
er the 7 years of enrollment were observed in the use of
terventional therapy and of major pharmacological thera-
es, including beta blockers, statins, ACE inhibitors (or
RBs), low molecular weight heparin, GP IIb/IIa inhibitors,
d thienopyridines. These changes were accompanied by
arked declines (by one half) in in-hospital rates of heart
ilure or cardiogenic shock and recurrent MI and in 6-month
tes of death (from 4.9% to 3.3%) and stroke (1.4% to 0.7%).
proved outcomes occurred despite an increase in patient
sk profile. The future should emphasize further improve-
ents in evidence-based guideline applications.
Improving prehospital and ED assessment should aim at
ore efficient entry into the health care system (e.g., limiting
lays for NTG-refractory angina before calling 9-1-1),
agnosis and risk stratification (e.g., using marker changes
hile they are still in the normal range; in the future, with the
d of nontraditional biomarkers), and initiation of therapy.
he future will see the increasing use of new imaging tests to
sess the chest pain patient. By simultaneously assessing
rdiac function, perfusion, and viability, CMR can yield a
gh sensitivity and specificity for diagnosis of CAD/ACS
03). Multislice cardiac computed tomography, which com-
nes coronary calcium scoring with noninvasive coronary
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vorable initial evaluation for assessment of the low- to
termediate-risk chest pain patient (304). The current status
d appropriate application of CMR and cardiac CT are
dressed in recent ACC/AHA documents (32,301).
The concept of a network of “heart attack centers” has been
oposed as a way to improve MI care in the future (1097–
99). These heart attack centers would be organized and
rtified to provide the highest levels of care and would be
ographically readily accessible to virtually all patients.
For high-risk patients, the concept of establishing and
aintaining normal levels of myocardial perfusion mechan-
ally continues to gain support, with evidence favoring
tervention at even shorter (e.g., less than 6 to 24 h) rather
an longer (i.e., greater than 48 to 96 h) intervals (624). The
ture should bring additional important information on this
sue.
In contrast, for low-risk patients, evidence is growing that
initially noninvasive approach may be preferred (e.g., PCI
ows benefit in high-risk women, as in men, but carries
verse risk potential in low-risk women) (436,653). This
pendence of therapeutic benefit on disease risk has also
en shown for antiplatelet and anticoagulant therapies.
ence, there is an increasing need to optimally stratify risk;
me progress has been made (e.g., with the use of biomark-
s integrated into an overall clinical risk score; see Section
2), but further development of risk assessment algorithms
ill be welcome in the future.
Platelets play a critical role UA/NSTEMI, and antiplatelet
erapy continues to undergo testing. Higher (e.g., 600 mg or
ore of clopidogrel) and earlier loading doses of clopidogrel,
addition to new P2Y12 receptor inhibitor (prasugrel and
cagrelor) have been tested since the previous guidelines
ere published (see Section 3.2), with evidence of earlier and
ore potent antiplatelet activity. However, an incremental
nefit of triple-antiplatelet therapy (ASA, GP IIb/IIIa inhib-
or, and clopidogrel) over double therapy with clopidogrel
us ASA (without GP IIb/IIIa inhibition) was recently shown
r PCI in the setting of UA/NSTEMI (250).
Late thrombosis of DES (504,506,507,1100), associated
ith delayed endothelialization (502,503), recently has
erged as a therapeutic issue (505). Thus, longer periods of
al-antiplatelet therapy (i.e., at least 1 year) increasingly are
vocated after PCI (see Section 3.2). More choices in
tiplatelet therapy can be expected, including intravenously
ministered and rapidly acting P2Y12 receptor inhibitor.
iocompatible stents can also be expected looking forward,
cluding biodegradable stents.
Triple-anticoagulant therapy (e.g., ASA, a P2Y12 receptor
hibitor, and warfarin) increasingly has a potential indication
.g., PCI plus atrial fibrillation, cardiac or vascular throm-
sis, or mechanical heart valve). Its current Class IIb
commendation (to be used “with caution” (8,9) is in need of
firmer evidence base (8,9).
Anticoagulant choices have proliferated since the last
idelines were published. Although LMWH (e.g., enoxa-
rin) gained recognition as an alternative or preferred
ticoagulant in the previous guidelines, subsequent study in
e setting of an early PCI strategy has suggested that either siFH or LWMH is acceptable (400). Meanwhile, agents from
newer classes have been tested favorably (see Section 3.2)
22,424). Fondaparinux, a synthetic factor Xa inhibitor, was
ninferior to enoxaparin at 9 d, with a lower bleeding
sk. However, catheter-related thrombosis with fondapa-
nux raises concerns about its use with PCI, a concern
plified by its failure with PCI in STEMI (534). In
ntrast, fondaparinux is an appealing choice with a
ninvasive approach to UA/NSTEMI, especially in those
higher risk of bleeding.
The ACUITY study, which tested bivalirudin for UA/
STEMI, has led to a guidelines change to allow bivalirudin
an anticoagulant option (424). Bivalirudin was found to be
ninferior to UFH/LMWH when given with a GP IIb/IIIa
hibitor. When given without a GP inhibitor, bleeding rates
ere lower but ischemic risk was higher unless clopidogrel
erapy had been given before the procedure. Bivalirudin use
as not tested with a conservative strategy. These guidelines
esent several options for anticoagulant/antiplatelet regi-
ens, but whether there are clear preferences must await
ditional analysis and an enriched evidence base and could
ry depending on the health care setting, the preferred
eatment strategy (e.g., invasive vs conservative), and indi-
dual patient factors.
This guideline revision recognizes ongoing develop-
ents in prevention (see Section 5.1.1). More aggressive
DL-C lowering (i.e., to the optimal LDL-C goal of less
an 70 mg per dL) further reduces cardiovascular events,
though an incremental mortality benefit remains to be
own (1101). An additional tool for smoking cessation
s appeared (varenicline), and others are in testing (see
ection 5.2). High compliance with recommended second-
y prevention measures has been shown to improve
tcomes, but optimal compliance is still lacking, includ-
g at hospitals peer-rated as top tier (1102). The evidence
se for therapeutic lifestyle change continues to grow; the
allenge for the future is more successful implementation
ee Section 5.2).
Primary prevention remains a major challenge. Risk is
rrently assessed by traditional factors (e.g., Framingham
sk score) and the intensity of treatment by risk score-
termined goals. The majority of coronary events occur in a
rge segment of the population whose risk is intermediate
either very low nor very high). Routine individual screen-
g for asymptomatic disease is widely accepted for common
ncers (e.g., colon and breast cancer) but not for atheroscle-
sis. Application of an “atherosclerosis test” (e.g., coronary
tery calcium scoring or carotid intima-media thickness
sessment) to middle-aged adults at intermediate risk has
en proposed (32,301,1093,1094). The future will determine
w broadly extended primary screening will be accepted to
entify the “ACS-vulnerable” patient.
Progress in UA/NSTEMI remains uneven, with rapid
olution in some areas but slow progress in others. Our hope
that guidelines increasingly become based on levels of
idence A (or B). Writing these guidelines has highlighted
e many holes in the fabric of the current evidence base.
cademia, regulatory agencies, practicing physicians, profes-
onal organizations, and patient advocacy groups, as well as
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lly evidence-based management strategy for UA/NSTEMI
the future. Strategies must include not only innovations in
agnosis and treatment but also fresh approaches to motivat-
g lifestyle changes, leading to improved diet, weight con-
ol, physical activity, and tobacco avoidance, as well as to
tter compliance with evidence-based medical therapies
92).
.1. Recommendations for Quality of Care
nd Outcomes for UA/NSTEMI (NEW
ECTION)
ASS IIa
It is reasonable for clinicians and hospitals that provide care to
patients with UA/NSTEMI to participate in a standardized
quality-of-care data registry designed to track and measure
outcomes, complications, and adherence to evidence-based
processes of care and quality improvement for UA/NSTEMI.
(Level of Evidence: B) (1103–1113)
.1.1. Quality Care and Outcomes
EW SECTION)
he development of regional systems of UA/NSTEMI care is
matter of utmost importance (1105,1107,1108). This in-
udes encouraging the participation of key stakeholders in
llaborative efforts to evaluate care using standardized
rformance and quality-improvement measures, such as
ose endorsed by the ACC and the AHA for UN/NSTEMI
108). Standardized quality-of-care data registries designed
track and measure outcomes, complications, and adherence
evidence-based processes of care for UA/NSTEMI are also
itical: programs such as the NCDR (National Cardiovascu-
r Data Registry) ACTION Registry-GWTG, the AHA’s Get
ith The Guidelines (GWTG) quality-improvement pro-
am, and those performance-measurement systems required
The Joint Commission and the Centers for Medicare and
edicaid Services (1103,1110–1112). More recently, the
HA has promoted its Mission: Lifeline initiative, which was
veloped to encourage closer cooperation and trust among
ehospital emergency services personnel and cardiac care
ofessionals (1103). The evaluation of UA/NSTEMI care
livery across traditional care-delivery boundaries with
ese tools and other resources is imperative to identify
stems problems and enable the application of modern
ality-improvement methods, such as Six Sigma, to make
ecessary improvements (1104,1106,1109,1113). The
ality-improvement data coming from registries like the
CTION-GTWG may prove pivotal in addressing opportu-
ties for quality improvement at the local, regional, and
tional level, including the elimination of healthcare
sparities and conduct of comparative effectiveness re-
arch.
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This table represents the actual or potential relationships with industry that were reported as of February 13, 2007. This table was updated in conjunction with
l meetings and conference calls of the writing committee.
*Indicates significant (greater than $10,000) relationship.
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S acute coronary syndrome
T activated clotting time
UITY Acute Catheterization and Urgent Intervention Triage strategy
A American Heart Association
I acute myocardial infarction
TT activated partial thromboplastin time
TS Arterial Revascularization Therapy Study
A aspirin
T, SGOT aspartate aminotransferase
atrioventricular
RI Bypass Angioplasty Revascularization Investigation
P B-type natriuretic peptide
BG coronary artery bypass graft
BRI Coronary Angioplasty versus Bypass Revascularization Investigation
D coronary artery disease
PTURE c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina trial
SS Coronary Artery Surgery Study
B calcium channel blocker
TA coronary computed tomographic angiogram
D coronary heart disease
confidence interval
D chronic kidney disease
-MB creatine kinase-myocardial band
R cardiac magnetic resonance
MMIT CIOpidogrel and Metoprolol in Myocardial Infarction Trial
X cyclooxygenase
R cardiopulmonary resuscitation
EDO Clopidogrel for the Reduction of Events During Observation trial
P C-reactive protein
computed tomography
n cardiac troponin
RE Clopidogrel in Unstable Angina to Prevent Recurrent Events trial
D cardiovascular disease
day
VIT Danish Study Group on Verapamil in Myocardial Infarction
S drug-eluting stent
GAMI Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction
G electrocardiogram
emergency department
S emergency medical services
IC Evaluation of c7E3 for the Prevention of Ischemic Complications
ILOG Evaluation of PTCA and Improve Long-term Outcome by c7E3 GP IIb/IIIa receptor blockade
ISTENT Evaluation of Platelet IIb/IIIa Inhibitor for STENTing
ACI-II Estudio Randomizado Argentino de Angioplastia vs. Clrugia-II
C European Society of Cardiology
SENCE Efficacy and Safety of Subcutaneous Enoxaparin in Unstable Angina and Non-Q Wave Myocaridal Infarction trial(Continued on next page)
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IC FRagmin In ustable Coronary artery disease
ISC Fast Revascularization During Instability in Coronary Artery Disease
ISC-II Fast Revascularization During Instability in Coronary Artery Disease-II
SSI Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto-1 1 trial
SSI-3 Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico
glycoprotein
ACE Global Registry of Acute Coronary Events
STO Global Utilization of Streptokinase and t-PA for Occluded Arteries
STO-II Global Use of Strategies to Open Occluded Coronary Arteries II
hour
hemoglobin
L-C high-density lipoprotein cholesterol
heart failure
PE Heart Outcomes Prevention Evaluation Study
hazard ratio
BP intra-aortic balloon pump
TUS Invasive versus Conservative Treatment in Unstable coronary Syndromes
U intensive care unit
T interpersonal psychotherapy
R international normalized ratio
AR-REACT Intracoronary stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment
IS-2 Second International Study of Infarct Survival
IS-4 Fourth International Study of Infarct Survival
international unit
intravenous
C 7 Seventh Joint National Committee on High Blood Pressure
kilogram
D left anterior descending coronary artery
L-C low-density lipoprotein choloesterol
WH low-molecular-weight heparin
left ventricular
EF left ventricular ejection fraction
ASS II Multicenter Anti Atherosclerotic Study II
ATE Medicine versus Angiography in Thrombolytic Exclusion
DPIT Multicenter Diltiazem Postinfarction Trial
DRD Modification of Diet and Renal Disease
ETS metabolic equivalents
I myocardial infarction
VO2 myocardial oxygen demand
EP National Cholesterol Education Program
LBI National Heart, Lung, and Blood Institute
nonsignificant
TEMI non–ST-segment elevation myocardial infarction
G nitroglycerin
-proBNP N-terminal B-type natriuretic peptide
SIS Organization to Assess Strategies for Ischemic Syndromes
odds ratio
I percutaneous coronary intervention(Continued on next page)
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A personal digital assistant
ISM Platelet Receptor Inhibition in Ischemic Syndrome Management
ISM-PLUS Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms
CA percutaneous transluminal coronary angioplasty
RSUIT Platelet Glycoprotein IIb/IIIa in Unstable 16 Angina: Receptor Suppression Using Integrilin Therapy
ACT Rapid Early Action for Coronary Treatment
PLACE-2 Randomized Evaluation of PCI Linking Angiomax to reduced Clinical Events
TA Research Group in Instability in Coronary Artery Disease trial
risk ratio
O2 arterial oxygen saturation
subcutaneous
AI Society for Cardiovascular Angiography and Interventions
OCK SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK study
S Stent or Surgery
EMI ST-elevation myocardial infarction
S Society of Thoracic Surgeons
G saphenous vein graft
NERGY Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors trial
CTICS-TIMI 18 Treat Angina with Aggrastat and determine Cost of therapy with Invasive or Conservative Strategy (TACTICS) TIMI-18 trial
RGET Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial
MI Thrombolysis In Myocardial Infarction
I troponin I
T troponin T
units
unstable angina
/NSTEMI unstable angina/non–ST-elevation myocardial infarction
H unfractionated heparin
NQWISH Veterans Affairs Non–Q-Wave Infarction Strategies in Hospital
NO Value of first day angiography/angioplasty In evolving Non-ST-Segment elevation myocardial infarction: Open randomized
trial
ISE Women’s Ischemia Syndrome Evaluation
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